{
  "category": "Clinical Pathology",
  "subject": {
    "name": "Clinical Chemistry",
    "url": "https://app.pathprimer.com/curriculum/3afffb4f-69ee-4aa9-a645-df20cda3fc15",
    "lessons": {
      "Renal Function": {
        "name": "Renal Function",
        "url": "https://app.pathprimer.com/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
        "topics": {
          "Laboratory Measurement of Creatinine": {
            "name": "Laboratory Measurement of Creatinine",
            "url": "https://app.pathprimer.com/document/879e0f65-ab8a-4435-83b0-bb7a43dbeaf3/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Jaffe reactionBased on reaction of creatinine with alkaline picrate resulting in orange-red color change (490-520 nm)Reaction not specific; other compounds (chromogens) react with alkaline picrate and result in similar color changeCommon positive chromogensAscorbic acid (vitamin C)GlucoseProteinsKetonesCephalosporin antibioticsCommon interferents that create falsely low results include bilirubin and hemoglobin",
                    "sub_points": [
                      "Based on reaction of creatinine with alkaline picrate resulting in orange-red color change (490-520 nm)",
                      "Reaction not specific; other compounds (chromogens) react with alkaline picrate and result in similar color change",
                      "Common positive chromogensAscorbic acid (vitamin C)GlucoseProteinsKetonesCephalosporin antibiotics",
                      "Ascorbic acid (vitamin C)",
                      "Glucose",
                      "Proteins",
                      "Ketones",
                      "Cephalosporin antibiotics",
                      "Common interferents that create falsely low results include bilirubin and hemoglobin"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gas chromatography-isotope dilution mass spectrometry (GC-IDMS)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "Creatinine is nitrogen compound created after either spontaneous hydrolysis of creatine or phosphocreatine cyclization"
                  },
                  {
                    "text": "Muscle contraction necessitates phosphocreatine interconversion with creatineContributes to creatinine production",
                    "sub_points": [
                      "Contributes to creatinine production"
                    ]
                  },
                  {
                    "text": "Creatine endogenously produced elsewhereKidneysPancreasLiver",
                    "sub_points": [
                      "Kidneys",
                      "Pancreas",
                      "Liver"
                    ]
                  },
                  {
                    "text": "Obtained exogenously through eating meat protein"
                  },
                  {
                    "text": "Serum concentration of creatinine is relatively constantMaintained by glomerular filtration in kidney",
                    "sub_points": [
                      "Maintained by glomerular filtration in kidney"
                    ]
                  },
                  {
                    "text": "Serum creatinine concentration is related to muscle massMen typically have higher basal levels",
                    "sub_points": [
                      "Men typically have higher basal levels"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methodologies": [
                  {
                    "text": "Chemical approachJaffe reactionOldest and most widely used method to measure creatinine (easily automated, inexpensive)Based on reaction of creatinine with alkaline picrate resulting in orange-red color change (490-520 nm)Reaction not specific; other compounds (chromogens) react with alkaline picrate and result in similar color changeFalsely increasing creatinine measurementCommon positive chromogensAscorbic acid (vitamin C)GlucoseProteinsKetonesCephalosporin antibioticsProblematic in states with high blood glucose (diabetic ketoacidosis)Common interferents that create falsely low results include bilirubin and hemoglobinInterference often mitigated by selecting specific time (20-60 seconds) for rate measurement (kinetic assay)Interferents may produce color slower or faster than creatinine",
                    "sub_points": [
                      "Jaffe reactionOldest and most widely used method to measure creatinine (easily automated, inexpensive)Based on reaction of creatinine with alkaline picrate resulting in orange-red color change (490-520 nm)Reaction not specific; other compounds (chromogens) react with alkaline picrate and result in similar color changeFalsely increasing creatinine measurementCommon positive chromogensAscorbic acid (vitamin C)GlucoseProteinsKetonesCephalosporin antibioticsProblematic in states with high blood glucose (diabetic ketoacidosis)Common interferents that create falsely low results include bilirubin and hemoglobinInterference often mitigated by selecting specific time (20-60 seconds) for rate measurement (kinetic assay)Interferents may produce color slower or faster than creatinine",
                      "Oldest and most widely used method to measure creatinine (easily automated, inexpensive)",
                      "Based on reaction of creatinine with alkaline picrate resulting in orange-red color change (490-520 nm)",
                      "Reaction not specific; other compounds (chromogens) react with alkaline picrate and result in similar color changeFalsely increasing creatinine measurement",
                      "Falsely increasing creatinine measurement",
                      "Common positive chromogensAscorbic acid (vitamin C)GlucoseProteinsKetonesCephalosporin antibiotics",
                      "Ascorbic acid (vitamin C)",
                      "Glucose",
                      "Proteins",
                      "Ketones",
                      "Cephalosporin antibiotics",
                      "Problematic in states with high blood glucose (diabetic ketoacidosis)",
                      "Common interferents that create falsely low results include bilirubin and hemoglobin",
                      "Interference often mitigated by selecting specific time (20-60 seconds) for rate measurement (kinetic assay)Interferents may produce color slower or faster than creatinine",
                      "Interferents may produce color slower or faster than creatinine"
                    ]
                  },
                  {
                    "text": "Enzymatic approachThree main enzymes used (creatininase, creatinase, creatinine deaminase)Many chromogen interferences do not occur with enzymatic methodsEnzymatic approach employed in dry chemistry methods and some point-of-care devicesNot widely used in clinical laboratory (prolonged analysis, expensive)",
                    "sub_points": [
                      "Three main enzymes used (creatininase, creatinase, creatinine deaminase)",
                      "Many chromogen interferences do not occur with enzymatic methods",
                      "Enzymatic approach employed in dry chemistry methods and some point-of-care devices",
                      "Not widely used in clinical laboratory (prolonged analysis, expensive)"
                    ]
                  },
                  {
                    "text": "GC-IDMSReference method to establish serum concentration of creatinineChromogen interference does not occurSample preparation more involved and method not routinely used",
                    "sub_points": [
                      "Reference method to establish serum concentration of creatinine",
                      "Chromogen interference does not occur",
                      "Sample preparation more involved and method not routinely used"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Type": [
                  {
                    "text": "Serum"
                  },
                  {
                    "text": "Plasma"
                  },
                  {
                    "text": "Diluted urine"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Adult upper limit for serum creatinine via Jaffe reaction (1.6-1.9 mg/dL)After chromogen interference removal, upper limit is 1.2-1.4 mg/dLUpper limit in women 0.1-0.2 mg/dL lower",
                    "sub_points": [
                      "After chromogen interference removal, upper limit is 1.2-1.4 mg/dL",
                      "Upper limit in women 0.1-0.2 mg/dL lower"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Preanalytic Considerations": [
                  {
                    "text": "Creatinine stable in serum and urine for 7 days at 4°C"
                  },
                  {
                    "text": "Stable long term at ₋20°C and belowEven with repeated thawing and refreezing",
                    "sub_points": [
                      "Even with repeated thawing and refreezing"
                    ]
                  },
                  {
                    "text": "Delayed separation of serum from erythrocytes causes falsely elevated serum creatinine"
                  },
                  {
                    "text": "Eating cooked meat can falsely elevate creatinine concentration in blood"
                  },
                  {
                    "text": "Interfering chromogens account for 4.5%-22.3% of falsely measured creatinine in normal renal function"
                  },
                  {
                    "text": "In renal dysfunction chromogens account for only 5% of falsely measured creatinine"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Blood Urea Nitrogen": {
            "name": "Blood Urea Nitrogen",
            "url": "https://app.pathprimer.com/document/ab7f0e91-a910-48a2-a322-f2aedf0c6afa/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Urea is major nitrogen-containing metabolite of protein breakdown"
                  },
                  {
                    "text": "Most urea is cleared by kidney, filtered freely by glomerulus with none secretedIn healthy kidney, up to 70% of urea passively reabsorbed through renal tubuleUrea clearance generally underestimates GFR",
                    "sub_points": [
                      "In healthy kidney, up to 70% of urea passively reabsorbed through renal tubule",
                      "Urea clearance generally underestimates GFR"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Urea is poor indicator of renal function because of extrarenal factors affecting its concentration"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Blood urea nitrogen (BUN)"
                  },
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  },
                  {
                    "text": "Reduced nicotinamide adenine dinucleotide (NADH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Urea"
                  },
                  {
                    "text": "Serum urea"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Azotemia: Elevation in BUN and other nitrogen-containing compounds"
                  },
                  {
                    "text": "BUN: Term used frequently in clinical practice but is less favored, as whole blood is not always sample submitted for analysis"
                  },
                  {
                    "text": "Uremia: Clinical toxic effects of increased BUN and other nitrogenous metabolites"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "Urea is major nitrogen-containing metabolite of protein breakdown"
                  },
                  {
                    "text": "Biosynthesis of urea occurs in liver via the urea cycle"
                  },
                  {
                    "text": "Most urea is cleared by kidney, filtered freely by glomerulus with none secretedIn healthy kidney, up to 70% of urea passively reabsorbed through renal tubuleUrea clearance generally underestimates GFR",
                    "sub_points": [
                      "In healthy kidney, up to 70% of urea passively reabsorbed through renal tubule",
                      "Urea clearance generally underestimates GFR"
                    ]
                  },
                  {
                    "text": "A small amount of urea is also cleared by gastrointestinal tract and skin"
                  },
                  {
                    "text": "Production of urea can change based on various factorsProtein intakeGastrointestinal bleedingCorticosteroid useReduced renal perfusion",
                    "sub_points": [
                      "Protein intake",
                      "Gastrointestinal bleeding",
                      "Corticosteroid use",
                      "Reduced renal perfusion"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methodologies": [
                  {
                    "text": "Modern methods to measure urea first employ enzyme urease to convert urea to ammonia"
                  },
                  {
                    "text": "Ammonia can be measured through various means (coupled enzymes, chemically, pH indicators, electrochemically)"
                  },
                  {
                    "text": "Most common method employed to quantitate ammonia uses enzyme glutamate dehydrogenase coupled with NADH reduction, with decrease in absorbance at 340 nm monitored"
                  },
                  {
                    "text": "Potential interference with preexisting ammonia in sample is overcome through kinetic analysis"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Significance": [
                  {
                    "text": "Urea is poor indicator of renal function because of extrarenal factors affecting its concentration"
                  },
                  {
                    "text": "Primary clinical use in determining whether uremia is prerenal or postrenal by calculating urea-to-creatinine ratio"
                  },
                  {
                    "text": "Also used to assess adequacy of hemodialysis (measuring dialysis fluids)"
                  },
                  {
                    "text": "Urine urea provides a general sense of nitrogen balance in the body and can be used to help guide parenteral nutrition (protein intake)"
                  },
                  {
                    "text": "Urea is one measured factor used to calculate serum osmolality"
                  },
                  {
                    "text": "In acute pancreatitis, BUN concentration increase over first 24 hours is strongly associated with increased mortality"
                  }
                ]
              },
              "SPECIMENS": {
                "Type": [
                  {
                    "text": "Serum/plasma, diluted urine, peritoneal dialysate"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Healthy adult serum: 6-20 mg/dL (2.1-7.1 mmol/L)"
                  },
                  {
                    "text": "Adult urine: 10-20 g/24 h (430-710 mmol//L)"
                  },
                  {
                    "text": "Untreated end-stage renal disease: 108-135 mg/dL (40-50 mmol/L)"
                  },
                  {
                    "text": "Serum urea concentration increases with age"
                  },
                  {
                    "text": "Values in children and pregnant women are slightly lower"
                  },
                  {
                    "text": "Values in men are higher, but difference is not significant enough to warrant gender-related ranges in clinical practice"
                  },
                  {
                    "text": "Historically, analysis of urea assessed actual quantity of nitrogen in urea and compared it with levels of other nonprotein nitrogen compoundsResults in urea concentration reported in United States on mass basis (mg/dL)International System reports intact molecules of urea in mmol/LConversion factor for urea nitrogen (mg/dL) to urea (mmol/L) is 0.357",
                    "sub_points": [
                      "Results in urea concentration reported in United States on mass basis (mg/dL)",
                      "International System reports intact molecules of urea in mmol/L",
                      "Conversion factor for urea nitrogen (mg/dL) to urea (mmol/L) is 0.357"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Preanalytic Considerations": [
                  {
                    "text": "Urea stable at 4°C for 1 week and at ₋20°C for 6 monthsBacteria can degrade urea over time in nonrefrigerated samples; immediate analysis preferred",
                    "sub_points": [
                      "Bacteria can degrade urea over time in nonrefrigerated samples; immediate analysis preferred"
                    ]
                  },
                  {
                    "text": "Any addition of exogenous ammonia to the specimen would affect accuracy"
                  },
                  {
                    "text": "Fluoride-oxalate tube unusable, as fluoride inhibits urease activity"
                  },
                  {
                    "text": "Urine samples can be preserved by lowering pH to < 4"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cystatin C": {
            "name": "Cystatin C",
            "url": "https://app.pathprimer.com/document/c8ada0f8-9a79-4ef3-b951-f7fb5b147dc8/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Studies show that increases in cystatin C predict cardiovascular disease risk and overall mortality better than serum creatinine-based eGFR"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  },
                  {
                    "text": "Estimated GFR (eGFR)"
                  },
                  {
                    "text": "Chronic Kidney Diseases in Children (CKiD) study"
                  },
                  {
                    "text": "Modification of Diet in Renal Disease (MDRD) study"
                  },
                  {
                    "text": "Blood urea nitrogen (BUN)"
                  },
                  {
                    "text": "Isotope dilution-mass spectrometry (ID-MS)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "Cystatin C is low-molecular-weight protein that serves as protease inhibitor"
                  },
                  {
                    "text": "Synthesized in all nucleated cells"
                  },
                  {
                    "text": "Possesses characteristics making it candidate for eGFR assessmentFreely filtered by glomerulusBasal production relatively constantNot significantly affected by diet, muscle mass, ethnicity, or genderElimination exclusively renal basedComplete reabsorption at proximal tubule with subsequent breakdown before any bloodstream reentrySeen only in urine with tubular dysfunctionRenders measurement of urinary clearance infeasible",
                    "sub_points": [
                      "Freely filtered by glomerulus",
                      "Basal production relatively constant",
                      "Not significantly affected by diet, muscle mass, ethnicity, or gender",
                      "Elimination exclusively renal basedComplete reabsorption at proximal tubule with subsequent breakdown before any bloodstream reentrySeen only in urine with tubular dysfunctionRenders measurement of urinary clearance infeasible",
                      "Complete reabsorption at proximal tubule with subsequent breakdown before any bloodstream reentry",
                      "Seen only in urine with tubular dysfunctionRenders measurement of urinary clearance infeasible",
                      "Renders measurement of urinary clearance infeasible"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methodology": [
                  {
                    "text": "Cystatin C increasingly used to calculate eGFR"
                  },
                  {
                    "text": "Measurement is often by immunoassayLatex particle or nephelometric methodologies",
                    "sub_points": [
                      "Latex particle or nephelometric methodologies"
                    ]
                  },
                  {
                    "text": "Not affected by same interferences seen in creatinine measurement (chromogens with Jaffe reaction)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Utility": [
                  {
                    "text": "Cystatin C found to be better indicator of renal function than serum creatinine"
                  },
                  {
                    "text": "Studies show that increases in cystatin C predict cardiovascular disease risk and overall mortality better than serum creatinine-based eGFRAssociation seems to increase when combining cystatin C with creatinine measurement",
                    "sub_points": [
                      "Association seems to increase when combining cystatin C with creatinine measurement"
                    ]
                  }
                ],
                "Pediatric Considerations": [
                  {
                    "text": "Cystatin C serum concentrations appear to more closely reflect GFR within first 3 months of life"
                  },
                  {
                    "text": "Diagnostic accuracy within pediatric patients for reductions in GFR are superior to creatinine"
                  }
                ],
                "﻿Modified Schwartz Equation": [
                  {
                    "text": "Creatinine clearance in children originally estimated using Schwartz formula developed in 1970s"
                  },
                  {
                    "text": "In 2009, as part of CKiD study, Schwartz formula was modified and became similar to MDRD study equationNow incorporates cystatin CAlso includesHeightGenderBUNSerum creatinineUses an ID-MS traceable enzymatic assay for creatinine measurement",
                    "sub_points": [
                      "Now incorporates cystatin C",
                      "Also includesHeightGenderBUNSerum creatinine",
                      "Height",
                      "Gender",
                      "BUN",
                      "Serum creatinine",
                      "Uses an ID-MS traceable enzymatic assay for creatinine measurement"
                    ]
                  },
                  {
                    "text": "Modified Schwartz equation estimates GFR more accurately in children"
                  }
                ]
              },
              "LIMITATIONS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Cystatin C production shown to be reduced by glucocorticoidsCreates risk of kidney function overestimation in renal transplant",
                    "sub_points": [
                      "Creates risk of kidney function overestimation in renal transplant"
                    ]
                  },
                  {
                    "text": "Cystatin C concentration also affected by other factorsDiabetesInflammationUrinary proteinThyroid status",
                    "sub_points": [
                      "Diabetes",
                      "Inflammation",
                      "Urinary protein",
                      "Thyroid status"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Instrumentation": [
                  {
                    "text": "Cystatin C is becoming more readily available on automated analyzers such as the Beckman Coulter AU and Immage analyzers"
                  },
                  {
                    "text": "These analyzers utilizes  immunoturbidimetric or nephelometric approach for measuring Cystatin C in serum and plasma"
                  },
                  {
                    "text": "Assay's measuring range is 0.4-8.0 mg/L, and it has sensitivity limit of quantification of 0.23mg/L"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Evaluation of Acute Renal Failure": {
            "name": "Laboratory Evaluation of Acute Renal Failure",
            "url": "https://app.pathprimer.com/document/e5044f6c-8a30-4c21-b4f6-d1e40e04dfbd/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "AKI, as defined by KDIGO in 2012Increase of plasma creatinine > 0.3 mg/dL within 48 hoursIncrease of plasma creatinine > 1.5 times baseline over prior 7 daysUrine output reduction (< 0.5 mL/kg/h) for more than 6 hours",
                    "sub_points": [
                      "Increase of plasma creatinine > 0.3 mg/dL within 48 hours",
                      "Increase of plasma creatinine > 1.5 times baseline over prior 7 days",
                      "Urine output reduction (< 0.5 mL/kg/h) for more than 6 hours"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Abbreviations": [
                  {
                    "text": "Acute kidney injury (AKI)"
                  },
                  {
                    "text": "Acute tubular necrosis (ATN)"
                  },
                  {
                    "text": "Blood urea nitrogen (BUN)"
                  },
                  {
                    "text": "Kidney Disease Improving Global Outcomes (KDIGO)"
                  },
                  {
                    "text": "Nonsteroidal anti-inflammatory drugs (NSAIDs)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "AKI, as defined by KDIGO in 2012Increase of plasma creatinine > 0.3 mg/dL within 48 hoursIncrease of plasma creatinine > 1.5 times baseline over prior 7 daysUrine output reduction (< 0.5 mL/kg/h) for more than 6 hours",
                    "sub_points": [
                      "Increase of plasma creatinine > 0.3 mg/dL within 48 hours",
                      "Increase of plasma creatinine > 1.5 times baseline over prior 7 days",
                      "Urine output reduction (< 0.5 mL/kg/h) for more than 6 hours"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "AKI risk factorsOlder patients (> 55 years old)Preexisting kidney diseaseDiabetesNephrotoxic drug recipientsHeart disease",
                    "sub_points": [
                      "Older patients (> 55 years old)",
                      "Preexisting kidney disease",
                      "Diabetes",
                      "Nephrotoxic drug recipients",
                      "Heart disease"
                    ]
                  }
                ],
                "Categories of AKI": [
                  {
                    "text": "Clinical assessment of AKI heavily dependent on laboratory analysis"
                  },
                  {
                    "text": "Can be subdivided into 3 categories (prerenal, intrarenal, and postrenal) based on location of etiologyPrerenal AKICaused by decreased renal perfusionHemorrhageSepsisAcute cardiac failureLaboratory findingsBUN:creatinine > 20:1Low urine sodium excretion < 1%Low urine urea excretion < 35%High urine specific gravity > 1.020High urine osmolarity > 500 mOsm/kgTreatment focused on expansion of intravascular volume, with fluid infusionIntrarenal AKICaused by nephron injury (e.g., ATN), typically ischemia or nephrotoxinsAminoglycoside antibioticsNSAIDsAmphotericinPyelonephritisGlomerulonephritisVasculitisAcute allergic interstitial nephritisLaboratory findingsBUN:creatinine < 20:1High urine sodium excretion > 1%High urine urea excretion > 35%Low urine specific gravity < 1.010Low urine osmolarity < 300-500 mOsm/kgTreatment focused on specific causePostrenal AKICaused by obstruction involving urine collecting system (renal pelvis, ureters, or bladder)Treatment often surgical in nature",
                    "sub_points": [
                      "Prerenal AKICaused by decreased renal perfusionHemorrhageSepsisAcute cardiac failureLaboratory findingsBUN:creatinine > 20:1Low urine sodium excretion < 1%Low urine urea excretion < 35%High urine specific gravity > 1.020High urine osmolarity > 500 mOsm/kgTreatment focused on expansion of intravascular volume, with fluid infusion",
                      "Caused by decreased renal perfusionHemorrhageSepsisAcute cardiac failure",
                      "Hemorrhage",
                      "Sepsis",
                      "Acute cardiac failure",
                      "Laboratory findingsBUN:creatinine > 20:1Low urine sodium excretion < 1%Low urine urea excretion < 35%High urine specific gravity > 1.020High urine osmolarity > 500 mOsm/kg",
                      "BUN:creatinine > 20:1",
                      "Low urine sodium excretion < 1%",
                      "Low urine urea excretion < 35%",
                      "High urine specific gravity > 1.020",
                      "High urine osmolarity > 500 mOsm/kg",
                      "Treatment focused on expansion of intravascular volume, with fluid infusion",
                      "Intrarenal AKICaused by nephron injury (e.g., ATN), typically ischemia or nephrotoxinsAminoglycoside antibioticsNSAIDsAmphotericinPyelonephritisGlomerulonephritisVasculitisAcute allergic interstitial nephritisLaboratory findingsBUN:creatinine < 20:1High urine sodium excretion > 1%High urine urea excretion > 35%Low urine specific gravity < 1.010Low urine osmolarity < 300-500 mOsm/kgTreatment focused on specific cause",
                      "Caused by nephron injury (e.g., ATN), typically ischemia or nephrotoxinsAminoglycoside antibioticsNSAIDsAmphotericinPyelonephritisGlomerulonephritisVasculitisAcute allergic interstitial nephritis",
                      "Aminoglycoside antibiotics",
                      "NSAIDs",
                      "Amphotericin",
                      "Pyelonephritis",
                      "Glomerulonephritis",
                      "Vasculitis",
                      "Acute allergic interstitial nephritis",
                      "Laboratory findingsBUN:creatinine < 20:1High urine sodium excretion > 1%High urine urea excretion > 35%Low urine specific gravity < 1.010Low urine osmolarity < 300-500 mOsm/kg",
                      "BUN:creatinine < 20:1",
                      "High urine sodium excretion > 1%",
                      "High urine urea excretion > 35%",
                      "Low urine specific gravity < 1.010",
                      "Low urine osmolarity < 300-500 mOsm/kg",
                      "Treatment focused on specific cause",
                      "Postrenal AKICaused by obstruction involving urine collecting system (renal pelvis, ureters, or bladder)Treatment often surgical in nature",
                      "Caused by obstruction involving urine collecting system (renal pelvis, ureters, or bladder)",
                      "Treatment often surgical in nature"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Creatinine and Glomerular Filtration Rate": {
            "name": "Creatinine and Glomerular Filtration Rate",
            "url": "https://app.pathprimer.com/document/dbf33003-0728-4bdc-b120-4e52d6f455dd/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Serum creatinine is endogenous marker most commonly used to assess GFR because of various factorsNone resorbed by tubules",
                    "sub_points": [
                      "None resorbed by tubules"
                    ]
                  },
                  {
                    "text": "Small amount of creatinine is secreted by proximal tubuleResults in creatinine clearance slightly overestimating GFR",
                    "sub_points": [
                      "Results in creatinine clearance slightly overestimating GFR"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "GFR used clinically to provide measure of renal capacity and generally indicates number of functioning nephrons"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  },
                  {
                    "text": "Modification of Diet in Renal Disease (MDRD) study"
                  },
                  {
                    "text": "Isotope dilution-mass spectrometry (ID-MS)"
                  },
                  {
                    "text": "Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study"
                  }
                ],
                "Definitions": [
                  {
                    "text": "GFR: Rate small molecules are filtered by kidney glomeruli, usually expressed in milliliters per minute"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Glomerular Filtrate": [
                  {
                    "text": "Formation dependent on net pressure differences along afferent arteriole and across glomerular membraneCreated by opposing oncotic and hydrostatic forcesMust be sufficient pressure to drive filtrate through entire nephron unit or tubules will collapse",
                    "sub_points": [
                      "Created by opposing oncotic and hydrostatic forces",
                      "Must be sufficient pressure to drive filtrate through entire nephron unit or tubules will collapse"
                    ]
                  }
                ],
                "Markers of GFR": [
                  {
                    "text": "Small molecules used to measure GFR can be divided broadly into molecules of endogenous or exogenous sources"
                  },
                  {
                    "text": "Endogenous markersSerum creatinine is endogenous marker most commonly used to assess GFR because of various factorsConvenience and cost-effectiveness in measurementProduced at fairly constant rateNot bound by plasma proteins and passes through glomerulus freelyNone resorbed by tubulesSmall amount of creatinine is secreted by proximal tubuleResults in creatinine clearance slightly overestimating GFRSecretion increases with higher renal impairmentCimetidine has been used to inhibit creatinine secretion with mixed efficacySerum creatinine concentration also affected byAgeSexExerciseVarious drugsMuscle massNutritional statusDiet (meat protein)RaceAdditional limitations of creatinineSerum creatinine stays within reference interval very late into renal dysfunctionExtrarenal losses of creatinine result in insensitivity for detecting mild to moderate kidney diseaseOther endogenous markers usedUreaCystatin Cβ-2-Microglobulin",
                    "sub_points": [
                      "Serum creatinine is endogenous marker most commonly used to assess GFR because of various factorsConvenience and cost-effectiveness in measurementProduced at fairly constant rateNot bound by plasma proteins and passes through glomerulus freelyNone resorbed by tubules",
                      "Convenience and cost-effectiveness in measurement",
                      "Produced at fairly constant rate",
                      "Not bound by plasma proteins and passes through glomerulus freely",
                      "None resorbed by tubules",
                      "Small amount of creatinine is secreted by proximal tubuleResults in creatinine clearance slightly overestimating GFRSecretion increases with higher renal impairmentCimetidine has been used to inhibit creatinine secretion with mixed efficacy",
                      "Results in creatinine clearance slightly overestimating GFR",
                      "Secretion increases with higher renal impairment",
                      "Cimetidine has been used to inhibit creatinine secretion with mixed efficacy",
                      "Serum creatinine concentration also affected byAgeSexExerciseVarious drugsMuscle massNutritional statusDiet (meat protein)Race",
                      "Age",
                      "Sex",
                      "Exercise",
                      "Various drugs",
                      "Muscle mass",
                      "Nutritional status",
                      "Diet (meat protein)",
                      "Race",
                      "Additional limitations of creatinineSerum creatinine stays within reference interval very late into renal dysfunctionExtrarenal losses of creatinine result in insensitivity for detecting mild to moderate kidney disease",
                      "Serum creatinine stays within reference interval very late into renal dysfunction",
                      "Extrarenal losses of creatinine result in insensitivity for detecting mild to moderate kidney disease",
                      "Other endogenous markers usedUreaCystatin Cβ-2-Microglobulin",
                      "Urea",
                      "Cystatin C",
                      "β-2-Microglobulin"
                    ]
                  },
                  {
                    "text": "Exogenous markersExogenous substance inulin is considered gold standard for GFR measurement; possesses ideal molecule characteristicsFreely filtered by glomerulusStable concentration in bloodNot metabolized, secreted, or resorbed by kidneyInulin not used clinically because of complicated measurementIntravenous infusion required with timed urine collectionsIohexol (nonradioactive) and iothalamate (radioactive) are most commonly used exogenous markers but are used far less frequently than creatinine",
                    "sub_points": [
                      "Exogenous substance inulin is considered gold standard for GFR measurement; possesses ideal molecule characteristicsFreely filtered by glomerulusStable concentration in bloodNot metabolized, secreted, or resorbed by kidney",
                      "Freely filtered by glomerulus",
                      "Stable concentration in blood",
                      "Not metabolized, secreted, or resorbed by kidney",
                      "Inulin not used clinically because of complicated measurementIntravenous infusion required with timed urine collections",
                      "Intravenous infusion required with timed urine collections",
                      "Iohexol (nonradioactive) and iothalamate (radioactive) are most commonly used exogenous markers but are used far less frequently than creatinine"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Estimating GFR With Serum Creatinine": [
                  {
                    "text": "Measuring serum creatinine favored over urinary measurements because of convenience and inaccuracy in urine collectionIncomplete bladder emptying is common problem in pediatric and elderly patients",
                    "sub_points": [
                      "Incomplete bladder emptying is common problem in pediatric and elderly patients"
                    ]
                  },
                  {
                    "text": "Various mathematical equations have been created to correct for nonlinear relationship between serum creatinine and GFR"
                  },
                  {
                    "text": "These equations use serum creatinine and 4 generalized confounding variables to estimate GFRSex: Men have more muscle and higher serum creatinineAge: Serum creatinine decreases with ageRace: People of African descent have higher serum creatinine than white peopleBody size: Kidney size and GFR are proportional to body sizeStandardization convention: Adjust GFR based on body surface area of normal young adults (1.73 m²)",
                    "sub_points": [
                      "Sex: Men have more muscle and higher serum creatinine",
                      "Age: Serum creatinine decreases with age",
                      "Race: People of African descent have higher serum creatinine than white people",
                      "Body size: Kidney size and GFR are proportional to body sizeStandardization convention: Adjust GFR based on body surface area of normal young adults (1.73 m²)",
                      "Standardization convention: Adjust GFR based on body surface area of normal young adults (1.73 m²)"
                    ]
                  },
                  {
                    "text": "MDRD study equationMost commonly used equation in United StatesOriginally developed in 1999 using data from 1628 patients with chronic kidney diseaseMore accurate than GFR calculated from creatinine clearance onlyValidated against urinary clearance of iothalamate and later calibrated to ID-MS assayEquation if assay calibrated to IDMSGFR (mL/min/1.73 m²) = 175 × [serum creatinine mg/dL)]⁻¹·¹⁵⁴ × (age)⁻⁰·²⁰³ × (1.210 if patient is black) × (0.742 if patient is female)If not calibrated to ID-MS, constant factor 175 is replaced with 186Limitation of MDRD equation is a negative bias at GFR values >60 mL/min/1.73 m²",
                    "sub_points": [
                      "Most commonly used equation in United States",
                      "Originally developed in 1999 using data from 1628 patients with chronic kidney disease",
                      "More accurate than GFR calculated from creatinine clearance only",
                      "Validated against urinary clearance of iothalamate and later calibrated to ID-MS assay",
                      "Equation if assay calibrated to IDMSGFR (mL/min/1.73 m²) = 175 × [serum creatinine mg/dL)]⁻¹·¹⁵⁴ × (age)⁻⁰·²⁰³ × (1.210 if patient is black) × (0.742 if patient is female)",
                      "GFR (mL/min/1.73 m²) = 175 × [serum creatinine mg/dL)]⁻¹·¹⁵⁴ × (age)⁻⁰·²⁰³ × (1.210 if patient is black) × (0.742 if patient is female)",
                      "If not calibrated to ID-MS, constant factor 175 is replaced with 186",
                      "Limitation of MDRD equation is a negative bias at GFR values >60 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "CKD-EPI study equationDeveloped in 2009 using serum creatinine, age, sex, and raceBetter categorizes kidney disease and mortality risk compared with MDRD study equationAs accurate as MDRD study equation in estimated GFR <60 mL/min/1.73 m²Magnitude of bias for estimated GFR >60 mL/min/1.73 m² seen in MDRD study equation not seen with CKD-EPI equationValues >90 mL/min/1.73 m² can be reported with CKD-EPI",
                    "sub_points": [
                      "Developed in 2009 using serum creatinine, age, sex, and race",
                      "Better categorizes kidney disease and mortality risk compared with MDRD study equation",
                      "As accurate as MDRD study equation in estimated GFR <60 mL/min/1.73 m²",
                      "Magnitude of bias for estimated GFR >60 mL/min/1.73 m² seen in MDRD study equation not seen with CKD-EPI equationValues >90 mL/min/1.73 m² can be reported with CKD-EPI",
                      "Values >90 mL/min/1.73 m² can be reported with CKD-EPI"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Renal Function": [
                  {
                    "text": "GFR used clinically to provide measure of renal capacity and generally indicates number of functioning nephrons"
                  },
                  {
                    "text": "Decreased GFR precedes renal failure"
                  },
                  {
                    "text": "GFR measurement in patient with established renal disease is usefulAdjust treatment (drug dosage) to avoid toxicityMonitor disease progressionPredict need for dialysis or transplant",
                    "sub_points": [
                      "Adjust treatment (drug dosage) to avoid toxicity",
                      "Monitor disease progression",
                      "Predict need for dialysis or transplant"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Screening for Chronic Kidney Disease": {
            "name": "Laboratory Screening for Chronic Kidney Disease",
            "url": "https://app.pathprimer.com/document/91601c47-5132-4dcd-81c3-50a47ee84879/lesson/60d355f7-9a72-4274-a9fc-f17f6ae86906",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Bone diseaseWith declining GFR, phosphorus excretion decreases, and renal activation of vitamin D is impairedReduces calcium absorption and levels, stimulating PTH releaseCalcium phosphate reabsorption from bone increasesRisk of fracture",
                    "sub_points": [
                      "With declining GFR, phosphorus excretion decreases, and renal activation of vitamin D is impaired",
                      "Reduces calcium absorption and levels, stimulating PTH release",
                      "Calcium phosphate reabsorption from bone increasesRisk of fracture",
                      "Risk of fracture"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "G1Albuminuria without decreased GFRGFR > 90 mL/min/1.73 m²",
                    "sub_points": [
                      "Albuminuria without decreased GFR",
                      "GFR > 90 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "G2Mild decrease in GFRGFR 60-89 mL/min/1.73 m²",
                    "sub_points": [
                      "Mild decrease in GFR",
                      "GFR 60-89 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "G3aMild to moderate decrease in GFRGFR 45-59 mL/min/1.73 m²",
                    "sub_points": [
                      "Mild to moderate decrease in GFR",
                      "GFR 45-59 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "G3bModerate to severe decrease in GFRGFR 30-44 mL/min/1.73 m²",
                    "sub_points": [
                      "Moderate to severe decrease in GFR",
                      "GFR 30-44 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "G4Severe decrease in GFRGFR 15-29 mL/min/1.73 m²",
                    "sub_points": [
                      "Severe decrease in GFR",
                      "GFR 15-29 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "G5Renal failure or dialysis dependenceGFR < 15 mL/min/1.73 m²",
                    "sub_points": [
                      "Renal failure or dialysis dependence",
                      "GFR < 15 mL/min/1.73 m²"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Abbreviations": [
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  },
                  {
                    "text": "Parathyroid hormone (PTH)"
                  },
                  {
                    "text": "Chronic kidney disease (CKD)"
                  },
                  {
                    "text": "Renin-angiotensin aldosterone system (RAAS)"
                  },
                  {
                    "text": "Myocardial infarction (MI)"
                  },
                  {
                    "text": "Congestive heart failure (CHF)"
                  },
                  {
                    "text": "Transient ischemic attack (TIA)"
                  },
                  {
                    "text": "Estimated GFR (eGFR)"
                  },
                  {
                    "text": "National Kidney Foundation (NKF)"
                  },
                  {
                    "text": "NKF Kidney Disease Outcomes Quality Initiative (NKF KDOQI)"
                  },
                  {
                    "text": "Kidney Disease Improving Global Outcomes (KDIGO)"
                  },
                  {
                    "text": "Albumin excretion rate in urine (AER)"
                  },
                  {
                    "text": "Albumin-to-creatinine ratio (ACR)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Causes of CKD progressing to renal failure in United States (1990-2009)Diabetes mellitus (44% of new dialysis patients)Hypertension (28% of new dialysis patients)High prevalence in African American patientsEnd-stage renal disease rate approximately 3.5 times higher than in white patientsGlomerulonephritisHereditary cystic kidney disease",
                    "sub_points": [
                      "Diabetes mellitus (44% of new dialysis patients)",
                      "Hypertension (28% of new dialysis patients)High prevalence in African American patientsEnd-stage renal disease rate approximately 3.5 times higher than in white patients",
                      "High prevalence in African American patients",
                      "End-stage renal disease rate approximately 3.5 times higher than in white patients",
                      "Glomerulonephritis",
                      "Hereditary cystic kidney disease"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Goal is to manage rate of CKD progression"
                  },
                  {
                    "text": "Nonmodifiable risk factorsAgeGenderEthnicityRenal function on presentationFamily history of renal disease",
                    "sub_points": [
                      "Age",
                      "Gender",
                      "Ethnicity",
                      "Renal function on presentation",
                      "Family history of renal disease"
                    ]
                  },
                  {
                    "text": "Modifiable risk factorsSmokingBlood pressureProteinuria",
                    "sub_points": [
                      "Smoking",
                      "Blood pressure",
                      "Proteinuria"
                    ]
                  },
                  {
                    "text": "Medications inhibiting RAAS often usedShown to reduce proteinuria and CKD progression",
                    "sub_points": [
                      "Shown to reduce proteinuria and CKD progression"
                    ]
                  },
                  {
                    "text": "Dietary guidance provided with focus on protein intake"
                  }
                ],
                "Complications": [
                  {
                    "text": "CardiovascularDisease incidence up to 10-fold greater in patients with CKDSpectrum of disease includes typical entities (e.g., MI, CHF, TIA) and vascular calcifications more prevalent in dialysis patients",
                    "sub_points": [
                      "Disease incidence up to 10-fold greater in patients with CKD",
                      "Spectrum of disease includes typical entities (e.g., MI, CHF, TIA) and vascular calcifications more prevalent in dialysis patients"
                    ]
                  },
                  {
                    "text": "Bone diseaseWith declining GFR, phosphorus excretion decreases, and renal activation of vitamin D is impairedReduces calcium absorption and levels, stimulating PTH releaseCalcium phosphate reabsorption from bone increasesRisk of fracture",
                    "sub_points": [
                      "With declining GFR, phosphorus excretion decreases, and renal activation of vitamin D is impaired",
                      "Reduces calcium absorption and levels, stimulating PTH release",
                      "Calcium phosphate reabsorption from bone increasesRisk of fracture",
                      "Risk of fracture"
                    ]
                  },
                  {
                    "text": "AnemiaKidney production of erythropoietin impaired in CKDErythropoietin analogues given to patients with hemoglobin target of 10-12 g/dLAggressive erythropoietin treatment no longer recommended because of risk of cardiovascular morbidity and mortality",
                    "sub_points": [
                      "Kidney production of erythropoietin impaired in CKD",
                      "Erythropoietin analogues given to patients with hemoglobin target of 10-12 g/dLAggressive erythropoietin treatment no longer recommended because of risk of cardiovascular morbidity and mortality",
                      "Aggressive erythropoietin treatment no longer recommended because of risk of cardiovascular morbidity and mortality"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Laboratory Screening": [
                  {
                    "text": "Early recognition of kidney disease crucial"
                  },
                  {
                    "text": "Laboratory screening includes initial urinalysisVisual, chemical, and microscopic inspectionChemical evaluation often involves reagent strip that assesses proteinuria and hematuria",
                    "sub_points": [
                      "Visual, chemical, and microscopic inspection",
                      "Chemical evaluation often involves reagent strip that assesses proteinuria and hematuria"
                    ]
                  },
                  {
                    "text": "Based on positive findings on initial urine screen, clinicians will seek plasma creatinine and eGFR measurementDetermines damageHelps place patients in accepted classification schemesFacilitates appropriate referral to specialist",
                    "sub_points": [
                      "Determines damage",
                      "Helps place patients in accepted classification schemes",
                      "Facilitates appropriate referral to specialist"
                    ]
                  },
                  {
                    "text": "Subsequent laboratory evaluation used to assess rate of damage"
                  },
                  {
                    "text": "NKF recommends annual testing for high-risk patients"
                  }
                ],
                "CKD Definition and Classification": [
                  {
                    "text": "CKD defined as either GFR < 60 mL/min/1.73 m² or albuminuria for > 3 consecutive months"
                  },
                  {
                    "text": "Renal disease progression and risk of death increase with decreased GFR and increased albuminuria"
                  },
                  {
                    "text": "In 2002, NKF KDOQI guidelines categorized CKD by GFR into stages"
                  },
                  {
                    "text": "Subsequent revision in 2013 from KDIGO categorized by groupsG1Albuminuria without decreased GFRGFR > 90 mL/min/1.73 m²G2Mild decrease in GFRGFR 60-89 mL/min/1.73 m²G3aMild to moderate decrease in GFRGFR 45-59 mL/min/1.73 m²G3bModerate to severe decrease in GFRGFR 30-44 mL/min/1.73 m²G4Severe decrease in GFRGFR 15-29 mL/min/1.73 m²G5Renal failure or dialysis dependenceGFR < 15 mL/min/1.73 m²",
                    "sub_points": [
                      "G1Albuminuria without decreased GFRGFR > 90 mL/min/1.73 m²",
                      "Albuminuria without decreased GFR",
                      "GFR > 90 mL/min/1.73 m²",
                      "G2Mild decrease in GFRGFR 60-89 mL/min/1.73 m²",
                      "Mild decrease in GFR",
                      "GFR 60-89 mL/min/1.73 m²",
                      "G3aMild to moderate decrease in GFRGFR 45-59 mL/min/1.73 m²",
                      "Mild to moderate decrease in GFR",
                      "GFR 45-59 mL/min/1.73 m²",
                      "G3bModerate to severe decrease in GFRGFR 30-44 mL/min/1.73 m²",
                      "Moderate to severe decrease in GFR",
                      "GFR 30-44 mL/min/1.73 m²",
                      "G4Severe decrease in GFRGFR 15-29 mL/min/1.73 m²",
                      "Severe decrease in GFR",
                      "GFR 15-29 mL/min/1.73 m²",
                      "G5Renal failure or dialysis dependenceGFR < 15 mL/min/1.73 m²",
                      "Renal failure or dialysis dependence",
                      "GFR < 15 mL/min/1.73 m²"
                    ]
                  },
                  {
                    "text": "Stratification employed mainly for consistency in epidemiologic reporting"
                  }
                ],
                "﻿Albumin Excretion Categorization": [
                  {
                    "text": "Albuminuria can be divided based on AER and approximate ACRA1< 30 mg/g AER< 3 mg/mmol ACRA230-300 mg/g AER3-30 mg/mmol ACRA3> 300 mg/g AER> 30 mg/mmol ACR",
                    "sub_points": [
                      "A1< 30 mg/g AER< 3 mg/mmol ACR",
                      "< 30 mg/g AER",
                      "< 3 mg/mmol ACR",
                      "A230-300 mg/g AER3-30 mg/mmol ACR",
                      "30-300 mg/g AER",
                      "3-30 mg/mmol ACR",
                      "A3> 300 mg/g AER> 30 mg/mmol ACR",
                      "> 300 mg/g AER",
                      "> 30 mg/mmol ACR"
                    ]
                  }
                ],
                "Other Laboratory Analytes to Measure in CKD": [
                  {
                    "text": "Complications widespread in patients with CKD"
                  },
                  {
                    "text": "Additional laboratory testing requested for CKD patient managementHemoglobin/hematocritPTHLipid profile",
                    "sub_points": [
                      "Hemoglobin/hematocrit",
                      "PTH",
                      "Lipid profile"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Acid Base": {
        "name": "Acid Base",
        "url": "https://app.pathprimer.com/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
        "topics": {
          "Metabolic Acidosis and Serum Anion Gap": {
            "name": "Metabolic Acidosis and Serum Anion Gap",
            "url": "https://app.pathprimer.com/document/04ac059a-5025-41fb-80d6-b7c3451c1532/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Metabolic acidosis often classified by presence of increased anion gapAnion gap = Na+ - (Cl⁻ + HCO₃⁻)Normal anion gap 8-16 mmol/L (average 12 mmol/L)",
                    "sub_points": [
                      "Anion gap = Na+ - (Cl⁻ + HCO₃⁻)",
                      "Normal anion gap 8-16 mmol/L (average 12 mmol/L)"
                    ]
                  },
                  {
                    "text": "MUDPILES mnemonic for anion gap metabolic acidosis﻿M﻿ethanol poisoning﻿U﻿remia﻿D﻿iabetic ketoacidosisParaldehyde toxicityIsoniazid, iron toxicity, or ischemia﻿L﻿actic acidosis﻿E﻿thylene glycol﻿S﻿alicylates",
                    "sub_points": [
                      "﻿M﻿ethanol poisoning",
                      "﻿U﻿remia",
                      "﻿D﻿iabetic ketoacidosis",
                      "Paraldehyde toxicity",
                      "Isoniazid, iron toxicity, or ischemia",
                      "﻿L﻿actic acidosis",
                      "﻿E﻿thylene glycol",
                      "﻿S﻿alicylates"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Most common acid-base disorder of hospitalized patients"
                  },
                  {
                    "text": "Fundamentally metabolic acidosis is decrease in plasma bicarbonate (HCO₃⁻) level"
                  },
                  {
                    "text": "Causes involve 2 main mechanismsHCO₃⁻ consumption in buffering processExcess organic acid (ketoacids, lactic acid) productionReduced acid excretionIncreased HCO₃⁻ loss",
                    "sub_points": [
                      "HCO₃⁻ consumption in buffering processExcess organic acid (ketoacids, lactic acid) productionReduced acid excretion",
                      "Excess organic acid (ketoacids, lactic acid) production",
                      "Reduced acid excretion",
                      "Increased HCO₃⁻ loss"
                    ]
                  },
                  {
                    "text": "Metabolic acidosis often classified by presence of increased anion gapAnion gap = Na+ - (Cl⁻ + HCO₃⁻)Normal anion gap 8-16 mmol/L (average 12 mmol/L)Normal anion gap is due to expected unmeasured anions (proteins, SO₄⁻², H₂PO₄⁻²)Increased anion gap suggests presence of additional unmeasured anions of endogenous or exogenous source",
                    "sub_points": [
                      "Anion gap = Na+ - (Cl⁻ + HCO₃⁻)",
                      "Normal anion gap 8-16 mmol/L (average 12 mmol/L)Normal anion gap is due to expected unmeasured anions (proteins, SO₄⁻², H₂PO₄⁻²)",
                      "Normal anion gap is due to expected unmeasured anions (proteins, SO₄⁻², H₂PO₄⁻²)",
                      "Increased anion gap suggests presence of additional unmeasured anions of endogenous or exogenous source"
                    ]
                  },
                  {
                    "text": "Anion gap metabolic acidosis results from overall consumption of HCO₃⁻"
                  },
                  {
                    "text": "Non-anion gap metabolic acidosis due to increased HCO₃⁻ loss"
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "MUDPILES mnemonic for anion gap metabolic acidosis﻿M﻿ethanol poisoningLiver metabolizes methanol into formaldehyde and formic acidMetabolites cause vision impairment with eventual blindness﻿U﻿remiaGlomerular filtration rate (GFR) < 20 mL/min/1.73 m² results in acidosis﻿D﻿iabetic ketoacidosisKetoacids include acetoacetic acid and β-hydroxybutyric acidMade from free fatty acids in liverExcessive amounts made in insulin-deficient statesDue to enhanced free fatty acid mobilization from adipose tissueKetoacids accumulate in starvation﻿P﻿araldehyde toxicityPatient's breath has pungent odorIsoniazid, iron toxicity, or ischemiaDrugs listed lead to production of toxic peroxides that inhibit mitochondrial functionAnaerobic metabolism occurs with ischemiaTechnically subgroup of lactic acidosis, as both mechanisms lead to lactic acid buildup﻿L﻿actic acidosisDefined as lactate level > 5 mmol/L with typical increase in H⁺Caused by disorders associated with severe tissue hypoxiaHeart failure or cyanotic heart disease﻿E﻿thylene glycolMetabolized to glycolic and oxalic acidsCalcium oxalate crystals eventually formLeads to acute renal failure due to deposition﻿S﻿alicylatesOccurs with concentrations > 30 mg/dLSalicylates also increase respiration leading to low PCO₂Results in mixed respiratory alkalosis/metabolic acidosis",
                    "sub_points": [
                      "﻿M﻿ethanol poisoningLiver metabolizes methanol into formaldehyde and formic acidMetabolites cause vision impairment with eventual blindness",
                      "Liver metabolizes methanol into formaldehyde and formic acid",
                      "Metabolites cause vision impairment with eventual blindness",
                      "﻿U﻿remiaGlomerular filtration rate (GFR) < 20 mL/min/1.73 m² results in acidosis",
                      "Glomerular filtration rate (GFR) < 20 mL/min/1.73 m² results in acidosis",
                      "﻿D﻿iabetic ketoacidosisKetoacids include acetoacetic acid and β-hydroxybutyric acidMade from free fatty acids in liverExcessive amounts made in insulin-deficient statesDue to enhanced free fatty acid mobilization from adipose tissueKetoacids accumulate in starvation",
                      "Ketoacids include acetoacetic acid and β-hydroxybutyric acidMade from free fatty acids in liver",
                      "Made from free fatty acids in liver",
                      "Excessive amounts made in insulin-deficient statesDue to enhanced free fatty acid mobilization from adipose tissue",
                      "Due to enhanced free fatty acid mobilization from adipose tissue",
                      "Ketoacids accumulate in starvation",
                      "﻿P﻿araldehyde toxicityPatient's breath has pungent odor",
                      "Patient's breath has pungent odor",
                      "Isoniazid, iron toxicity, or ischemiaDrugs listed lead to production of toxic peroxides that inhibit mitochondrial functionAnaerobic metabolism occurs with ischemiaTechnically subgroup of lactic acidosis, as both mechanisms lead to lactic acid buildup",
                      "Drugs listed lead to production of toxic peroxides that inhibit mitochondrial function",
                      "Anaerobic metabolism occurs with ischemia",
                      "Technically subgroup of lactic acidosis, as both mechanisms lead to lactic acid buildup",
                      "﻿L﻿actic acidosisDefined as lactate level > 5 mmol/L with typical increase in H⁺Caused by disorders associated with severe tissue hypoxiaHeart failure or cyanotic heart disease",
                      "Defined as lactate level > 5 mmol/L with typical increase in H⁺",
                      "Caused by disorders associated with severe tissue hypoxiaHeart failure or cyanotic heart disease",
                      "Heart failure or cyanotic heart disease",
                      "﻿E﻿thylene glycolMetabolized to glycolic and oxalic acidsCalcium oxalate crystals eventually formLeads to acute renal failure due to deposition",
                      "Metabolized to glycolic and oxalic acids",
                      "Calcium oxalate crystals eventually formLeads to acute renal failure due to deposition",
                      "Leads to acute renal failure due to deposition",
                      "﻿S﻿alicylatesOccurs with concentrations > 30 mg/dLSalicylates also increase respiration leading to low PCO₂Results in mixed respiratory alkalosis/metabolic acidosis",
                      "Occurs with concentrations > 30 mg/dL",
                      "Salicylates also increase respiration leading to low PCO₂Results in mixed respiratory alkalosis/metabolic acidosis",
                      "Results in mixed respiratory alkalosis/metabolic acidosis"
                    ]
                  },
                  {
                    "text": "Non-anion gap metabolic acidosis (a.k.a. hyperchloremic metabolic acidosis)Cl⁻ (along with Na⁺ and K⁺) reabsorption is increased as part of compensation for HCO₃⁻ lostMaintains electric neutralityCauses hyperchloremiaCausesGastrointestinal (GI) fluid lossDiarrheaPancreatitisIntestinal fistulaRenal tubular acidosisCarbonic anhydrase inhibitors (acetazolamide)Used in treatment of open-angle glaucoma and altitude sickness",
                    "sub_points": [
                      "Cl⁻ (along with Na⁺ and K⁺) reabsorption is increased as part of compensation for HCO₃⁻ lostMaintains electric neutralityCauses hyperchloremia",
                      "Maintains electric neutralityCauses hyperchloremia",
                      "Causes hyperchloremia",
                      "CausesGastrointestinal (GI) fluid lossDiarrheaPancreatitisIntestinal fistulaRenal tubular acidosisCarbonic anhydrase inhibitors (acetazolamide)Used in treatment of open-angle glaucoma and altitude sickness",
                      "Gastrointestinal (GI) fluid lossDiarrheaPancreatitisIntestinal fistula",
                      "Diarrhea",
                      "Pancreatitis",
                      "Intestinal fistula",
                      "Renal tubular acidosis",
                      "Carbonic anhydrase inhibitors (acetazolamide)Used in treatment of open-angle glaucoma and altitude sickness",
                      "Used in treatment of open-angle glaucoma and altitude sickness"
                    ]
                  }
                ],
                "Compensatory Mechanisms": [
                  {
                    "text": "Physiologic compensation for metabolic acidosis includes 2 main mechanismsRespiratory compensationHyperventilation increasing carbon dioxide removalRenal compensationIncreased acid excretion viaEnhanced Na⁺-H⁺ exchangeAmmonia formationEnhanced HCO₃⁻ reabsorption",
                    "sub_points": [
                      "Respiratory compensationHyperventilation increasing carbon dioxide removal",
                      "Hyperventilation increasing carbon dioxide removal",
                      "Renal compensationIncreased acid excretion viaEnhanced Na⁺-H⁺ exchangeAmmonia formationEnhanced HCO₃⁻ reabsorption",
                      "Increased acid excretion viaEnhanced Na⁺-H⁺ exchangeAmmonia formationEnhanced HCO₃⁻ reabsorption",
                      "Enhanced Na⁺-H⁺ exchange",
                      "Ammonia formation",
                      "Enhanced HCO₃⁻ reabsorption"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Interfering Substances": [
                  {
                    "text": "Measured serum anion gap (< 2 mmol/L) can be low due to various causesLithiumBromideLow albuminMonoclonal gammopathies",
                    "sub_points": [
                      "Lithium",
                      "Bromide",
                      "Low albumin",
                      "Monoclonal gammopathies"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Metabolic Alkalosis": {
            "name": "Metabolic Alkalosis",
            "url": "https://app.pathprimer.com/document/48a85e01-a982-4c9c-badb-40d31ef90043/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Metabolic alkalosis is defined as primary HCO₃⁻ excessRatio of HCO₃⁻ to CO₂⁻ concentration increases to > 20:1Serum HCO₃⁻ > 24 mmol/L",
                    "sub_points": [
                      "Ratio of HCO₃⁻ to CO₂⁻ concentration increases to > 20:1",
                      "Serum HCO₃⁻ > 24 mmol/L"
                    ]
                  },
                  {
                    "text": "Urine chloride is measured in patients with metabolic alkalosis creating 2 categoriesChloride-responsive metabolic alkalosis (urine chloride < 10 mmol/L)Chloride-resistant metabolic alkalosis (urine chloride > 20 mmol/L)",
                    "sub_points": [
                      "Chloride-responsive metabolic alkalosis (urine chloride < 10 mmol/L)",
                      "Chloride-resistant metabolic alkalosis (urine chloride > 20 mmol/L)"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Metabolic alkalosis is defined as primary HCO₃⁻ excessRatio of HCO₃⁻ to CO₂⁻ concentration increases to > 20:1Serum HCO₃⁻ > 24 mmol/L",
                    "sub_points": [
                      "Ratio of HCO₃⁻ to CO₂⁻ concentration increases to > 20:1",
                      "Serum HCO₃⁻ > 24 mmol/L"
                    ]
                  },
                  {
                    "text": "Occurs through different general mechanismsExcess HCO₃⁻ addedDecreased HCO₃⁻ excretionAcid-rich fluid lost",
                    "sub_points": [
                      "Excess HCO₃⁻ added",
                      "Decreased HCO₃⁻ excretion",
                      "Acid-rich fluid lost"
                    ]
                  },
                  {
                    "text": "Urine chloride is measured in patients with metabolic alkalosis creating 2 categoriesChloride-responsive metabolic alkalosis (urine chloride < 10 mmol/L)Results from hypovolemia (contraction alkalosis)Prolonged vomiting (loss of HCl)Nasogastric suctioning (loss of HCl)Upper duodenal obstructionDehydrationVolume loss causes increased Na⁺, HCO₃⁻ reabsorptionChloride follows Na⁺, HCO₃⁻, which reduces chloride found in urineLoss of volume also increases K⁺ and H⁺ excretionChloride-resistant metabolic alkalosis (urine chloride > 20 mmol/L)Associated with various disease states that have increased Na⁺ reabsorption and enhanced K⁺ (hypokalemia) and H⁺ lossPrimary hyperaldosteronismCushing syndromeBartter syndrome (impaired renal chloride reabsorption)Hypokalemia further contributes to alkalosisK⁺-H⁺ ATPase in renal collecting duct increases K⁺ reabsorption in exchange for H⁺ loss",
                    "sub_points": [
                      "Chloride-responsive metabolic alkalosis (urine chloride < 10 mmol/L)Results from hypovolemia (contraction alkalosis)Prolonged vomiting (loss of HCl)Nasogastric suctioning (loss of HCl)Upper duodenal obstructionDehydrationVolume loss causes increased Na⁺, HCO₃⁻ reabsorptionChloride follows Na⁺, HCO₃⁻, which reduces chloride found in urineLoss of volume also increases K⁺ and H⁺ excretion",
                      "Results from hypovolemia (contraction alkalosis)Prolonged vomiting (loss of HCl)Nasogastric suctioning (loss of HCl)Upper duodenal obstructionDehydration",
                      "Prolonged vomiting (loss of HCl)",
                      "Nasogastric suctioning (loss of HCl)",
                      "Upper duodenal obstruction",
                      "Dehydration",
                      "Volume loss causes increased Na⁺, HCO₃⁻ reabsorptionChloride follows Na⁺, HCO₃⁻, which reduces chloride found in urine",
                      "Chloride follows Na⁺, HCO₃⁻, which reduces chloride found in urine",
                      "Loss of volume also increases K⁺ and H⁺ excretion",
                      "Chloride-resistant metabolic alkalosis (urine chloride > 20 mmol/L)Associated with various disease states that have increased Na⁺ reabsorption and enhanced K⁺ (hypokalemia) and H⁺ lossPrimary hyperaldosteronismCushing syndromeBartter syndrome (impaired renal chloride reabsorption)Hypokalemia further contributes to alkalosisK⁺-H⁺ ATPase in renal collecting duct increases K⁺ reabsorption in exchange for H⁺ loss",
                      "Associated with various disease states that have increased Na⁺ reabsorption and enhanced K⁺ (hypokalemia) and H⁺ lossPrimary hyperaldosteronismCushing syndromeBartter syndrome (impaired renal chloride reabsorption)",
                      "Primary hyperaldosteronism",
                      "Cushing syndrome",
                      "Bartter syndrome (impaired renal chloride reabsorption)",
                      "Hypokalemia further contributes to alkalosisK⁺-H⁺ ATPase in renal collecting duct increases K⁺ reabsorption in exchange for H⁺ loss",
                      "K⁺-H⁺ ATPase in renal collecting duct increases K⁺ reabsorption in exchange for H⁺ loss"
                    ]
                  },
                  {
                    "text": "Metabolic alkalosis from increased base intakeMassive transfusionBlood product bags have citrate (base) to prevent clotting of bloodIntravenous HCO₃⁻ infusions (sodium lactate)Milk-alkali syndromeExcessive antacid ingestion to treat gastric ulcers",
                    "sub_points": [
                      "Massive transfusionBlood product bags have citrate (base) to prevent clotting of blood",
                      "Blood product bags have citrate (base) to prevent clotting of blood",
                      "Intravenous HCO₃⁻ infusions (sodium lactate)",
                      "Milk-alkali syndromeExcessive antacid ingestion to treat gastric ulcers",
                      "Excessive antacid ingestion to treat gastric ulcers"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Treatments directed toward specific cause of metabolic alkalosisVolume replenishmentAdministration of chloride-containing fluidsK⁺ replacement therapyRemoval of base excess",
                    "sub_points": [
                      "Volume replenishmentAdministration of chloride-containing fluids",
                      "Administration of chloride-containing fluids",
                      "K⁺ replacement therapy",
                      "Removal of base excess"
                    ]
                  }
                ],
                "Compensatory Mechanisms": [
                  {
                    "text": "Physiologic compensation for metabolic alkalosis includes 2 main mechanismsRespiratory compensationHypoventilation to increase PCO₂ and lower pH normalizing HCO₃⁻-to-CO₂⁻ ratioRenal compensationDecreased acid excretion viaDecreased Na⁺-H⁺ exchangeDecreased ammonia formationDecreased HCO₃⁻ absorption",
                    "sub_points": [
                      "Respiratory compensationHypoventilation to increase PCO₂ and lower pH normalizing HCO₃⁻-to-CO₂⁻ ratio",
                      "Hypoventilation to increase PCO₂ and lower pH normalizing HCO₃⁻-to-CO₂⁻ ratio",
                      "Renal compensationDecreased acid excretion viaDecreased Na⁺-H⁺ exchangeDecreased ammonia formationDecreased HCO₃⁻ absorption",
                      "Decreased acid excretion viaDecreased Na⁺-H⁺ exchangeDecreased ammonia formation",
                      "Decreased Na⁺-H⁺ exchange",
                      "Decreased ammonia formation",
                      "Decreased HCO₃⁻ absorption"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Respiratory Acidosis": {
            "name": "Respiratory Acidosis",
            "url": "https://app.pathprimer.com/document/86e0acc4-4e69-4dba-bce2-d087ec6e6186/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Respiratory acidosis occurs when CO₂ elimination by lungs is impairedResults in increased H₂CO₃ through action of carbonic anhydrase enzymeH₂CO₃ dissociates to HCO₃⁻ and H⁺ (pH increases)",
                    "sub_points": [
                      "Results in increased H₂CO₃ through action of carbonic anhydrase enzymeH₂CO₃ dissociates to HCO₃⁻ and H⁺ (pH increases)",
                      "H₂CO₃ dissociates to HCO₃⁻ and H⁺ (pH increases)"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Respiratory acidosis occurs when carbon dioxide (CO₂) elimination by lungs is impairedPCO₂ increased (> 40 mm Hg)Results in increased carbonic acid (H₂CO₃) through action of carbonic anhydrase enzymeH₂CO₃ dissociates to bicarbonate (HCO₃⁻) and H⁺ (pH increases)",
                    "sub_points": [
                      "PCO₂ increased (> 40 mm Hg)",
                      "Results in increased carbonic acid (H₂CO₃) through action of carbonic anhydrase enzymeH₂CO₃ dissociates to bicarbonate (HCO₃⁻) and H⁺ (pH increases)",
                      "H₂CO₃ dissociates to bicarbonate (HCO₃⁻) and H⁺ (pH increases)"
                    ]
                  },
                  {
                    "text": "CausesCentral nervous system (CNS) depressionDrugs (narcotics)Tumors and traumaEncephalitis and meningitisImpaired respiratory movementChronic obstructive pulmonary disease (COPD)Most commonPneumothoraxPleural effusionMuscular dystrophySevere pneumonia or bronchitis",
                    "sub_points": [
                      "Central nervous system (CNS) depressionDrugs (narcotics)Tumors and traumaEncephalitis and meningitis",
                      "Drugs (narcotics)",
                      "Tumors and trauma",
                      "Encephalitis and meningitis",
                      "Impaired respiratory movementChronic obstructive pulmonary disease (COPD)Most commonPneumothoraxPleural effusionMuscular dystrophySevere pneumonia or bronchitis",
                      "Chronic obstructive pulmonary disease (COPD)Most common",
                      "Most common",
                      "Pneumothorax",
                      "Pleural effusion",
                      "Muscular dystrophy",
                      "Severe pneumonia or bronchitis"
                    ]
                  }
                ],
                "Compensatory Mechanisms": [
                  {
                    "text": "Excess H₂CO₃ buffered by protein buffer system (hemoglobin)Effect is immediate",
                    "sub_points": [
                      "Effect is immediate"
                    ]
                  },
                  {
                    "text": "Renal compensation takes daysIncludes increased acid excretion viaEnhanced Na⁺-H⁺ exchangeAmmonia formationEnhanced HCO₃⁻ reabsorption",
                    "sub_points": [
                      "Includes increased acid excretion viaEnhanced Na⁺-H⁺ exchangeAmmonia formationEnhanced HCO₃⁻ reabsorption",
                      "Enhanced Na⁺-H⁺ exchange",
                      "Ammonia formation",
                      "Enhanced HCO₃⁻ reabsorption"
                    ]
                  },
                  {
                    "text": "Pulmonary compensation (if possible) involves PCO₂ stimulation of respiratory centerBreathing rate and depth increased (CO₂ is blown off)",
                    "sub_points": [
                      "Breathing rate and depth increased (CO₂ is blown off)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Respiratory Alkalosis": {
            "name": "Respiratory Alkalosis",
            "url": "https://app.pathprimer.com/document/ff704e75-ce77-4080-9d8c-8e48adc28dd6/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Respiratory alkalosis results from decrease in CO₂ due to increased pulmonary effort"
                  },
                  {
                    "text": "With reduction in PCO₂, ratio of HCO₃⁻ to CO₂ increased"
                  },
                  {
                    "text": "Shift in HCO₃⁻/H₂CO₃ buffer system leads to decreased H⁺ ion concentration (decreased pH)"
                  },
                  {
                    "text": "Causes include stimulation of respiration (e.g., salicylates [aspirin])"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Respiratory alkalosis results from decrease in carbon dioxide (CO₂) due to increased pulmonary effortWith reduction in PCO₂, ratio of bicarbonate (HCO₃⁻) to CO₂ increasedShift in HCO₃⁻/carbonic acid (H₂CO₃) buffer system leads to decreased H⁺ ion concentration (decreased pH)",
                    "sub_points": [
                      "With reduction in PCO₂, ratio of bicarbonate (HCO₃⁻) to CO₂ increasedShift in HCO₃⁻/carbonic acid (H₂CO₃) buffer system leads to decreased H⁺ ion concentration (decreased pH)",
                      "Shift in HCO₃⁻/carbonic acid (H₂CO₃) buffer system leads to decreased H⁺ ion concentration (decreased pH)"
                    ]
                  },
                  {
                    "text": "CausesPulmonary disordersPulmonary emboliInterstitial lung diseasePneumoniaCongestive heart failureStimulation of respirationCerebrovascular accidentSalicylates (aspirin)HyperthyroidismHypoxiaAnxiety",
                    "sub_points": [
                      "Pulmonary disordersPulmonary emboliInterstitial lung diseasePneumoniaCongestive heart failure",
                      "Pulmonary emboli",
                      "Interstitial lung disease",
                      "Pneumonia",
                      "Congestive heart failure",
                      "Stimulation of respirationCerebrovascular accidentSalicylates (aspirin)HyperthyroidismHypoxiaAnxiety",
                      "Cerebrovascular accident",
                      "Salicylates (aspirin)",
                      "Hyperthyroidism",
                      "Hypoxia",
                      "Anxiety"
                    ]
                  }
                ],
                "Compensatory Mechanisms": [
                  {
                    "text": "Physiologic compensation for respiratory alkalosisInitially, H⁺ ions from red blood cells and tissue buffers consume minor amount of HCO₃⁻Renal compensation occurs with prolonged respiratory alkalosisDecreased HCO₃⁻ absorption",
                    "sub_points": [
                      "Initially, H⁺ ions from red blood cells and tissue buffers consume minor amount of HCO₃⁻",
                      "Renal compensation occurs with prolonged respiratory alkalosisDecreased HCO₃⁻ absorption",
                      "Decreased HCO₃⁻ absorption"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Renal Tubular Acidosis": {
            "name": "Renal Tubular Acidosis",
            "url": "https://app.pathprimer.com/document/ba6c64f5-7353-40e7-b77f-390f79241053/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Site of defect within nephron tubule (proximal or distal) determines RTA typeDistal RTA (type I)H+ excretion into urine impairedAcidotic patients excrete alkaline urineProximal RTA (type II)Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%Seen in Fanconi syndromeAldosterone deficiency or resistance (type IV)Results in hyperkalemiaBicarbonate load in urine < 5%",
                    "sub_points": [
                      "Distal RTA (type I)H+ excretion into urine impairedAcidotic patients excrete alkaline urine",
                      "H+ excretion into urine impaired",
                      "Acidotic patients excrete alkaline urine",
                      "Proximal RTA (type II)Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%Seen in Fanconi syndrome",
                      "Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%",
                      "Results in hypokalemia due to plasma volume contraction with increased aldosterone secretion",
                      "Bicarbonate load in urine > 15%",
                      "Seen in Fanconi syndrome",
                      "Aldosterone deficiency or resistance (type IV)Results in hyperkalemiaBicarbonate load in urine < 5%",
                      "Results in hyperkalemiaBicarbonate load in urine < 5%",
                      "Bicarbonate load in urine < 5%"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Renal tubular acidosis (RTA) caused by defect within nephron tubule"
                  },
                  {
                    "text": "Normally, when body H+ concentration increases (acidosis), kidneys help compensate through 2 general mechanismsSecretion of H+Reabsorption of bicarbonate",
                    "sub_points": [
                      "Secretion of H+",
                      "Reabsorption of bicarbonate"
                    ]
                  },
                  {
                    "text": "These mechanisms are faulty in various forms of RTAResults in inappropriate acid/base excretion when considering plasma pHInability to secrete H+ ionFailure to retain bicarbonate",
                    "sub_points": [
                      "Results in inappropriate acid/base excretion when considering plasma pHInability to secrete H+ ionFailure to retain bicarbonate",
                      "Inability to secrete H+ ion",
                      "Failure to retain bicarbonate"
                    ]
                  },
                  {
                    "text": "Due to inherited or acquired causesInherited causes includeInborn errors in metabolism (cystinosis, Wilson disease, glycogen storage diseases)Mutations in renal tubule transmembrane transporter proteinsAcquired causesDrugs (acetazolamide)Toxins (mercury, lead)",
                    "sub_points": [
                      "Inherited causes includeInborn errors in metabolism (cystinosis, Wilson disease, glycogen storage diseases)Mutations in renal tubule transmembrane transporter proteins",
                      "Inborn errors in metabolism (cystinosis, Wilson disease, glycogen storage diseases)",
                      "Mutations in renal tubule transmembrane transporter proteins",
                      "Acquired causesDrugs (acetazolamide)Toxins (mercury, lead)",
                      "Drugs (acetazolamide)",
                      "Toxins (mercury, lead)"
                    ]
                  },
                  {
                    "text": "RTA is characterized by hyperchloremic normal anion gap metabolic acidosis"
                  }
                ],
                "﻿RTA Classification﻿": [
                  {
                    "text": "Site of defect within nephron tubule (proximal or distal) determines RTA typeDistal RTA (type I)H+ excretion into urine impairedAcidotic patients excrete alkaline urineProximal RTA (type II)Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%Seen in Fanconi syndromeAldosterone deficiency or resistance (type IV)Results in hyperkalemiaBicarbonate load in urine < 5%Note that use of mixed proximal/distal (type III) has been abandonedNo longer considered distinct entity",
                    "sub_points": [
                      "Distal RTA (type I)H+ excretion into urine impairedAcidotic patients excrete alkaline urine",
                      "H+ excretion into urine impaired",
                      "Acidotic patients excrete alkaline urine",
                      "Proximal RTA (type II)Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%Seen in Fanconi syndrome",
                      "Impaired bicarbonate absorptionResults in hypokalemia due to plasma volume contraction with increased aldosterone secretionBicarbonate load in urine > 15%",
                      "Results in hypokalemia due to plasma volume contraction with increased aldosterone secretion",
                      "Bicarbonate load in urine > 15%",
                      "Seen in Fanconi syndrome",
                      "Aldosterone deficiency or resistance (type IV)Results in hyperkalemiaBicarbonate load in urine < 5%",
                      "Results in hyperkalemiaBicarbonate load in urine < 5%",
                      "Bicarbonate load in urine < 5%",
                      "Note that use of mixed proximal/distal (type III) has been abandonedNo longer considered distinct entity",
                      "No longer considered distinct entity"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Work-Up": [
                  {
                    "text": "RTA is suspected in hyperchloremic normal anion gap metabolic acidosis without evidence of cause (gastrointestinal bicarbonate loss, pharmacologic)"
                  },
                  {
                    "text": "Initial clinical work-up includes measuringPlasma electrolytes (potassium)Urinary pHUrine pH > 5.5 with hypokalemia (distal RTA)Urine pH < 5.5 with hypokalemia (proximal RTA)Urine pH < 5.5 with hyperkalemia (type IV RTA)",
                    "sub_points": [
                      "Plasma electrolytes (potassium)",
                      "Urinary pHUrine pH > 5.5 with hypokalemia (distal RTA)Urine pH < 5.5 with hypokalemia (proximal RTA)Urine pH < 5.5 with hyperkalemia (type IV RTA)",
                      "Urine pH > 5.5 with hypokalemia (distal RTA)",
                      "Urine pH < 5.5 with hypokalemia (proximal RTA)",
                      "Urine pH < 5.5 with hyperkalemia (type IV RTA)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acid-Base Homeostasis and the Henderson-Hasselbalch Equation": {
            "name": "Acid-Base Homeostasis and the Henderson-Hasselbalch Equation",
            "url": "https://app.pathprimer.com/document/ab660efd-2abc-4f22-92d6-1ad7226a22d5/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Henderson-Hasselbalch equation is a mathematical expression of pHpH = pKa + log (base/acid)pH =7.4pKa = 6.1“Base” represents HCO₃⁻“Acid” represents H₂CO₃Can be derived from (arterial CO₂ x 0.03)",
                    "sub_points": [
                      "pH = pKa + log (base/acid)",
                      "pH =7.4",
                      "pKa = 6.1",
                      "“Base” represents HCO₃⁻",
                      "“Acid” represents H₂CO₃Can be derived from (arterial CO₂ x 0.03)",
                      "Can be derived from (arterial CO₂ x 0.03)"
                    ]
                  },
                  {
                    "text": "Final equation formpH= 6.1 + log (HCO₃⁻/[0.03 x PaCO₂])",
                    "sub_points": [
                      "pH= 6.1 + log (HCO₃⁻/[0.03 x PaCO₂])"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Bicarbonate (HCO₃⁻)"
                  },
                  {
                    "text": "Carbonate (CO₃²⁻)"
                  },
                  {
                    "text": "Carbon dioxide (CO₂)"
                  },
                  {
                    "text": "Partial pressure of arterial CO₂ (PaCO₂)"
                  },
                  {
                    "text": "Carbonic acid (H₂CO₃)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acids: Chemical species in solution that donate H+ ions"
                  },
                  {
                    "text": "Bases: Chemical species in solution that accept H+ ions"
                  },
                  {
                    "text": "pH: Negative log of hydrogen ion activity (dimensionless quantity)"
                  },
                  {
                    "text": "pKa: pH where acidic species is disassociated into equal amounts of acid and conjugate base"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Acid Base Physiology": [
                  {
                    "text": "Normal metabolism produces considerable amount of acidic byproducts"
                  },
                  {
                    "text": "Acidic byproducts can be divided into 2 typesVolatile acidMajor example is CO₂CO₂ forms H₂CO₃, upon addition of H₂OReaction catalyzed by carbonic anhydraseH₂CO₃ dissociates into H⁺ and HCO₃⁻Nonvolatile acidSulfuric acid (from protein breakdown)Phosphoric acid (from phospholipid breakdown)",
                    "sub_points": [
                      "Volatile acidMajor example is CO₂CO₂ forms H₂CO₃, upon addition of H₂OReaction catalyzed by carbonic anhydraseH₂CO₃ dissociates into H⁺ and HCO₃⁻",
                      "Major example is CO₂",
                      "CO₂ forms H₂CO₃, upon addition of H₂OReaction catalyzed by carbonic anhydrase",
                      "Reaction catalyzed by carbonic anhydrase",
                      "H₂CO₃ dissociates into H⁺ and HCO₃⁻",
                      "Nonvolatile acidSulfuric acid (from protein breakdown)Phosphoric acid (from phospholipid breakdown)",
                      "Sulfuric acid (from protein breakdown)",
                      "Phosphoric acid (from phospholipid breakdown)"
                    ]
                  },
                  {
                    "text": "Excretion of this acid load occurs byKidneysLungs",
                    "sub_points": [
                      "Kidneys",
                      "Lungs"
                    ]
                  },
                  {
                    "text": "Transport of these acids does not cause significant change to body pH"
                  },
                  {
                    "text": "Maintaining pH hemostasis is accomplished byIntracellular buffering systemsOrganic phosphatesProteins, such as hemoglobin (major)Extracellular buffering systemsBuffer systems are chemical solutions that resist change in pH upon addition of strong acids or basesBicarbonate-carbonic acid buffering system is most important",
                    "sub_points": [
                      "Intracellular buffering systemsOrganic phosphatesProteins, such as hemoglobin (major)",
                      "Organic phosphates",
                      "Proteins, such as hemoglobin (major)",
                      "Extracellular buffering systemsBuffer systems are chemical solutions that resist change in pH upon addition of strong acids or basesBicarbonate-carbonic acid buffering system is most important",
                      "Buffer systems are chemical solutions that resist change in pH upon addition of strong acids or bases",
                      "Bicarbonate-carbonic acid buffering system is most important"
                    ]
                  },
                  {
                    "text": "Relatively constant pH must be maintained for physiological functionImportant because changes in pH will alterEnzyme functionBiologic structural componentsOxygen uptake and release",
                    "sub_points": [
                      "Important because changes in pH will alterEnzyme functionBiologic structural componentsOxygen uptake and release",
                      "Enzyme function",
                      "Biologic structural components",
                      "Oxygen uptake and release"
                    ]
                  }
                ],
                "﻿Henderson-Hasselbalch Equation": [
                  {
                    "text": "Buffer system often consists of HA and the conjugate A⁻ or salt of weak acid (HA↔H⁺ + A⁻)"
                  },
                  {
                    "text": "Equilibrium equation can then be derived defining Ka (acid dissociation constant)Ka = [H⁺] [A⁻]/[HA]",
                    "sub_points": [
                      "Ka = [H⁺] [A⁻]/[HA]"
                    ]
                  },
                  {
                    "text": "In 1916, Hasselbalch determined that logarithmic transformation of above equation (termed Henderson-Hasselbalch equation) was more useful in understanding action of solution buffers"
                  },
                  {
                    "text": "Henderson-Hasselbalch equation is a mathematical expression of pHpH = pKa + log (base/acid)pH = 7.4pKa = 6.1“Base” represents HCO₃⁻“Acid” represents H₂CO₃Can be derived from (arterial CO₂ x 0.03)Final equation formpH = 6.1 + log (HCO₃⁻/[0.03 x PaCO₂])",
                    "sub_points": [
                      "pH = pKa + log (base/acid)pH = 7.4pKa = 6.1“Base” represents HCO₃⁻“Acid” represents H₂CO₃Can be derived from (arterial CO₂ x 0.03)",
                      "pH = 7.4",
                      "pKa = 6.1",
                      "“Base” represents HCO₃⁻",
                      "“Acid” represents H₂CO₃Can be derived from (arterial CO₂ x 0.03)",
                      "Can be derived from (arterial CO₂ x 0.03)",
                      "Final equation formpH = 6.1 + log (HCO₃⁻/[0.03 x PaCO₂])",
                      "pH = 6.1 + log (HCO₃⁻/[0.03 x PaCO₂])"
                    ]
                  },
                  {
                    "text": "Henderson-Hasselbalch equation shows that ratio of HCO₃⁻/ pCO₂ determines pHRatio increase indicates alkalosisRatio decrease indicates acidosis",
                    "sub_points": [
                      "Ratio increase indicates alkalosis",
                      "Ratio decrease indicates acidosis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Classification of Acid-Base Disorders": {
            "name": "Classification of Acid-Base Disorders",
            "url": "https://app.pathprimer.com/document/93ecca50-32d0-4b83-b682-1ee9aef3a39c/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Algorithm for determining acid-base disorder(1) Determine primary change (either HCO₃⁻ or pCO₂)﻿(2) Determine if expected compensation has occurred﻿(3) Assess further if mixed acid-base disorder suspected",
                    "sub_points": [
                      "(1) Determine primary change (either HCO₃⁻ or pCO₂)",
                      "﻿(2) Determine if expected compensation has occurred",
                      "﻿(3) Assess further if mixed acid-base disorder suspected"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Classification of Acid-Base Disorders": [
                  {
                    "text": "Ability to interpret appropriate laboratory data to determine a patient's acid-base disorder is critical in real-world and standardized testing environments"
                  },
                  {
                    "text": "Developing consistent stepwise process enhances speed of diagnosis"
                  },
                  {
                    "text": "Main acid-base disordersMetabolic acidosisMetabolic alkalosisRespiratory acidosisRespiratory alkalosisMixed acid-base disorder",
                    "sub_points": [
                      "Metabolic acidosis",
                      "Metabolic alkalosis",
                      "Respiratory acidosis",
                      "Respiratory alkalosis",
                      "Mixed acid-base disorder"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Bicarbonate (HCO₃⁻)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Acidemia: Arterial blood pH < 7.35"
                  },
                  {
                    "text": "Alkalemia: Arterial blood pH > 7.45"
                  },
                  {
                    "text": "Normal pCO₂: 32-45 mm Hg"
                  },
                  {
                    "text": "Normal HCO₃⁻: 22-30 mmol/L"
                  },
                  {
                    "text": "Mixed acid-base disorder: Combination of > 1 acid-base disturbance simultaneouslyResulting in variable blood pH",
                    "sub_points": [
                      "Resulting in variable blood pH"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Algorithm for Determining Acid-Base Disorder": [
                  {
                    "text": "(1) Determine primary change (either HCO₃⁻ or pCO₂)Metabolic acidosis (pH < 7.35)HCO₃⁻ and pCO₂ trend down and in same directionMetabolic alkalosis (pH > 7.45)HCO₃⁻ and pCO₂ trend up and in same directionRespiratory acidosis ( pH < 7.35)HCO₃⁻ and pCO₂ trend up and in same directionRespiratory alkalosis (pH > 7.45)HCO₃⁻ and pCO₂ trend down and in same direction",
                    "sub_points": [
                      "Metabolic acidosis (pH < 7.35)HCO₃⁻ and pCO₂ trend down and in same direction",
                      "HCO₃⁻ and pCO₂ trend down and in same direction",
                      "Metabolic alkalosis (pH > 7.45)HCO₃⁻ and pCO₂ trend up and in same direction",
                      "HCO₃⁻ and pCO₂ trend up and in same direction",
                      "Respiratory acidosis ( pH < 7.35)HCO₃⁻ and pCO₂ trend up and in same direction",
                      "HCO₃⁻ and pCO₂ trend up and in same direction",
                      "Respiratory alkalosis (pH > 7.45)HCO₃⁻ and pCO₂ trend down and in same direction",
                      "HCO₃⁻ and pCO₂ trend down and in same direction"
                    ]
                  },
                  {
                    "text": "﻿(2) Determine if expected compensation has occurredMetabolic acidosispCO₂ falls 1 mm Hg for each 1 mmol/L fall in HCO₃⁻Metabolic alkalosispCO₂ rises 6 mm Hg for each 10 mmol/L rise in HCO₃⁻Respiratory acidosisAcute compensationHCO₃⁻ rises 1 mmol/L for each 10 mm Hg rise in pCO₂Chronic compensationHCO₃⁻ rises 3.5 mmol/L for each 10 mm Hg rise in pCO₂Respiratory alkalosisAcute compensationHCO₃⁻ falls 2 mmol/L for each 10 mm Hg falls in pCO₂Chronic compensationHCO₃⁻ falls 5 mmol/L for each 10 mm Hg falls in pCO₂",
                    "sub_points": [
                      "Metabolic acidosispCO₂ falls 1 mm Hg for each 1 mmol/L fall in HCO₃⁻",
                      "pCO₂ falls 1 mm Hg for each 1 mmol/L fall in HCO₃⁻",
                      "Metabolic alkalosispCO₂ rises 6 mm Hg for each 10 mmol/L rise in HCO₃⁻",
                      "pCO₂ rises 6 mm Hg for each 10 mmol/L rise in HCO₃⁻",
                      "Respiratory acidosisAcute compensationHCO₃⁻ rises 1 mmol/L for each 10 mm Hg rise in pCO₂Chronic compensationHCO₃⁻ rises 3.5 mmol/L for each 10 mm Hg rise in pCO₂",
                      "Acute compensationHCO₃⁻ rises 1 mmol/L for each 10 mm Hg rise in pCO₂",
                      "HCO₃⁻ rises 1 mmol/L for each 10 mm Hg rise in pCO₂",
                      "Chronic compensationHCO₃⁻ rises 3.5 mmol/L for each 10 mm Hg rise in pCO₂",
                      "HCO₃⁻ rises 3.5 mmol/L for each 10 mm Hg rise in pCO₂",
                      "Respiratory alkalosisAcute compensationHCO₃⁻ falls 2 mmol/L for each 10 mm Hg falls in pCO₂Chronic compensationHCO₃⁻ falls 5 mmol/L for each 10 mm Hg falls in pCO₂",
                      "Acute compensationHCO₃⁻ falls 2 mmol/L for each 10 mm Hg falls in pCO₂",
                      "HCO₃⁻ falls 2 mmol/L for each 10 mm Hg falls in pCO₂",
                      "Chronic compensationHCO₃⁻ falls 5 mmol/L for each 10 mm Hg falls in pCO₂",
                      "HCO₃⁻ falls 5 mmol/L for each 10 mm Hg falls in pCO₂"
                    ]
                  },
                  {
                    "text": "﻿(3) Assess further if mixed acid-base disorder suspectedIf pCO₂ and HCO₃⁻ change in different directions, presence of mixed acid-base disorder likelyUse pH as guide to determine primary acid-base disorder in mixed acid-base disorderIf pH is low, acidosis (metabolic or respiratory) is predominant or primary disorder",
                    "sub_points": [
                      "If pCO₂ and HCO₃⁻ change in different directions, presence of mixed acid-base disorder likely",
                      "Use pH as guide to determine primary acid-base disorder in mixed acid-base disorderIf pH is low, acidosis (metabolic or respiratory) is predominant or primary disorder",
                      "If pH is low, acidosis (metabolic or respiratory) is predominant or primary disorder"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Blood Gas Instrumentation": {
            "name": "Blood Gas Instrumentation",
            "url": "https://app.pathprimer.com/document/790e6e50-a573-46dc-bd2d-e8d382341365/lesson/759a44fa-fcda-4a35-ac90-c486f310df6f",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Routine specimen is whole blood collected in plastic sterile syringe"
                  },
                  {
                    "text": "Lyophilized (freeze-dried) heparin preferred because liquid heparin can significantly dilute blood sample"
                  },
                  {
                    "text": "Blood should be collected as close to anaerobic conditions as possible (technically needle and syringe hub have atmospheric air dead space)"
                  },
                  {
                    "text": "Atmospheric air has less CO₂ than bloodCO₂ will leave sample blood for atmosphere, lowering pCO₂ measured in samplepH in sample will increase due to loss of CO₂",
                    "sub_points": [
                      "CO₂ will leave sample blood for atmosphere, lowering pCO₂ measured in sample",
                      "pH in sample will increase due to loss of CO₂"
                    ]
                  },
                  {
                    "text": "Atmospheric air has more O₂ than arterial bloodSamples will gain O₂",
                    "sub_points": [
                      "Samples will gain O₂"
                    ]
                  },
                  {
                    "text": "Longer delays in analysis are impacted by changes related to glycolysisIncrease in lactate with decrease in pHIncrease in pCO₂Decrease in pO₂",
                    "sub_points": [
                      "Increase in lactate with decrease in pH",
                      "Increase in pCO₂",
                      "Decrease in pO₂"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Carbon dioxide (CO₂)"
                  },
                  {
                    "text": "Partial pressure of carbon dioxide (pCO₂)"
                  },
                  {
                    "text": "Oxygen (O₂)"
                  },
                  {
                    "text": "Partial pressure of oxygen (pO₂)"
                  },
                  {
                    "text": "White blood cell (WBC)"
                  },
                  {
                    "text": "Silver chloride (AgCl)"
                  },
                  {
                    "text": "Potassium chloride (KCl)"
                  },
                  {
                    "text": "Silver (Ag)"
                  },
                  {
                    "text": "Sodium bicarbonate (NaHCO₃)"
                  },
                  {
                    "text": "Sodium chloride (NaCl)"
                  },
                  {
                    "text": "Clinical Laboratory Improvement Amendments (CLIA)"
                  },
                  {
                    "text": "Quality control (QC)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Routine specimen is whole blood collected in plastic sterile syringeTheoretically, glass is better at preventing gas exchange but is not routinely used",
                    "sub_points": [
                      "Theoretically, glass is better at preventing gas exchange but is not routinely used"
                    ]
                  },
                  {
                    "text": "Lyophilized (freeze-dried) heparin preferred because liquid heparin can significantly dilute blood sample"
                  },
                  {
                    "text": "Blood should be collected as close to anaerobic conditions as possible (technically needle and syringe hub have atmospheric air dead space)Atmospheric air has less CO₂ than bloodCO₂ will leave sample blood for atmosphere, lowering pCO₂ measured in samplepH in sample will increase due to loss of CO₂Atmospheric air has more O₂ than arterial bloodSamples will gain O₂",
                    "sub_points": [
                      "Atmospheric air has less CO₂ than bloodCO₂ will leave sample blood for atmosphere, lowering pCO₂ measured in samplepH in sample will increase due to loss of CO₂",
                      "CO₂ will leave sample blood for atmosphere, lowering pCO₂ measured in samplepH in sample will increase due to loss of CO₂",
                      "pH in sample will increase due to loss of CO₂",
                      "Atmospheric air has more O₂ than arterial bloodSamples will gain O₂",
                      "Samples will gain O₂"
                    ]
                  },
                  {
                    "text": "As expected, blood gas measurements between arterial and venous blood differpO₂ approximately 60 mm Hg lower in venous bloodpCO₂ up to 8 mm Hg higher in venous bloodpH up to 0.05 units lower in venous blood",
                    "sub_points": [
                      "pO₂ approximately 60 mm Hg lower in venous blood",
                      "pCO₂ up to 8 mm Hg higher in venous blood",
                      "pH up to 0.05 units lower in venous blood"
                    ]
                  },
                  {
                    "text": "If cutaneous sample taken, free-flowing blood is necessary"
                  },
                  {
                    "text": "Specimens can be analyzed 1 hr after collection with minimal impact on measured valuesAnalysis within 30 minutes of collection is ideal",
                    "sub_points": [
                      "Analysis within 30 minutes of collection is ideal"
                    ]
                  },
                  {
                    "text": "Longer delays in analysis are impacted by changes related to glycolysisIncrease in lactate with decrease in pHIncrease in pCO₂Decrease in pO₂Elevated WBCs exacerbate changes (leukemia)",
                    "sub_points": [
                      "Increase in lactate with decrease in pH",
                      "Increase in pCO₂",
                      "Decrease in pO₂",
                      "Elevated WBCs exacerbate changes (leukemia)"
                    ]
                  }
                ],
                "Blood Gas Analyzer": [
                  {
                    "text": "Modern instruments have sophisticated microprocessor support and are highly automated"
                  },
                  {
                    "text": "Analyzers typically have 3 main electrodespH and associated reference electrodeMade of H⁺ sensitive glassAllows for development of potential gradient across glass membranepO₂ electrodeMembrane is made of polypropyleneElectrode solution contains phosphate buffer with AgCl and KClSolution is in contact with cathode made of polarized platinum and anode made of Ag-AgClO₂ from sample diffuses into electrolyte solution, reacting with platinum cathode and creating current flow, which is measuredpCO₂ electrodeH⁺ sensitive glass with membrane made of silicone rubberElectrode solution containsNaHCO₃NaClAgClCO₂ from sample diffuses into electrode solutionIncrease in H⁺ occurs when H₂O combines with CO₂ and is measured as a change in pHChange in pH transformed electronically to log change in pCO₂",
                    "sub_points": [
                      "pH and associated reference electrodeMade of H⁺ sensitive glassAllows for development of potential gradient across glass membrane",
                      "Made of H⁺ sensitive glassAllows for development of potential gradient across glass membrane",
                      "Allows for development of potential gradient across glass membrane",
                      "pO₂ electrodeMembrane is made of polypropyleneElectrode solution contains phosphate buffer with AgCl and KClSolution is in contact with cathode made of polarized platinum and anode made of Ag-AgClO₂ from sample diffuses into electrolyte solution, reacting with platinum cathode and creating current flow, which is measured",
                      "Membrane is made of polypropylene",
                      "Electrode solution contains phosphate buffer with AgCl and KClSolution is in contact with cathode made of polarized platinum and anode made of Ag-AgCl",
                      "Solution is in contact with cathode made of polarized platinum and anode made of Ag-AgCl",
                      "O₂ from sample diffuses into electrolyte solution, reacting with platinum cathode and creating current flow, which is measured",
                      "pCO₂ electrodeH⁺ sensitive glass with membrane made of silicone rubberElectrode solution containsNaHCO₃NaClAgClCO₂ from sample diffuses into electrode solutionIncrease in H⁺ occurs when H₂O combines with CO₂ and is measured as a change in pHChange in pH transformed electronically to log change in pCO₂",
                      "H⁺ sensitive glass with membrane made of silicone rubber",
                      "Electrode solution containsNaHCO₃NaClAgCl",
                      "NaHCO₃",
                      "NaCl",
                      "AgCl",
                      "CO₂ from sample diffuses into electrode solution",
                      "Increase in H⁺ occurs when H₂O combines with CO₂ and is measured as a change in pHChange in pH transformed electronically to log change in pCO₂",
                      "Change in pH transformed electronically to log change in pCO₂"
                    ]
                  },
                  {
                    "text": "User operation involves presenting patient sample to instrument probeSample is taken up and pumped into analysis chamber and exposed to electrodesThermal equilibration also occursCalculations based on Henderson-Hasselbalch equation require a temperature of 37°CBicarbonate concentration derived from equation in blood gas analyzer softwareBecause samples can come from a wide array of patient body temperatures, thermal equilibration is criticalFebrile patients (40°C) or surgical patients made to have temperature as low as 23°CInstrumentation can calculate temperature-corrected pH and pCO₂ when time for equilibration not feasible",
                    "sub_points": [
                      "Sample is taken up and pumped into analysis chamber and exposed to electrodes",
                      "Thermal equilibration also occursCalculations based on Henderson-Hasselbalch equation require a temperature of 37°CBicarbonate concentration derived from equation in blood gas analyzer softwareBecause samples can come from a wide array of patient body temperatures, thermal equilibration is criticalFebrile patients (40°C) or surgical patients made to have temperature as low as 23°CInstrumentation can calculate temperature-corrected pH and pCO₂ when time for equilibration not feasible",
                      "Calculations based on Henderson-Hasselbalch equation require a temperature of 37°CBicarbonate concentration derived from equation in blood gas analyzer software",
                      "Bicarbonate concentration derived from equation in blood gas analyzer software",
                      "Because samples can come from a wide array of patient body temperatures, thermal equilibration is criticalFebrile patients (40°C) or surgical patients made to have temperature as low as 23°C",
                      "Febrile patients (40°C) or surgical patients made to have temperature as low as 23°C",
                      "Instrumentation can calculate temperature-corrected pH and pCO₂ when time for equilibration not feasible"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "Quality Control": [
                  {
                    "text": "External QC is required under CLIA, and acceptable interlaboratory performance criteria for blood gas analysis have been establishedpH measured by laboratory = target value ± 0.04pO₂ measured by laboratory = target value ± 3 SDpCO₂ measured by laboratory = target value ± 8% or 5 mm Hg (whichever is greater)",
                    "sub_points": [
                      "pH measured by laboratory = target value ± 0.04",
                      "pO₂ measured by laboratory = target value ± 3 SD",
                      "pCO₂ measured by laboratory = target value ± 8% or 5 mm Hg (whichever is greater)"
                    ]
                  },
                  {
                    "text": "Commercially available blood-based control material available (used less commonly)Consists of sealed vials withKnown gas content mixtureBuffered solution suspended with human-derived erythrocytes or synthetic fluorocarbon",
                    "sub_points": [
                      "Consists of sealed vials withKnown gas content mixtureBuffered solution suspended with human-derived erythrocytes or synthetic fluorocarbon",
                      "Known gas content mixture",
                      "Buffered solution suspended with human-derived erythrocytes or synthetic fluorocarbon"
                    ]
                  },
                  {
                    "text": "Aqueous commercial controls (without erythrocytes or erythrocyte analogues) are most common material usedConsists of sealed vials filled fluid and known concentration of gases",
                    "sub_points": [
                      "Consists of sealed vials filled fluid and known concentration of gases"
                    ]
                  },
                  {
                    "text": "Modern analyzers and point of care devices have on-board QCConducted automatically at designated intervals making fulfillment of regulatory requirements simpler",
                    "sub_points": [
                      "Conducted automatically at designated intervals making fulfillment of regulatory requirements simpler"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Electrolytes": {
        "name": "Electrolytes",
        "url": "https://app.pathprimer.com/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
        "topics": {
          "Renin-Angiotensin Aldosterone System": {
            "name": "Renin-Angiotensin Aldosterone System",
            "url": "https://app.pathprimer.com/document/f7bfd9b2-c8d9-4d30-8e68-1166e1b6d4de/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Aldosterone works on distal tubule of kidney to increase sodium reabsorptionWater follows absorbed sodiumIncreased extracellular fluid and blood volumes",
                    "sub_points": [
                      "Water follows absorbed sodium",
                      "Increased extracellular fluid and blood volumes"
                    ]
                  },
                  {
                    "text": "RAAS response steps to acute hemorrhage(1) Decreased renal perfusion is sensed by JG cells, inducing renin secretion(2) Renin works in plasma to catalyze conversion of angiotensinogen to angiotensin I(3) ACE catalyzes conversion of angiotensin I to angiotensin II, primarily in lungs(4) Angiotensin II stimulates aldosterone release and causes arteriole vasoconstriction throughout body",
                    "sub_points": [
                      "(1) Decreased renal perfusion is sensed by JG cells, inducing renin secretion",
                      "(2) Renin works in plasma to catalyze conversion of angiotensinogen to angiotensin I",
                      "(3) ACE catalyzes conversion of angiotensin I to angiotensin II, primarily in lungs",
                      "(4) Angiotensin II stimulates aldosterone release and causes arteriole vasoconstriction throughout body"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Pathway Discovery and Importance": [
                  {
                    "text": "Investigation into etiologies of hypertension led to understanding great importance of RAAS"
                  },
                  {
                    "text": "Knowledge of RAAS crucial to interpreting laboratory values presented in clinical situations"
                  },
                  {
                    "text": "Major class of medication (ACE inhibitors) exploits RAAS to lower blood pressure in millions of patients"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Renin-angiotensin aldosterone system (RAAS)"
                  },
                  {
                    "text": "Angiotensin-converting enzyme (ACE)"
                  },
                  {
                    "text": "Juxtaglomerular (JG)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Function": [
                  {
                    "text": "Main function of RAAS is to regulate blood pressure in response to changes in blood volumeMechanism is hormonal based and slow",
                    "sub_points": [
                      "Mechanism is hormonal based and slow"
                    ]
                  }
                ],
                "RAAS Components": [
                  {
                    "text": "ReninProteolytic enzyme primarily created and stored by JG apparatus cellsJG apparatus resides within macula densa of kidneyRelease stimulated by low plasma volume or low serum sodium",
                    "sub_points": [
                      "Proteolytic enzyme primarily created and stored by JG apparatus cells",
                      "JG apparatus resides within macula densa of kidney",
                      "Release stimulated by low plasma volume or low serum sodium"
                    ]
                  },
                  {
                    "text": "AngiotensinPeptide hormone produced by liver that comes in 3 main formsAngiotensinogen (precursor form)Angiotensin I (physiologically inactive)Angiotensin II (physiologically active)Potent vasoconstrictor",
                    "sub_points": [
                      "Peptide hormone produced by liver that comes in 3 main formsAngiotensinogen (precursor form)Angiotensin I (physiologically inactive)Angiotensin II (physiologically active)Potent vasoconstrictor",
                      "Angiotensinogen (precursor form)",
                      "Angiotensin I (physiologically inactive)",
                      "Angiotensin II (physiologically active)Potent vasoconstrictor",
                      "Potent vasoconstrictor"
                    ]
                  },
                  {
                    "text": "ACEWidely distributedPulmonary and vascular endotheliumKidney, heart, and brain cell membranes",
                    "sub_points": [
                      "Widely distributedPulmonary and vascular endotheliumKidney, heart, and brain cell membranes",
                      "Pulmonary and vascular endothelium",
                      "Kidney, heart, and brain cell membranes"
                    ]
                  },
                  {
                    "text": "AldosteroneMineralocorticoid hormone produced by zona glomerulosa of adrenal cortexSynthesized by aldosterone synthetase conversion of corticosteroneHyperkalemia stimulates aldosterone releaseWorks on distal tubule of kidney to increase sodium reabsorptionWater follows absorbed sodiumIncreased extracellular fluid and blood volumes",
                    "sub_points": [
                      "Mineralocorticoid hormone produced by zona glomerulosa of adrenal cortexSynthesized by aldosterone synthetase conversion of corticosteroneHyperkalemia stimulates aldosterone release",
                      "Synthesized by aldosterone synthetase conversion of corticosterone",
                      "Hyperkalemia stimulates aldosterone release",
                      "Works on distal tubule of kidney to increase sodium reabsorptionWater follows absorbed sodiumIncreased extracellular fluid and blood volumes",
                      "Water follows absorbed sodium",
                      "Increased extracellular fluid and blood volumes"
                    ]
                  }
                ],
                "﻿RAAS Response Steps to Acute Hemorrhage": [
                  {
                    "text": "(1) Decreased renal perfusion is sensed by JG cells, inducing renin secretion"
                  },
                  {
                    "text": "(2) Renin works in plasma to catalyze conversion of angiotensinogen to angiotensin I"
                  },
                  {
                    "text": "(3) ACE catalyzes conversion of angiotensin I to angiotensin II, primarily in lungs"
                  },
                  {
                    "text": "(4) Angiotensin II stimulates aldosterone release and causes arteriole vasoconstriction throughout body"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Renin Measurement": [
                  {
                    "text": "Enzymatic activity measured by monitoring conversion of angiotensinogen to angiotensin IRequires blocking of ACE to keep angiotensin I from conversion",
                    "sub_points": [
                      "Requires blocking of ACE to keep angiotensin I from conversion"
                    ]
                  },
                  {
                    "text": "Renin concentration can also be measured via immunoassayInferior to activity measurement",
                    "sub_points": [
                      "Inferior to activity measurement"
                    ]
                  }
                ],
                "Aldosterone Measurement": [
                  {
                    "text": "Automated immunoassay available to measure aldosterone in plasma or urine"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Elevated Renin": [
                  {
                    "text": "Approximately 15% of primary hypertension found to be caused by elevated renin"
                  },
                  {
                    "text": "Elevated renin is independent risk factor for myocardial infarction"
                  },
                  {
                    "text": "Regardless of success in blood pressure control by medication, elevated renin activity is not addressedContributes to worse outcomes",
                    "sub_points": [
                      "Contributes to worse outcomes"
                    ]
                  },
                  {
                    "text": "Select causesRenin-secreting tumorJG apparatusRenal artery stenosisAmenable to cure by surgeryTransplant rejectionRenin elevation indicates possible renal ischemia",
                    "sub_points": [
                      "Renin-secreting tumorJG apparatus",
                      "JG apparatus",
                      "Renal artery stenosisAmenable to cure by surgery",
                      "Amenable to cure by surgery",
                      "Transplant rejectionRenin elevation indicates possible renal ischemia",
                      "Renin elevation indicates possible renal ischemia"
                    ]
                  }
                ],
                "Pharmaceuticals": [
                  {
                    "text": "Mechanism of action of ACE inhibitors to block conversion of angiotensin I to angiotensin II"
                  },
                  {
                    "text": "Names of drugs in class end in \"-pril\" (e.g., lisinopril)"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Posture and blood volume can affect measured renin and aldosterone levelsHighest in upright position",
                    "sub_points": [
                      "Highest in upright position"
                    ]
                  },
                  {
                    "text": "Prorenin (precursor form) converted to renin under refrigerated temperaturesFalsely elevates renin measurementDo not collect specimen on ice",
                    "sub_points": [
                      "Falsely elevates renin measurement",
                      "Do not collect specimen on ice"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sodium": {
            "name": "Sodium",
            "url": "https://app.pathprimer.com/document/40c1a610-539e-4d4b-a87d-d689af3340e4/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Sodium is major extracellular cation of body"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Hypernatremia defined as plasma sodium > 145 mmol/LPatients typically exhibit neurologic symptoms due to CNS water loss to ECF",
                    "sub_points": [
                      "Patients typically exhibit neurologic symptoms due to CNS water loss to ECF"
                    ]
                  },
                  {
                    "text": "Hyperosmotic hyponatremiaCaused by extracellular shift of water or intracellular shift of sodiumHyperglycemia (most common cause)Every 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L",
                    "sub_points": [
                      "Caused by extracellular shift of water or intracellular shift of sodium",
                      "Hyperglycemia (most common cause)Every 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L",
                      "Every 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Extracellular fluid (ECF)"
                  },
                  {
                    "text": "Syndrome of inappropriate antidiuretic hormone (SIADH)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "Sodium is major extracellular cation of body"
                  },
                  {
                    "text": "Sodium represents 90% of inorganic cation found in plasmaResponsible for 50% of plasma osmotic strength",
                    "sub_points": [
                      "Responsible for 50% of plasma osmotic strength"
                    ]
                  },
                  {
                    "text": "Sodium hemostasis maintained by kidneysIn proximal tubule, 70-80% of filtered sodium is actively reabsorbedIn ascending loop of Henle, chloride and sodium are actively reabsorbedAldosterone enhances sodium reabsorption in distal tubule through collecting ductExcess sodium is excreted",
                    "sub_points": [
                      "In proximal tubule, 70-80% of filtered sodium is actively reabsorbed",
                      "In ascending loop of Henle, chloride and sodium are actively reabsorbed",
                      "Aldosterone enhances sodium reabsorption in distal tubule through collecting duct",
                      "Excess sodium is excreted"
                    ]
                  },
                  {
                    "text": "Diurnal variationSodium excretion peaks during dayOnly 20% of excretion takes place at night",
                    "sub_points": [
                      "Sodium excretion peaks during day",
                      "Only 20% of excretion takes place at night"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hypernatremia": [
                  {
                    "text": "Plasma sodium concentration > 145 mmol/L"
                  },
                  {
                    "text": "Patients typically exhibit neurologic symptoms due to CNS water loss to ECFIrritabilityTremorsAtaxiaAltered mental status, eventually coma",
                    "sub_points": [
                      "Irritability",
                      "Tremors",
                      "Ataxia",
                      "Altered mental status, eventually coma"
                    ]
                  },
                  {
                    "text": "Hypernatremia can occur regardless of volume statusNormovolemic hypernatremiaCausesInsensible losses from lung and skinCentral or nephrogenic diabetes insipidus (urine osmolality < 200 mOsmol/L)Diabetes mellitus (urine osmolality > 300 mOsmol/L)Hypovolemic hypernatremiaRenal and extrarenal fluid loss leading to dehydrationConcentrated urine (urine osmolality > 800 mOsm/L)Low urine sodium (< 20 mmol/L)Hypervolemic hypernatremiaRare; often iatrogenically inducedHospital patients receiving fluids (hypertonic saline or sodium bicarbonate)Cushing syndromeHyperaldosteronism",
                    "sub_points": [
                      "Normovolemic hypernatremiaCausesInsensible losses from lung and skinCentral or nephrogenic diabetes insipidus (urine osmolality < 200 mOsmol/L)Diabetes mellitus (urine osmolality > 300 mOsmol/L)",
                      "CausesInsensible losses from lung and skinCentral or nephrogenic diabetes insipidus (urine osmolality < 200 mOsmol/L)Diabetes mellitus (urine osmolality > 300 mOsmol/L)",
                      "Insensible losses from lung and skin",
                      "Central or nephrogenic diabetes insipidus (urine osmolality < 200 mOsmol/L)",
                      "Diabetes mellitus (urine osmolality > 300 mOsmol/L)",
                      "Hypovolemic hypernatremiaRenal and extrarenal fluid loss leading to dehydrationConcentrated urine (urine osmolality > 800 mOsm/L)Low urine sodium (< 20 mmol/L)",
                      "Renal and extrarenal fluid loss leading to dehydrationConcentrated urine (urine osmolality > 800 mOsm/L)Low urine sodium (< 20 mmol/L)",
                      "Concentrated urine (urine osmolality > 800 mOsm/L)",
                      "Low urine sodium (< 20 mmol/L)",
                      "Hypervolemic hypernatremiaRare; often iatrogenically inducedHospital patients receiving fluids (hypertonic saline or sodium bicarbonate)Cushing syndromeHyperaldosteronism",
                      "Rare; often iatrogenically inducedHospital patients receiving fluids (hypertonic saline or sodium bicarbonate)",
                      "Hospital patients receiving fluids (hypertonic saline or sodium bicarbonate)",
                      "Cushing syndrome",
                      "Hyperaldosteronism"
                    ]
                  }
                ],
                "Hyponatremia": [
                  {
                    "text": "Plasma sodium concentration < 135 mmol/L"
                  },
                  {
                    "text": "Results from changes in osmolality that patients can experienceNauseaGeneralized weaknessGeneral confusion and further altered mental statusComa",
                    "sub_points": [
                      "Nausea",
                      "Generalized weakness",
                      "General confusion and further altered mental status",
                      "Coma"
                    ]
                  },
                  {
                    "text": "Hyponatremia assessment requires plasma osmolality measurement"
                  },
                  {
                    "text": "Hypo-osmotic hyponatremiaExcess sodium lossExtrarenal loss, low urine sodium (< 10 mmol/L)Vomiting and diarrheaBurnsRenal loss, high urine sodium (> 20 mmol/L)Diuretic drugsAddison disease (distal tubule sodium reabsorption impaired due to low aldosterone)Increased ECF volumeWith blood volume decreaseCongestive heart failure (urine sodium < 10 mmol/L)Nephrotic syndrome (urine sodium < 10 mmol/L)Cirrhosis (urine sodium < 10 mmol/L)Advanced renal failure (urine sodium > 20 mmol/L)With normal blood volumeSIADHHypothyroidismPrimary polydipsia",
                    "sub_points": [
                      "Excess sodium lossExtrarenal loss, low urine sodium (< 10 mmol/L)Vomiting and diarrheaBurnsRenal loss, high urine sodium (> 20 mmol/L)Diuretic drugsAddison disease (distal tubule sodium reabsorption impaired due to low aldosterone)",
                      "Extrarenal loss, low urine sodium (< 10 mmol/L)Vomiting and diarrheaBurns",
                      "Vomiting and diarrhea",
                      "Burns",
                      "Renal loss, high urine sodium (> 20 mmol/L)Diuretic drugsAddison disease (distal tubule sodium reabsorption impaired due to low aldosterone)",
                      "Diuretic drugs",
                      "Addison disease (distal tubule sodium reabsorption impaired due to low aldosterone)",
                      "Increased ECF volumeWith blood volume decreaseCongestive heart failure (urine sodium < 10 mmol/L)Nephrotic syndrome (urine sodium < 10 mmol/L)Cirrhosis (urine sodium < 10 mmol/L)Advanced renal failure (urine sodium > 20 mmol/L)With normal blood volumeSIADHHypothyroidismPrimary polydipsia",
                      "With blood volume decreaseCongestive heart failure (urine sodium < 10 mmol/L)Nephrotic syndrome (urine sodium < 10 mmol/L)Cirrhosis (urine sodium < 10 mmol/L)Advanced renal failure (urine sodium > 20 mmol/L)",
                      "Congestive heart failure (urine sodium < 10 mmol/L)",
                      "Nephrotic syndrome (urine sodium < 10 mmol/L)",
                      "Cirrhosis (urine sodium < 10 mmol/L)",
                      "Advanced renal failure (urine sodium > 20 mmol/L)",
                      "With normal blood volumeSIADHHypothyroidismPrimary polydipsia",
                      "SIADH",
                      "Hypothyroidism",
                      "Primary polydipsia"
                    ]
                  },
                  {
                    "text": "Hyperosmotic hyponatremiaCaused by extracellular shift of water or intracellular shift of sodiumHyperglycemiaMost common causeEvery 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L",
                    "sub_points": [
                      "Caused by extracellular shift of water or intracellular shift of sodiumHyperglycemiaMost common causeEvery 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L",
                      "HyperglycemiaMost common causeEvery 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L",
                      "Most common cause",
                      "Every 100 mg/dL increase in blood glucose > 100 mg/dL results in sodium decrease of 1.6-2.4 mmol/L"
                    ]
                  },
                  {
                    "text": "Isosmotic hyponatremiaPseudohyponatremia",
                    "sub_points": [
                      "Pseudohyponatremia"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Common specimen typesSerumPlasmaUrine",
                    "sub_points": [
                      "Serum",
                      "Plasma",
                      "Urine"
                    ]
                  },
                  {
                    "text": "Storage4°CSamples can be frozen",
                    "sub_points": [
                      "4°C",
                      "Samples can be frozen"
                    ]
                  },
                  {
                    "text": "Other considerationsHemolysis has little effect on sodium values in serum or plasmaSodium content of erythrocytes is 1/10 of plasma",
                    "sub_points": [
                      "Hemolysis has little effect on sodium values in serum or plasmaSodium content of erythrocytes is 1/10 of plasma",
                      "Sodium content of erythrocytes is 1/10 of plasma"
                    ]
                  },
                  {
                    "text": "Reference intervalAdults: 136-145 mmol/LPremature newborns at 48 hours of life: 128-148 mmol/L",
                    "sub_points": [
                      "Adults: 136-145 mmol/L",
                      "Premature newborns at 48 hours of life: 128-148 mmol/L"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Potassium": {
            "name": "Potassium",
            "url": "https://app.pathprimer.com/document/58688fb2-b5e9-494b-9911-677241323b6e/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Limitations": [
                  {
                    "text": "Various preanalytic conditions result in spurious hyperkalemia, including hemolysis, thrombocytosis, and leukocytosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine triphosphatase (ATPase)"
                  },
                  {
                    "text": "Angiotensin-converting enzyme (ACE)"
                  },
                  {
                    "text": "Nonsteroidal antiinflammatory drug (NSAID)"
                  },
                  {
                    "text": "Cerebrospinal fluid (CSF)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "Major intracellular cation is K⁺"
                  },
                  {
                    "text": "Intracellular K⁺ concentration maintained by energy-dependent sodium-potassium ATPase"
                  },
                  {
                    "text": "When ATPase activity is decreased, K⁺ diffusion out of cell also increases"
                  },
                  {
                    "text": "K⁺ hemostasis maintained by kidneys"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hyperkalemia": [
                  {
                    "text": "Plasma K⁺ > 5 mmol/L"
                  },
                  {
                    "text": "K⁺ concentrations > 10 mmol/L often fatal"
                  },
                  {
                    "text": "SymptomsMental confusionMuscle weaknessBradycardiaConduction defect leading to severe arrhythmia",
                    "sub_points": [
                      "Mental confusion",
                      "Muscle weakness",
                      "Bradycardia",
                      "Conduction defect leading to severe arrhythmia"
                    ]
                  },
                  {
                    "text": "CausesK⁺ redistributionIntracellular K⁺ moving to extracellular spaceAcidotic statesTissue hypoxiaSevere burnTumor lysis syndromeDiabetic ketoacidosisIntravascular hemolysisIncreased intakeIatrogenic causes—intravenous fluidsIncreased retentionModerate to severe renal diseaseAddison diseaseDecreased aldosteroneDrugsACE inhibitorsNSAIDsAngiotensin II receptor blockers",
                    "sub_points": [
                      "K⁺ redistributionIntracellular K⁺ moving to extracellular spaceAcidotic statesTissue hypoxiaSevere burnTumor lysis syndromeDiabetic ketoacidosisIntravascular hemolysis",
                      "Intracellular K⁺ moving to extracellular spaceAcidotic statesTissue hypoxiaSevere burnTumor lysis syndromeDiabetic ketoacidosisIntravascular hemolysis",
                      "Acidotic states",
                      "Tissue hypoxia",
                      "Severe burn",
                      "Tumor lysis syndrome",
                      "Diabetic ketoacidosis",
                      "Intravascular hemolysis",
                      "Increased intakeIatrogenic causes—intravenous fluids",
                      "Iatrogenic causes—intravenous fluids",
                      "Increased retentionModerate to severe renal diseaseAddison diseaseDecreased aldosteroneDrugsACE inhibitorsNSAIDsAngiotensin II receptor blockers",
                      "Moderate to severe renal disease",
                      "Addison diseaseDecreased aldosterone",
                      "Decreased aldosterone",
                      "DrugsACE inhibitorsNSAIDsAngiotensin II receptor blockers",
                      "ACE inhibitors",
                      "NSAIDs",
                      "Angiotensin II receptor blockers"
                    ]
                  }
                ],
                "Hypokalemia": [
                  {
                    "text": "Plasma K⁺ < 3.5 mmol/L"
                  },
                  {
                    "text": "SymptomsIrritabilityParalysisMuscle weaknessCardiac conduction defects (flattened T waves)Cardiac arrest",
                    "sub_points": [
                      "Irritability",
                      "Paralysis",
                      "Muscle weakness",
                      "Cardiac conduction defects (flattened T waves)",
                      "Cardiac arrest"
                    ]
                  },
                  {
                    "text": "CausesK⁺ redistributionExtracellular K⁺ moving to intracellular spaceInsulin therapy—K⁺ follows glucose into cellAlkalosisK⁺ rich fluid lossRenal causes (urine K⁺ > 30 mmol/day)Acute tubular necrosisHyperaldosteronismCushing syndromeThiazide and loop diureticsRenal tubular acidosisNonrenal causes (urine K⁺ < 30 mmol/day)DiarrheaExcessive sweatingStarvation",
                    "sub_points": [
                      "K⁺ redistributionExtracellular K⁺ moving to intracellular spaceInsulin therapy—K⁺ follows glucose into cellAlkalosis",
                      "Extracellular K⁺ moving to intracellular spaceInsulin therapy—K⁺ follows glucose into cellAlkalosis",
                      "Insulin therapy—K⁺ follows glucose into cell",
                      "Alkalosis",
                      "K⁺ rich fluid lossRenal causes (urine K⁺ > 30 mmol/day)Acute tubular necrosisHyperaldosteronismCushing syndromeThiazide and loop diureticsRenal tubular acidosisNonrenal causes (urine K⁺ < 30 mmol/day)DiarrheaExcessive sweatingStarvation",
                      "Renal causes (urine K⁺ > 30 mmol/day)Acute tubular necrosisHyperaldosteronismCushing syndromeThiazide and loop diureticsRenal tubular acidosis",
                      "Acute tubular necrosis",
                      "Hyperaldosteronism",
                      "Cushing syndrome",
                      "Thiazide and loop diuretics",
                      "Renal tubular acidosis",
                      "Nonrenal causes (urine K⁺ < 30 mmol/day)DiarrheaExcessive sweatingStarvation",
                      "Diarrhea",
                      "Excessive sweating",
                      "Starvation"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Pseudohyperkalemia": [
                  {
                    "text": "Various preanalytic conditions result in spurious hyperkalemiaHemolysisThrombocytosisLeukocytosis",
                    "sub_points": [
                      "Hemolysis",
                      "Thrombocytosis",
                      "Leukocytosis"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Hemolysis falsely elevates K⁺ valueIntracellular K⁺ in erythrocytes is high (105 mmol/L)",
                    "sub_points": [
                      "Intracellular K⁺ in erythrocytes is high (105 mmol/L)"
                    ]
                  },
                  {
                    "text": "Serum K⁺ higher than plasma potassiumPlatelets release K⁺ during clot formation",
                    "sub_points": [
                      "Platelets release K⁺ during clot formation"
                    ]
                  },
                  {
                    "text": "Thrombocytosis"
                  },
                  {
                    "text": "If whole-blood specimens are refrigerated (4°C) before centrifugation, falsely elevated K⁺ concentration is observedGlycolysis inhibited with resulting impaired sodium-potassium ATPase on cells (K⁺ leakage)",
                    "sub_points": [
                      "Glycolysis inhibited with resulting impaired sodium-potassium ATPase on cells (K⁺ leakage)"
                    ]
                  },
                  {
                    "text": "Falsely decreased K⁺In unspun specimens at 37°CGlycolysis uninhibitedIntracellular K⁺ shift occursLeukocytosisLack of release of tourniquet during blood draw after fist clenchingK⁺ leak from muscle cells occurs during skeletal muscle contraction",
                    "sub_points": [
                      "In unspun specimens at 37°CGlycolysis uninhibitedIntracellular K⁺ shift occurs",
                      "Glycolysis uninhibited",
                      "Intracellular K⁺ shift occurs",
                      "Leukocytosis",
                      "Lack of release of tourniquet during blood draw after fist clenchingK⁺ leak from muscle cells occurs during skeletal muscle contraction",
                      "K⁺ leak from muscle cells occurs during skeletal muscle contraction"
                    ]
                  },
                  {
                    "text": "Centrifugation of specimen within 1 hr of collection and maintenance of room temperature minimize preanalytic error"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "Serum3.5-5.1 mmol/L, adult (due to clotting step slightly higher than plasma reference interval)3.7-5.9 mmol/L, newborn",
                    "sub_points": [
                      "3.5-5.1 mmol/L, adult (due to clotting step slightly higher than plasma reference interval)",
                      "3.7-5.9 mmol/L, newborn"
                    ]
                  },
                  {
                    "text": "Plasma3.4-4.8 mmol/L, adult",
                    "sub_points": [
                      "3.4-4.8 mmol/L, adult"
                    ]
                  },
                  {
                    "text": "CSF70% of plasma values",
                    "sub_points": [
                      "70% of plasma values"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Calcium": {
            "name": "Calcium",
            "url": "https://app.pathprimer.com/document/3ff78c0e-bf28-4eef-9f78-763da3fcc227/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Calcium in blood is found in 3 main formsFree or ionized (50%)Protein bound (40%)Complexed with small anions (10%)",
                    "sub_points": [
                      "Free or ionized (50%)",
                      "Protein bound (40%)",
                      "Complexed with small anions (10%)"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "In states of hypoalbuminemia, measured total calcium can be falsely low"
                  },
                  {
                    "text": "Equation to correct for decreased albumin: Correct total calcium (mg/dL) = Total calcium measured + 0.8(4.4 - measured albumin)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Granulomatous disease (sarcoidosis): Granuloma macrophages generate unregulated 1,25-dihydroxyvitamin D enhancing intestinal absorption of calcium"
                  }
                ],
                "Specimens": [
                  {
                    "text": "Alteration in pH should be avoidedpH increases within specimen enhance negative charge on albumin, which increases calcium binding and decreases free calciumFor decreases in pH, opposite effect is observed",
                    "sub_points": [
                      "pH increases within specimen enhance negative charge on albumin, which increases calcium binding and decreases free calcium",
                      "For decreases in pH, opposite effect is observed"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Parathyroid hormone (PTH)"
                  },
                  {
                    "text": "PTH-related protein (PTHrp)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "99% of calcium found in skeleton"
                  },
                  {
                    "text": "Calcium in blood is found in 3 main formsFree or ionized (50%)Biologically active formRegulated by PTH and 1,25-dihydroxyvitamin DProtein bound (40%)Primarily to albuminCalcium released from protein in acidotic statesComplexed with small anions (10%)HCO₃⁻H₂PO₄⁻(HPO₄⁻)₂CitrateLactate",
                    "sub_points": [
                      "Free or ionized (50%)Biologically active formRegulated by PTH and 1,25-dihydroxyvitamin D",
                      "Biologically active form",
                      "Regulated by PTH and 1,25-dihydroxyvitamin D",
                      "Protein bound (40%)Primarily to albuminCalcium released from protein in acidotic states",
                      "Primarily to albumin",
                      "Calcium released from protein in acidotic states",
                      "Complexed with small anions (10%)HCO₃⁻H₂PO₄⁻(HPO₄⁻)₂CitrateLactate",
                      "HCO₃⁻",
                      "H₂PO₄⁻",
                      "(HPO₄⁻)₂",
                      "Citrate",
                      "Lactate"
                    ]
                  },
                  {
                    "text": "Intracellular calcium important in various physiologic functionsMuscle contractionHormone secretionGlycogen metabolismMitoses",
                    "sub_points": [
                      "Muscle contraction",
                      "Hormone secretion",
                      "Glycogen metabolism",
                      "Mitoses"
                    ]
                  },
                  {
                    "text": "Extracellular calcium primary functionsBone mineralizationCoagulationStabilization of plasma membranes",
                    "sub_points": [
                      "Bone mineralization",
                      "Coagulation",
                      "Stabilization of plasma membranes"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Measurement of Free and Total Calcium": [
                  {
                    "text": "Free and total calcium are measured in clinical laboratories"
                  },
                  {
                    "text": "Free calcium is often called ionized calciumAlthough technically a misnomer, terms are used interchangeably",
                    "sub_points": [
                      "Although technically a misnomer, terms are used interchangeably"
                    ]
                  },
                  {
                    "text": "Measurement of total calcium includes free and protein bound fractions"
                  },
                  {
                    "text": "In states of hypoalbuminemia, measured total calcium can be falsely lowEquation can be used to correct for decreased albuminCorrect total calcium (mg/dL) = Total calcium measured + 0.8 (4.4 - measured albumin)",
                    "sub_points": [
                      "Equation can be used to correct for decreased albuminCorrect total calcium (mg/dL) = Total calcium measured + 0.8 (4.4 - measured albumin)",
                      "Correct total calcium (mg/dL) = Total calcium measured + 0.8 (4.4 - measured albumin)"
                    ]
                  },
                  {
                    "text": "Measurement of free calcium is routinely obtained via ion-specific electrode"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hypercalcemia": [
                  {
                    "text": "Most commonly caused by calcium shift from intracellular to extracellular spaceIncreased intestinal absorptionIncreased renal retentionIncreased skeleton resorption",
                    "sub_points": [
                      "Increased intestinal absorption",
                      "Increased renal retention",
                      "Increased skeleton resorption"
                    ]
                  },
                  {
                    "text": "Causes of hypercalcemiaPrimary hyperparathyroidism (most common cause in outpatients)AdenomaMalignancy (most common cause in hospitalized patients)Skeletal metastasisPTHrpEndocrine disordersHyperthyroidism or hypothyroidismGranulomatous disease (sarcoidosis)Granuloma macrophages generate unregulated 1,25-dihydroxyvitamin D enhancing intestinal absorption of calciumRenal failure",
                    "sub_points": [
                      "Primary hyperparathyroidism (most common cause in outpatients)Adenoma",
                      "Adenoma",
                      "Malignancy (most common cause in hospitalized patients)Skeletal metastasisPTHrp",
                      "Skeletal metastasis",
                      "PTHrp",
                      "Endocrine disordersHyperthyroidism or hypothyroidism",
                      "Hyperthyroidism or hypothyroidism",
                      "Granulomatous disease (sarcoidosis)Granuloma macrophages generate unregulated 1,25-dihydroxyvitamin D enhancing intestinal absorption of calciumRenal failure",
                      "Granuloma macrophages generate unregulated 1,25-dihydroxyvitamin D enhancing intestinal absorption of calcium",
                      "Renal failure"
                    ]
                  },
                  {
                    "text": "Increased free calcium in blood causesDecreased neuromuscular excitability",
                    "sub_points": [
                      "Decreased neuromuscular excitability"
                    ]
                  }
                ],
                "Hypocalcemia": [
                  {
                    "text": "CausesHypoalbuminemiaHypoparathyroidismVitamin D deficiencyChronic renal failureMagnesium deficiency",
                    "sub_points": [
                      "Hypoalbuminemia",
                      "Hypoparathyroidism",
                      "Vitamin D deficiency",
                      "Chronic renal failure",
                      "Magnesium deficiency"
                    ]
                  },
                  {
                    "text": "Decreased free calcium in blood causesNeuromuscular excitabilityTetany",
                    "sub_points": [
                      "Neuromuscular excitability",
                      "Tetany"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Alteration in pH should be avoidedpH increases within specimen enhance negative charge on albuminIncreases calcium binding and decreases free calciumFor decreases in pH, opposite effect is observed",
                    "sub_points": [
                      "pH increases within specimen enhance negative charge on albuminIncreases calcium binding and decreases free calcium",
                      "Increases calcium binding and decreases free calcium",
                      "For decreases in pH, opposite effect is observed"
                    ]
                  },
                  {
                    "text": "Strategies to prevent pH shiftsMaintain specimen on icePrevents aerobic metabolismPrompt analysis",
                    "sub_points": [
                      "Maintain specimen on icePrevents aerobic metabolism",
                      "Prevents aerobic metabolism",
                      "Prompt analysis"
                    ]
                  },
                  {
                    "text": "Collect plasma sample in lithium heparin tubeOther anticoagulants can bind calcium, falsely lowering results",
                    "sub_points": [
                      "Other anticoagulants can bind calcium, falsely lowering results"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ion-Selective Electrodes": {
            "name": "Ion-Selective Electrodes",
            "url": "https://app.pathprimer.com/document/57f55ff6-844f-449d-8feb-d16a2c99981c/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "ISEs measure potential difference across selective membraneImportant membrane materialPotassium: Membranes incorporate antimicrobial valinomycin",
                    "sub_points": [
                      "Important membrane materialPotassium: Membranes incorporate antimicrobial valinomycin",
                      "Potassium: Membranes incorporate antimicrobial valinomycin"
                    ]
                  },
                  {
                    "text": "Electrolyte exclusion effectPhenomenon describes electrolyte exclusion seen when solids (proteins and lipids) are present in patient sampleProteins and lipids decrease water content, which can alter ion concentrations measuredSodium most commonly affectedSeen in indirect ISE measurements",
                    "sub_points": [
                      "Phenomenon describes electrolyte exclusion seen when solids (proteins and lipids) are present in patient sample",
                      "Proteins and lipids decrease water content, which can alter ion concentrations measured",
                      "Sodium most commonly affected",
                      "Seen in indirect ISE measurements"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ion-selective electrode (ISE)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Potentiometry": [
                  {
                    "text": "Used in clinical laboratories to measurepHpCO₂Various electrolytes",
                    "sub_points": [
                      "pH",
                      "pCO₂",
                      "Various electrolytes"
                    ]
                  },
                  {
                    "text": "Measures electrical potential differences between 2 electrodes (reference electrode and measuring electrode) in solution"
                  },
                  {
                    "text": "Reference electrode is held at constant voltageStandard reference electrodes are either calomel or Ag-AgCl types",
                    "sub_points": [
                      "Standard reference electrodes are either calomel or Ag-AgCl types"
                    ]
                  },
                  {
                    "text": "This potential difference correlates to analyte molar concentration in patient samplesDerived through Nernst equation",
                    "sub_points": [
                      "Derived through Nernst equation"
                    ]
                  },
                  {
                    "text": "Electrical potentials exist between metal interfaced with solutions containing ions of that metal"
                  },
                  {
                    "text": "Similar potential differences exist when semipermeable membrane separates ions at different concentrations"
                  }
                ],
                "Ion-Selective Electrodes": [
                  {
                    "text": "Most common indicator electrodes used in clinical laboratories"
                  },
                  {
                    "text": "Measure potential difference across selective membranePotential between selective membrane and sample solution is proportional to concentration of ion after logarithmic transformationSelective membranes differ depending on analyte measurement desiredSelectivity of membrane is crucial because clinical samples are complex mixturesNonanalyte ions could interfere with analysisImportant membrane materials include those used for sodium, potassium, chlorideSodiumMembranes composed of glassPotassiumPolymer membranes incorporate antimicrobial valinomycinChloridePolymer membranes incorporate ammonium salt anion exchangers such as tri-n-octylpropylammonium chloride decanol",
                    "sub_points": [
                      "Potential between selective membrane and sample solution is proportional to concentration of ion after logarithmic transformation",
                      "Selective membranes differ depending on analyte measurement desired",
                      "Selectivity of membrane is crucial because clinical samples are complex mixturesNonanalyte ions could interfere with analysis",
                      "Nonanalyte ions could interfere with analysis",
                      "Important membrane materials include those used for sodium, potassium, chlorideSodiumMembranes composed of glassPotassiumPolymer membranes incorporate antimicrobial valinomycinChloridePolymer membranes incorporate ammonium salt anion exchangers such as tri-n-octylpropylammonium chloride decanol",
                      "SodiumMembranes composed of glass",
                      "Membranes composed of glass",
                      "PotassiumPolymer membranes incorporate antimicrobial valinomycin",
                      "Polymer membranes incorporate antimicrobial valinomycin",
                      "ChloridePolymer membranes incorporate ammonium salt anion exchangers such as tri-n-octylpropylammonium chloride decanol",
                      "Polymer membranes incorporate ammonium salt anion exchangers such as tri-n-octylpropylammonium chloride decanol"
                    ]
                  },
                  {
                    "text": "ISEs seen commonly in 2 configurationsIndirectPatient sample mixed with volume of diluent within measurement chamberIndirect ISE is found in most automated chemistry analyzersDirectSample directly interacts with electrode without dilutionMost commonly used in dedicated blood gas analyzers",
                    "sub_points": [
                      "IndirectPatient sample mixed with volume of diluent within measurement chamberIndirect ISE is found in most automated chemistry analyzers",
                      "Patient sample mixed with volume of diluent within measurement chamber",
                      "Indirect ISE is found in most automated chemistry analyzers",
                      "DirectSample directly interacts with electrode without dilutionMost commonly used in dedicated blood gas analyzers",
                      "Sample directly interacts with electrode without dilution",
                      "Most commonly used in dedicated blood gas analyzers"
                    ]
                  }
                ],
                "Electrolyte Exclusion Effect": [
                  {
                    "text": "Phenomenon describes electrolyte exclusion seen when solids (proteins and lipids) are present in patient sampleProteins and lipids decrease water contentCan alter ion concentrations measuredSodium most commonly affected",
                    "sub_points": [
                      "Proteins and lipids decrease water contentCan alter ion concentrations measuredSodium most commonly affected",
                      "Can alter ion concentrations measured",
                      "Sodium most commonly affected"
                    ]
                  },
                  {
                    "text": "Seen in indirect ISE measurements"
                  }
                ]
              },
              "LIMITATIONS": {
                "Protein Coating": [
                  {
                    "text": "Over time, ISE membranes can develop protein coating or contamination that interferes with electrode response"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Chloride and Sweat Testing": {
            "name": "Chloride and Sweat Testing",
            "url": "https://app.pathprimer.com/document/0c7f1661-1461-4ebd-b743-77d3b14f6c0e/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Sweat chloride testing is used to confirm CF diagnosis"
                  },
                  {
                    "text": "CF is caused by defects in gene for CFTR protein, which regulates epithelial membrane transport of chloride; 1 in 20 whites are carriers of defective gene"
                  },
                  {
                    "text": "> 1,500 mutations have been identified, which makes molecular genetic analysis challenging and creates need for quantitative sweat chloride diagnostic testing"
                  }
                ],
                "Specimens": [
                  {
                    "text": "Hemolysis has minor impact on chloride measurement"
                  },
                  {
                    "text": "Posture change or use of tourniquet has minimal effectMost chloride not bound to protein",
                    "sub_points": [
                      "Most chloride not bound to protein"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Extracellular fluid (ECF)"
                  },
                  {
                    "text": "Intracellular fluid (ICF)"
                  },
                  {
                    "text": "Silver chloride (AgCl)"
                  },
                  {
                    "text": "Clinical and Laboratory Standards Institute (CLSI)"
                  },
                  {
                    "text": "Quantity not sufficient (QNS)"
                  },
                  {
                    "text": "Normal saline (NS)"
                  },
                  {
                    "text": "Cystic fibrosis (CF)"
                  },
                  {
                    "text": "Cystic fibrosis transmembrane conductance regulator (CFTR) protein"
                  },
                  {
                    "text": "Immunoreactive trypsinogen (IRT)"
                  },
                  {
                    "text": "College of American Pathologists (CAP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Physiology": [
                  {
                    "text": "Chloride is major extracellular anionChloride concentration much greater in ECF than ICFErythrocytes have low chloride concentration",
                    "sub_points": [
                      "Chloride concentration much greater in ECF than ICFErythrocytes have low chloride concentration",
                      "Erythrocytes have low chloride concentration"
                    ]
                  },
                  {
                    "text": "Chloride involved in various maintenance functionsBody water distributionECF ion balanceOsmotic pressure",
                    "sub_points": [
                      "Body water distribution",
                      "ECF ion balance",
                      "Osmotic pressure"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Quantitative Tests": [
                  {
                    "text": "Chloride concentration determined generally by 2 methodsCoulometric-amperometric titrationChloride measured by combining with silver ion (Ag⁺) forming insoluble AgClAg⁺ generated at constant rate by silver electrodeAfter equilibrium is reached, excess Ag⁺ in mixture inhibits further Ag⁺ generationTime elapsed from start to stop of Ag⁺ generation proportional to chloride amount in sampleMost precise method for measuring chloride over widest range of body fluid concentrations",
                    "sub_points": [
                      "Coulometric-amperometric titrationChloride measured by combining with silver ion (Ag⁺) forming insoluble AgClAg⁺ generated at constant rate by silver electrodeAfter equilibrium is reached, excess Ag⁺ in mixture inhibits further Ag⁺ generation",
                      "Chloride measured by combining with silver ion (Ag⁺) forming insoluble AgClAg⁺ generated at constant rate by silver electrodeAfter equilibrium is reached, excess Ag⁺ in mixture inhibits further Ag⁺ generation",
                      "Ag⁺ generated at constant rate by silver electrode",
                      "After equilibrium is reached, excess Ag⁺ in mixture inhibits further Ag⁺ generation",
                      "Time elapsed from start to stop of Ag⁺ generation proportional to chloride amount in sample",
                      "Most precise method for measuring chloride over widest range of body fluid concentrations"
                    ]
                  },
                  {
                    "text": "Ion-selective electrodesMost common method",
                    "sub_points": [
                      "Most common method"
                    ]
                  }
                ],
                "﻿Sweat Chloride Testing": [
                  {
                    "text": "Quantitative sweat testing guidelines provided by CLSI (document C34-A3)﻿> 48 hr oldPatient requirements> 2 weeks of age if asymptomaticPhysiologically stableAppropriate nutrition and hydrationNo acute illnessSkin integrity intact",
                    "sub_points": [
                      "> 48 hr old",
                      "Patient requirements> 2 weeks of age if asymptomaticPhysiologically stableAppropriate nutrition and hydrationNo acute illnessSkin integrity intact",
                      "> 2 weeks of age if asymptomatic",
                      "Physiologically stable",
                      "Appropriate nutrition and hydration",
                      "No acute illness",
                      "Skin integrity intact"
                    ]
                  },
                  {
                    "text": "Sweat testing divided into 3 partsSweat stimulationSmall electrical current usedDrug (pilocarpine) delivered by iontophoresis into sweat glandsInduces sweat gland secretionCollectionGeneral goal is collection of 75 mg of sweat in 30 minSweat collected using techniques that minimize evaporationOften via preweighed gauze padsCollecting correct volume is importantAvoids false-positive or false-negative resultsQNS samples must not be pooled",
                    "sub_points": [
                      "Sweat stimulationSmall electrical current usedDrug (pilocarpine) delivered by iontophoresis into sweat glandsInduces sweat gland secretion",
                      "Small electrical current used",
                      "Drug (pilocarpine) delivered by iontophoresis into sweat glands",
                      "Induces sweat gland secretion",
                      "CollectionGeneral goal is collection of 75 mg of sweat in 30 minSweat collected using techniques that minimize evaporationOften via preweighed gauze pads",
                      "General goal is collection of 75 mg of sweat in 30 min",
                      "Sweat collected using techniques that minimize evaporationOften via preweighed gauze pads",
                      "Often via preweighed gauze pads",
                      "Collecting correct volume is importantAvoids false-positive or false-negative results",
                      "Avoids false-positive or false-negative results",
                      "QNS samples must not be pooled"
                    ]
                  },
                  {
                    "text": "Analysis via quantitative testsLower limit of detection should be < 10 mmol/L",
                    "sub_points": [
                      "Lower limit of detection should be < 10 mmol/L"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Hyperchloremia": [
                  {
                    "text": "Causes of increased chlorideDehydration/fluid lossDiarrhea with sodium bicarbonate lossDiabetes insipidusIatrogenicExcessive NS administrationNS has ~ 154 mmol/L of chlorideRespiratory alkalosis",
                    "sub_points": [
                      "Dehydration/fluid lossDiarrhea with sodium bicarbonate loss",
                      "Diarrhea with sodium bicarbonate loss",
                      "Diabetes insipidus",
                      "IatrogenicExcessive NS administrationNS has ~ 154 mmol/L of chloride",
                      "Excessive NS administrationNS has ~ 154 mmol/L of chloride",
                      "NS has ~ 154 mmol/L of chloride",
                      "Respiratory alkalosis"
                    ]
                  }
                ],
                "﻿Hypochloremia": [
                  {
                    "text": "Causes of decreased chlorideCongestive heart failureCirrhosisRenal failureNephrotic syndromeRespiratory acidosis",
                    "sub_points": [
                      "Congestive heart failure",
                      "Cirrhosis",
                      "Renal failure",
                      "Nephrotic syndrome",
                      "Respiratory acidosis"
                    ]
                  }
                ],
                "﻿Diagnosis of Acid-Base Abnormality": [
                  {
                    "text": "Plasma chloride concentration essential forAnion gap calculationAcid-base disorder differential diagnosis",
                    "sub_points": [
                      "Anion gap calculation",
                      "Acid-base disorder differential diagnosis"
                    ]
                  }
                ],
                "﻿Cystic Fibrosis": [
                  {
                    "text": "Sweat chloride testing used to confirm CF diagnosis"
                  },
                  {
                    "text": "CF caused by defects in gene for CFTR proteinCFTR protein regulates epithelial membrane transport of chloride1 in 20 whites are carriers of defective gene",
                    "sub_points": [
                      "CFTR protein regulates epithelial membrane transport of chloride",
                      "1 in 20 whites are carriers of defective gene"
                    ]
                  },
                  {
                    "text": "> 1,500 mutations have been identifiedMakes molecular genetic analysis challengingCreates need for quantitative sweat chloride diagnostic testing",
                    "sub_points": [
                      "Makes molecular genetic analysis challenging",
                      "Creates need for quantitative sweat chloride diagnostic testing"
                    ]
                  },
                  {
                    "text": "Sweat testing widely performed in concert with newborn screening programs"
                  },
                  {
                    "text": "Newborn screening often starts with dried blood spot analysis by IRT assay or DNA testingPositive screening results referred for sweat testing",
                    "sub_points": [
                      "Positive screening results referred for sweat testing"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "﻿Collection": [
                  {
                    "text": "Hemolysis has minor impact on chloride measurement"
                  },
                  {
                    "text": "Posture change or use of tourniquet has minimal effectMost chloride not bound to protein",
                    "sub_points": [
                      "Most chloride not bound to protein"
                    ]
                  }
                ],
                "﻿Sweat Chloride Reference Intervals": [
                  {
                    "text": "< 6 months of age: Approximate values< 29 mmol/L (CF unlikely)30-59 mmol/L (intermediate risk)> 60 mmol/L (consistent with CF)",
                    "sub_points": [
                      "< 29 mmol/L (CF unlikely)",
                      "30-59 mmol/L (intermediate risk)",
                      "> 60 mmol/L (consistent with CF)"
                    ]
                  },
                  {
                    "text": "> 6 months of age: Approximate values< 39 mmol/L (CF unlikely)40-59 mmol/L (intermediate risk)> 60 mmol/L (consistent with CF)",
                    "sub_points": [
                      "< 39 mmol/L (CF unlikely)",
                      "40-59 mmol/L (intermediate risk)",
                      "> 60 mmol/L (consistent with CF)"
                    ]
                  }
                ]
              },
              "QUALITY": {
                "﻿Sweat Chloride": [
                  {
                    "text": "Robust quality assurance programs for sweat chloride testing includeParticipation in CAP proficiency testing programMonitoring QNS collection ratesGeneral goals10% QNS for < 3 months old5% QNS for > 3 months old",
                    "sub_points": [
                      "Participation in CAP proficiency testing program",
                      "Monitoring QNS collection ratesGeneral goals10% QNS for < 3 months old5% QNS for > 3 months old",
                      "General goals10% QNS for < 3 months old5% QNS for > 3 months old",
                      "10% QNS for < 3 months old",
                      "5% QNS for > 3 months old"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Osmolality": {
            "name": "Osmolality",
            "url": "https://app.pathprimer.com/document/2cafa3d4-48a7-4e7e-a9ef-8363b9290211/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Four properties of solution (colligative) are changed when a solute is dissolved in a solvent"
                  },
                  {
                    "text": "Serum osmolality (mOsmol/kg) = 1.86 [Na⁺ (mmol/L) + glucose (mg/dL)]/18 + urea (mg/dL)/2.8Freezing point (decreased)Vapor pressure (decreased)Boiling point (increased)Osmotic pressure (increased)",
                    "sub_points": [
                      "Freezing point (decreased)",
                      "Vapor pressure (decreased)",
                      "Boiling point (increased)",
                      "Osmotic pressure (increased)"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Osmolality (measured via osmometry) ₋ osmolality (calculated)"
                  },
                  {
                    "text": "Normal osmolal gap < 10 mOsm/kg"
                  }
                ]
              },
              "OVERVIEW": {
                "﻿Osmolality": [
                  {
                    "text": "Osmolality is number of moles of particles per kg of water"
                  },
                  {
                    "text": "Major osmotic substances found in plasmaSodium (Na⁺)Chloride (Cl⁻)GlucoseUrea",
                    "sub_points": [
                      "Sodium (Na⁺)",
                      "Chloride (Cl⁻)",
                      "Glucose",
                      "Urea"
                    ]
                  },
                  {
                    "text": "Osmolality calculated through following equationSerum osmolality (mOsmol/kg) = 1.86 [Na⁺ (mmol/L) + glucose (mg/dL)]/18 + urea (mg/dL)/2.8Some forms of equation add ethanol (mg/dL)/3.8Numbers dividing glucose, urea, and ethanol used to convert mg/dL to mmol/L",
                    "sub_points": [
                      "Serum osmolality (mOsmol/kg) = 1.86 [Na⁺ (mmol/L) + glucose (mg/dL)]/18 + urea (mg/dL)/2.8",
                      "Some forms of equation add ethanol (mg/dL)/3.8",
                      "Numbers dividing glucose, urea, and ethanol used to convert mg/dL to mmol/L"
                    ]
                  },
                  {
                    "text": "Normal serum osmolality = 275-300 mOsm/kg of water"
                  }
                ],
                "﻿Colligative Properties": [
                  {
                    "text": "Four properties of solution (colligative) are changed when a solute is dissolved in a solventFreezing point (decreased)Vapor pressure (decreased)Boiling point (increased)Osmotic pressure (increased)",
                    "sub_points": [
                      "Freezing point (decreased)",
                      "Vapor pressure (decreased)",
                      "Boiling point (increased)",
                      "Osmotic pressure (increased)"
                    ]
                  },
                  {
                    "text": "These colligative properties depend on number of particles (molal concentration) introduced into solution"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Osmolality: Number of moles of solute per mass (kg) of solvent (water)"
                  },
                  {
                    "text": "Osmolarity: Number of moles of solute per volume (liter)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Osmometry": [
                  {
                    "text": "Osmolality is measured by a technique used to measure solute particle concentration, termed osmometry"
                  },
                  {
                    "text": "Common clinical laboratory osmometers function on the freezing point colligative property of solutionWhen a mole of any nonionic solute is dissolved in 1 kg of water, the freezing point of the solution is depressed by a known amount (1.86°C for water)Ionic solutes (solutes that dissociate such as sodium chloride) cause more profound freezing point depression",
                    "sub_points": [
                      "When a mole of any nonionic solute is dissolved in 1 kg of water, the freezing point of the solution is depressed by a known amount (1.86°C for water)",
                      "Ionic solutes (solutes that dissociate such as sodium chloride) cause more profound freezing point depression"
                    ]
                  },
                  {
                    "text": "Procedurally, patient specimen (often serum) is first rapidly cooled below freezing (₋7°C)"
                  },
                  {
                    "text": "A brief vibration is then introduced causing crystallization, and heat is released, termed heat of fusion"
                  },
                  {
                    "text": "Rate of heat release reaches an equilibrium, termed freezing point temperature, and stays constant for minutes"
                  },
                  {
                    "text": "This temperature is measured by a sensitive thermistor"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Osmolal Gap": [
                  {
                    "text": "Serum osmolality determination used to calculate osmotic gap in assessment of electrolyte and acid-base disorders"
                  },
                  {
                    "text": "Serum osmolal gap is calculated asOsmolality (measured via osmometry) ₋ osmolality (calculated)Normal osmolal gap < 10 mOsm/kgDifference due to normal ions present and not accounted for in calculation (potassium, calcium, proteins)",
                    "sub_points": [
                      "Osmolality (measured via osmometry) ₋ osmolality (calculated)",
                      "Normal osmolal gap < 10 mOsm/kg",
                      "Difference due to normal ions present and not accounted for in calculation (potassium, calcium, proteins)"
                    ]
                  },
                  {
                    "text": "Large abnormal osmolal gaps (> 40 mOsm/kg) suggests presence of additional solutes"
                  },
                  {
                    "text": "These solutes may be toxic and contributing to patient’s clinical pictureMetabolic by-products due to endogenous disorderExogenous substances (ethylene glycol, methanol)",
                    "sub_points": [
                      "Metabolic by-products due to endogenous disorder",
                      "Exogenous substances (ethylene glycol, methanol)"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Preferred specimen is serum, removed from cells promptly, without use of anticoagulant"
                  },
                  {
                    "text": "Centrifuged urine and body fluids also acceptableTo account for variability in random urine analytes, 24-hour collection of urine preferred",
                    "sub_points": [
                      "To account for variability in random urine analytes, 24-hour collection of urine preferred"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Preanalytical Variables in Electrolyte Measurement": {
            "name": "Preanalytical Variables in Electrolyte Measurement",
            "url": "https://app.pathprimer.com/document/11356f27-762f-4dec-8b6f-d16a5ce6a372/lesson/6ca1b46d-71d4-44ae-9c15-249e67e3ff1a",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Postural effectsUpon standing, venous pressure increasesResults in fluid flow from intravascular to extravascular spaceWhile electrolytes are small and will move freely between intravascular and extravascular spaces, protein-bound fraction of electrolytes can be retainedFalsely elevates total calcium measurement by up to 10%Portion of magnesium bound to albumin can be falsely elevated up to 5%",
                    "sub_points": [
                      "Upon standing, venous pressure increases",
                      "Results in fluid flow from intravascular to extravascular space",
                      "While electrolytes are small and will move freely between intravascular and extravascular spaces, protein-bound fraction of electrolytes can be retainedFalsely elevates total calcium measurement by up to 10%Portion of magnesium bound to albumin can be falsely elevated up to 5%",
                      "Falsely elevates total calcium measurement by up to 10%",
                      "Portion of magnesium bound to albumin can be falsely elevated up to 5%"
                    ]
                  },
                  {
                    "text": "Exercise-induced lactate production affects pH, thereby altering protein-bound calcium fractionIncreased ionized calcium levels",
                    "sub_points": [
                      "Increased ionized calcium levels"
                    ]
                  },
                  {
                    "text": "Prolonged tourniquet application results in hemoconcentrationProduces effects similar to those seen with posture",
                    "sub_points": [
                      "Produces effects similar to those seen with posture"
                    ]
                  },
                  {
                    "text": "Order of collectionTubes with additives should be drawn last to eliminate contaminationError results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                    "sub_points": [
                      "Tubes with additives should be drawn last to eliminate contaminationError results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                      "Error results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                      "EDTA falsely increases potassium",
                      "Lowers magnesium and calcium levels through chelation"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytical Considerations in Electrolyte Measurement": [
                  {
                    "text": "Electrolyte measurement interpretation requires consideration for a number of preanalytical variables"
                  },
                  {
                    "text": "Physiological variablesPostural effectsUpon standing, venous pressure increasesResults in fluid flow from intravascular to extravascular spaceIncreases concentration of cellular and protein fractions with up to 15% decrease in plasma volumeWhile electrolytes are small and will move freely between intravascular and extravascular spaces, protein-bound fraction of electrolytes can be retainedFalsely elevates total calcium measurement by up to 10%Portion of magnesium bound to albumin can be falsely elevated up to 5%Standing posture activates renin-angiotensin aldosterone system thereby affecting renal sodium and potassium handlingFood intakeTransient post-prandial increases in phosphate (15%) and potassium (5%) are observedExerciseCan induce intracellular ion releasePotassiumMagnesiumPhosphateExercise-induced lactate production affects pH, thereby altering protein-bound calcium fractionIncreased ionized calcium levelsDrugsACE inhibitors and diuretics affect renal handling of electrolytesStressCatecholamines induce influx of potassium and phosphate into cellsSeasonal pseudohyperkalemiaSome literature shows patient sample exposure to temperature variations during transport to laboratory can affect potassium measurementPotassium has been observed to have lower average levels in summer, and higher average levels in winter",
                    "sub_points": [
                      "Postural effectsUpon standing, venous pressure increasesResults in fluid flow from intravascular to extravascular spaceIncreases concentration of cellular and protein fractions with up to 15% decrease in plasma volumeWhile electrolytes are small and will move freely between intravascular and extravascular spaces, protein-bound fraction of electrolytes can be retainedFalsely elevates total calcium measurement by up to 10%Portion of magnesium bound to albumin can be falsely elevated up to 5%Standing posture activates renin-angiotensin aldosterone system thereby affecting renal sodium and potassium handling",
                      "Upon standing, venous pressure increasesResults in fluid flow from intravascular to extravascular spaceIncreases concentration of cellular and protein fractions with up to 15% decrease in plasma volume",
                      "Results in fluid flow from intravascular to extravascular space",
                      "Increases concentration of cellular and protein fractions with up to 15% decrease in plasma volume",
                      "While electrolytes are small and will move freely between intravascular and extravascular spaces, protein-bound fraction of electrolytes can be retainedFalsely elevates total calcium measurement by up to 10%Portion of magnesium bound to albumin can be falsely elevated up to 5%",
                      "Falsely elevates total calcium measurement by up to 10%",
                      "Portion of magnesium bound to albumin can be falsely elevated up to 5%",
                      "Standing posture activates renin-angiotensin aldosterone system thereby affecting renal sodium and potassium handling",
                      "Food intakeTransient post-prandial increases in phosphate (15%) and potassium (5%) are observed",
                      "Transient post-prandial increases in phosphate (15%) and potassium (5%) are observed",
                      "ExerciseCan induce intracellular ion releasePotassiumMagnesiumPhosphateExercise-induced lactate production affects pH, thereby altering protein-bound calcium fractionIncreased ionized calcium levels",
                      "Can induce intracellular ion releasePotassiumMagnesiumPhosphate",
                      "Potassium",
                      "Magnesium",
                      "Phosphate",
                      "Exercise-induced lactate production affects pH, thereby altering protein-bound calcium fractionIncreased ionized calcium levels",
                      "Increased ionized calcium levels",
                      "DrugsACE inhibitors and diuretics affect renal handling of electrolytes",
                      "ACE inhibitors and diuretics affect renal handling of electrolytes",
                      "StressCatecholamines induce influx of potassium and phosphate into cells",
                      "Catecholamines induce influx of potassium and phosphate into cells",
                      "Seasonal pseudohyperkalemiaSome literature shows patient sample exposure to temperature variations during transport to laboratory can affect potassium measurementPotassium has been observed to have lower average levels in summer, and higher average levels in winter",
                      "Some literature shows patient sample exposure to temperature variations during transport to laboratory can affect potassium measurementPotassium has been observed to have lower average levels in summer, and higher average levels in winter",
                      "Potassium has been observed to have lower average levels in summer, and higher average levels in winter"
                    ]
                  },
                  {
                    "text": "Sample collectionProlonged tourniquet application results in hemoconcentrationProduces effects similar to those seen in postureWhen coupled with fist clenching, increased intracellular potassium release occursDecreased pH is also seenIncreases ionized calciumNeedle gaugeIn vitro hemolysisOrder of collectionTubes with additives should be drawn last to eliminate contaminationError results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                    "sub_points": [
                      "Prolonged tourniquet application results in hemoconcentrationProduces effects similar to those seen in postureWhen coupled with fist clenching, increased intracellular potassium release occursDecreased pH is also seenIncreases ionized calcium",
                      "Produces effects similar to those seen in posture",
                      "When coupled with fist clenching, increased intracellular potassium release occurs",
                      "Decreased pH is also seenIncreases ionized calcium",
                      "Increases ionized calcium",
                      "Needle gaugeIn vitro hemolysis",
                      "In vitro hemolysis",
                      "Order of collectionTubes with additives should be drawn last to eliminate contaminationError results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                      "Tubes with additives should be drawn last to eliminate contamination",
                      "Error results from drawing purple top (EDTA) at inappropriate timeEDTA falsely increases potassiumLowers magnesium and calcium levels through chelation",
                      "EDTA falsely increases potassium",
                      "Lowers magnesium and calcium levels through chelation"
                    ]
                  },
                  {
                    "text": "Sample handlingAdditives require sample tube inversion for mixing and accurate subsequent analysisAggressive mixing or handling can cause spurious hyperkalemia due to hemolysis",
                    "sub_points": [
                      "Additives require sample tube inversion for mixing and accurate subsequent analysis",
                      "Aggressive mixing or handling can cause spurious hyperkalemia due to hemolysis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Lipids": {
        "name": "Lipids",
        "url": "https://app.pathprimer.com/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
        "topics": {
          "LDL Measurement": {
            "name": "LDL Measurement",
            "url": "https://app.pathprimer.com/document/1cce9440-d9e3-45b9-8cc6-e6b83bb227ae/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Measured values used to calculate LDL-C (mg/dL)LDL-C = Total cholesterol ₋ HDL cholesterol ₋ [triglyceride/5]",
                    "sub_points": [
                      "LDL-C = Total cholesterol ₋ HDL cholesterol ₋ [triglyceride/5]"
                    ]
                  }
                ],
                "Limitations": [
                  {
                    "text": "Friedewald equation inaccurate in certain samplesTriglyceride concentration > 400 mg/dLCalculated LDL-C falsely depressedHigh chylomicronsNonfastingType III dyslipidemia (dysbetalipoproteinemia)",
                    "sub_points": [
                      "Triglyceride concentration > 400 mg/dLCalculated LDL-C falsely depressed",
                      "Calculated LDL-C falsely depressed",
                      "High chylomicronsNonfastingType III dyslipidemia (dysbetalipoproteinemia)",
                      "Nonfasting",
                      "Type III dyslipidemia (dysbetalipoproteinemia)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Low-density lipoprotein cholesterol (LDL-C)"
                  },
                  {
                    "text": "National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  },
                  {
                    "text": "Very-low-density lipoprotein (VLDL)"
                  },
                  {
                    "text": "Intermediate-density lipoprotein (IDL)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Indirect Methods": [
                  {
                    "text": "Friedewald equation first described in 1972 by Friedewald et al.Most common and important method of LDL-C determinationNCEP ATP-III LDL recommendations based on measurement by Friedewald equationTotal cholesterol, triglycerides, and HDL cholesterol measured directly by routine methodsMeasured values used to calculate LDL-C (mg/dL)LDL-C = Total cholesterol ₋ HDL cholesterol ₋ [triglyceride/5]If LDL-C reported in mmol/L, use triglyceride/2.22Triglyceride/5 or triglyceride/2.22 represents VLDL cholesterolVLDL cholesterol contains largest quantity of triglyceride",
                    "sub_points": [
                      "Most common and important method of LDL-C determinationNCEP ATP-III LDL recommendations based on measurement by Friedewald equation",
                      "NCEP ATP-III LDL recommendations based on measurement by Friedewald equation",
                      "Total cholesterol, triglycerides, and HDL cholesterol measured directly by routine methods",
                      "Measured values used to calculate LDL-C (mg/dL)LDL-C = Total cholesterol ₋ HDL cholesterol ₋ [triglyceride/5]If LDL-C reported in mmol/L, use triglyceride/2.22",
                      "LDL-C = Total cholesterol ₋ HDL cholesterol ₋ [triglyceride/5]If LDL-C reported in mmol/L, use triglyceride/2.22",
                      "If LDL-C reported in mmol/L, use triglyceride/2.22",
                      "Triglyceride/5 or triglyceride/2.22 represents VLDL cholesterolVLDL cholesterol contains largest quantity of triglyceride",
                      "VLDL cholesterol contains largest quantity of triglyceride"
                    ]
                  },
                  {
                    "text": "Chemical precipitationTotal cholesterol measuredLDL-C precipitated, and cholesterol measured againDifference represents LDL-C fractionAccurate if triglyceride is low",
                    "sub_points": [
                      "Total cholesterol measured",
                      "LDL-C precipitated, and cholesterol measured again",
                      "Difference represents LDL-C fraction",
                      "Accurate if triglyceride is low"
                    ]
                  },
                  {
                    "text": "Beta quantificationReference method to measure LDL-CMore reflective of LDL-C because triglyceride-rich fraction removedPlasma sample undergoes ultracentrifugation105,000gfor at least 18 hoursSupernatant is discardedContains triglyceride-rich lipoproteins (chylomicrons and VLDL)Total cholesterol of remaining solution measuredContains LDL and HDLLDL precipitated, and cholesterol measured once moreLDL-C calculated by difference in 2 measurementsMethod also better represents cholesterol transported by proatherogenic particlesCaptures IDL-C and Lp(a) in measurement",
                    "sub_points": [
                      "Reference method to measure LDL-C",
                      "More reflective of LDL-C because triglyceride-rich fraction removed",
                      "Plasma sample undergoes ultracentrifugation105,000gfor at least 18 hours",
                      "105,000gfor at least 18 hours",
                      "Supernatant is discardedContains triglyceride-rich lipoproteins (chylomicrons and VLDL)",
                      "Contains triglyceride-rich lipoproteins (chylomicrons and VLDL)",
                      "Total cholesterol of remaining solution measuredContains LDL and HDL",
                      "Contains LDL and HDL",
                      "LDL precipitated, and cholesterol measured once more",
                      "LDL-C calculated by difference in 2 measurements",
                      "Method also better represents cholesterol transported by proatherogenic particlesCaptures IDL-C and Lp(a) in measurement",
                      "Captures IDL-C and Lp(a) in measurement"
                    ]
                  }
                ],
                "﻿Direct Methods": [
                  {
                    "text": "No better than calculated LDL-C (Friedewald equation) in patient treatment group classificationAssuming triglyceride level < 400 mg/dL",
                    "sub_points": [
                      "Assuming triglyceride level < 400 mg/dL"
                    ]
                  },
                  {
                    "text": "Direct methods useful in certain clinical situationsWhen triglycerides are elevated (> 400 mg/dL)Nonfasting individuals",
                    "sub_points": [
                      "When triglycerides are elevated (> 400 mg/dL)",
                      "Nonfasting individuals"
                    ]
                  },
                  {
                    "text": "Various methods available, but most share general 2-reagent approachFirst reagent removes non-LDL lipoproteinSecond reagent induces cholesterol release from LDLReleased LDL-C then measured enzymatically",
                    "sub_points": [
                      "First reagent removes non-LDL lipoprotein",
                      "Second reagent induces cholesterol release from LDL",
                      "Released LDL-C then measured enzymatically"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Atherosclerosis": [
                  {
                    "text": "LDL-C level shown to have causal role in atherosclerosis development"
                  },
                  {
                    "text": "Initiation of cholesterol-lowering therapy directed by LDL-C level"
                  }
                ]
              },
              "LIMITATIONS": {
                "﻿Inaccuracy": [
                  {
                    "text": "Friedewald equation inaccurate in certain samplesTriglyceride concentration > 400 mg/dLCalculated LDL-C falsely depressedHigh chylomicronsNonfastingType III dyslipidemia (dysbetalipoproteinemia)",
                    "sub_points": [
                      "Triglyceride concentration > 400 mg/dLCalculated LDL-C falsely depressed",
                      "Calculated LDL-C falsely depressed",
                      "High chylomicronsNonfastingType III dyslipidemia (dysbetalipoproteinemia)",
                      "Nonfasting",
                      "Type III dyslipidemia (dysbetalipoproteinemia)"
                    ]
                  },
                  {
                    "text": "Limitations do not justify added expense of direct LDL-C measurementIf triglycerides > 400 mg/dL, focus of therapy will be first lowering triglycerides",
                    "sub_points": [
                      "If triglycerides > 400 mg/dL, focus of therapy will be first lowering triglycerides"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Patients should be fasting at least 9 hours (preferably 12 hours)Chylomicrons increase in postprandial plasmaMainly affects LDL-C and triglyceride measurement",
                    "sub_points": [
                      "Chylomicrons increase in postprandial plasmaMainly affects LDL-C and triglyceride measurement",
                      "Mainly affects LDL-C and triglyceride measurement"
                    ]
                  },
                  {
                    "text": "NCEP guidelines also recommendPatients sit for 5 minutes before venipunctureTourniquet not applied for > 1-2 minutesBoth recommendations help prevent hemoconcentration of cholesterol",
                    "sub_points": [
                      "Patients sit for 5 minutes before venipuncture",
                      "Tourniquet not applied for > 1-2 minutes",
                      "Both recommendations help prevent hemoconcentration of cholesterol"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lipoprotein Classes": {
            "name": "Lipoprotein Classes",
            "url": "https://app.pathprimer.com/document/cba2dd7e-30b0-46f2-9fd6-88844798fdd4/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Apolipoprotein E2 associated with type 3 hyperlipoproteinemia"
                  },
                  {
                    "text": "Apolipoprotein E4 associated with high risk of Alzheimer disease"
                  }
                ]
              },
              "OVERVIEW": {
                "﻿Lipoproteins": [
                  {
                    "text": "Lipids are transported in plasma within macromolecular complexes known as lipoproteins"
                  },
                  {
                    "text": "Lipoprotein particles take on spherical shape with nonpolar lipids (cholesterol, ester, and triglycerides) in their core and polar lipids (phospholipids) at their surface"
                  },
                  {
                    "text": "Proteins called apolipoproteins are embedded on their surface"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Very-low-density lipoprotein (VLDL)"
                  },
                  {
                    "text": "Intermediate-density lipoprotein (IDL)"
                  },
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  },
                  {
                    "text": "Lipoprotein A (Lp(a))"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Classes of Lipoprotein": [
                  {
                    "text": "Lipoproteins have varying proportions of lipids and proteins, imparting unique physical and chemical properties"
                  },
                  {
                    "text": "Lipoproteins can be differentiated by density (ultracentrifugation) into 6 classesChylomicronsContain mainly triglycerideVLDLIDLLDLCarries approximately 70% of total plasma cholesterolHDLCarries 20%-30% of plasma cholesterolLp(a)Distinct class, structurally related to LDLBoth lipoproteins process apolipoprotein B-100Unique because it contains apolipoprotein AProcesses significant homology with plasminogen",
                    "sub_points": [
                      "ChylomicronsContain mainly triglyceride",
                      "Contain mainly triglyceride",
                      "VLDL",
                      "IDL",
                      "LDLCarries approximately 70% of total plasma cholesterol",
                      "Carries approximately 70% of total plasma cholesterol",
                      "HDLCarries 20%-30% of plasma cholesterol",
                      "Carries 20%-30% of plasma cholesterol",
                      "Lp(a)Distinct class, structurally related to LDLBoth lipoproteins process apolipoprotein B-100Unique because it contains apolipoprotein AProcesses significant homology with plasminogen",
                      "Distinct class, structurally related to LDLBoth lipoproteins process apolipoprotein B-100",
                      "Both lipoproteins process apolipoprotein B-100",
                      "Unique because it contains apolipoprotein AProcesses significant homology with plasminogen",
                      "Processes significant homology with plasminogen"
                    ]
                  },
                  {
                    "text": "Larger lipoproteins contain more nonpolar lipids at their core and less apolipoprotein at their surface"
                  },
                  {
                    "text": "Each lipoprotein class carries varying proportions of apolipoproteinsHDL (Apo A-I major protein)LDL and Lp(a) (Apo B-100 major protein)Chylomicrons (B-48 major protein)",
                    "sub_points": [
                      "HDL (Apo A-I major protein)",
                      "LDL and Lp(a) (Apo B-100 major protein)",
                      "Chylomicrons (B-48 major protein)"
                    ]
                  },
                  {
                    "text": "Apolipoprotein functionsAct as ligand for cell receptors facilitating lipoprotein cellular uptakeModulation of enzymes acting on lipoproteinsSupport structural integrity of lipoproteins",
                    "sub_points": [
                      "Act as ligand for cell receptors facilitating lipoprotein cellular uptake",
                      "Modulation of enzymes acting on lipoproteins",
                      "Support structural integrity of lipoproteins"
                    ]
                  },
                  {
                    "text": "Certain apolipoproteins possess significant characteristicsApolipoprotein E possess 3 isoforms (E2, E3, E4)E2 associated with type 3 hyperlipoproteinemiaE4 associated with high risk of Alzheimer disease",
                    "sub_points": [
                      "Apolipoprotein E possess 3 isoforms (E2, E3, E4)E2 associated with type 3 hyperlipoproteinemiaE4 associated with high risk of Alzheimer disease",
                      "E2 associated with type 3 hyperlipoproteinemia",
                      "E4 associated with high risk of Alzheimer disease"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Electrophoresis": [
                  {
                    "text": "Early analysis of lipoproteins involved electrophoretic separation at pH 8.6This forms early phenotypic classification of inherited dyslipidemiasElectrophoretic regions toward the anode includeα > pre-β > β > origin",
                    "sub_points": [
                      "This forms early phenotypic classification of inherited dyslipidemias",
                      "Electrophoretic regions toward the anode includeα > pre-β > β > origin",
                      "α > pre-β > β > origin"
                    ]
                  },
                  {
                    "text": "Lipoproteins have distinct migration pattern on high-resolution electrophoresisHDL (α)VLDL (pre-β)Lp(a) (pre-β)IDL (broad band pre-β to β)LDL (β)Chylomicron (origin)",
                    "sub_points": [
                      "HDL (α)",
                      "VLDL (pre-β)",
                      "Lp(a) (pre-β)",
                      "IDL (broad band pre-β to β)",
                      "LDL (β)",
                      "Chylomicron (origin)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Quantification of Non-LDL Cholesterol": {
            "name": "Laboratory Quantification of Non-LDL Cholesterol",
            "url": "https://app.pathprimer.com/document/6e8a5158-dd6c-46d9-a761-aeafb189b86f/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Routine measurement of cholesterol is done by enzymatic methodsCholesteryl ester + H₂O → cholesterol + fatty acidCholesterol + O₂ → choles-4-en-3-one + H₂O₂",
                    "sub_points": [
                      "Cholesteryl ester + H₂O → cholesterol + fatty acid",
                      "Cholesterol + O₂ → choles-4-en-3-one + H₂O₂"
                    ]
                  },
                  {
                    "text": "H₂O₂ produced is catalyzed by peroxidase to form colored dye that absorbs light at 500 nm"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Interferences in enzymatic methods for cholesterol measurement include ascorbic acid (vitamin C)"
                  },
                  {
                    "text": "Considerations in triglyceride methods include increased glycerol (metabolism or disease states) that could alter triglyceride measurement"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  },
                  {
                    "text": "Very-low-density lipoprotein (VLDL)"
                  },
                  {
                    "text": "Intermediate-density lipoprotein (IDL)"
                  },
                  {
                    "text": "Lipoprotein A (Lp(a))"
                  },
                  {
                    "text": "Low-density lipoprotein (LDL)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Measurement of Cholesterol": [
                  {
                    "text": "Routine measurement of cholesterol done by enzymatic methodsCommon approach includes first using cholesterol esterase, then cholesterol oxidase to catalyze 2 reactionsCholesteryl ester + H₂O → cholesterol + fatty acidCholesterol + O₂ → choles-4-en-3-one + H₂O₂H₂O₂ produced is catalyzed by peroxidase to form colored dye that absorbs light at 500 nmH₂O₂ +phenol + 4-aminoantipyrine → quinone imine dye + 2 H₂O",
                    "sub_points": [
                      "Common approach includes first using cholesterol esterase, then cholesterol oxidase to catalyze 2 reactionsCholesteryl ester + H₂O → cholesterol + fatty acidCholesterol + O₂ → choles-4-en-3-one + H₂O₂",
                      "Cholesteryl ester + H₂O → cholesterol + fatty acid",
                      "Cholesterol + O₂ → choles-4-en-3-one + H₂O₂",
                      "H₂O₂ produced is catalyzed by peroxidase to form colored dye that absorbs light at 500 nmH₂O₂ +phenol + 4-aminoantipyrine → quinone imine dye + 2 H₂O",
                      "H₂O₂ +phenol + 4-aminoantipyrine → quinone imine dye + 2 H₂O"
                    ]
                  }
                ],
                "Measurement of Triglycerides": [
                  {
                    "text": "Enzymatic methods used in routine triglyceride measurementMethod enzyme sequences vary but generally start with lipase-mediated triglyceride hydrolysisTriglyceride + 3 H₂O → glycerol + 3 fatty acidsGlycerol formed undergoes reaction with glycerol kinaseGlycerol + ATP → glycerophosphate + ADPGlycerol-3-phosphate oxidase catalyzes reaction with eventual H₂O₂ productionGlycerol-3-phosphate + O₂ → dihydroxyacetone + H₂O₂As in case of cholesterol measurement, H₂O₂ produced is used to produce color change (light absorbed at 500 nm)",
                    "sub_points": [
                      "Method enzyme sequences vary but generally start with lipase-mediated triglyceride hydrolysisTriglyceride + 3 H₂O → glycerol + 3 fatty acids",
                      "Triglyceride + 3 H₂O → glycerol + 3 fatty acids",
                      "Glycerol formed undergoes reaction with glycerol kinaseGlycerol + ATP → glycerophosphate + ADP",
                      "Glycerol + ATP → glycerophosphate + ADP",
                      "Glycerol-3-phosphate oxidase catalyzes reaction with eventual H₂O₂ productionGlycerol-3-phosphate + O₂ → dihydroxyacetone + H₂O₂",
                      "Glycerol-3-phosphate + O₂ → dihydroxyacetone + H₂O₂",
                      "As in case of cholesterol measurement, H₂O₂ produced is used to produce color change (light absorbed at 500 nm)"
                    ]
                  }
                ],
                "Measurement of HDL": [
                  {
                    "text": "Measurement of HDL classically involved removal (precipitation with polyanions and subsequent centrifugation) of non-HDL lipoproteinsVLDL, IDL, Lp(a), LDL, chylomicrons",
                    "sub_points": [
                      "VLDL, IDL, Lp(a), LDL, chylomicrons"
                    ]
                  },
                  {
                    "text": "Supernatant after centrifugation contains only HDLHDL measured enzymatically",
                    "sub_points": [
                      "HDL measured enzymatically"
                    ]
                  },
                  {
                    "text": "Automated direct methods (homogeneous assays) currently available for HDL measurementFirst a stable complex is formed with non-HDL lipoproteins essentially blocking their participation in assay reactionsA second reagent is added that releases cholesterol in HDL moleculeCholesterol is measured through enzymatic methods",
                    "sub_points": [
                      "First a stable complex is formed with non-HDL lipoproteins essentially blocking their participation in assay reactions",
                      "A second reagent is added that releases cholesterol in HDL molecule",
                      "Cholesterol is measured through enzymatic methods"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Interferences": [
                  {
                    "text": "Interferences in enzymatic methods for cholesterol measurementAscorbic acid (vitamin C)BilirubinHemoglobin",
                    "sub_points": [
                      "Ascorbic acid (vitamin C)",
                      "Bilirubin",
                      "Hemoglobin"
                    ]
                  },
                  {
                    "text": "Assays require dilution protocols above cholesterol values of 700 mg/dLTypical upper limit of assay linearity",
                    "sub_points": [
                      "Typical upper limit of assay linearity"
                    ]
                  },
                  {
                    "text": "Considerations in triglyceride methodsIncreased glycerol (metabolism or disease states) could alter triglyceride measurement",
                    "sub_points": [
                      "Increased glycerol (metabolism or disease states) could alter triglyceride measurement"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "National Cholesterol Education Program ATP III Guidelines": {
            "name": "National Cholesterol Education Program ATP III Guidelines",
            "url": "https://app.pathprimer.com/document/cd9c1bff-c497-4582-96b1-a436165745cc/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "LDL-C< 100 (optimal)100-129 (near optimal/above optimal)130-159 (borderline high)160-189 (high)≥ 190 (very high)",
                    "sub_points": [
                      "< 100 (optimal)",
                      "100-129 (near optimal/above optimal)",
                      "130-159 (borderline high)",
                      "160-189 (high)",
                      "≥ 190 (very high)"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "﻿Cholesterol Reference Intervals": [
                  {
                    "text": "Laboratory reference intervals generally are based on central 95% of population concentration distributions for analyte measured"
                  },
                  {
                    "text": "Cholesterol reference intervals are based on epidemiologic studies that establish levels associated with CHD risk"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Coronary heart disease (CHD)"
                  },
                  {
                    "text": "National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)"
                  },
                  {
                    "text": "Low-density lipoprotein cholesterol (LDL-C)"
                  },
                  {
                    "text": "High-density lipoprotein cholesterol (HDL-C)"
                  },
                  {
                    "text": "High-sensitivity C-reactive protein (hs-CRP)"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿NCEP ATP III": [
                  {
                    "text": "Program started in 1988 with periodic updatesATP III released in 2002",
                    "sub_points": [
                      "ATP III released in 2002"
                    ]
                  },
                  {
                    "text": "Provides guidelines for cholesterol testing and managementRecommends fasting lipid panel testing in all patientsTotal cholesterolLDL-CHDL-CTriglycerideTesting recommended in all adults ≥ 20 years oldRepeat testing should occur at least every 5 years",
                    "sub_points": [
                      "Recommends fasting lipid panel testing in all patientsTotal cholesterolLDL-CHDL-CTriglyceride",
                      "Total cholesterol",
                      "LDL-C",
                      "HDL-C",
                      "Triglyceride",
                      "Testing recommended in all adults ≥ 20 years old",
                      "Repeat testing should occur at least every 5 years"
                    ]
                  },
                  {
                    "text": "Identifies major risk factors for CHDSmokingHypertensionFamily history of premature CHDLow HDL-CAge (men ≥ 45; women ≥ 55)Men ≥ 45 years oldWomen ≥ 55 years oldDiabetes mellitus",
                    "sub_points": [
                      "Smoking",
                      "Hypertension",
                      "Family history of premature CHD",
                      "Low HDL-C",
                      "Age (men ≥ 45; women ≥ 55)Men ≥ 45 years oldWomen ≥ 55 years old",
                      "Men ≥ 45 years old",
                      "Women ≥ 55 years old",
                      "Diabetes mellitus"
                    ]
                  },
                  {
                    "text": "Classifies risk-based cutoffs for fasting lipid panel components (mg/dL)LDL-C< 100 (optimal)100-129 (near optimal/above optimal)130-159 (borderline high)160-189 (high)≥ 190 (very high)Total cholesterol< 200 (desirable)200-239 (borderline high)≥ 240 (high)HDL-C< 40 (low)≥ 60 (high)Triglycerides< 150 (normal)150-199 (borderline high)200-499 (high)≥ 500 (very high)",
                    "sub_points": [
                      "LDL-C< 100 (optimal)100-129 (near optimal/above optimal)130-159 (borderline high)160-189 (high)≥ 190 (very high)",
                      "< 100 (optimal)",
                      "100-129 (near optimal/above optimal)",
                      "130-159 (borderline high)",
                      "160-189 (high)",
                      "≥ 190 (very high)",
                      "Total cholesterol< 200 (desirable)200-239 (borderline high)≥ 240 (high)",
                      "< 200 (desirable)",
                      "200-239 (borderline high)",
                      "≥ 240 (high)",
                      "HDL-C< 40 (low)≥ 60 (high)",
                      "< 40 (low)",
                      "≥ 60 (high)",
                      "Triglycerides< 150 (normal)150-199 (borderline high)200-499 (high)≥ 500 (very high)",
                      "< 150 (normal)",
                      "150-199 (borderline high)",
                      "200-499 (high)",
                      "≥ 500 (very high)"
                    ]
                  },
                  {
                    "text": "Establishes LDL-C (mg/dL) goals based on CHD risk factorsRisk factors are countedFramingham scoring used on patients with > 2 risk factors for further stratificationIdentifies patients requiring intensive therapy with cholesterol-lowering agents (e.g., statins, nicotinic acid)",
                    "sub_points": [
                      "Risk factors are counted",
                      "Framingham scoring used on patients with > 2 risk factors for further stratification",
                      "Identifies patients requiring intensive therapy with cholesterol-lowering agents (e.g., statins, nicotinic acid)"
                    ]
                  },
                  {
                    "text": "LDL-C < 100 mg/dL recommended forPatients with CHD and CHD risk equivalentsCHD equivalentsFramingham 10-year risk of > 20%DiabetesAtherosclerotic vascular disease (noncoronary)",
                    "sub_points": [
                      "Patients with CHD and CHD risk equivalents",
                      "CHD equivalentsFramingham 10-year risk of > 20%DiabetesAtherosclerotic vascular disease (noncoronary)",
                      "Framingham 10-year risk of > 20%",
                      "Diabetes",
                      "Atherosclerotic vascular disease (noncoronary)"
                    ]
                  },
                  {
                    "text": "LDL-C < 130 mg/dL recommended forPatients with ≥ 2 risk factorsFramingham 10-year risk of 10%-20%",
                    "sub_points": [
                      "Patients with ≥ 2 risk factors",
                      "Framingham 10-year risk of 10%-20%"
                    ]
                  },
                  {
                    "text": "LDL-C < 160 mg/dL recommended forPatients with 0 or 1 risk factor",
                    "sub_points": [
                      "Patients with 0 or 1 risk factor"
                    ]
                  }
                ],
                "﻿Potential Risk Factors": [
                  {
                    "text": "NCEP ATP III identifies other emerging risk factorsLp(a)Small LDL particlesFibrinogenHomocysteinehs-CRPImpaired fasting plasma glucose (110-125 mg/dL)Subclinical atherosclerosis (e.g., coronary artery calcium deposition)",
                    "sub_points": [
                      "Lp(a)",
                      "Small LDL particles",
                      "Fibrinogen",
                      "Homocysteine",
                      "hs-CRP",
                      "Impaired fasting plasma glucose (110-125 mg/dL)",
                      "Subclinical atherosclerosis (e.g., coronary artery calcium deposition)"
                    ]
                  },
                  {
                    "text": "Not routinely used for screening but useful in management of patients with known risk"
                  }
                ]
              },
              "LABORATORY STATISTICS": {
                "﻿Method Validation Considerations": [
                  {
                    "text": "NCEP established acceptable total error in cholesterol measurementCholesterol ≤ 9%Triglyceride ≤ 15%HDL-C ≤ 13%LDL-C ≤ 12%",
                    "sub_points": [
                      "Cholesterol ≤ 9%",
                      "Triglyceride ≤ 15%",
                      "HDL-C ≤ 13%",
                      "LDL-C ≤ 12%"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Familial Lipid Disorders": {
            "name": "Familial Lipid Disorders",
            "url": "https://app.pathprimer.com/document/ea35b682-c6b9-4673-a19c-84df37260477/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Tangier diseaseAutosomal recessive disorder characterized by decreased HDLUnique clinical findings include orange hyperplastic tonsils, peripheral neuropathy, and splenomegaly",
                    "sub_points": [
                      "Autosomal recessive disorder characterized by decreased HDL",
                      "Unique clinical findings include orange hyperplastic tonsils, peripheral neuropathy, and splenomegaly"
                    ]
                  },
                  {
                    "text": "FHDefect in LDL receptor pathway that results in up to 6-fold LDL elevation in plasma compared with healthy individualsSevere atherosclerosis seen in patients, along with LDL deposits in skin and tendonsCommon genetic lipid disorder with carrier frequency 1 per 500 in United StatesDeath by myocardial infarction occurs within second or third decades of life",
                    "sub_points": [
                      "Defect in LDL receptor pathway that results in up to 6-fold LDL elevation in plasma compared with healthy individuals",
                      "Severe atherosclerosis seen in patients, along with LDL deposits in skin and tendons",
                      "Common genetic lipid disorder with carrier frequency 1 per 500 in United States",
                      "Death by myocardial infarction occurs within second or third decades of life"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Overview": [
                  {
                    "text": "Defect in any part of lipid metabolism pathways results in lipoprotein accumulation"
                  },
                  {
                    "text": "Classification of familial lipid disorders based onBiochemical phenotypeBlood lipid concentrationClinical phenotypeAbnormal lipoprotein patterns",
                    "sub_points": [
                      "Biochemical phenotype",
                      "Blood lipid concentration",
                      "Clinical phenotype",
                      "Abnormal lipoprotein patterns"
                    ]
                  },
                  {
                    "text": "Most lipid metabolism disorders are rareFamilial hypercholesterolemia (FH) is exception",
                    "sub_points": [
                      "Familial hypercholesterolemia (FH) is exception"
                    ]
                  },
                  {
                    "text": "Characteristic findings on visual inspection develop when familial lipid disorder patient specimens are held at 4°C and left to stand for 24 hr"
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Established genetic lipid disordersLipoprotein lipase (LPL) deficiencyAutosomal recessive disorderCharacterized bySeverely elevated (up to 10,000 mg/dL) triglycerides (hyperchylomicronemia)Fredrickson type I disorderFrequency 1 per 1 millionCarrier frequency 1 per 500Diagnosis made in childhoodEpisodes of pancreatitis with abdominal painEruptive xanthomas (nodules of fat under skin)Patient not predisposed to atherosclerotic diseaseElevation is in chylomicron particleDiagnosis made by LPL activity measurementPatient injected with heparin, which induces LPL release on endothelial cell surfaceAPOmutations also cause impaired chylomicron catabolismAPOrequired for LPL activationCreamy supernatant layer over clear plasma displayed in 24-hr standing plasma specimenFamilial combined hyperlipidemiaAccounts for premature coronary heart disease (CHD) in 15% of casesIncreased plasma concentrations of low-density lipoprotein (LDL) &/or triglycerideSimilar to Fredrickson type II-A, II-B, IVApolipoprotein B-100 concentration increasedTriglycerides 200-400 mg/dLLDL modestly increased to approximately 190 mg/dLUnderlying genetic mechanism unknownVariable 24-hr standing plasma specimenFamilial hypertriglyceridemiaAutosomal dominantModerate increase in triglycerides due to overproduction of large very-low-density lipoprotein (VLDL) particlesFrequency 1 per 500Type V hyperlipoproteinemiaIncrease in chylomicrons and VLDLLPL activity may be normal or lowNormal APOC-IIClinical findingsEruptive xanthomasElevated glucosePancreatitisDysbetalipoproteinemiaSimilar to Fredrickson type IIIApolipoprotein E2 decreased affinity for LDL receptorCaused by homozygous trait E2/E2Only 1% of population—1 per 10,000Requires other factors for disease presentationObesityDiabetesHypothyroidismTurbid to milky 24-hr standing plasma specimenFHDefect in LDL receptor pathway that results in LDL elevation in plasmaUp to 6-fold elevation compared with healthy individualsSevere atherosclerosis and LDL deposits in skin and tendonsPossible defective genesLDLRAPOBPCSK9Carrier frequency 1 per 500 in United StatesCommon genetic lipid disorderDeath by myocardial infarction occurs within second or third decades of life in patients with homozygous FHFamilial defective apolipoprotein B-100Mutation inAPOBgene resulting in reduced affinity of apolipoprotein B-100 for LDL receptorIsolated LDL increase observed in patientsIncreased incidence of CHDHypoalphalipoproteinemiaDisorder characterized by low high-density lipoprotein (HDL)Defect inAPOA1geneCharacteristic clinical findingsCloudy corneasGlomerulosclerosisTangier diseaseAutosomal recessive disorder characterized by decreased HDLUnique clinical findingsOrange hyperplastic tonsilsPeripheral neuropathySplenomegalyMutation inABCA1geneABCA1 transporter protein mediates efflux of cholesterol from cells (earliest step in reverse cholesterol pathway)",
                    "sub_points": [
                      "Lipoprotein lipase (LPL) deficiencyAutosomal recessive disorderCharacterized bySeverely elevated (up to 10,000 mg/dL) triglycerides (hyperchylomicronemia)Fredrickson type I disorderFrequency 1 per 1 millionCarrier frequency 1 per 500Diagnosis made in childhoodEpisodes of pancreatitis with abdominal painEruptive xanthomas (nodules of fat under skin)Patient not predisposed to atherosclerotic diseaseElevation is in chylomicron particleDiagnosis made by LPL activity measurementPatient injected with heparin, which induces LPL release on endothelial cell surfaceAPOmutations also cause impaired chylomicron catabolismAPOrequired for LPL activationCreamy supernatant layer over clear plasma displayed in 24-hr standing plasma specimen",
                      "Autosomal recessive disorder",
                      "Characterized bySeverely elevated (up to 10,000 mg/dL) triglycerides (hyperchylomicronemia)Fredrickson type I disorder",
                      "Severely elevated (up to 10,000 mg/dL) triglycerides (hyperchylomicronemia)",
                      "Fredrickson type I disorder",
                      "Frequency 1 per 1 million",
                      "Carrier frequency 1 per 500",
                      "Diagnosis made in childhoodEpisodes of pancreatitis with abdominal painEruptive xanthomas (nodules of fat under skin)",
                      "Episodes of pancreatitis with abdominal pain",
                      "Eruptive xanthomas (nodules of fat under skin)",
                      "Patient not predisposed to atherosclerotic diseaseElevation is in chylomicron particle",
                      "Elevation is in chylomicron particle",
                      "Diagnosis made by LPL activity measurementPatient injected with heparin, which induces LPL release on endothelial cell surface",
                      "Patient injected with heparin, which induces LPL release on endothelial cell surface",
                      "APOmutations also cause impaired chylomicron catabolismAPOrequired for LPL activation",
                      "APOrequired for LPL activation",
                      "Creamy supernatant layer over clear plasma displayed in 24-hr standing plasma specimen",
                      "Familial combined hyperlipidemiaAccounts for premature coronary heart disease (CHD) in 15% of casesIncreased plasma concentrations of low-density lipoprotein (LDL) &/or triglycerideSimilar to Fredrickson type II-A, II-B, IVApolipoprotein B-100 concentration increasedTriglycerides 200-400 mg/dLLDL modestly increased to approximately 190 mg/dLUnderlying genetic mechanism unknownVariable 24-hr standing plasma specimen",
                      "Accounts for premature coronary heart disease (CHD) in 15% of cases",
                      "Increased plasma concentrations of low-density lipoprotein (LDL) &/or triglyceride",
                      "Similar to Fredrickson type II-A, II-B, IV",
                      "Apolipoprotein B-100 concentration increased",
                      "Triglycerides 200-400 mg/dL",
                      "LDL modestly increased to approximately 190 mg/dL",
                      "Underlying genetic mechanism unknown",
                      "Variable 24-hr standing plasma specimen",
                      "Familial hypertriglyceridemiaAutosomal dominantModerate increase in triglycerides due to overproduction of large very-low-density lipoprotein (VLDL) particlesFrequency 1 per 500",
                      "Autosomal dominant",
                      "Moderate increase in triglycerides due to overproduction of large very-low-density lipoprotein (VLDL) particles",
                      "Frequency 1 per 500",
                      "Type V hyperlipoproteinemiaIncrease in chylomicrons and VLDLLPL activity may be normal or lowNormal APOC-IIClinical findingsEruptive xanthomasElevated glucosePancreatitis",
                      "Increase in chylomicrons and VLDL",
                      "LPL activity may be normal or lowNormal APOC-II",
                      "Normal APOC-II",
                      "Clinical findingsEruptive xanthomasElevated glucosePancreatitis",
                      "Eruptive xanthomas",
                      "Elevated glucose",
                      "Pancreatitis",
                      "DysbetalipoproteinemiaSimilar to Fredrickson type IIIApolipoprotein E2 decreased affinity for LDL receptorCaused by homozygous trait E2/E2Only 1% of population—1 per 10,000Requires other factors for disease presentationObesityDiabetesHypothyroidismTurbid to milky 24-hr standing plasma specimen",
                      "Similar to Fredrickson type III",
                      "Apolipoprotein E2 decreased affinity for LDL receptor",
                      "Caused by homozygous trait E2/E2Only 1% of population—1 per 10,000",
                      "Only 1% of population—1 per 10,000",
                      "Requires other factors for disease presentationObesityDiabetesHypothyroidism",
                      "Obesity",
                      "Diabetes",
                      "Hypothyroidism",
                      "Turbid to milky 24-hr standing plasma specimen",
                      "FHDefect in LDL receptor pathway that results in LDL elevation in plasmaUp to 6-fold elevation compared with healthy individualsSevere atherosclerosis and LDL deposits in skin and tendonsPossible defective genesLDLRAPOBPCSK9Carrier frequency 1 per 500 in United StatesCommon genetic lipid disorderDeath by myocardial infarction occurs within second or third decades of life in patients with homozygous FH",
                      "Defect in LDL receptor pathway that results in LDL elevation in plasmaUp to 6-fold elevation compared with healthy individuals",
                      "Up to 6-fold elevation compared with healthy individuals",
                      "Severe atherosclerosis and LDL deposits in skin and tendons",
                      "Possible defective genesLDLRAPOBPCSK9",
                      "LDLR",
                      "APOB",
                      "PCSK9",
                      "Carrier frequency 1 per 500 in United StatesCommon genetic lipid disorder",
                      "Common genetic lipid disorder",
                      "Death by myocardial infarction occurs within second or third decades of life in patients with homozygous FH",
                      "Familial defective apolipoprotein B-100Mutation inAPOBgene resulting in reduced affinity of apolipoprotein B-100 for LDL receptorIsolated LDL increase observed in patientsIncreased incidence of CHD",
                      "Mutation inAPOBgene resulting in reduced affinity of apolipoprotein B-100 for LDL receptor",
                      "Isolated LDL increase observed in patients",
                      "Increased incidence of CHD",
                      "HypoalphalipoproteinemiaDisorder characterized by low high-density lipoprotein (HDL)Defect inAPOA1geneCharacteristic clinical findingsCloudy corneasGlomerulosclerosis",
                      "Disorder characterized by low high-density lipoprotein (HDL)",
                      "Defect inAPOA1gene",
                      "Characteristic clinical findingsCloudy corneasGlomerulosclerosis",
                      "Cloudy corneas",
                      "Glomerulosclerosis",
                      "Tangier diseaseAutosomal recessive disorder characterized by decreased HDLUnique clinical findingsOrange hyperplastic tonsilsPeripheral neuropathySplenomegalyMutation inABCA1geneABCA1 transporter protein mediates efflux of cholesterol from cells (earliest step in reverse cholesterol pathway)",
                      "Autosomal recessive disorder characterized by decreased HDL",
                      "Unique clinical findingsOrange hyperplastic tonsilsPeripheral neuropathySplenomegaly",
                      "Orange hyperplastic tonsils",
                      "Peripheral neuropathy",
                      "Splenomegaly",
                      "Mutation inABCA1geneABCA1 transporter protein mediates efflux of cholesterol from cells (earliest step in reverse cholesterol pathway)",
                      "ABCA1 transporter protein mediates efflux of cholesterol from cells (earliest step in reverse cholesterol pathway)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lipid Metabolism": {
            "name": "Lipid Metabolism",
            "url": "https://app.pathprimer.com/document/46293630-8399-4017-ad32-bf14e4008696/lesson/aba56655-e503-4fd2-810e-01bdede936a0",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Commonly divided into 4 pathwaysExogenous pathwayEndogenous pathwayIntracellular cholesterol transportReverse cholesterol transport",
                    "sub_points": [
                      "Exogenous pathway",
                      "Endogenous pathway",
                      "Intracellular cholesterol transport",
                      "Reverse cholesterol transport"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cholesteryl ester transfer protein (CETP)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  },
                  {
                    "text": "Intermediate-density lipoprotein (IDL)"
                  },
                  {
                    "text": "Lecithin-cholesterol acyltransferase (LCAT)"
                  },
                  {
                    "text": "Lipoprotein lipase (LPL)"
                  },
                  {
                    "text": "Low-density-lipoprotein cholesterol (LDL-C)"
                  },
                  {
                    "text": "Very-low-density lipoprotein (VLDL)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Lipoprotein Metabolism": [
                  {
                    "text": "Commonly divided into 4 pathways"
                  },
                  {
                    "text": "(1) Exogenous pathwayEncompasses dietary transport of lipids from intestine to liver, for further metabolismMediated by chylomicronsChylomicrons formed from combination of triglycerides, lipid, and ApoB-48 protein within endoplasmic reticulum of enterocytesChylomicrons enter circulation and acquire additional apolipoproteins (ApoE, ApoC-II)ApoE binds to liver receptor, and mediates uptake of chylomicron into liverApoC-II activates LPL (found on luminal surface of endothelial cells)LPL metabolizes chylomicron triglycerides to free fatty acidsFree fatty acids combine with albumin to be used as energy by muscle or by adipose tissueChylomicron remnants then travel to liver and are taken up",
                    "sub_points": [
                      "Encompasses dietary transport of lipids from intestine to liver, for further metabolism",
                      "Mediated by chylomicronsChylomicrons formed from combination of triglycerides, lipid, and ApoB-48 protein within endoplasmic reticulum of enterocytesChylomicrons enter circulation and acquire additional apolipoproteins (ApoE, ApoC-II)ApoE binds to liver receptor, and mediates uptake of chylomicron into liverApoC-II activates LPL (found on luminal surface of endothelial cells)",
                      "Chylomicrons formed from combination of triglycerides, lipid, and ApoB-48 protein within endoplasmic reticulum of enterocytes",
                      "Chylomicrons enter circulation and acquire additional apolipoproteins (ApoE, ApoC-II)ApoE binds to liver receptor, and mediates uptake of chylomicron into liverApoC-II activates LPL (found on luminal surface of endothelial cells)",
                      "ApoE binds to liver receptor, and mediates uptake of chylomicron into liver",
                      "ApoC-II activates LPL (found on luminal surface of endothelial cells)",
                      "LPL metabolizes chylomicron triglycerides to free fatty acidsFree fatty acids combine with albumin to be used as energy by muscle or by adipose tissue",
                      "Free fatty acids combine with albumin to be used as energy by muscle or by adipose tissue",
                      "Chylomicron remnants then travel to liver and are taken up"
                    ]
                  },
                  {
                    "text": "(2) Endogenous pathwayResponsible for transfer of lipids from liver to peripheral cellsTransport mediated by ApoB-100-containing lipoproteinsVLDL is primary ApoB-containing lipoproteinVLDL surface ApoC-II activates LPL on endothelial cellsLPL-mediated hydrolysis of VLDL triglycerides again releases free fatty acids, which are taken up by the peripheryVLDL remnant (now termed IDL) eventually becomes LDLLDL binds to its receptor via its surface ApoB-100 and is taken up by various cellsPrimary uptake is within liverLDL taken up by liver; liver uses LDL return to produce bile salts and other lipoproteins, or excretes cholesterol directly into bile",
                    "sub_points": [
                      "Responsible for transfer of lipids from liver to peripheral cells",
                      "Transport mediated by ApoB-100-containing lipoproteinsVLDL is primary ApoB-containing lipoprotein",
                      "VLDL is primary ApoB-containing lipoprotein",
                      "VLDL surface ApoC-II activates LPL on endothelial cells",
                      "LPL-mediated hydrolysis of VLDL triglycerides again releases free fatty acids, which are taken up by the periphery",
                      "VLDL remnant (now termed IDL) eventually becomes LDL",
                      "LDL binds to its receptor via its surface ApoB-100 and is taken up by various cellsPrimary uptake is within liver",
                      "Primary uptake is within liver",
                      "LDL taken up by liver; liver uses LDL return to produce bile salts and other lipoproteins, or excretes cholesterol directly into bile"
                    ]
                  },
                  {
                    "text": "(3) Intracellular cholesterol transportMaintains cholesterol homeostasis within cellsCholesterol used to maintain cell membranes, but excess cholesterol can cause cellular toxicityWithin cells, lipoproteins taken up are delivered to lysosomes and degraded into free cholesterolCholesterol can then beUsed for cellular membrane creationStored in intracellular lipid dropsRemoved by reverse cholesterol transport pathwayExcess intracellular cholesterol inhibits cholesterol biosynthesis and LDL receptor expression",
                    "sub_points": [
                      "Maintains cholesterol homeostasis within cells",
                      "Cholesterol used to maintain cell membranes, but excess cholesterol can cause cellular toxicity",
                      "Within cells, lipoproteins taken up are delivered to lysosomes and degraded into free cholesterol",
                      "Cholesterol can then beUsed for cellular membrane creationStored in intracellular lipid dropsRemoved by reverse cholesterol transport pathway",
                      "Used for cellular membrane creation",
                      "Stored in intracellular lipid drops",
                      "Removed by reverse cholesterol transport pathway",
                      "Excess intracellular cholesterol inhibits cholesterol biosynthesis and LDL receptor expression"
                    ]
                  },
                  {
                    "text": "(4) Reverse cholesterol transportFunctions to remove excess cellular cholesterol from peripheral cellsCholesterol then transported to liver for excretionHDL is primary pathway mediatorExcess cholesterol is actively secreted by ABCA1 transporter and picked up by HDLLCAT esterifies HDL cholesterol, changing its confirmation from disc-shaped to sphericalSpherical HDL then can return to liver where cholesterol esters are removedLipid-depleted HDL then returns to circulation for repeat periphery cholesterol removal",
                    "sub_points": [
                      "Functions to remove excess cellular cholesterol from peripheral cells",
                      "Cholesterol then transported to liver for excretion",
                      "HDL is primary pathway mediator",
                      "Excess cholesterol is actively secreted by ABCA1 transporter and picked up by HDL",
                      "LCAT esterifies HDL cholesterol, changing its confirmation from disc-shaped to spherical",
                      "Spherical HDL then can return to liver where cholesterol esters are removed",
                      "Lipid-depleted HDL then returns to circulation for repeat periphery cholesterol removal"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Carbohydrates": {
        "name": "Carbohydrates",
        "url": "https://app.pathprimer.com/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
        "topics": {
          "Hemoglobin A1c": {
            "name": "Hemoglobin A1c",
            "url": "https://app.pathprimer.com/document/e24e2b37-3824-4414-b5bc-a425beef71f3/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Provides window into long-term glycemic controlRepresents blood glucose levels over prior 8-12 weeks under certain conditionsNormal RBC survival (no hemolytic disease or major blood loss)Hemoglobinopathy not present (sickle cell disease)No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)",
                    "sub_points": [
                      "Represents blood glucose levels over prior 8-12 weeks under certain conditionsNormal RBC survival (no hemolytic disease or major blood loss)Hemoglobinopathy not present (sickle cell disease)No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)",
                      "Normal RBC survival (no hemolytic disease or major blood loss)",
                      "Hemoglobinopathy not present (sickle cell disease)",
                      "No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)"
                    ]
                  },
                  {
                    "text": "In 2009, International Expert Committee recommended HbA1c could be used to diagnose diabetes mellitusSupported by ADA and WHO",
                    "sub_points": [
                      "Supported by ADA and WHO"
                    ]
                  },
                  {
                    "text": "HBA1c value > 6.5% now considered diagnostic for diabetes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Hemoglobin A1c (HbA1c)"
                  },
                  {
                    "text": "Diabetes Control and Complications Trial (DCCT)"
                  },
                  {
                    "text": "National Glycohemoglobin Standardization Program (NGSP)"
                  },
                  {
                    "text": "High-performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "American Diabetes Association (ADA)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "World Health Organization (WHO)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "DCCT: Trial completed in 1993 that showed glycemic control closely mirrored development and advancement of chronic complications in diabetics"
                  },
                  {
                    "text": "NGSP: Program begun in 1996 to implement protocols developed to calibrate glycohemoglobin testing results to values attained in DCCTManufacturers can apply for certification with NGSPNGSP will help calibrate manufacturers' method to DCCT reference method",
                    "sub_points": [
                      "Manufacturers can apply for certification with NGSP",
                      "NGSP will help calibrate manufacturers' method to DCCT reference method"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Diabetes and Nonenzymatic Glycation": [
                  {
                    "text": "Nonenzymatic glycosylation of hemoglobinInvolves placement of a sugar residue on proteinsOccurs under normal physiologic conditionsIncreased in prolonged hyperglycemia",
                    "sub_points": [
                      "Involves placement of a sugar residue on proteins",
                      "Occurs under normal physiologic conditions",
                      "Increased in prolonged hyperglycemia"
                    ]
                  },
                  {
                    "text": "Adult hemoglobin comprises 3 main fractionsHbA1 (97%)Minor fractions have been identified through chromatographic analysis (HbA1a, HbA1b, HbA1c)HbA1c nonlabileHbA2 (2.5%)HbF (0.5%)",
                    "sub_points": [
                      "HbA1 (97%)Minor fractions have been identified through chromatographic analysis (HbA1a, HbA1b, HbA1c)HbA1c nonlabile",
                      "Minor fractions have been identified through chromatographic analysis (HbA1a, HbA1b, HbA1c)",
                      "HbA1c nonlabile",
                      "HbA2 (2.5%)",
                      "HbF (0.5%)"
                    ]
                  },
                  {
                    "text": "HbA1c formed when glucose binds to HbA1Binding results in unstable Schiff base (pre-HbA1c)Undergoes Amadori rearrangement to form stable ketoamine (HbA1c)",
                    "sub_points": [
                      "Binding results in unstable Schiff base (pre-HbA1c)",
                      "Undergoes Amadori rearrangement to form stable ketoamine (HbA1c)"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Overview": [
                  {
                    "text": "Numerous methods available to determine glycated hemoglobinBased on separating nonglycated from glycated fractionsMost US laboratories use immunoassay or HPLC methodologies",
                    "sub_points": [
                      "Based on separating nonglycated from glycated fractions",
                      "Most US laboratories use immunoassay or HPLC methodologies"
                    ]
                  }
                ],
                "Assay Standardization": [
                  {
                    "text": "ADA recommends assays are certified by NGSP as traceable to DCCT referenceCreated standardization among varying test methodologiesAllows for clinical application of outcomes data from DCCTHighly variable results among laboratories before NGSP standardization",
                    "sub_points": [
                      "Created standardization among varying test methodologies",
                      "Allows for clinical application of outcomes data from DCCT",
                      "Highly variable results among laboratories before NGSP standardization"
                    ]
                  }
                ],
                "Chromatographic Methods": [
                  {
                    "text": "HPLCCation exchange chromatography often used to exploit charge differences between glycated and nonglycated hemoglobinPreparation involves sample hemolysis by borate reagent with subsequent removal of Schiff base (pre-HbA1c)Postchromatography detection carried out at 415 nm and 690 nmHPLC was used in DCCT",
                    "sub_points": [
                      "Cation exchange chromatography often used to exploit charge differences between glycated and nonglycated hemoglobin",
                      "Preparation involves sample hemolysis by borate reagent with subsequent removal of Schiff base (pre-HbA1c)",
                      "Postchromatography detection carried out at 415 nm and 690 nm",
                      "HPLC was used in DCCT"
                    ]
                  },
                  {
                    "text": "Affinity chromatographyAffinity gel column selectively binds glycated hemoglobin fractionNonglycated hemoglobin does not bindAddition of sorbitol induces release of glycated hemoglobin from columnAbsorbance between bound and nonbound fractions at 415 nm used to calculate percentage of glycated hemoglobinMeasures total glycated hemoglobinReports HbA1c fraction by using onboard calibration equation",
                    "sub_points": [
                      "Affinity gel column selectively binds glycated hemoglobin fraction",
                      "Nonglycated hemoglobin does not bind",
                      "Addition of sorbitol induces release of glycated hemoglobin from column",
                      "Absorbance between bound and nonbound fractions at 415 nm used to calculate percentage of glycated hemoglobin",
                      "Measures total glycated hemoglobinReports HbA1c fraction by using onboard calibration equation",
                      "Reports HbA1c fraction by using onboard calibration equation"
                    ]
                  }
                ],
                "Immunoassay": [
                  {
                    "text": "Antibodies that bind Amadori product (HbA1c) have been developed"
                  },
                  {
                    "text": "Latex agglutination immunoassay also widely used"
                  },
                  {
                    "text": "Immunoassay calibrated to match HPLC results"
                  }
                ],
                "Removal of Labile Glycated Hemoglobin": [
                  {
                    "text": "Schiff base (pre-HbA1c) is labile and has fluctuating concentrationCould affect measurement and should be removed from analysisOften accomplished by preanalytic treatment of sampleIncubation in pH buffer or salineCommercial reagent sets",
                    "sub_points": [
                      "Could affect measurement and should be removed from analysis",
                      "Often accomplished by preanalytic treatment of sampleIncubation in pH buffer or salineCommercial reagent sets",
                      "Incubation in pH buffer or saline",
                      "Commercial reagent sets"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Diabetes Management": [
                  {
                    "text": "Measuring HbA1c has become integral to management of patients with diabetesHbA1c values followed seriallyAccounts for wide fluctuation in single blood glucose measurementProvides window into long-term glycemic controlRepresents blood glucose levels over prior 8-12 weeks under certain conditionsNormal RBC survival (no hemolytic disease or major blood loss)Hemoglobinopathy not present (sickle cell disease)No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)",
                    "sub_points": [
                      "HbA1c values followed seriallyAccounts for wide fluctuation in single blood glucose measurement",
                      "Accounts for wide fluctuation in single blood glucose measurement",
                      "Provides window into long-term glycemic controlRepresents blood glucose levels over prior 8-12 weeks under certain conditionsNormal RBC survival (no hemolytic disease or major blood loss)Hemoglobinopathy not present (sickle cell disease)No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)",
                      "Represents blood glucose levels over prior 8-12 weeks under certain conditionsNormal RBC survival (no hemolytic disease or major blood loss)Hemoglobinopathy not present (sickle cell disease)No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)",
                      "Normal RBC survival (no hemolytic disease or major blood loss)",
                      "Hemoglobinopathy not present (sickle cell disease)",
                      "No renal failure (urea presence forms carbamylated hemoglobin, an interferent to testing)"
                    ]
                  }
                ],
                "Diabetes Diagnosis": [
                  {
                    "text": "In 2009, International Expert Committee recommended HbA1c could be used to diagnose diabetes mellitusSupported by ADA and WHO",
                    "sub_points": [
                      "Supported by ADA and WHO"
                    ]
                  },
                  {
                    "text": "HBA1c value > 6.5% considered diagnostic for diabetesBased on diabetic retinopathy prevalence",
                    "sub_points": [
                      "Based on diabetic retinopathy prevalence"
                    ]
                  }
                ],
                "Testing Frequency": [
                  {
                    "text": "ADA recommends HbA1c be routinely monitored every 6 months in patients with type 1 or type 2 diabetes"
                  },
                  {
                    "text": "ADA recommends diabetic patient treatment goal be < 7%"
                  }
                ],
                "Other Considerations": [
                  {
                    "text": "Individuals at high risk for developing diabetes have HbA1c of 5.7%-6.4%"
                  },
                  {
                    "text": "Mean HbA1c concentration determines risk of nephropathy and retinopathy in patients with diabetes"
                  },
                  {
                    "text": "Elevated HbA1c has been shown to be a risk factor for diabetic microvascular complications"
                  },
                  {
                    "text": "HbA1c shown to be directly related to cardiovascular disease risk in patients who do not have diabetes"
                  }
                ]
              },
              "SPECIMENS": {
                "Collection and Storage": [
                  {
                    "text": "Venous samples can be collected in EDTA, oxalate, or fluoride"
                  },
                  {
                    "text": "Whole blood can be stored at 4°C for 1 weekLabile glycated hemoglobin (HbA1a, HbA1b) increase > 4°C",
                    "sub_points": [
                      "Labile glycated hemoglobin (HbA1a, HbA1b) increase > 4°C"
                    ]
                  },
                  {
                    "text": "Whole blood samples stored at ₋70°C are stable for approximately 18 months"
                  },
                  {
                    "text": "Samples are unstable at ₋20°C"
                  }
                ],
                "Reference Intervals": [
                  {
                    "text": "NGSP certified method reference interval 4%-5.6%"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Preanalytical Considerations in Glucose Measurement": {
            "name": "Preanalytical Considerations in Glucose Measurement",
            "url": "https://app.pathprimer.com/document/3750f314-010e-44fc-aab8-073a9bf460b9/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Specimens": [
                  {
                    "text": "At room temperature, glucose concentration in whole blood decreases at rate of up to 10 mg/dL per hourGlucose specimen should be centrifuged immediately following collection prior to transport to laboratory",
                    "sub_points": [
                      "Glucose specimen should be centrifuged immediately following collection prior to transport to laboratory"
                    ]
                  },
                  {
                    "text": "If prolonged specimen transport anticipated (distant outpatient clinic, home care), sample collection should occur in grey-top tube (preservative is sodium fluoride, potent inhibitor of glycolysis)"
                  }
                ]
              },
              "OVERVIEW": {
                "Glucose Measurement": [
                  {
                    "text": "Accurate measurement of glucose in blood is critical in diabetes diagnosis and clinical management"
                  },
                  {
                    "text": "Prompt delivery, processing, and storage of blood glucose specimens is critical to avoid inaccurate measurement"
                  }
                ]
              },
              "SPECIMENS": {
                "Specimen Types": [
                  {
                    "text": "Glucose can be measured in many specimen typesWhole bloodGlucose concentration in fasting whole blood 12-15% lower than plasma glucose valuesDue to higher water content in plasmaPlasma and serumGlucose concentration in plasma is 5% lower than serumUrinePleural fluidCerebrospinal fluid",
                    "sub_points": [
                      "Whole bloodGlucose concentration in fasting whole blood 12-15% lower than plasma glucose valuesDue to higher water content in plasma",
                      "Glucose concentration in fasting whole blood 12-15% lower than plasma glucose valuesDue to higher water content in plasma",
                      "Due to higher water content in plasma",
                      "Plasma and serumGlucose concentration in plasma is 5% lower than serum",
                      "Glucose concentration in plasma is 5% lower than serum",
                      "Urine",
                      "Pleural fluid",
                      "Cerebrospinal fluid"
                    ]
                  },
                  {
                    "text": "Venous plasma glucose is routine clinical specimenDiagnostic and management data for diabetes derived from this sample type",
                    "sub_points": [
                      "Diagnostic and management data for diabetes derived from this sample type"
                    ]
                  }
                ],
                "Collection, Transport, and Other Considerations": [
                  {
                    "text": "Delays in specimen arrival to clinical laboratory can compromise result accuracy"
                  },
                  {
                    "text": "Conceptually, cells found in blood metabolize glucose in samplesFalsely lowers glucose concentration in sampleStates that induce leukocytosis (sepsis) are particularly problematic",
                    "sub_points": [
                      "Falsely lowers glucose concentration in sample",
                      "States that induce leukocytosis (sepsis) are particularly problematic"
                    ]
                  },
                  {
                    "text": "At 4⁰C, glucose decreases at rate of 2 mg/dL per hour"
                  },
                  {
                    "text": "At room temperature, glucose concentration in whole blood decreases at rate of up to 10 mg/dL per hourTherefore, in serum and plasma specimens, centrifugation should occur without delayGenerally, serum specimens should be centrifuged within 30 minutes of collection to prevent glycolysis",
                    "sub_points": [
                      "Therefore, in serum and plasma specimens, centrifugation should occur without delayGenerally, serum specimens should be centrifuged within 30 minutes of collection to prevent glycolysis",
                      "Generally, serum specimens should be centrifuged within 30 minutes of collection to prevent glycolysis"
                    ]
                  },
                  {
                    "text": "Fluid specimens for glucose analysis should be collected in either fluoride or oxalate tubes or in no additive"
                  },
                  {
                    "text": "In fasting patient, capillary blood specimen (finger stick) are up to 5 mg/dL higher than venous blood"
                  },
                  {
                    "text": "When delays in transport or processing are known to occur, various steps should be takenSamples should be stored at 4°C or -20°CIf refrigerated, serum or plasma specimen glucose is stable for 48 hoursCollection in sodium fluoride tubes (grey top)Sodium fluoride inhibits enolase enzyme in glycolytic pathwayCan prevent glycolysis for up to 48 hours in whole bloodHowever, arrest of glycolysis takes up to 2 hours (results in ~ 7 mg/dL decrease in glucose)Basic metabolic panel should not be run on grey-top tube due to sodium interference from preservative",
                    "sub_points": [
                      "Samples should be stored at 4°C or -20°CIf refrigerated, serum or plasma specimen glucose is stable for 48 hours",
                      "If refrigerated, serum or plasma specimen glucose is stable for 48 hours",
                      "Collection in sodium fluoride tubes (grey top)Sodium fluoride inhibits enolase enzyme in glycolytic pathwayCan prevent glycolysis for up to 48 hours in whole bloodHowever, arrest of glycolysis takes up to 2 hours (results in ~ 7 mg/dL decrease in glucose)Basic metabolic panel should not be run on grey-top tube due to sodium interference from preservative",
                      "Sodium fluoride inhibits enolase enzyme in glycolytic pathwayCan prevent glycolysis for up to 48 hours in whole bloodHowever, arrest of glycolysis takes up to 2 hours (results in ~ 7 mg/dL decrease in glucose)",
                      "Can prevent glycolysis for up to 48 hours in whole blood",
                      "However, arrest of glycolysis takes up to 2 hours (results in ~ 7 mg/dL decrease in glucose)",
                      "Basic metabolic panel should not be run on grey-top tube due to sodium interference from preservative"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hypoglycemia": {
            "name": "Hypoglycemia",
            "url": "https://app.pathprimer.com/document/7dde67d6-aeb5-4572-89fb-1467bd79e3c7/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Hypoglycemia is defined as blood glucose level below lower end of established reference interval"
                  },
                  {
                    "text": "Setting specific hypoglycemia glucose concentration limit is difficult, but 50 mg/dL often used"
                  },
                  {
                    "text": "Central nervous system (CNS) function depends on normal blood glucose values"
                  },
                  {
                    "text": "Symptoms appear at < 55 mg/dL"
                  },
                  {
                    "text": "Differential diagnosis includes tumors, insulinoma, tumor of beta islet cells, various sarcomas and carcinomas, pheochromocytoma"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Normal neonatal blood glucose concentrations lower than in adults"
                  },
                  {
                    "text": "Levels of < 35 mg/dL in a newborn may be clinically insignificant"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Hypoglycemia is defined as blood glucose level below lower end of established reference intervalSetting specific hypoglycemia glucose concentration limit is difficult, but 50 mg/dL often used",
                    "sub_points": [
                      "Setting specific hypoglycemia glucose concentration limit is difficult, but 50 mg/dL often used"
                    ]
                  },
                  {
                    "text": "Central nervous system (CNS) function depends on normal blood glucose valuesSymptoms appear at < 55 mg/dLSevere dysfunction seen at < 30 mg/dL",
                    "sub_points": [
                      "Symptoms appear at < 55 mg/dL",
                      "Severe dysfunction seen at < 30 mg/dL"
                    ]
                  },
                  {
                    "text": "Hypoglycemia can occur 1.5-2 hours after a meal"
                  },
                  {
                    "text": "Hypoglycemia is rare in nondiabetic patients"
                  },
                  {
                    "text": "In fasting or hypoglycemic states, the body uses ketones for energy"
                  },
                  {
                    "text": "Most common cause of hypoglycemia is drug ingestion"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "In the setting of long-standing type 1 diabetes, adrenergic symptoms bluntedThought to be due to decreased epinephrine response to hypoglycemia",
                    "sub_points": [
                      "Thought to be due to decreased epinephrine response to hypoglycemia"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Returning blood glucose concentration to normal levels reverses CNS dysfunction rapidlyPermanent damage still may have occurred",
                    "sub_points": [
                      "Permanent damage still may have occurred"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "TumorsInsulinomaTumor of beta islet cellsVarious sarcomas and carcinomasPheochromocytoma",
                    "sub_points": [
                      "InsulinomaTumor of beta islet cells",
                      "Tumor of beta islet cells",
                      "Various sarcomas and carcinomas",
                      "Pheochromocytoma"
                    ]
                  },
                  {
                    "text": "DrugsDrug-induced hypoglycemia agents tend to be insulin or insulin secretion stimulatorsInsulinSulfonylureasAlcoholQuinine",
                    "sub_points": [
                      "Drug-induced hypoglycemia agents tend to be insulin or insulin secretion stimulatorsInsulinSulfonylureasAlcoholQuinine",
                      "Insulin",
                      "Sulfonylureas",
                      "Alcohol",
                      "Quinine"
                    ]
                  },
                  {
                    "text": "Critical illnessHepatic failureRenal failureSepsisMalnutrition",
                    "sub_points": [
                      "Hepatic failure",
                      "Renal failure",
                      "Sepsis",
                      "Malnutrition"
                    ]
                  },
                  {
                    "text": "Hormonal deficiencyGlucagonEpinephrineCortisolGrowth hormone",
                    "sub_points": [
                      "Glucagon",
                      "Epinephrine",
                      "Cortisol",
                      "Growth hormone"
                    ]
                  },
                  {
                    "text": "Endogenous insulin productionNesidioblastosisHyperfunction of pancreatic beta cells",
                    "sub_points": [
                      "NesidioblastosisHyperfunction of pancreatic beta cells",
                      "Hyperfunction of pancreatic beta cells"
                    ]
                  },
                  {
                    "text": "AutoimmuneAntibodies to insulin and insulin receptors",
                    "sub_points": [
                      "Antibodies to insulin and insulin receptors"
                    ]
                  },
                  {
                    "text": "Hematologic malignancies"
                  },
                  {
                    "text": "Hypoglycemia of infancy and childhoodHyperinsulinismBeckwith-Wiedemann syndromeUncontrolled gestational diabetesVarious inborn errors of metabolism",
                    "sub_points": [
                      "Hyperinsulinism",
                      "Beckwith-Wiedemann syndrome",
                      "Uncontrolled gestational diabetes",
                      "Various inborn errors of metabolism"
                    ]
                  },
                  {
                    "text": "Post-gastric surgery"
                  },
                  {
                    "text": "Idiopathic"
                  },
                  {
                    "text": "Autonomic symptoms in hypoglycemia found in other disordersHyperthyroidismPanic attack and anxiety",
                    "sub_points": [
                      "Hyperthyroidism",
                      "Panic attack and anxiety"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Reference Intervals": [
                  {
                    "text": "Normal neonatal fasting blood glucose concentrations lower than in adultsReference intervals for term neonates can range from 30-60 mg/dL",
                    "sub_points": [
                      "Reference intervals for term neonates can range from 30-60 mg/dL"
                    ]
                  }
                ],
                "72-Hour Fasting Test": [
                  {
                    "text": "Classic approach to determine hypoglycemia"
                  },
                  {
                    "text": "Calories are withheld"
                  },
                  {
                    "text": "Blood samples drawn approximately every 6 hours, then every 1-2 hours once blood glucose is < 60 mg/dL"
                  },
                  {
                    "text": "Analytes measured should includeGlucoseInsulinProinsulinC-peptideUsed to assess exogenous administration of insulin",
                    "sub_points": [
                      "Glucose",
                      "Insulin",
                      "Proinsulin",
                      "C-peptideUsed to assess exogenous administration of insulin",
                      "Used to assess exogenous administration of insulin"
                    ]
                  },
                  {
                    "text": "Testing concludes whenBlood glucose < 45 mg/dLAfter 72 hoursSymptoms of hypoglycemia present",
                    "sub_points": [
                      "Blood glucose < 45 mg/dL",
                      "After 72 hours",
                      "Symptoms of hypoglycemia present"
                    ]
                  },
                  {
                    "text": "Most patients with true hypoglycemia conclude testing within 12 hours"
                  },
                  {
                    "text": "Absence of signs or symptoms of hypoglycemia excludes diagnosis of most hypoglycemia disorders"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Diagnosis and Monitoring of Diabetes Mellitus": {
            "name": "Laboratory Diagnosis and Monitoring of Diabetes Mellitus",
            "url": "https://app.pathprimer.com/document/28428594-1b78-4adf-a947-58576bcd061b/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Diagnosis": [
                  {
                    "text": "Laboratory diagnostic criteriaHbA1c ≥ 6.5%: Testing should be performed by National Glycohemoglobin Standardization Program-certified method that is standardized to Diabetes Control and Complications Trial assayFasting plasma glucose > 126 mg/dL: Patient must be tested more than once (must be on different days)2-hr plasma glucose > 200 mg/dL during OGTT: Patient must be tested more than once (must be on different days)",
                    "sub_points": [
                      "HbA1c ≥ 6.5%: Testing should be performed by National Glycohemoglobin Standardization Program-certified method that is standardized to Diabetes Control and Complications Trial assay",
                      "Fasting plasma glucose > 126 mg/dL: Patient must be tested more than once (must be on different days)",
                      "2-hr plasma glucose > 200 mg/dL during OGTT: Patient must be tested more than once (must be on different days)"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Diabetes Mellitus Diagnosis": [
                  {
                    "text": "Previously, only hyperglycemia required for diabetes diagnosis"
                  },
                  {
                    "text": "Currently, other laboratory-derived values used in clinical diagnosis of diabetesChanges in diagnostic criteria endorsed by American Diabetes Association (ADA)",
                    "sub_points": [
                      "Changes in diagnostic criteria endorsed by American Diabetes Association (ADA)"
                    ]
                  },
                  {
                    "text": "Laboratory diagnostic criteriaHemoglobin A1c (HbA1c) ≥ 6.5%Testing should be performed by National Glycohemoglobin Standardization Program-certified method that is standardized to Diabetes Control and Complications Trial assayFasting plasma glucose > 126 mg/dLPatient must be tested more than once (must be on different days)2-hr plasma glucose > 200 mg/dL during oral glucose tolerance test (OGTT)Patient must be tested more than once (must be on different days)",
                    "sub_points": [
                      "Hemoglobin A1c (HbA1c) ≥ 6.5%Testing should be performed by National Glycohemoglobin Standardization Program-certified method that is standardized to Diabetes Control and Complications Trial assay",
                      "Testing should be performed by National Glycohemoglobin Standardization Program-certified method that is standardized to Diabetes Control and Complications Trial assay",
                      "Fasting plasma glucose > 126 mg/dLPatient must be tested more than once (must be on different days)",
                      "Patient must be tested more than once (must be on different days)",
                      "2-hr plasma glucose > 200 mg/dL during oral glucose tolerance test (OGTT)Patient must be tested more than once (must be on different days)",
                      "Patient must be tested more than once (must be on different days)"
                    ]
                  },
                  {
                    "text": "In 30% of patients, fasting hyperglycemia may be discovered only after serious complications of diabetes are presentRetinopathyNerve damageKidney damage with proteinuria",
                    "sub_points": [
                      "Retinopathy",
                      "Nerve damage",
                      "Kidney damage with proteinuria"
                    ]
                  },
                  {
                    "text": "Diabetes screening in high-risk patients recommended"
                  },
                  {
                    "text": "Asymptomatic patients age ≥ 45 yr should have fasting glucose or HbA1c measuredFollow-up testing once every 3 years recommended",
                    "sub_points": [
                      "Follow-up testing once every 3 years recommended"
                    ]
                  }
                ],
                "Diabetes Mellitus Monitoring": [
                  {
                    "text": "Diabetics can have clinically acute and chronic consequences"
                  },
                  {
                    "text": "Laboratory testing useful in establishing diagnosis of acute complications and following their treatmentsDiabetic ketoacidosisHypoglycemiaHyperosmolar nonketotic coma",
                    "sub_points": [
                      "Diabetic ketoacidosis",
                      "Hypoglycemia",
                      "Hyperosmolar nonketotic coma"
                    ]
                  },
                  {
                    "text": "Lower glucose in type 1 diabetics reduces development of retinopathy, neuropathy, nephropathy"
                  },
                  {
                    "text": "Glycemic control in type 2 diabetics correlated with reduction in microvascular complicationsHbA1c measured every 3-6 months in type 2 diabetics",
                    "sub_points": [
                      "HbA1c measured every 3-6 months in type 2 diabetics"
                    ]
                  },
                  {
                    "text": "Diabetic glycemic control goals recommended by ADAHbA1c < 7%Fasting glucose 70-130 mg/dLPostprandial glucose < 180 mg/dL",
                    "sub_points": [
                      "HbA1c < 7%",
                      "Fasting glucose 70-130 mg/dL",
                      "Postprandial glucose < 180 mg/dL"
                    ]
                  }
                ],
                "Oral Glucose Tolerance Test and Gestational Diabetes": [
                  {
                    "text": "OGTT starts with fasting baseline plasma glucose measurement"
                  },
                  {
                    "text": "Patient is given oral glucose loadRecommended glucose loads differ based on patient type75 g for nonpregnant adults1.75 g/kg for children (75 g maximum)50 g screen for pregnant patients",
                    "sub_points": [
                      "Recommended glucose loads differ based on patient type75 g for nonpregnant adults1.75 g/kg for children (75 g maximum)50 g screen for pregnant patients",
                      "75 g for nonpregnant adults",
                      "1.75 g/kg for children (75 g maximum)",
                      "50 g screen for pregnant patients"
                    ]
                  },
                  {
                    "text": "Plasma glucose measured 2 hr after glucose load"
                  },
                  {
                    "text": "Patient should not smoke and must be ambulatoryTest should not be performed on hospitalized, acutely ill, or other patients on bed rest",
                    "sub_points": [
                      "Test should not be performed on hospitalized, acutely ill, or other patients on bed rest"
                    ]
                  },
                  {
                    "text": "All pregnant women without past medical history of diabetes should be screened for gestational diabetes at 24-28 weeks' gestationInvolves giving 50-g oral glucose load and measuring 1-hr plasma glucoseIf glucose ≥ 140 mg/dL, further testing requiredOGTT with 100-g oral glucose loadPlasma glucose measurements over next 3 hr",
                    "sub_points": [
                      "Involves giving 50-g oral glucose load and measuring 1-hr plasma glucose",
                      "If glucose ≥ 140 mg/dL, further testing requiredOGTT with 100-g oral glucose loadPlasma glucose measurements over next 3 hr",
                      "OGTT with 100-g oral glucose load",
                      "Plasma glucose measurements over next 3 hr"
                    ]
                  },
                  {
                    "text": "Diagnosis of gestational diabetes confirmed if 2 plasma glucose values during OGTT exceed the following (based on 100-g dose) criteriaFasting ≥ 95 mg/dL1-hr ≥ 180 mg/dL2-hr ≥ 155 mg/dL3-hr ≥ 140 mg/dL",
                    "sub_points": [
                      "Fasting ≥ 95 mg/dL",
                      "1-hr ≥ 180 mg/dL",
                      "2-hr ≥ 155 mg/dL",
                      "3-hr ≥ 140 mg/dL"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fructosamine": {
            "name": "Fructosamine",
            "url": "https://app.pathprimer.com/document/0691fd64-82e2-4181-a8eb-6f8879415fb7/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Fructosamine (glycated serum albumin) represents blood glucose control over period of 2-3 weeks"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Fructosamine used to follow blood glucose control in certain patients when HbA1c measurement compromisedHemoglobinopathies (HbS, HbC, or other variants)Disease states resulting in shortened red cell life span (hemorrhage, thalassemia)",
                    "sub_points": [
                      "Hemoglobinopathies (HbS, HbC, or other variants)",
                      "Disease states resulting in shortened red cell life span (hemorrhage, thalassemia)"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Concepts": [
                  {
                    "text": "Fructosamine is general name given to nonhemoglobin glycated serum proteinsNonenzymatic glycosylation of proteins by glucose not exclusive to hemoglobin",
                    "sub_points": [
                      "Nonenzymatic glycosylation of proteins by glucose not exclusive to hemoglobin"
                    ]
                  },
                  {
                    "text": "Albumin is most abundant serum proteinAny glycated serum protein test will primarily measure glycated albuminTerms \"fructosamine\" and \"glycated albumin\" often used interchangeablySerum protein turnover more frequent than RBCsHalf-life of albumin approximately 20 daysFructosamine (glycated serum albumin) represents blood glucose control over period of 2-3 weeks",
                    "sub_points": [
                      "Any glycated serum protein test will primarily measure glycated albuminTerms \"fructosamine\" and \"glycated albumin\" often used interchangeably",
                      "Terms \"fructosamine\" and \"glycated albumin\" often used interchangeably",
                      "Serum protein turnover more frequent than RBCsHalf-life of albumin approximately 20 days",
                      "Half-life of albumin approximately 20 days",
                      "Fructosamine (glycated serum albumin) represents blood glucose control over period of 2-3 weeks"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Red blood cells (RBCs)"
                  },
                  {
                    "text": "High-performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "Hemoglobin A1c (HbA1c)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Glycosylation of albumin forms ring structure similar in appearance to fructose (hence \"fructosamine\")"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Methods": [
                  {
                    "text": "Affinity chromatography and HPLC can be used to measure glycated albumin﻿Not commonly used",
                    "sub_points": [
                      "Not commonly used"
                    ]
                  },
                  {
                    "text": "Automated methodsFructosamine undergoes Amadori rearrangement under alkaline conditionsEventual production of a chromophore (formazan)Measurement of absorbance at 530 nm at 2 time points is comparedAbsorbance change is proportional to concentration of fructosamine",
                    "sub_points": [
                      "Fructosamine undergoes Amadori rearrangement under alkaline conditionsEventual production of a chromophore (formazan)",
                      "Eventual production of a chromophore (formazan)",
                      "Measurement of absorbance at 530 nm at 2 time points is comparedAbsorbance change is proportional to concentration of fructosamine",
                      "Absorbance change is proportional to concentration of fructosamine"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Clinical Utility": [
                  {
                    "text": "Fructosamine used to follow blood glucose control in certain patients when HbA1c measurement compromisedHemoglobinopathies (HbS, HbC, or other variants)Disease states resulting in shortened red cell life span (hemorrhage, thalassemia)",
                    "sub_points": [
                      "Hemoglobinopathies (HbS, HbC, or other variants)",
                      "Disease states resulting in shortened red cell life span (hemorrhage, thalassemia)"
                    ]
                  },
                  {
                    "text": "Not used to diagnose diabetes"
                  },
                  {
                    "text": "Useful in evaluating glycemic control during diabetic pregnancyEvaluating shorter periods during gestation preferableHbA1c represents last 2-3 months of glycemic control",
                    "sub_points": [
                      "Evaluating shorter periods during gestation preferable",
                      "HbA1c represents last 2-3 months of glycemic control"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Considerations": [
                  {
                    "text": "Fructosamine invalid in certain disease states that affect serum protein concentrationsNephrotic syndromeLiver cirrhosisInflammatory states (acute phase reactants)",
                    "sub_points": [
                      "Nephrotic syndrome",
                      "Liver cirrhosis",
                      "Inflammatory states (acute phase reactants)"
                    ]
                  },
                  {
                    "text": "Fructosamine measurement should not be done if serum albumin level < 0.3 mg/dL"
                  },
                  {
                    "text": "Ascorbic acid may cause negative interference in automated test methods"
                  }
                ]
              },
              "SPECIMENS": {
                "Reference Intervals": [
                  {
                    "text": "Nondiabetics 205-285 μmol/L"
                  },
                  {
                    "text": "Adjustments to account for high or low albumin 191-265 μmol/L"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Diabetic Ketoacidosis": {
            "name": "Diabetic Ketoacidosis",
            "url": "https://app.pathprimer.com/document/cba11aad-d606-476b-810c-8282d8a3880b/lesson/70f070a3-6123-4ec6-ae83-daad1ca185f9",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "DKA is hyperglycemic condition seen primarily in patients with type 1 diabetesOften brought on by severe stress or illnessBlood glucose usually > 250 mg/dLResults in production of significant amount of ketone bodiesAcetoacetateβ-Hydroxybutyrate (major fraction in diabetic state)Acetone",
                    "sub_points": [
                      "Often brought on by severe stress or illness",
                      "Blood glucose usually > 250 mg/dL",
                      "Results in production of significant amount of ketone bodiesAcetoacetateβ-Hydroxybutyrate (major fraction in diabetic state)Acetone",
                      "Acetoacetate",
                      "β-Hydroxybutyrate (major fraction in diabetic state)",
                      "Acetone"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Ketones in blood and urine often measured by nitroprusside-based methodsPrimarily measure acetoacetate and some acetoneProblematic because β-hydroxybutyrate not measured",
                    "sub_points": [
                      "Primarily measure acetoacetate and some acetone",
                      "Problematic because β-hydroxybutyrate not measured"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Diabetic ketoacidosis (DKA) is hyperglycemic condition seen primarily in patients with type 1 diabetesOften brought on by severe stress or illnessBlood glucose usually > 250 mg/dL",
                    "sub_points": [
                      "Often brought on by severe stress or illness",
                      "Blood glucose usually > 250 mg/dL"
                    ]
                  },
                  {
                    "text": "In states of extremely low insulin or insulin resistance (poorly controlled diabetes)Fat cell use for energy is increasedInduces increased mobilization of fatty acids from triglyceridesExcessive acetyl coenzyme A produced from increased fatty acid production and catabolismResults in production of significant amount of ketone bodiesAcetoacetateβ-Hydroxybutyrate (major fraction in diabetic state)AcetoneKetone bodies consume bicarbonate (HCO₃⁻) and induce acidosisHCO₃⁻ < 15 mEq/LpH < 7.30Kidneys excrete ketone bodies with significant simultaneous loss of sodium and potassiumSodium and potassium loss results in retention of hydrogen ions",
                    "sub_points": [
                      "Fat cell use for energy is increasedInduces increased mobilization of fatty acids from triglyceridesExcessive acetyl coenzyme A produced from increased fatty acid production and catabolismResults in production of significant amount of ketone bodiesAcetoacetateβ-Hydroxybutyrate (major fraction in diabetic state)AcetoneKetone bodies consume bicarbonate (HCO₃⁻) and induce acidosisHCO₃⁻ < 15 mEq/LpH < 7.30Kidneys excrete ketone bodies with significant simultaneous loss of sodium and potassiumSodium and potassium loss results in retention of hydrogen ions",
                      "Induces increased mobilization of fatty acids from triglycerides",
                      "Excessive acetyl coenzyme A produced from increased fatty acid production and catabolism",
                      "Results in production of significant amount of ketone bodiesAcetoacetateβ-Hydroxybutyrate (major fraction in diabetic state)Acetone",
                      "Acetoacetate",
                      "β-Hydroxybutyrate (major fraction in diabetic state)",
                      "Acetone",
                      "Ketone bodies consume bicarbonate (HCO₃⁻) and induce acidosisHCO₃⁻ < 15 mEq/LpH < 7.30",
                      "HCO₃⁻ < 15 mEq/L",
                      "pH < 7.30",
                      "Kidneys excrete ketone bodies with significant simultaneous loss of sodium and potassiumSodium and potassium loss results in retention of hydrogen ions",
                      "Sodium and potassium loss results in retention of hydrogen ions"
                    ]
                  },
                  {
                    "text": "Diabetic patients with DKA at increased risk of necrotizing invasive fungal infections (zygomycosis)"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Patient presentation early onAbdominal painNauseaVomitingElectrolyte disturbancesDehydration",
                    "sub_points": [
                      "Abdominal pain",
                      "Nausea",
                      "Vomiting",
                      "Electrolyte disturbances",
                      "Dehydration"
                    ]
                  },
                  {
                    "text": "As DKA progressesAltered breathingEventual comaDeath if untreated",
                    "sub_points": [
                      "Altered breathing",
                      "Eventual coma",
                      "Death if untreated"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Depends on exact cause but often includesInsulin and fluid administrationElectrolyte corrections",
                    "sub_points": [
                      "Insulin and fluid administration",
                      "Electrolyte corrections"
                    ]
                  },
                  {
                    "text": "Important: As DKA is treated, increase in serum ketones is observedDue to conversion of β-hydroxybutyrate to acetoacetate and acetone",
                    "sub_points": [
                      "Due to conversion of β-hydroxybutyrate to acetoacetate and acetone"
                    ]
                  },
                  {
                    "text": "Despite this increase, total ketone bodies are decreasing"
                  },
                  {
                    "text": "Insulin administration causes serum potassium to shift into cellsProfound hypokalemia on treatment",
                    "sub_points": [
                      "Profound hypokalemia on treatment"
                    ]
                  }
                ],
                "Differential Diagnosis": [
                  {
                    "text": "Ketoacidosis can be caused by other conditionsSevere starvationGlycogen storage disease (von Gierke disease)Low-carbohydrate, high-fat dietsAlcohol consumption",
                    "sub_points": [
                      "Severe starvation",
                      "Glycogen storage disease (von Gierke disease)",
                      "Low-carbohydrate, high-fat diets",
                      "Alcohol consumption"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "﻿Ketones in Blood and Urine": [
                  {
                    "text": "Ketones in blood and urine often measured by nitroprusside-based methodsPrimarily measure acetoacetate and some acetoneProblematic because β-hydroxybutyrate not measuredRoutine measurement of ketone bodies quantitates only small fraction of total ketone bodies in bloodNegative nitroprusside test does not rule out DKANitroprusside-based testing not as useful for monitoring therapyβ-Hydroxybutyrate can be detected by enzymatic methods",
                    "sub_points": [
                      "Primarily measure acetoacetate and some acetone",
                      "Problematic because β-hydroxybutyrate not measured",
                      "Routine measurement of ketone bodies quantitates only small fraction of total ketone bodies in bloodNegative nitroprusside test does not rule out DKANitroprusside-based testing not as useful for monitoring therapy",
                      "Negative nitroprusside test does not rule out DKA",
                      "Nitroprusside-based testing not as useful for monitoring therapy",
                      "β-Hydroxybutyrate can be detected by enzymatic methods"
                    ]
                  }
                ],
                "﻿Other Testing": [
                  {
                    "text": "Patients with DKA often diagnosed and followed by other testingBlood glucoseSeverity cannot be determined by glucose levelSerum electrolytesPotassium often elevated due to intracellular to extracellular shiftHydrogen ion bufferingTotal body potassium actually decreasedLoss in urineHCO₃⁻ with anion gap calculation and pHKetone bodies represent unmeasured anionsIncreased ketone bodies cause high anion gap (> 10-12 mEq/L)Decreasing anion gap used to monitor DKA recoveryMetabolic acidosis",
                    "sub_points": [
                      "Blood glucoseSeverity cannot be determined by glucose level",
                      "Severity cannot be determined by glucose level",
                      "Serum electrolytesPotassium often elevated due to intracellular to extracellular shiftHydrogen ion bufferingTotal body potassium actually decreasedLoss in urine",
                      "Potassium often elevated due to intracellular to extracellular shiftHydrogen ion buffering",
                      "Hydrogen ion buffering",
                      "Total body potassium actually decreasedLoss in urine",
                      "Loss in urine",
                      "HCO₃⁻ with anion gap calculation and pHKetone bodies represent unmeasured anionsIncreased ketone bodies cause high anion gap (> 10-12 mEq/L)Decreasing anion gap used to monitor DKA recoveryMetabolic acidosis",
                      "Ketone bodies represent unmeasured anionsIncreased ketone bodies cause high anion gap (> 10-12 mEq/L)Decreasing anion gap used to monitor DKA recovery",
                      "Increased ketone bodies cause high anion gap (> 10-12 mEq/L)",
                      "Decreasing anion gap used to monitor DKA recovery",
                      "Metabolic acidosis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Cardiac Markers": {
        "name": "Cardiac Markers",
        "url": "https://app.pathprimer.com/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
        "topics": {
          "Troponin": {
            "name": "Troponin",
            "url": "https://app.pathprimer.com/document/d14a5c18-65e9-4b03-b69f-08e3673e6c14/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Cardiac troponins are protein molecules specific to cardiac muscle that are encoded by different genes than troponins found in other muscle types"
                  },
                  {
                    "text": "Cardiac troponin found in complex and noncomplex forms in blood after myocardial injuryTroponin C, T, I complexTroponin C, I complexFree troponin I",
                    "sub_points": [
                      "Troponin C, T, I complex",
                      "Troponin C, I complex",
                      "Free troponin I"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "99th percentile of reference interval should be determined by each laboratory with imprecision < 10% CVUsed as cutoff for AMI",
                    "sub_points": [
                      "Used as cutoff for AMI"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Other conditions can lead to cardiac myocyte damage and troponin elevations including CHF, renal failure, aortic valve disease, sepsis, transplant vasculopathy, and hypothyroidism"
                  }
                ],
                "Specimens": [
                  {
                    "text": "EDTA and heparin interfere with monoclonal antibody binding to TnI and TnT"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Troponin I (TnI)"
                  },
                  {
                    "text": "Troponin T (TnT)"
                  },
                  {
                    "text": "Troponin C (TnC)"
                  },
                  {
                    "text": "Coefficient of variation (CV)"
                  },
                  {
                    "text": "Acute myocardial infarction (AMI)"
                  },
                  {
                    "text": "Congestive heart failure (CHF)"
                  },
                  {
                    "text": "Coronary heart disease (CHD)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  },
                  {
                    "text": "National Academy of Clinical Biochemistry (NACB)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "Cardiac troponins are protein molecules specific to cardiac muscleCardiac troponins encoded by different genes than troponins found in other muscle typesMost are localized within myofibrilsSmall portion localized within cytoplasm",
                    "sub_points": [
                      "Cardiac troponins encoded by different genes than troponins found in other muscle types",
                      "Most are localized within myofibrilsSmall portion localized within cytoplasm",
                      "Small portion localized within cytoplasm"
                    ]
                  },
                  {
                    "text": "Muscle contraction depends on troponin complex formed by 3 subunits that regulate actin and myosin interactionTnTFunctions in tropomyosin bindingTnIInhibitory componentTnCFunctions to bind calcium",
                    "sub_points": [
                      "TnTFunctions in tropomyosin binding",
                      "Functions in tropomyosin binding",
                      "TnIInhibitory component",
                      "Inhibitory component",
                      "TnCFunctions to bind calcium",
                      "Functions to bind calcium"
                    ]
                  },
                  {
                    "text": "TnT and TnI are cardiac specificAmino acid residue distinguishes them from other locations",
                    "sub_points": [
                      "Amino acid residue distinguishes them from other locations"
                    ]
                  },
                  {
                    "text": "TnC found in cardiac muscle is nonspecific to heart"
                  },
                  {
                    "text": "Cardiac troponin found in complex and noncomplex forms in blood after myocardial injuryTroponin C, T, I complexTroponin C, I complexFree troponin I",
                    "sub_points": [
                      "Troponin C, T, I complex",
                      "Troponin C, I complex",
                      "Free troponin I"
                    ]
                  },
                  {
                    "text": "Released complex forms undergo various modifications (oxidation, dephosphorylation, amino acid removal)OxidationDephosphorylationAmino acid removal",
                    "sub_points": [
                      "Oxidation",
                      "Dephosphorylation",
                      "Amino acid removal"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Troponin Assay Considerations": [
                  {
                    "text": "Cardiac troponin measured in clinical laboratory by immunoassay"
                  },
                  {
                    "text": "Because of normal modification of postinjury complexes, immunoassays must recognize stable complex epitopes"
                  },
                  {
                    "text": "Troponin assays have lower limit of detection for quantitative assays0.01-0.1 μg/L",
                    "sub_points": [
                      "0.01-0.1 μg/L"
                    ]
                  },
                  {
                    "text": "Qualitative assays have been developed for TnI"
                  },
                  {
                    "text": "High-sensitivity cardiac troponinLower limit of detection 0.1-3.0 ng/L",
                    "sub_points": [
                      "Lower limit of detection 0.1-3.0 ng/L"
                    ]
                  },
                  {
                    "text": "High sensitivity TnI and TnT assaysLower limit of detection 0.1-3.0 ng/L",
                    "sub_points": [
                      "Lower limit of detection 0.1-3.0 ng/L"
                    ]
                  },
                  {
                    "text": "TnI does not have primary reference material making standardization between assays difficult"
                  },
                  {
                    "text": "Standardization also difficult because of differences in recognized epitopes by monoclonal antibodies found in commercial assays"
                  }
                ],
                "Reference interval": [
                  {
                    "text": "99th percentile of reference interval should be determined by each laboratory with imprecision < 10% CVUsed as cutoff for AMI",
                    "sub_points": [
                      "Used as cutoff for AMI"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Cardiac Conditions": [
                  {
                    "text": "Cardiac troponin is essential biomarker used in AMI diagnosisRising pattern of troponins in appropriate clinical setting is necessary for AMI diagnosisOther conditions can lead to cardiac myocyte damage and troponin elevationsCHFRenal failureAortic valve diseaseSepsisTransplant vasculopathyHypothyroidism",
                    "sub_points": [
                      "Rising pattern of troponins in appropriate clinical setting is necessary for AMI diagnosisOther conditions can lead to cardiac myocyte damage and troponin elevationsCHFRenal failureAortic valve diseaseSepsisTransplant vasculopathyHypothyroidism",
                      "Other conditions can lead to cardiac myocyte damage and troponin elevationsCHFRenal failureAortic valve diseaseSepsisTransplant vasculopathyHypothyroidism",
                      "CHF",
                      "Renal failure",
                      "Aortic valve disease",
                      "Sepsis",
                      "Transplant vasculopathy",
                      "Hypothyroidism"
                    ]
                  },
                  {
                    "text": "CHD more severe in patients with increased cardiac troponin concentration vs. patients without increased cardiac troponin concentration"
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Anticoagulated plasma or whole blood preferred specimensEliminates additional time required for clotting in serum samples",
                    "sub_points": [
                      "Eliminates additional time required for clotting in serum samples"
                    ]
                  },
                  {
                    "text": "EDTA and heparin interfere with monoclonal antibody binding to TnI and TnT"
                  },
                  {
                    "text": "Only 1 sample type should be used for entire work-up of patient"
                  }
                ]
              },
              "POINT OF CARE": {
                "Considerations": [
                  {
                    "text": "NACB developed practice guidelines for cardiac biomarker point of care testing"
                  },
                  {
                    "text": "Quantitative point of care troponin assay should be implemented if laboratory cannot consistently provide turnaround time of < 1 hr"
                  },
                  {
                    "text": "Point of care devices generally less sensitive compared with main laboratory methods"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cardiac Marker Release Kinetics": {
            "name": "Cardiac Marker Release Kinetics",
            "url": "https://app.pathprimer.com/document/b2bbf26f-d604-4b54-b682-4fd75859e50c/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "MyoglobinEarlier marker of myocardial infarction",
                    "sub_points": [
                      "Earlier marker of myocardial infarction"
                    ]
                  },
                  {
                    "text": "Troponin T or IHas become gold standard and replaced other markers in AMI testingSuperior cardiac specificityDoes not return to normal levels until several days after AMI (some sources report 7-10 days)",
                    "sub_points": [
                      "Has become gold standard and replaced other markers in AMI testingSuperior cardiac specificityDoes not return to normal levels until several days after AMI (some sources report 7-10 days)",
                      "Superior cardiac specificity",
                      "Does not return to normal levels until several days after AMI (some sources report 7-10 days)"
                    ]
                  },
                  {
                    "text": "Lactate dehydrogenaseNote flipped LD isoenzyme ratio (LD1 > LD2) in AMI",
                    "sub_points": [
                      "Note flipped LD isoenzyme ratio (LD1 > LD2) in AMI"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Relation in Rise of Cardiac Markers": [
                  {
                    "text": "Understanding of post-AMI cardiac marker release timing is useful in clinical management of patients"
                  },
                  {
                    "text": "Equally important is understanding relation in rise after AMI of various cardiac markersOften expected knowledge in standardized testing environments",
                    "sub_points": [
                      "Often expected knowledge in standardized testing environments"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myocardial infarction (AMI)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Release Kinetics": [
                  {
                    "text": "Following AMI, cardiac markers are released as followsMyoglobinEarlier marker of myocardial infarctionElevated within 2-4 hours post AMILevels normalize within 24 hours post AMINot useful in delayed patient presentationCK-MBElevated 6-12 hours post AMIApproximately 48 hours post AMI, levels return to normalTroponin T or IElevated within 4-6 hoursDoes not return to normal levels until several days after AMI (some sources report 7-10 days)Longer elevation time makes it less useful for detecting re-infarction within 48 hours of primary infarctionHas become gold standard and replaced other markers in AMI testingSuperior cardiac specificityUseful in delayed patient presentationsSerial measurements are preferred (at presentation, 6 hours post, and 12 hours post)Lactate dehydrogenaseUse in AMI setting has regressed and is limitedNote flipped LD isoenzyme ratio (LD1 > LD2) in AMINormally LD2 > LD1",
                    "sub_points": [
                      "MyoglobinEarlier marker of myocardial infarctionElevated within 2-4 hours post AMILevels normalize within 24 hours post AMINot useful in delayed patient presentation",
                      "Earlier marker of myocardial infarctionElevated within 2-4 hours post AMI",
                      "Elevated within 2-4 hours post AMI",
                      "Levels normalize within 24 hours post AMINot useful in delayed patient presentation",
                      "Not useful in delayed patient presentation",
                      "CK-MBElevated 6-12 hours post AMIApproximately 48 hours post AMI, levels return to normal",
                      "Elevated 6-12 hours post AMI",
                      "Approximately 48 hours post AMI, levels return to normal",
                      "Troponin T or IElevated within 4-6 hoursDoes not return to normal levels until several days after AMI (some sources report 7-10 days)Longer elevation time makes it less useful for detecting re-infarction within 48 hours of primary infarctionHas become gold standard and replaced other markers in AMI testingSuperior cardiac specificityUseful in delayed patient presentationsSerial measurements are preferred (at presentation, 6 hours post, and 12 hours post)",
                      "Elevated within 4-6 hours",
                      "Does not return to normal levels until several days after AMI (some sources report 7-10 days)Longer elevation time makes it less useful for detecting re-infarction within 48 hours of primary infarction",
                      "Longer elevation time makes it less useful for detecting re-infarction within 48 hours of primary infarction",
                      "Has become gold standard and replaced other markers in AMI testingSuperior cardiac specificityUseful in delayed patient presentationsSerial measurements are preferred (at presentation, 6 hours post, and 12 hours post)",
                      "Superior cardiac specificity",
                      "Useful in delayed patient presentations",
                      "Serial measurements are preferred (at presentation, 6 hours post, and 12 hours post)",
                      "Lactate dehydrogenaseUse in AMI setting has regressed and is limitedNote flipped LD isoenzyme ratio (LD1 > LD2) in AMINormally LD2 > LD1",
                      "Use in AMI setting has regressed and is limited",
                      "Note flipped LD isoenzyme ratio (LD1 > LD2) in AMINormally LD2 > LD1",
                      "Normally LD2 > LD1"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Creatine Kinase": {
            "name": "Creatine Kinase",
            "url": "https://app.pathprimer.com/document/415faa79-4808-4bd0-b6e4-529ab1ee1122/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "CK is distributed throughout the bodyHeart muscleBrainGastrointestinal tract, urinary bladder",
                    "sub_points": [
                      "Heart muscle",
                      "Brain",
                      "Gastrointestinal tract, urinary bladder"
                    ]
                  },
                  {
                    "text": "CK composed of 2 subunits (B and M), which form 3 active isoenzymes found in the cytosolCK-BB (CK₁)Most widely distributedMainly in brain and smooth muscleCK-MB (CK₂)Predominant isoenzyme in heart muscleSometimes called “cardiac isoenzyme”CK-MM (CK₃)Predominant isoenzyme in skeletal muscle",
                    "sub_points": [
                      "CK-BB (CK₁)Most widely distributedMainly in brain and smooth muscle",
                      "Most widely distributed",
                      "Mainly in brain and smooth muscle",
                      "CK-MB (CK₂)Predominant isoenzyme in heart muscleSometimes called “cardiac isoenzyme”",
                      "Predominant isoenzyme in heart muscle",
                      "Sometimes called “cardiac isoenzyme”",
                      "CK-MM (CK₃)Predominant isoenzyme in skeletal muscle",
                      "Predominant isoenzyme in skeletal muscle"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Creatine kinase (CK)"
                  },
                  {
                    "text": "Adenosine triphosphate (ATP)"
                  },
                  {
                    "text": "Adenosine diphosphate (ADP)"
                  },
                  {
                    "text": "Mitochondrial CK (CK-Mt)"
                  },
                  {
                    "text": "Oxidized form of nicotinamide adenine dinucleotide phosphate (NADP⁺)"
                  },
                  {
                    "text": "Reduced nicotinamide adenine dinucleotide phosphate (NADPH)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology": [
                  {
                    "text": "CK is an isoenzyme integral to muscle contractionDuring normal contraction, ATP is converted to ADPCK catalyzes the re-phosphorylation of ADP back to ATP using phosphocreatine",
                    "sub_points": [
                      "During normal contraction, ATP is converted to ADPCK catalyzes the re-phosphorylation of ADP back to ATP using phosphocreatine",
                      "CK catalyzes the re-phosphorylation of ADP back to ATP using phosphocreatine"
                    ]
                  },
                  {
                    "text": "In normal childbirth, 6-fold increase in serum CK activity can occur in the mother"
                  },
                  {
                    "text": "Newborns also have higher CK activity due to process of normal delivery"
                  }
                ],
                "CK Distribution": [
                  {
                    "text": "CK is distributed throughout the bodySkeletal muscleHeart muscleBrainGastrointestinal tract, urinary bladder",
                    "sub_points": [
                      "Skeletal muscle",
                      "Heart muscle",
                      "Brain",
                      "Gastrointestinal tract, urinary bladder"
                    ]
                  }
                ],
                "﻿Isoenzymes and Isoforms": [
                  {
                    "text": "CK composed of 2 subunits (B and M), which form 3 active isoenzymes found in the cytosolCK-BB (CK₁)Most widely distributedMainly in brain and smooth muscleCK-MB (CK₂)Predominant isoenzyme in heart muscleSometimes called “cardiac isoenzyme”CK-MM (CK₃)Predominant isoenzyme in skeletal muscle",
                    "sub_points": [
                      "CK-BB (CK₁)Most widely distributedMainly in brain and smooth muscle",
                      "Most widely distributed",
                      "Mainly in brain and smooth muscle",
                      "CK-MB (CK₂)Predominant isoenzyme in heart muscleSometimes called “cardiac isoenzyme”",
                      "Predominant isoenzyme in heart muscle",
                      "Sometimes called “cardiac isoenzyme”",
                      "CK-MM (CK₃)Predominant isoenzyme in skeletal muscle",
                      "Predominant isoenzyme in skeletal muscle"
                    ]
                  },
                  {
                    "text": "Posttranslational modification CK isoenzymes creates CK isoformsIsoforms seen in isoenzymes possessing M subunitTwo isoforms for CK-MM (CK-MM1, CK-MM2)One true isoform for CK-MB (CK-MB1)CK-MB2 isoform is technically the unmodified isoenzyme",
                    "sub_points": [
                      "Isoforms seen in isoenzymes possessing M subunit",
                      "Two isoforms for CK-MM (CK-MM1, CK-MM2)",
                      "One true isoform for CK-MB (CK-MB1)CK-MB2 isoform is technically the unmodified isoenzyme",
                      "CK-MB2 isoform is technically the unmodified isoenzyme"
                    ]
                  },
                  {
                    "text": "Other CK typesMacro-CK (2 types), formed by immunoglobulin binding of CK (often CK-BB)Macro-CK1Not associated with pathologic conditionsFalsely elevates CK and creates diagnostic confusionMacro-CK2 (CK-Mt)Located between inner and outer mitochondrial membraneFound in up to 6% of hospitalized patientsSeen in malignancy or liver diseaseAssociated with poor prognosis",
                    "sub_points": [
                      "Macro-CK (2 types), formed by immunoglobulin binding of CK (often CK-BB)Macro-CK1Not associated with pathologic conditionsFalsely elevates CK and creates diagnostic confusionMacro-CK2 (CK-Mt)Located between inner and outer mitochondrial membraneFound in up to 6% of hospitalized patientsSeen in malignancy or liver diseaseAssociated with poor prognosis",
                      "Macro-CK1Not associated with pathologic conditionsFalsely elevates CK and creates diagnostic confusion",
                      "Not associated with pathologic conditions",
                      "Falsely elevates CK and creates diagnostic confusion",
                      "Macro-CK2 (CK-Mt)Located between inner and outer mitochondrial membraneFound in up to 6% of hospitalized patientsSeen in malignancy or liver diseaseAssociated with poor prognosis",
                      "Located between inner and outer mitochondrial membrane",
                      "Found in up to 6% of hospitalized patients",
                      "Seen in malignancy or liver disease",
                      "Associated with poor prognosis"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Electrophoresis": [
                  {
                    "text": "Isoenzymes have distinct migration patterns on high-resolution electrophoresisToward the anodeBB > MB1 > MB2 > MM > Macro-CK1 > MM2 > MM1 > MM > Macro-CK2Electrophoresis analysis no longer common",
                    "sub_points": [
                      "Toward the anodeBB > MB1 > MB2 > MM > Macro-CK1 > MM2 > MM1 > MM > Macro-CK2",
                      "BB > MB1 > MB2 > MM > Macro-CK1 > MM2 > MM1 > MM > Macro-CK2",
                      "Electrophoresis analysis no longer common"
                    ]
                  }
                ],
                "Other Methods": [
                  {
                    "text": "Total CK measurementCommercial assays follow CK-induced conversion of phosphocreatine to creatineATP produced by conversion coupled to subsequent reactions that ultimately convert NADP+ to NADPHMonitored spectrophotometrically at 340 nm",
                    "sub_points": [
                      "Commercial assays follow CK-induced conversion of phosphocreatine to creatine",
                      "ATP produced by conversion coupled to subsequent reactions that ultimately convert NADP+ to NADPH",
                      "Monitored spectrophotometrically at 340 nm"
                    ]
                  },
                  {
                    "text": "CK-MB measurementMeasured by automated sandwich immunoassay (“mass” assay)Sensitive (lower limit of detection of 1 μg/L)",
                    "sub_points": [
                      "Measured by automated sandwich immunoassay (“mass” assay)Sensitive (lower limit of detection of 1 μg/L)",
                      "Sensitive (lower limit of detection of 1 μg/L)"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Cardiac": [
                  {
                    "text": "CK-MB isoenzyme long used in diagnosis of myocardial infarctionImportance has lessened with wide adoption of troponin measurement",
                    "sub_points": [
                      "Importance has lessened with wide adoption of troponin measurement"
                    ]
                  }
                ],
                "Noncardiac": [
                  {
                    "text": "Increased serum CK seen in patients with inflammation, muscular necrosis, or other injurySerum CK activity elevated in all types of muscular dystrophyIn acute rhabdomyolysis, serum CK activity can exceed 200 times upper reference limit",
                    "sub_points": [
                      "Serum CK activity elevated in all types of muscular dystrophy",
                      "In acute rhabdomyolysis, serum CK activity can exceed 200 times upper reference limit"
                    ]
                  },
                  {
                    "text": "Various drugs can cause serum CK increaseStatinsFibratesAntiretroviralAngiotensin II receptor antagonist",
                    "sub_points": [
                      "Statins",
                      "Fibrates",
                      "Antiretroviral",
                      "Angiotensin II receptor antagonist"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Preanalytic Variables": [
                  {
                    "text": "CK activity influenced bySex (men higher CK than women)Ethnicity (African descent higher CK than non-African descent)AgeMuscle massExercise",
                    "sub_points": [
                      "Sex (men higher CK than women)",
                      "Ethnicity (African descent higher CK than non-African descent)",
                      "Age",
                      "Muscle mass",
                      "Exercise"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Collect heparinized tube (serum or plasma) onlyOther anticoagulants inhibit CK activity",
                    "sub_points": [
                      "Other anticoagulants inhibit CK activity"
                    ]
                  },
                  {
                    "text": "Short stability< 8 hours at room temperature48 hours at 4°C1 month at -20°C",
                    "sub_points": [
                      "< 8 hours at room temperature",
                      "48 hours at 4°C",
                      "1 month at -20°C"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myoglobin": {
            "name": "Myoglobin",
            "url": "https://app.pathprimer.com/document/6a9d9ee3-0193-4b99-a708-ecfe0e39362a/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Myoglobin is first serum cardiac protein to increase in concentration after AMISerum myoglobin begins to increase 1-4 hours after AMIPeak serum concentration seen approximately 6 hours after AMIReturns to baseline after 24-36 hours",
                    "sub_points": [
                      "Serum myoglobin begins to increase 1-4 hours after AMI",
                      "Peak serum concentration seen approximately 6 hours after AMIReturns to baseline after 24-36 hours",
                      "Returns to baseline after 24-36 hours"
                    ]
                  },
                  {
                    "text": "Negative serum myoglobin has high negative predictive value for AMI in patients presenting within first 6 hours of chest pain onset"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Acute myocardial infarction (AMI)"
                  },
                  {
                    "text": "Sodium hydroxide (NaOH)"
                  },
                  {
                    "text": "Creatine kinase, myocardial (CK-MB)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Biochemistry and Physiology": [
                  {
                    "text": "Myoglobin is oxygen-binding protein found in cardiac and skeletal muscleContains single heme moietyResembles single subunit of hemoglobinFunctions to enhance oxygen diffusion rate within muscle tissue",
                    "sub_points": [
                      "Contains single heme moiety",
                      "Resembles single subunit of hemoglobin",
                      "Functions to enhance oxygen diffusion rate within muscle tissue"
                    ]
                  },
                  {
                    "text": "Myoglobin is cleared by kidneys"
                  },
                  {
                    "text": "Myoglobin leaks from damaged cells rapidly because of its low molecular weight (18,000 Da)"
                  },
                  {
                    "text": "Basal myoglobin serum levels vary byAgeRaceSex (mostly a reflection of muscle mass)",
                    "sub_points": [
                      "Age",
                      "Race",
                      "Sex (mostly a reflection of muscle mass)"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Visual Inspection": [
                  {
                    "text": "Urine and blood samples can appear reddish-brown when myoglobin is present at concentration of 1 g/LHas been used as bedside test in patients with muscle disorders",
                    "sub_points": [
                      "Has been used as bedside test in patients with muscle disorders"
                    ]
                  }
                ],
                "Quantitative Analysis": [
                  {
                    "text": "Immunoassay currently used to measure serum myoglobinAutomated 2-site sandwich immunoassaySignal production by turbidity, nephelometry, or chemiluminescenceLack of reference method and standardization between assay manufacturers is still major concern",
                    "sub_points": [
                      "Automated 2-site sandwich immunoassaySignal production by turbidity, nephelometry, or chemiluminescence",
                      "Signal production by turbidity, nephelometry, or chemiluminescence",
                      "Lack of reference method and standardization between assay manufacturers is still major concern"
                    ]
                  }
                ],
                "Urinalysis": [
                  {
                    "text": "Myoglobin is component of common urine dipstick tests"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Acute Myocardial Infarction": [
                  {
                    "text": "Myoglobin is first serum cardiac protein to increase in concentration after AMISerum myoglobin begins to increase 1-4 hours after AMIPeak serum concentration seen approximately 6 hours after AMIReturns to baseline after 24-36 hoursFalse negatives possibleMyoglobin cleared rapidlyMay be useful in setting of reinfarction during AMI courseSerial measurement of myoglobin more clinically useful than single measure",
                    "sub_points": [
                      "Serum myoglobin begins to increase 1-4 hours after AMI",
                      "Peak serum concentration seen approximately 6 hours after AMIReturns to baseline after 24-36 hours",
                      "Returns to baseline after 24-36 hours",
                      "False negatives possibleMyoglobin cleared rapidly",
                      "Myoglobin cleared rapidly",
                      "May be useful in setting of reinfarction during AMI course",
                      "Serial measurement of myoglobin more clinically useful than single measure"
                    ]
                  },
                  {
                    "text": "Negative serum myoglobin has high negative predictive value for AMI in patients presenting within first 6 hours of chest pain onset"
                  }
                ],
                "Muscle Disorders": [
                  {
                    "text": "Myoglobin measurement used to diagnose rhabdomyolysis"
                  },
                  {
                    "text": "Used in combination with creatine kinase, myoglobin can detect myopathies such as Duchenne muscular dystrophy"
                  }
                ]
              },
              "LIMITATIONS": {
                "﻿Myoglobin Specificity": [
                  {
                    "text": "Myoglobin found in skeletal muscle; minor injury can increase measured concentrationChance of AMI misinterpretationCardiac and skeletal myoglobin are immunologically indistinctRendering differentiation by immunoassay impossible",
                    "sub_points": [
                      "Chance of AMI misinterpretation",
                      "Cardiac and skeletal myoglobin are immunologically indistinctRendering differentiation by immunoassay impossible",
                      "Rendering differentiation by immunoassay impossible"
                    ]
                  },
                  {
                    "text": "Trauma and crush injuries can increase serum myoglobin concentration"
                  },
                  {
                    "text": "Increases in myoglobin can be result of other conditionsCongestive heart failureRenal failureProlonged shock",
                    "sub_points": [
                      "Congestive heart failure",
                      "Renal failure",
                      "Prolonged shock"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection and Storage": [
                  {
                    "text": "Serum or plasma are stableUp to 1 week at 4°C4 weeks at ₋20°C",
                    "sub_points": [
                      "Up to 1 week at 4°C",
                      "4 weeks at ₋20°C"
                    ]
                  },
                  {
                    "text": "Urine specimens should be assayed soon after collectionAcceptable within 24 hours if kept refrigeratedFor long-term urine sample storage, pH must be alkalineAdjusted with NaOH to pH 9.0",
                    "sub_points": [
                      "Acceptable within 24 hours if kept refrigerated",
                      "For long-term urine sample storage, pH must be alkalineAdjusted with NaOH to pH 9.0",
                      "Adjusted with NaOH to pH 9.0"
                    ]
                  },
                  {
                    "text": "Myoglobin demonstrates diurnal variationPeak at 9 AMLowest between 6 PM and midnightDrawing sample at consistent time may be important in serially following patients with muscle disease",
                    "sub_points": [
                      "Peak at 9 AM",
                      "Lowest between 6 PM and midnight",
                      "Drawing sample at consistent time may be important in serially following patients with muscle disease"
                    ]
                  }
                ],
                "Interference": [
                  {
                    "text": "Rheumatoid factor affects myoglobin analysis"
                  }
                ]
              },
              "POINT OF CARE": {
                "Current Method": [
                  {
                    "text": "Devices currently on market combine myoglobin and other cardiac markersTroponin and CK-MB in single testing cartridge",
                    "sub_points": [
                      "Troponin and CK-MB in single testing cartridge"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "B-Type Natriuretic Peptide": {
            "name": "B-Type Natriuretic Peptide",
            "url": "https://app.pathprimer.com/document/20a39d09-313b-4de4-8f39-78bf1a62a51f/lesson/e051e1e5-ea70-4bb6-a205-93b17534d281",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Upon release, proBNP cleaved by corin enzyme into 2 fragments"
                  },
                  {
                    "text": "BNP (active hormone)"
                  },
                  {
                    "text": "NT-proBNP (inactive hormone)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "NT-proBNP and BNP used in assessment of patients with shortness of breath and suspected CHF"
                  },
                  {
                    "text": "Useful to rule out CHF in patientsBNP < 100 pg/mL seen in healthy patients",
                    "sub_points": [
                      "BNP < 100 pg/mL seen in healthy patients"
                    ]
                  },
                  {
                    "text": "Not as useful if elevated"
                  }
                ],
                "Processing": [
                  {
                    "text": "BNP unstable in blood due to protease breakdown"
                  },
                  {
                    "text": "Analysis ideally performed within 4 hours post-collection"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "B-type natriuretic peptide (BNP)"
                  },
                  {
                    "text": "Congestive heart failure (CHF)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  },
                  {
                    "text": "N-terminal proBNP (NT-proBNP)"
                  },
                  {
                    "text": "Renin-angiotensin-aldosterone system (RAAS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Brain natriuretic peptideTerm due to hormone originally isolated in porcine brainMisleading in humans",
                    "sub_points": [
                      "Term due to hormone originally isolated in porcine brain",
                      "Misleading in humans"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Biochemistry and Physiology": [
                  {
                    "text": "BNP is a 32-amino-acid peptide hormoneHas N-terminal region and physiologically active C-terminal region",
                    "sub_points": [
                      "Has N-terminal region and physiologically active C-terminal region"
                    ]
                  },
                  {
                    "text": "BNP derived from inactive precursor form proBNP"
                  },
                  {
                    "text": "ProBNP produced by cardiac ventricular myocytesRelease stimulated by ventricular wall stretch",
                    "sub_points": [
                      "Release stimulated by ventricular wall stretch"
                    ]
                  },
                  {
                    "text": "Upon release proBNP cleaved by corin enzyme into 2 fragmentsBNP (active hormone)NT-proBNP (inactive hormone)",
                    "sub_points": [
                      "BNP (active hormone)",
                      "NT-proBNP (inactive hormone)"
                    ]
                  },
                  {
                    "text": "Half-life of BNP is approximately 20 minutes"
                  },
                  {
                    "text": "NT-proBNP has longer half-life at 1-2 hours"
                  },
                  {
                    "text": "BNP cleared byEndopeptidase degradationReceptor-mediated clearance",
                    "sub_points": [
                      "Endopeptidase degradation",
                      "Receptor-mediated clearance"
                    ]
                  },
                  {
                    "text": "NT-proBNP primarily cleared by kidneysHalf-life extended in renal failure",
                    "sub_points": [
                      "Half-life extended in renal failure"
                    ]
                  },
                  {
                    "text": "Physiological functions of BNPDownregulate RAAS leading to enhanced renal loss of sodium and waterInduce vasodilation",
                    "sub_points": [
                      "Downregulate RAAS leading to enhanced renal loss of sodium and water",
                      "Induce vasodilation"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methods": [
                  {
                    "text": "NT-proBNP and BNP measured by 2-site immunoassay"
                  },
                  {
                    "text": "No clear clinical utility over using NT-proBNP versus BNP"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Congestive Heart Failure Diagnosis": [
                  {
                    "text": "CHF most common cause of hospitalization in patients older than 65 years"
                  },
                  {
                    "text": "NT-proBNP and BNP used in assessment of patients with shortness of breath and suspected CHFUseful to rule out CHF in patientsBNP < 100 pg/mL seen in healthy patientsNot as useful if elevatedNT-proBNP and BNP elevated in a number of disordersSepsisCirrhosisCushing syndromeRenal failure",
                    "sub_points": [
                      "Useful to rule out CHF in patientsBNP < 100 pg/mL seen in healthy patients",
                      "BNP < 100 pg/mL seen in healthy patients",
                      "Not as useful if elevatedNT-proBNP and BNP elevated in a number of disordersSepsisCirrhosisCushing syndromeRenal failure",
                      "NT-proBNP and BNP elevated in a number of disordersSepsisCirrhosisCushing syndromeRenal failure",
                      "Sepsis",
                      "Cirrhosis",
                      "Cushing syndrome",
                      "Renal failure"
                    ]
                  },
                  {
                    "text": "NT-proBNP and BNP used in prognosis assessmentBetter outcome with significant reduction in BNP levels during hospitalization",
                    "sub_points": [
                      "Better outcome with significant reduction in BNP levels during hospitalization"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Requirements": [
                  {
                    "text": "BNPEDTA whole blood/plasma only acceptable specimenPlastic blood collection tube necessary",
                    "sub_points": [
                      "EDTA whole blood/plasma only acceptable specimen",
                      "Plastic blood collection tube necessary"
                    ]
                  },
                  {
                    "text": "NT-proBNPSerum, heparin plasma, or EDTA plasma are acceptableNT-proBNP value approximately 10% lower in EDTA plasmaGlass or plastic collection tube acceptable",
                    "sub_points": [
                      "Serum, heparin plasma, or EDTA plasma are acceptableNT-proBNP value approximately 10% lower in EDTA plasma",
                      "NT-proBNP value approximately 10% lower in EDTA plasma",
                      "Glass or plastic collection tube acceptable"
                    ]
                  }
                ]
              },
              "PROCESSING": {
                "Stability": [
                  {
                    "text": "BNP unstable in blood due to protease breakdownAnalysis ideally performed within 4 hours post-collectionCan only be refrigerated for 24 hours before significant degradation",
                    "sub_points": [
                      "Analysis ideally performed within 4 hours post-collection",
                      "Can only be refrigerated for 24 hours before significant degradation"
                    ]
                  },
                  {
                    "text": "NT-proBNP much more stableCan be refrigerated for 3 days",
                    "sub_points": [
                      "Can be refrigerated for 3 days"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Liver Enzymes": {
        "name": "Liver Enzymes",
        "url": "https://app.pathprimer.com/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
        "topics": {
          "Bilirubin": {
            "name": "Bilirubin",
            "url": "https://app.pathprimer.com/document/e42c792a-3684-4737-9275-f35daa8b2f18/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Unconjugated bilirubin is water insolubleNormally transported in blood bound reversibly to albumin",
                    "sub_points": [
                      "Normally transported in blood bound reversibly to albumin"
                    ]
                  },
                  {
                    "text": "Conjugated bilirubin is water solubleNormally excreted into bile and, ultimately, intestines",
                    "sub_points": [
                      "Normally excreted into bile and, ultimately, intestines"
                    ]
                  },
                  {
                    "text": "Urobilinogen in the blood can also be filtered and excreted by kidneyIncreased urobilinogen in urine signifies elevated production of bilirubin (hemolysis)",
                    "sub_points": [
                      "Increased urobilinogen in urine signifies elevated production of bilirubin (hemolysis)"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Diazo reaction mainly measures conjugated (direct) bilirubinUnconjugated (indirect) bilirubin can react with diazotized sulfanilic acid, but does so slowlyTo speed up reaction accelerant is added (often caffeine)Causes unconjugated bilirubin to dissociate from albumin",
                    "sub_points": [
                      "Unconjugated (indirect) bilirubin can react with diazotized sulfanilic acid, but does so slowly",
                      "To speed up reaction accelerant is added (often caffeine)Causes unconjugated bilirubin to dissociate from albumin",
                      "Causes unconjugated bilirubin to dissociate from albumin"
                    ]
                  },
                  {
                    "text": "Unlike diazo method, HPLC can measure main bilirubin fractions directlyDelta bilirubinFraction of conjugated bilirubin permanently bound to albumin",
                    "sub_points": [
                      "Delta bilirubinFraction of conjugated bilirubin permanently bound to albumin",
                      "Fraction of conjugated bilirubin permanently bound to albumin"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "High-performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "Uridine diphosphate-glucuronyltransferase (UDP-GT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Bilirubin: Hematoidin"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Bilirubin: Orange-yellow pigment molecule"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Heme Degradation": [
                  {
                    "text": "~ 85% of total bilirubin produced arises from breakdown of heme molecules found in older erythrocytesHeme breakdown occurs in reticuloendothelial cells (macrophages) found in sites, such as spleen and bone marrowProtoporphyrin from heme metabolism is degraded by heme oxygenase, producing biliverdinIron and carbon dioxide also released in degradationExplains why carboxyhemoglobin can be used in hemolytic anemia diagnosisBiliverdin further reduced by biliverdin reductase to unconjugated bilirubin",
                    "sub_points": [
                      "Heme breakdown occurs in reticuloendothelial cells (macrophages) found in sites, such as spleen and bone marrowProtoporphyrin from heme metabolism is degraded by heme oxygenase, producing biliverdinIron and carbon dioxide also released in degradationExplains why carboxyhemoglobin can be used in hemolytic anemia diagnosisBiliverdin further reduced by biliverdin reductase to unconjugated bilirubin",
                      "Protoporphyrin from heme metabolism is degraded by heme oxygenase, producing biliverdinIron and carbon dioxide also released in degradationExplains why carboxyhemoglobin can be used in hemolytic anemia diagnosis",
                      "Iron and carbon dioxide also released in degradation",
                      "Explains why carboxyhemoglobin can be used in hemolytic anemia diagnosis",
                      "Biliverdin further reduced by biliverdin reductase to unconjugated bilirubin"
                    ]
                  },
                  {
                    "text": "Remaining 15% of total bilirubin produced as followsDestruction of red cell precursors within bone marrowCatabolism of other heme-containing proteinsMyoglobinCytochromesPeroxidases",
                    "sub_points": [
                      "Destruction of red cell precursors within bone marrow",
                      "Catabolism of other heme-containing proteinsMyoglobinCytochromesPeroxidases",
                      "Myoglobin",
                      "Cytochromes",
                      "Peroxidases"
                    ]
                  }
                ],
                "﻿Bilirubin Conjugation": [
                  {
                    "text": "Unconjugated bilirubin is water insolubleNormally transported in blood bound reversibly to albuminOnce at liver, bilirubin dissociates from albumin and is taken into hepatocytesIn hepatocytes, bilirubin is conjugated with glucuronic acid via UDP-GTUGT1A1gene encodes UDP-GT enzyme",
                    "sub_points": [
                      "Normally transported in blood bound reversibly to albumin",
                      "Once at liver, bilirubin dissociates from albumin and is taken into hepatocytes",
                      "In hepatocytes, bilirubin is conjugated with glucuronic acid via UDP-GTUGT1A1gene encodes UDP-GT enzyme",
                      "UGT1A1gene encodes UDP-GT enzyme"
                    ]
                  },
                  {
                    "text": "Conjugated bilirubin is water solubleNormally excreted into bile and, ultimately, intestinesIn intestines, anaerobic intestinal microbes further metabolize conjugated bilirubin into compounds collectively termed urobilinogen",
                    "sub_points": [
                      "Normally excreted into bile and, ultimately, intestinesIn intestines, anaerobic intestinal microbes further metabolize conjugated bilirubin into compounds collectively termed urobilinogen",
                      "In intestines, anaerobic intestinal microbes further metabolize conjugated bilirubin into compounds collectively termed urobilinogen"
                    ]
                  },
                  {
                    "text": "UrobilinogenCan be absorbed by gut and returned to liver to be reexcreted in bileUrobilinogen in blood can also be filtered and excreted by kidneyIncreased urobilinogen in urine signifies elevated production of bilirubin (hemolysis)Some urobilinogen undergoes spontaneous oxidation to stercobilins (major stool pigment)Abnormal stool color (pale or clay) can suggest defect in bilirubin excretion (obstruction)",
                    "sub_points": [
                      "Can be absorbed by gut and returned to liver to be reexcreted in bile",
                      "Urobilinogen in blood can also be filtered and excreted by kidneyIncreased urobilinogen in urine signifies elevated production of bilirubin (hemolysis)",
                      "Increased urobilinogen in urine signifies elevated production of bilirubin (hemolysis)",
                      "Some urobilinogen undergoes spontaneous oxidation to stercobilins (major stool pigment)Abnormal stool color (pale or clay) can suggest defect in bilirubin excretion (obstruction)",
                      "Abnormal stool color (pale or clay) can suggest defect in bilirubin excretion (obstruction)"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Diazo Method": [
                  {
                    "text": "Most common method to measure bilirubin in blood"
                  },
                  {
                    "text": "Diazo reaction mainly measures conjugated (direct) bilirubinDiazotized sulfanilic acid reacts quickly with conjugated bilirubin, producing azobilirubinAzobilirubin absorbs light at 540 nm and can be measured spectrophotometrically",
                    "sub_points": [
                      "Diazotized sulfanilic acid reacts quickly with conjugated bilirubin, producing azobilirubin",
                      "Azobilirubin absorbs light at 540 nm and can be measured spectrophotometrically"
                    ]
                  },
                  {
                    "text": "Unconjugated (indirect) bilirubin can react with diazotized sulfanilic acid, but does so slowly"
                  },
                  {
                    "text": "To speed up reaction an accelerant is added (often caffeine)Causes unconjugated bilirubin to dissociate from albumin",
                    "sub_points": [
                      "Causes unconjugated bilirubin to dissociate from albumin"
                    ]
                  },
                  {
                    "text": "Unconjugated bilirubin can then be measured, allowing for total bilirubin determination"
                  },
                  {
                    "text": "By subtracting conjugated bilirubin from total bilirubin, unconjugated bilirubin fraction is indirectly measured"
                  }
                ],
                "﻿HPLC": [
                  {
                    "text": "Unlike the diazo method, HPLC can measure main bilirubin fractions directlyUnconjugatedConjugatedDelta bilirubinFraction of conjugated bilirubin permanently bound to albuminIn states of conjugated hyperbilirubinemia, delta bilirubin fraction increased",
                    "sub_points": [
                      "Unconjugated",
                      "Conjugated",
                      "Delta bilirubinFraction of conjugated bilirubin permanently bound to albuminIn states of conjugated hyperbilirubinemia, delta bilirubin fraction increased",
                      "Fraction of conjugated bilirubin permanently bound to albumin",
                      "In states of conjugated hyperbilirubinemia, delta bilirubin fraction increased"
                    ]
                  },
                  {
                    "text": "Useful because delta bilirubin is water soluble and interacts with diazotized sulfanilic acid in diazo methodFalsely elevates measured direct bilirubin",
                    "sub_points": [
                      "Falsely elevates measured direct bilirubin"
                    ]
                  },
                  {
                    "text": "Because delta bilirubin half-life is that of albumin (17-19 days), can persist long after conjugated hyperbilirubinemia has resolvedCreated diagnostic confusion until delta bilirubin discovery",
                    "sub_points": [
                      "Created diagnostic confusion until delta bilirubin discovery"
                    ]
                  }
                ],
                "﻿Urine Bilirubin": [
                  {
                    "text": "Often a dipstick method with diazo reagentMeasures conjugated bilirubin",
                    "sub_points": [
                      "Measures conjugated bilirubin"
                    ]
                  },
                  {
                    "text": "Lower limit of detection: 0.5 mg/dL"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Jaundice": [
                  {
                    "text": "Hyperbilirubinemia leads to clinical condition termed jaundice"
                  },
                  {
                    "text": "Jaundiced patients display characteristic yellow appearance (icterus) due to bile pigment depositionIn skinIn scleraIn mucous membranes",
                    "sub_points": [
                      "In skin",
                      "In sclera",
                      "In mucous membranes"
                    ]
                  },
                  {
                    "text": "Jaundice can have various causesIncreased unconjugated bilirubinHemolysisIneffective erythropoiesisHepatic defect in conjugationHyperthyroidismCongestive heart failureDrugs that inhibitUGT1A1Oral contraceptivesHIV protease inhibitorsIncreased conjugated bilirubinHepatocellular diseaseHepatitisCirrhosisExtra and intrahepatic obstructionGallstonesBiliary tract stricturesTumorsPrimary biliary cirrhosisPrimary sclerosing cholangitis",
                    "sub_points": [
                      "Increased unconjugated bilirubinHemolysisIneffective erythropoiesisHepatic defect in conjugationHyperthyroidismCongestive heart failureDrugs that inhibitUGT1A1Oral contraceptivesHIV protease inhibitors",
                      "Hemolysis",
                      "Ineffective erythropoiesis",
                      "Hepatic defect in conjugation",
                      "Hyperthyroidism",
                      "Congestive heart failure",
                      "Drugs that inhibitUGT1A1Oral contraceptivesHIV protease inhibitors",
                      "Oral contraceptives",
                      "HIV protease inhibitors",
                      "Increased conjugated bilirubinHepatocellular diseaseHepatitisCirrhosisExtra and intrahepatic obstructionGallstonesBiliary tract stricturesTumorsPrimary biliary cirrhosisPrimary sclerosing cholangitis",
                      "Hepatocellular diseaseHepatitisCirrhosis",
                      "Hepatitis",
                      "Cirrhosis",
                      "Extra and intrahepatic obstructionGallstonesBiliary tract stricturesTumorsPrimary biliary cirrhosisPrimary sclerosing cholangitis",
                      "Gallstones",
                      "Biliary tract strictures",
                      "Tumors",
                      "Primary biliary cirrhosis",
                      "Primary sclerosing cholangitis"
                    ]
                  }
                ],
                "﻿Inherited Hyperbilirubinemia Disorders": [
                  {
                    "text": "Various inherited disorders result in hyperbilirubinemia in setting of normal liver function tests"
                  },
                  {
                    "text": "Often due to varying degree of defects inUGT1A1gene"
                  },
                  {
                    "text": "Most are rare (with exception of Gilbert syndrome) and can be divided into 2 categoriesUnconjugated hyperbilirubinemiaGilbert syndromeBenign autosomal recessive condition seen in up to 5% of populationLow hepatic UDP-GT activityUnconjugated bilirubin 1.5-3.0 mg/dLIncreases with fastingCan be misdiagnosed as chronic hepatitisPatients affected might also be predisposed to acetaminophen toxicityCrigler-Najjar syndrome (type I)Complete absence of UDP-GT via autosomal recessive inheritanceSerum unconjugated bilirubin exceeds 25 mg/dLPatients die from encephalopathy (kernicterus) within 1st year of lifeLiver transplant is only effective therapyCrigler-Najjar syndrome (type 2)Autosomal dominant disorder resulting in partial deficiency of UDP-GTSerum unconjugated bilirubin 5-20 mg/dLPhenobarbital is effective treatmentNormal life expectancyLucey-Driscoll syndromeResults from circulating inhibiting factor of bilirubin conjugationMild unconjugated hyperbilirubinemia with onset at birthLasts only for 2-3 weeks of lifeConjugated hyperbilirubinemiaDubin-Johnson syndromeBenign autosomal recessive disorderCaused by defects in canalicular multispecific organic anion transporter proteinResults in impaired excretion of organic anions (conjugated bilirubin) into canaliculiNoteworthy for black pigmentation of liver on resection or autopsyRotor syndromeBenign autosomal recessive disorder similar to Dubin-Johnson syndromeDefect in organic anion storageNormal liver pigmentation",
                    "sub_points": [
                      "Unconjugated hyperbilirubinemiaGilbert syndromeBenign autosomal recessive condition seen in up to 5% of populationLow hepatic UDP-GT activityUnconjugated bilirubin 1.5-3.0 mg/dLIncreases with fastingCan be misdiagnosed as chronic hepatitisPatients affected might also be predisposed to acetaminophen toxicityCrigler-Najjar syndrome (type I)Complete absence of UDP-GT via autosomal recessive inheritanceSerum unconjugated bilirubin exceeds 25 mg/dLPatients die from encephalopathy (kernicterus) within 1st year of lifeLiver transplant is only effective therapyCrigler-Najjar syndrome (type 2)Autosomal dominant disorder resulting in partial deficiency of UDP-GTSerum unconjugated bilirubin 5-20 mg/dLPhenobarbital is effective treatmentNormal life expectancyLucey-Driscoll syndromeResults from circulating inhibiting factor of bilirubin conjugationMild unconjugated hyperbilirubinemia with onset at birthLasts only for 2-3 weeks of life",
                      "Gilbert syndromeBenign autosomal recessive condition seen in up to 5% of populationLow hepatic UDP-GT activityUnconjugated bilirubin 1.5-3.0 mg/dLIncreases with fastingCan be misdiagnosed as chronic hepatitisPatients affected might also be predisposed to acetaminophen toxicity",
                      "Benign autosomal recessive condition seen in up to 5% of population",
                      "Low hepatic UDP-GT activity",
                      "Unconjugated bilirubin 1.5-3.0 mg/dL",
                      "Increases with fasting",
                      "Can be misdiagnosed as chronic hepatitis",
                      "Patients affected might also be predisposed to acetaminophen toxicity",
                      "Crigler-Najjar syndrome (type I)Complete absence of UDP-GT via autosomal recessive inheritanceSerum unconjugated bilirubin exceeds 25 mg/dLPatients die from encephalopathy (kernicterus) within 1st year of lifeLiver transplant is only effective therapy",
                      "Complete absence of UDP-GT via autosomal recessive inheritance",
                      "Serum unconjugated bilirubin exceeds 25 mg/dL",
                      "Patients die from encephalopathy (kernicterus) within 1st year of life",
                      "Liver transplant is only effective therapy",
                      "Crigler-Najjar syndrome (type 2)Autosomal dominant disorder resulting in partial deficiency of UDP-GTSerum unconjugated bilirubin 5-20 mg/dLPhenobarbital is effective treatmentNormal life expectancy",
                      "Autosomal dominant disorder resulting in partial deficiency of UDP-GT",
                      "Serum unconjugated bilirubin 5-20 mg/dL",
                      "Phenobarbital is effective treatment",
                      "Normal life expectancy",
                      "Lucey-Driscoll syndromeResults from circulating inhibiting factor of bilirubin conjugationMild unconjugated hyperbilirubinemia with onset at birthLasts only for 2-3 weeks of life",
                      "Results from circulating inhibiting factor of bilirubin conjugation",
                      "Mild unconjugated hyperbilirubinemia with onset at birth",
                      "Lasts only for 2-3 weeks of life",
                      "Conjugated hyperbilirubinemiaDubin-Johnson syndromeBenign autosomal recessive disorderCaused by defects in canalicular multispecific organic anion transporter proteinResults in impaired excretion of organic anions (conjugated bilirubin) into canaliculiNoteworthy for black pigmentation of liver on resection or autopsyRotor syndromeBenign autosomal recessive disorder similar to Dubin-Johnson syndromeDefect in organic anion storageNormal liver pigmentation",
                      "Dubin-Johnson syndromeBenign autosomal recessive disorderCaused by defects in canalicular multispecific organic anion transporter proteinResults in impaired excretion of organic anions (conjugated bilirubin) into canaliculiNoteworthy for black pigmentation of liver on resection or autopsy",
                      "Benign autosomal recessive disorder",
                      "Caused by defects in canalicular multispecific organic anion transporter protein",
                      "Results in impaired excretion of organic anions (conjugated bilirubin) into canaliculi",
                      "Noteworthy for black pigmentation of liver on resection or autopsy",
                      "Rotor syndromeBenign autosomal recessive disorder similar to Dubin-Johnson syndromeDefect in organic anion storageNormal liver pigmentation",
                      "Benign autosomal recessive disorder similar to Dubin-Johnson syndrome",
                      "Defect in organic anion storage",
                      "Normal liver pigmentation"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Considerations": [
                  {
                    "text": "CollectionProlonged exposure to light causes photoisomerization of bilirubin in samplesFalsely increases measured conjugated (direct) bilirubinSerum samples often wrapped in aluminum foilStrenuous exercise increases measured bilirubin significantly",
                    "sub_points": [
                      "Prolonged exposure to light causes photoisomerization of bilirubin in samplesFalsely increases measured conjugated (direct) bilirubinSerum samples often wrapped in aluminum foil",
                      "Falsely increases measured conjugated (direct) bilirubin",
                      "Serum samples often wrapped in aluminum foil",
                      "Strenuous exercise increases measured bilirubin significantly"
                    ]
                  },
                  {
                    "text": "SexBilirubin values higher in men (at all ages) compared to women",
                    "sub_points": [
                      "Bilirubin values higher in men (at all ages) compared to women"
                    ]
                  },
                  {
                    "text": "EthnicityAfrican Americans appear to have lower bilirubin levels compared to caucasians",
                    "sub_points": [
                      "African Americans appear to have lower bilirubin levels compared to caucasians"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Aspartate Transaminase (AST) and Alanine Transaminase (ALT)": {
            "name": "Aspartate Transaminase (AST) and Alanine Transaminase (ALT)",
            "url": "https://app.pathprimer.com/document/521a84a3-3298-4808-bd7a-cd4729f08d75/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "AST and ALT are specific types of aminotransferases used in liver disease assessmentIn addition to liver, both AST and ALT are found in other body areasHeartSkeletal muscleKidneyRed blood cells (AST)",
                    "sub_points": [
                      "In addition to liver, both AST and ALT are found in other body areasHeartSkeletal muscleKidneyRed blood cells (AST)",
                      "Heart",
                      "Skeletal muscle",
                      "Kidney",
                      "Red blood cells (AST)"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "AST/ALT ratio (De Ritis ratio) in the setting of high levels can be used to determine liver injury etiologyNormal ratio approximately 0.7-1.4Ratio < 2Viral hepatitisAutoimmune hepatitisCholangitisHemochromatosisNASHCirrhosisRatio > 2Alcoholic hepatitis (usually 3-4:1)Acute ischemiaLiver metastasisReye syndromePrimary biliary cirrhosisToxic ingestion (acetaminophen)",
                    "sub_points": [
                      "Normal ratio approximately 0.7-1.4",
                      "Ratio < 2Viral hepatitisAutoimmune hepatitisCholangitisHemochromatosisNASHCirrhosis",
                      "Viral hepatitis",
                      "Autoimmune hepatitis",
                      "Cholangitis",
                      "Hemochromatosis",
                      "NASH",
                      "Cirrhosis",
                      "Ratio > 2Alcoholic hepatitis (usually 3-4:1)Acute ischemiaLiver metastasisReye syndromePrimary biliary cirrhosisToxic ingestion (acetaminophen)",
                      "Alcoholic hepatitis (usually 3-4:1)",
                      "Acute ischemia",
                      "Liver metastasis",
                      "Reye syndrome",
                      "Primary biliary cirrhosis",
                      "Toxic ingestion (acetaminophen)"
                    ]
                  }
                ],
                "Limitations": [
                  {
                    "text": "While aminotransferase elevation is primarily associated with liver disease, remember nonliver and iatrogenic causesMyocardial infarctionMuscle diseaseHemolytic diseaseAST elevation with normal ALTHeparin therapy",
                    "sub_points": [
                      "Myocardial infarction",
                      "Muscle disease",
                      "Hemolytic diseaseAST elevation with normal ALT",
                      "AST elevation with normal ALT",
                      "Heparin therapy"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nonalcoholic steatohepatitis (NASH)"
                  },
                  {
                    "text": "Polyethylene glycol (PEG) 6000"
                  },
                  {
                    "text": "Upper reference limit (URL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "AST or ALT: Aminotransferase"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Biochemistry and Physiology": [
                  {
                    "text": "Aminotransferases are a group of enzymes that catalyze transfer of amino groups (-NH₂)Requires vitamin B6 as a cofactor for activity",
                    "sub_points": [
                      "Requires vitamin B6 as a cofactor for activity"
                    ]
                  },
                  {
                    "text": "AST and ALT are specific types of aminotransferases used in liver disease assessmentIn addition to liver, both AST and ALT are found in other body areasHeartSkeletal muscleKidneyRed blood cells (AST)",
                    "sub_points": [
                      "In addition to liver, both AST and ALT are found in other body areasHeartSkeletal muscleKidneyRed blood cells (AST)",
                      "Heart",
                      "Skeletal muscle",
                      "Kidney",
                      "Red blood cells (AST)"
                    ]
                  },
                  {
                    "text": "Cellular locationsAST: Mitochondria and cytoplasmALT: Exclusively cytoplasmic and generally more liver-specific",
                    "sub_points": [
                      "AST: Mitochondria and cytoplasm",
                      "ALT: Exclusively cytoplasmic and generally more liver-specific"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Liver Disease": [
                  {
                    "text": "High levels of AST and ALT release into blood (> 3 times URL) signifies hepatocellular damage"
                  },
                  {
                    "text": "Aminotrasferase threshold for acute liver injury diagnosis is 7 times URLAcetaminophen overdose induces aminotransferase activity 85 times URL",
                    "sub_points": [
                      "Acetaminophen overdose induces aminotransferase activity 85 times URL"
                    ]
                  },
                  {
                    "text": "ALT activity for > 6 months signifies chronic hepatitis"
                  },
                  {
                    "text": "AST/ALT ratio (De Ritis ratio) in the setting of high levels can be used to determine liver injury etiologyNormal ratio approximately 0.7-1.4Ratio < 2Viral hepatitisAutoimmune hepatitisCholangitisHemochromatosisNASHCirrhosisRatio > 2Alcoholic hepatitis (usually 3-4:1)Acute ischemiaLiver metastasisReye syndromePrimary biliary cirrhosisToxic ingestion (acetaminophen)",
                    "sub_points": [
                      "Normal ratio approximately 0.7-1.4",
                      "Ratio < 2Viral hepatitisAutoimmune hepatitisCholangitisHemochromatosisNASHCirrhosis",
                      "Viral hepatitis",
                      "Autoimmune hepatitis",
                      "Cholangitis",
                      "Hemochromatosis",
                      "NASH",
                      "Cirrhosis",
                      "Ratio > 2Alcoholic hepatitis (usually 3-4:1)Acute ischemiaLiver metastasisReye syndromePrimary biliary cirrhosisToxic ingestion (acetaminophen)",
                      "Alcoholic hepatitis (usually 3-4:1)",
                      "Acute ischemia",
                      "Liver metastasis",
                      "Reye syndrome",
                      "Primary biliary cirrhosis",
                      "Toxic ingestion (acetaminophen)"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Nonliver Disease": [
                  {
                    "text": "While aminotransferase elevation is primarily associated with liver disease, remember nonliver and iatrogenic causesMyocardial infarctionMuscular dystrophyDermatomyositisHemolytic diseaseAST elevation with normal ALTHeparin therapy",
                    "sub_points": [
                      "Myocardial infarction",
                      "Muscular dystrophy",
                      "Dermatomyositis",
                      "Hemolytic diseaseAST elevation with normal ALT",
                      "AST elevation with normal ALT",
                      "Heparin therapy"
                    ]
                  }
                ],
                "Macro-AST": [
                  {
                    "text": "AST can combine with immunoglobulins in circulation, forming macro-ASTSimilar to macroamylase phenomenonDifferential precipitation with PEG 6000 used to demonstrate macro-AST",
                    "sub_points": [
                      "Similar to macroamylase phenomenon",
                      "Differential precipitation with PEG 6000 used to demonstrate macro-AST"
                    ]
                  },
                  {
                    "text": "Seen in asymptomatic patients with elevated serum AST activityIdentification important, to avoid unnecessary management",
                    "sub_points": [
                      "Identification important, to avoid unnecessary management"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytical Considerations": [
                  {
                    "text": "AST and ALTLevels in males 40% higher than in femalesDiurnal variation (highest in afternoon)Increased by strenuous exerciseHigher baseline level in children",
                    "sub_points": [
                      "Levels in males 40% higher than in females",
                      "Diurnal variation (highest in afternoon)",
                      "Increased by strenuous exercise",
                      "Higher baseline level in children"
                    ]
                  },
                  {
                    "text": "AST aloneHemolyzed specimens are unacceptableAST activity stable for 48 hours at 4°C15% higher in African American menHalf-life in serum 16-18 hours",
                    "sub_points": [
                      "Hemolyzed specimens are unacceptable",
                      "AST activity stable for 48 hours at 4°C",
                      "15% higher in African American men",
                      "Half-life in serum 16-18 hours"
                    ]
                  },
                  {
                    "text": "ALT aloneShould be run on day of collectionActivity lost even at refrigerated temperaturesHalf-life in serum 42-48 hours",
                    "sub_points": [
                      "Should be run on day of collectionActivity lost even at refrigerated temperatures",
                      "Activity lost even at refrigerated temperatures",
                      "Half-life in serum 42-48 hours"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Alkaline Phosphatase and Other Enzymes in Hepatobiliary Disease": {
            "name": "Alkaline Phosphatase and Other Enzymes in Hepatobiliary Disease",
            "url": "https://app.pathprimer.com/document/d0e91555-a85e-4fad-9e71-6bd1d938669c/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "ALP activity is found in 4 clinically relevant tissues, each with unique isoenzyme forms: bone, liver, small intestine mucosa, placenta"
                  },
                  {
                    "text": "Four isoenzyme types can be differentiated by their loss of activity on heating (65°C)Bone ALP activity almost completely gonePlacental ALP activity not impactedIntestinal and liver ALP activity reduced",
                    "sub_points": [
                      "Bone ALP activity almost completely gone",
                      "Placental ALP activity not impacted",
                      "Intestinal and liver ALP activity reduced"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Assays to measure ALP isoenzymes are requested when source of elevated ALP activity needs to be clarified"
                  },
                  {
                    "text": "ALP isoenzymes traditionally were measured by electrophoresis; this is labor intensive and currently is not routinely used"
                  },
                  {
                    "text": "Other markers of hepatobiliary origin are measured including GGT and 5'-nucleotidase"
                  },
                  {
                    "text": "If either GGT or 5'-nucleotidase is elevated, liver ALP is likely source of elevation"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Alkaline phosphatase (ALP)"
                  },
                  {
                    "text": "Upper reference limit (URL)"
                  },
                  {
                    "text": "γ-Glutamyltransferase (GGT)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "ALP activity found in 4 clinically relevant tissues, each with unique isoenzyme formsBoneLiverSmall intestine mucosaPlacenta",
                    "sub_points": [
                      "Bone",
                      "Liver",
                      "Small intestine mucosa",
                      "Placenta"
                    ]
                  },
                  {
                    "text": "Four isoenzyme types can be differentiated by loss of activity on heating (65°C)Bone ALP activity almost completely gonePlacental ALP activity not impactedIntestinal and liver ALP activity reduced",
                    "sub_points": [
                      "Bone ALP activity almost completely gone",
                      "Placental ALP activity not impacted",
                      "Intestinal and liver ALP activity reduced"
                    ]
                  },
                  {
                    "text": "In healthy adults, ALP activity mainly derived from liver and skeletonIf individual is blood type B or O, some intestinal ALP may be present",
                    "sub_points": [
                      "If individual is blood type B or O, some intestinal ALP may be present"
                    ]
                  },
                  {
                    "text": "Measurement of ALP should occur in fasting stateIntestinal ALP activity increases after meals",
                    "sub_points": [
                      "Intestinal ALP activity increases after meals"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Elevated ALP Activity": [
                  {
                    "text": "ALP activity routinely measured through enzymatic reaction creating chromogenic substrate"
                  },
                  {
                    "text": "Assays to measure ALP isoenzymes requested when source of elevated ALP activity needs to be clarifiedDifferentiating between liver ALP and bone ALP",
                    "sub_points": [
                      "Differentiating between liver ALP and bone ALP"
                    ]
                  },
                  {
                    "text": "ALP isoenzymes traditionally were measured by electrophoresisLabor intensive and currently not routinely used",
                    "sub_points": [
                      "Labor intensive and currently not routinely used"
                    ]
                  },
                  {
                    "text": "Other markers of hepatobiliary origin are measuredGGTEnzyme that aids in amino acid transport across cell membranesCritical for intracellular maintenance of antioxidants (reduced glutathione)Found on hepatocyte canalicular membraneAside from hepatobiliary disease, elevated GGT can be seen in patients receiving antiseizure medication (phenobarbital and phenytoin)Baseline elevations may be seen in alcohol abuse5'-NucleotidaseIncreased in cholestatic disorders and displays high specificityNo activity increase seen in bone disease",
                    "sub_points": [
                      "GGTEnzyme that aids in amino acid transport across cell membranesCritical for intracellular maintenance of antioxidants (reduced glutathione)Found on hepatocyte canalicular membraneAside from hepatobiliary disease, elevated GGT can be seen in patients receiving antiseizure medication (phenobarbital and phenytoin)Baseline elevations may be seen in alcohol abuse",
                      "Enzyme that aids in amino acid transport across cell membranes",
                      "Critical for intracellular maintenance of antioxidants (reduced glutathione)",
                      "Found on hepatocyte canalicular membrane",
                      "Aside from hepatobiliary disease, elevated GGT can be seen in patients receiving antiseizure medication (phenobarbital and phenytoin)",
                      "Baseline elevations may be seen in alcohol abuse",
                      "5'-NucleotidaseIncreased in cholestatic disorders and displays high specificityNo activity increase seen in bone disease",
                      "Increased in cholestatic disorders and displays high specificity",
                      "No activity increase seen in bone disease"
                    ]
                  },
                  {
                    "text": "If either GGT or 5'-nucleotidase is elevated, liver ALP is likely source of elevation"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Commonly Encounter Clinical Elevations in ALP": [
                  {
                    "text": "ALP measurement used clinically to investigate various conditionsHepatobiliary diseasesBiliary tree obstruction (intrahepatic or extrahepatic) induces ALP synthesis by hepatocytesALP then enters circulation at elevated levelsExtrahepatic obstruction generally shows 3-fold higher increase in ALP than intrahepatic obstructionBoneOsteoblasts produce bone ALPBone ALP is indicator of overall bone formationClinically significant elevations in bone ALP seen with Paget disease (osteitis deformans)Minor elevations may be seen in patients with vitamin D deficiency or hyperparathyroidismBone ALP may be elevated transiently during bone fracture healingNormal bone growth in children increases bone ALP serum levelsAccounts for normal ALP elevation seen in pediatric reference intervalsOtherPregnant women in third trimester have elevations in ALP activity2-3 times URLDue to placental ALPPatients with malignant disease can display ALP isoenzyme similar to placental typeTermed Regan isoenzyme",
                    "sub_points": [
                      "Hepatobiliary diseasesBiliary tree obstruction (intrahepatic or extrahepatic) induces ALP synthesis by hepatocytesALP then enters circulation at elevated levelsExtrahepatic obstruction generally shows 3-fold higher increase in ALP than intrahepatic obstruction",
                      "Biliary tree obstruction (intrahepatic or extrahepatic) induces ALP synthesis by hepatocytes",
                      "ALP then enters circulation at elevated levelsExtrahepatic obstruction generally shows 3-fold higher increase in ALP than intrahepatic obstruction",
                      "Extrahepatic obstruction generally shows 3-fold higher increase in ALP than intrahepatic obstruction",
                      "BoneOsteoblasts produce bone ALPBone ALP is indicator of overall bone formationClinically significant elevations in bone ALP seen with Paget disease (osteitis deformans)Minor elevations may be seen in patients with vitamin D deficiency or hyperparathyroidismBone ALP may be elevated transiently during bone fracture healingNormal bone growth in children increases bone ALP serum levelsAccounts for normal ALP elevation seen in pediatric reference intervals",
                      "Osteoblasts produce bone ALPBone ALP is indicator of overall bone formation",
                      "Bone ALP is indicator of overall bone formation",
                      "Clinically significant elevations in bone ALP seen with Paget disease (osteitis deformans)",
                      "Minor elevations may be seen in patients with vitamin D deficiency or hyperparathyroidism",
                      "Bone ALP may be elevated transiently during bone fracture healing",
                      "Normal bone growth in children increases bone ALP serum levelsAccounts for normal ALP elevation seen in pediatric reference intervals",
                      "Accounts for normal ALP elevation seen in pediatric reference intervals",
                      "OtherPregnant women in third trimester have elevations in ALP activity2-3 times URLDue to placental ALPPatients with malignant disease can display ALP isoenzyme similar to placental typeTermed Regan isoenzyme",
                      "Pregnant women in third trimester have elevations in ALP activity2-3 times URLDue to placental ALP",
                      "2-3 times URL",
                      "Due to placental ALP",
                      "Patients with malignant disease can display ALP isoenzyme similar to placental typeTermed Regan isoenzyme",
                      "Termed Regan isoenzyme"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ammonia": {
            "name": "Ammonia",
            "url": "https://app.pathprimer.com/document/faf72998-f03c-45f1-88b4-abdb33aeb49e/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Ammonia: By-product of cellular metabolismMeasurement has variety of preanalytic variables to consider",
                    "sub_points": [
                      "Measurement has variety of preanalytic variables to consider"
                    ]
                  },
                  {
                    "text": "Causes of false-positive ammoniaSmoking (smokers have higher baseline values and should abstain before testing)Use of serum specimen (plasma sample necessary)Sample hemolysisProlonged tourniquet useFailure to put sample on ice or chill after collection",
                    "sub_points": [
                      "Smoking (smokers have higher baseline values and should abstain before testing)",
                      "Use of serum specimen (plasma sample necessary)",
                      "Sample hemolysis",
                      "Prolonged tourniquet use",
                      "Failure to put sample on ice or chill after collection"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Gamma-aminobutyric acid (GABA)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Ammonia Metabolism": [
                  {
                    "text": "Ammonia is a toxic compound created by amino acid and nucleic acid metabolism"
                  },
                  {
                    "text": "Portal vein ammonia concentration is up to 10 times that of general circulation"
                  },
                  {
                    "text": "Most ammonia is metabolized by liver via urea cycleUrea produced from cycle is then excreted into urine",
                    "sub_points": [
                      "Urea produced from cycle is then excreted into urine"
                    ]
                  }
                ],
                "Pathophysiology": [
                  {
                    "text": "Elevated ammonia concentration is neurotoxicLowers concentrations of GABA neurotransmitterGlutamic acid reacts with ammonia to form glutamineReduces amount of glutamic acid available for GABA formationIncreases cerebral inflammation and edema",
                    "sub_points": [
                      "Lowers concentrations of GABA neurotransmitterGlutamic acid reacts with ammonia to form glutamineReduces amount of glutamic acid available for GABA formationIncreases cerebral inflammation and edema",
                      "Glutamic acid reacts with ammonia to form glutamine",
                      "Reduces amount of glutamic acid available for GABA formationIncreases cerebral inflammation and edema",
                      "Increases cerebral inflammation and edema"
                    ]
                  },
                  {
                    "text": "Causes of elevated of ammoniaCongenital deficiency of urea cycle enzymesCirrhosisUrea cycle enzymes no longer functioningVenous shunting also causes ammonia bypass of liverReye syndromeRenal failureBacterial production within gastrointestinal tractExcess of protein intakeGastrointestinal bleeding",
                    "sub_points": [
                      "Congenital deficiency of urea cycle enzymes",
                      "CirrhosisUrea cycle enzymes no longer functioningVenous shunting also causes ammonia bypass of liver",
                      "Urea cycle enzymes no longer functioning",
                      "Venous shunting also causes ammonia bypass of liver",
                      "Reye syndrome",
                      "Renal failure",
                      "Bacterial production within gastrointestinal tractExcess of protein intakeGastrointestinal bleeding",
                      "Excess of protein intake",
                      "Gastrointestinal bleeding"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Ammonia: By-product of cellular metabolismMeasurement has variety of preanalytic variables to consider",
                    "sub_points": [
                      "Measurement has variety of preanalytic variables to consider"
                    ]
                  },
                  {
                    "text": "Causes of false-positive ammoniaSmokingSmokers have higher baseline values and should abstain before testingDelayed analysisUse of serum specimen (plasma sample necessary)Fibrin molecules produce ammonia as by-product during clotting processClotting process delays analysis (15 min)Sample hemolysisHigh concentration of ammonia within erythrocytes (3 times plasma)Ammonia heparin anticoagulantProlonged tourniquet useFailure to put sample on ice or chill after collectionMetabolic production of ammonia not slowed",
                    "sub_points": [
                      "SmokingSmokers have higher baseline values and should abstain before testing",
                      "Smokers have higher baseline values and should abstain before testing",
                      "Delayed analysis",
                      "Use of serum specimen (plasma sample necessary)Fibrin molecules produce ammonia as by-product during clotting processClotting process delays analysis (15 min)",
                      "Fibrin molecules produce ammonia as by-product during clotting process",
                      "Clotting process delays analysis (15 min)",
                      "Sample hemolysisHigh concentration of ammonia within erythrocytes (3 times plasma)",
                      "High concentration of ammonia within erythrocytes (3 times plasma)",
                      "Ammonia heparin anticoagulant",
                      "Prolonged tourniquet use",
                      "Failure to put sample on ice or chill after collectionMetabolic production of ammonia not slowed",
                      "Metabolic production of ammonia not slowed"
                    ]
                  },
                  {
                    "text": "Elevated ammonia in healthy subjects requires further investigation"
                  },
                  {
                    "text": "Unexpected increases in ammonia should be confirmed with 2nd sample to exclude sample handling errors"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Encephalopathy Treatment": [
                  {
                    "text": "Elevated ammonia can be treated by reducing ammonia load from gutPatients are given lactuloseGastrointestinal bacteria metabolize ingested lactulose producing lactic acidLactic acid traps ammonia in gut, inhibiting its absorptionAmmonia-producing gastrointestinal bacteria are treated with antibiotics",
                    "sub_points": [
                      "Patients are given lactuloseGastrointestinal bacteria metabolize ingested lactulose producing lactic acidLactic acid traps ammonia in gut, inhibiting its absorption",
                      "Gastrointestinal bacteria metabolize ingested lactulose producing lactic acid",
                      "Lactic acid traps ammonia in gut, inhibiting its absorption",
                      "Ammonia-producing gastrointestinal bacteria are treated with antibiotics"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "﻿Encephalopathy Correlation": [
                  {
                    "text": "Small correlation exists between level of ammonia elevation and level of liver function impairment"
                  },
                  {
                    "text": "However, little correlation exists between plasma ammonia concentration and level of encephalopathy in an individual patient"
                  }
                ]
              },
              "SPECIMENS": {
                "Reference Intervals": [
                  {
                    "text": "﻿PlasmaPremature neonate < 200 μmol/LTerm neonate < 100 μmol/LInfant/child < 40 μmol/LAdult < 40 μmol/L",
                    "sub_points": [
                      "Premature neonate < 200 μmol/L",
                      "Term neonate < 100 μmol/L",
                      "Infant/child < 40 μmol/L",
                      "Adult < 40 μmol/L"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Neonatal Jaundice": {
            "name": "Neonatal Jaundice",
            "url": "https://app.pathprimer.com/document/bddc013e-d125-4a07-a11c-786536713e11/lesson/c9a0127d-d1ca-4c50-82e1-2e0b12100709",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Neonates can normally present with transient physiological jaundice in 1st week of life"
                  },
                  {
                    "text": "Pathological causes of jaundice during this critical period must be differentiated to prevent development of permanent neurological damageNormally measured total bilirubinShould be < 75th percentile for age in 1st few hours of lifePeak seen in days 2-3 of lifeShould decline dramatically by days 4-5",
                    "sub_points": [
                      "Normally measured total bilirubinShould be < 75th percentile for age in 1st few hours of lifePeak seen in days 2-3 of lifeShould decline dramatically by days 4-5",
                      "Should be < 75th percentile for age in 1st few hours of life",
                      "Peak seen in days 2-3 of life",
                      "Should decline dramatically by days 4-5"
                    ]
                  },
                  {
                    "text": "Premature infants or low birthweight infants are especially susceptible to acute bilirubin encephalopathy (kernicterus)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Unconjugated Hyperbilirubinemia": [
                  {
                    "text": "Physiological jaundiceNewborns are often transiently jaundiced in 1st few days of life due to certain factorsIncreased fetal hemoglobin turnover results in increased unconjugated bilirubinReduced uridine diphosphate (UDP) glucuronyltransferase in newborn liverDecreased conjugation of bilirubinUnconjugated bilirubin levels peak should follow pattern above or causes of pathologic jaundice should be entertained",
                    "sub_points": [
                      "Newborns are often transiently jaundiced in 1st few days of life due to certain factors",
                      "Increased fetal hemoglobin turnover results in increased unconjugated bilirubin",
                      "Reduced uridine diphosphate (UDP) glucuronyltransferase in newborn liverDecreased conjugation of bilirubin",
                      "Decreased conjugation of bilirubin",
                      "Unconjugated bilirubin levels peak should follow pattern above or causes of pathologic jaundice should be entertained"
                    ]
                  },
                  {
                    "text": "Hemolysis in newbornMaternal alloantibody against fetal red cell antigens (often Rh blood group) induces hemolysis in fetusResulting unconjugated hyperbilirubinemia puts fetus at riskMay develop kernicterusMay develop hydrops fetalisMay be treated with exchange transfusion",
                    "sub_points": [
                      "Maternal alloantibody against fetal red cell antigens (often Rh blood group) induces hemolysis in fetus",
                      "Resulting unconjugated hyperbilirubinemia puts fetus at riskMay develop kernicterusMay develop hydrops fetalis",
                      "May develop kernicterus",
                      "May develop hydrops fetalis",
                      "May be treated with exchange transfusion"
                    ]
                  },
                  {
                    "text": "Breast milk ingestionBreast milk jaundice (BMJ) and breastfeeding-associated (BFAJ) jaundiceBMJ: Common cause of indirect hyperbilirubinemiaDevelops after 1st 4-7 days of life; peaks at day 15General well baby: Monitor bilirubin; usually resolves on its ownBFAJ: Manifests in 1st 3 days of lifePresents with weight loss, dehydrationCaused by insufficient breast milk intakeGeneral sick baby: Monitor bilirubin; may require supplementation/phototherapy",
                    "sub_points": [
                      "Breast milk jaundice (BMJ) and breastfeeding-associated (BFAJ) jaundiceBMJ: Common cause of indirect hyperbilirubinemiaDevelops after 1st 4-7 days of life; peaks at day 15General well baby: Monitor bilirubin; usually resolves on its ownBFAJ: Manifests in 1st 3 days of lifePresents with weight loss, dehydrationCaused by insufficient breast milk intakeGeneral sick baby: Monitor bilirubin; may require supplementation/phototherapy",
                      "BMJ: Common cause of indirect hyperbilirubinemiaDevelops after 1st 4-7 days of life; peaks at day 15General well baby: Monitor bilirubin; usually resolves on its own",
                      "Develops after 1st 4-7 days of life; peaks at day 15",
                      "General well baby: Monitor bilirubin; usually resolves on its own",
                      "BFAJ: Manifests in 1st 3 days of lifePresents with weight loss, dehydrationCaused by insufficient breast milk intakeGeneral sick baby: Monitor bilirubin; may require supplementation/phototherapy",
                      "Presents with weight loss, dehydration",
                      "Caused by insufficient breast milk intake",
                      "General sick baby: Monitor bilirubin; may require supplementation/phototherapy"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Unconjugated hypobilirubinemia of various causes is often treated with phototherapyInfant exposed to light at 450 nm, disrupting hydrogen bonds in bilirubin moleculeResults in more water soluble isomer (E-E) that is excreted into bile",
                    "sub_points": [
                      "Infant exposed to light at 450 nm, disrupting hydrogen bonds in bilirubin molecule",
                      "Results in more water soluble isomer (E-E) that is excreted into bile"
                    ]
                  },
                  {
                    "text": "In severe cases, can also be treated with exchange transfusions"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Pancreatic Enzymes": {
        "name": "Pancreatic Enzymes",
        "url": "https://app.pathprimer.com/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
        "topics": {
          "Amylase": {
            "name": "Amylase",
            "url": "https://app.pathprimer.com/document/ca82ceb8-2320-4e0f-9540-7499f87f04ca/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Amylase is a digestive enzyme that catalyzes the hydrolysis of complex carbohydrates"
                  },
                  {
                    "text": "P-type and S-type amylase are the predominant forms found in normal serum and urine"
                  },
                  {
                    "text": "Amylase is the only plasma enzyme found in normal urine"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Amylase is usually increased and one of the most significant markers in acute pancreatitis"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Amylase elevations can be caused by nonpancreatic conditions"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Alpha-amylase"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiologic Function and Biochemistry": [
                  {
                    "text": "Amylase is a digestive enzyme that catalyzes the hydrolysis of complex carbohydratesBreaks down linkages between glucose residues (α-1-4-glucosidic)Low molecular weight (52,000-64,000 Da)Salivary glands have highest concentration of amylase (S-type)Initial breakdown of food in the mouthAcinar cells of pancreas also produce amylase (P-type)Breaks down carbohydrates in intestinal tractAmylase has also been found inLungOvaryFallopian tubeAdipose tissueSemen extractsP-type and S-type amylase are predominant forms found in normal serum and urine",
                    "sub_points": [
                      "Breaks down linkages between glucose residues (α-1-4-glucosidic)",
                      "Low molecular weight (52,000-64,000 Da)",
                      "Salivary glands have highest concentration of amylase (S-type)Initial breakdown of food in the mouth",
                      "Initial breakdown of food in the mouth",
                      "Acinar cells of pancreas also produce amylase (P-type)Breaks down carbohydrates in intestinal tract",
                      "Breaks down carbohydrates in intestinal tract",
                      "Amylase has also been found inLungOvaryFallopian tubeAdipose tissueSemen extracts",
                      "Lung",
                      "Ovary",
                      "Fallopian tube",
                      "Adipose tissue",
                      "Semen extracts",
                      "P-type and S-type amylase are predominant forms found in normal serum and urine"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Automated Assays": [
                  {
                    "text": "Because of lack of specificity, laboratory analysis has shifted from measuring total amylase activity to targeting P-type amylase activity"
                  },
                  {
                    "text": "Modern P-type amylase analysis is directly measured in a two-step process(1) S-type amylase is inhibited by monoclonal antibodies, excluding it from analysis(2) P-type amylase remains, and its activity is measured using a specific substrate with enzymatic product detection through absorption at 405 nm",
                    "sub_points": [
                      "(1) S-type amylase is inhibited by monoclonal antibodies, excluding it from analysis",
                      "(2) P-type amylase remains, and its activity is measured using a specific substrate with enzymatic product detection through absorption at 405 nm"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Significance": [
                  {
                    "text": "Amylase is usually increased and one of the most significant markers in acute pancreatitisSeverity of acute pancreatitis does not correlate with magnitude of amylase elevation",
                    "sub_points": [
                      "Severity of acute pancreatitis does not correlate with magnitude of amylase elevation"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Other Causes of Elevation": [
                  {
                    "text": "Amylase elevations can be caused by nonpancreatic conditionsPeptic ulcer diseaseIntestinal obstruction/ischemiaKidney failureEctopic pregnancyDiabetic ketoacidosis, most cases",
                    "sub_points": [
                      "Peptic ulcer disease",
                      "Intestinal obstruction/ischemia",
                      "Kidney failure",
                      "Ectopic pregnancy",
                      "Diabetic ketoacidosis, most cases"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Heparin is the only acceptable common anticoagulant for plasma amylase specimensAll common plasma tube anticoagulants (e.g., EDTA, citrate) bind calciumAmylase is a metalloenzyme and requires calcium for normal activity",
                    "sub_points": [
                      "All common plasma tube anticoagulants (e.g., EDTA, citrate) bind calciumAmylase is a metalloenzyme and requires calcium for normal activity",
                      "Amylase is a metalloenzyme and requires calcium for normal activity"
                    ]
                  }
                ],
                "Storage and Handling": [
                  {
                    "text": "Serum or heparinized plasma amylase activity is stable for 4 days at room temperature, 2 weeks at 5°C, 1 year at ₋28°C, or 5 years at ₋75°C"
                  },
                  {
                    "text": "Urine at room temperature should be tested within 12 hours"
                  },
                  {
                    "text": "Urine is stable for amylase testing at 5°C for 5 days, and freezing is unacceptable"
                  },
                  {
                    "text": "Contamination with saliva should be avoidedFalsely elevates results",
                    "sub_points": [
                      "Falsely elevates results"
                    ]
                  },
                  {
                    "text": "Hemolysis does not usually affect analysisAmylase not found in red cells",
                    "sub_points": [
                      "Amylase not found in red cells"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Acute Pancreatitis": {
            "name": "Acute Pancreatitis",
            "url": "https://app.pathprimer.com/document/c38cb9cc-b87f-414d-bd4c-0b61b2f71d84/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Acute pancreatitis is a reversible inflammatory disease"
                  },
                  {
                    "text": "Results when exocrine digestive enzymes produced by the pancreas autodigest pancreatic parenchyma"
                  },
                  {
                    "text": "Common causes (> 75% of cases)Gallstones (main pancreatic duct obstruction)Alcohol abuse",
                    "sub_points": [
                      "Gallstones (main pancreatic duct obstruction)",
                      "Alcohol abuse"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "AmylaseDiagnosis strongly suggested by 3-fold increase above normal",
                    "sub_points": [
                      "Diagnosis strongly suggested by 3-fold increase above normal"
                    ]
                  },
                  {
                    "text": "LipaseDiagnosis strongly suggested by 3-fold increase above normalMore sensitive than amylase in establishing presence of acute pancreatitis",
                    "sub_points": [
                      "Diagnosis strongly suggested by 3-fold increase above normal",
                      "More sensitive than amylase in establishing presence of acute pancreatitis"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Acute pancreatitis: Reversible inflammatory disease"
                  },
                  {
                    "text": "Results when exocrine digestive enzymes produced by pancreas autodigest pancreatic parenchymaTrypsin activates other proteolytic enzymesObstruction of pancreatic duct system is common",
                    "sub_points": [
                      "Trypsin activates other proteolytic enzymes",
                      "Obstruction of pancreatic duct system is common"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Can occur at any age, but often between 30 and 70 years"
                  },
                  {
                    "text": "Rare in children"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Abdominal pain"
                  },
                  {
                    "text": "Nausea"
                  },
                  {
                    "text": "Vomiting"
                  }
                ],
                "Etiologies": [
                  {
                    "text": "Common causes (> 75% of cases)Gallstones (main pancreatic duct obstruction)Alcohol abuse",
                    "sub_points": [
                      "Gallstones (main pancreatic duct obstruction)",
                      "Alcohol abuse"
                    ]
                  },
                  {
                    "text": "Uncommon causesObstructing tumors of the pancreasVarious drugs (corticosteroids, azathioprine)HypertriglyceridemiaAbdominal traumaViral infections (mumps, coxsackievirus A)HypercalcemiaIdiopathic (from endoscopic procedures)Scorpion bite",
                    "sub_points": [
                      "Obstructing tumors of the pancreas",
                      "Various drugs (corticosteroids, azathioprine)",
                      "Hypertriglyceridemia",
                      "Abdominal trauma",
                      "Viral infections (mumps, coxsackievirus A)",
                      "Hypercalcemia",
                      "Idiopathic (from endoscopic procedures)",
                      "Scorpion bite"
                    ]
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Confirmation of Acute Pancreatitis": [
                  {
                    "text": "Serum amylase and lipase are often measured in suspected acute pancreatitis casesSome argue combination ordering unnecessary and only lipase should be ordered",
                    "sub_points": [
                      "Some argue combination ordering unnecessary and only lipase should be ordered"
                    ]
                  },
                  {
                    "text": "AmylaseDiagnosis strongly suggested by 3-fold increase above normalPeaks 20-30 hours and returns to normal within 2-3 daysSerum amylase sensitivity 72% and specificity 99%Patients with acute pancreatitis and hyperlipidemia often display normal amylase levels (serum or urine)Thought to be due to triglyceride suppression of amylase activity",
                    "sub_points": [
                      "Diagnosis strongly suggested by 3-fold increase above normalPeaks 20-30 hours and returns to normal within 2-3 daysSerum amylase sensitivity 72% and specificity 99%Patients with acute pancreatitis and hyperlipidemia often display normal amylase levels (serum or urine)Thought to be due to triglyceride suppression of amylase activity",
                      "Peaks 20-30 hours and returns to normal within 2-3 days",
                      "Serum amylase sensitivity 72% and specificity 99%",
                      "Patients with acute pancreatitis and hyperlipidemia often display normal amylase levels (serum or urine)Thought to be due to triglyceride suppression of amylase activity",
                      "Thought to be due to triglyceride suppression of amylase activity"
                    ]
                  },
                  {
                    "text": "LipaseDiagnosis strongly suggested by 3-fold increase above normalMore sensitive than amylase in establishing presence of acute pancreatitisRises 4-8 hours, peaks at 24 hours, and returns to normal within 1-2 weeksSerum lipase sensitivity 95% and specificity 99%Prolonged elevation associated with poor prognosis",
                    "sub_points": [
                      "Diagnosis strongly suggested by 3-fold increase above normal",
                      "More sensitive than amylase in establishing presence of acute pancreatitisRises 4-8 hours, peaks at 24 hours, and returns to normal within 1-2 weeksSerum lipase sensitivity 95% and specificity 99%",
                      "Rises 4-8 hours, peaks at 24 hours, and returns to normal within 1-2 weeks",
                      "Serum lipase sensitivity 95% and specificity 99%",
                      "Prolonged elevation associated with poor prognosis"
                    ]
                  }
                ],
                "Ranson Criteria": [
                  {
                    "text": "Amylase or lipase levels alone do not predict acute pancreatitisExtent of pancreatic involvementSpecific etiology",
                    "sub_points": [
                      "Extent of pancreatic involvement",
                      "Specific etiology"
                    ]
                  },
                  {
                    "text": "Certain laboratory criteria in combination with clinical findings have been studiedFound to aid in predicting severity of acute pancreatitis courseAdmission criteriaAge > 55 yearsWhite blood cell (WBC) count > 16,000/μLGlucose > 200 mg/dLAspartate aminotransferase (AST) > 250 U/LLactate dehydrogenase > 350 U/L48 hours into admissionIncrease in blood urea nitrogen (BUN) > 5 mg/dLFluid sequestration > 6 LHematocrit decrease > 10%PaO₂ < 60 mm HgCalcium < 8 mg/dLBase deficit > 4 mmol/L",
                    "sub_points": [
                      "Found to aid in predicting severity of acute pancreatitis course",
                      "Admission criteriaAge > 55 yearsWhite blood cell (WBC) count > 16,000/μLGlucose > 200 mg/dLAspartate aminotransferase (AST) > 250 U/LLactate dehydrogenase > 350 U/L",
                      "Age > 55 years",
                      "White blood cell (WBC) count > 16,000/μL",
                      "Glucose > 200 mg/dL",
                      "Aspartate aminotransferase (AST) > 250 U/L",
                      "Lactate dehydrogenase > 350 U/L",
                      "48 hours into admissionIncrease in blood urea nitrogen (BUN) > 5 mg/dLFluid sequestration > 6 LHematocrit decrease > 10%PaO₂ < 60 mm HgCalcium < 8 mg/dLBase deficit > 4 mmol/L",
                      "Increase in blood urea nitrogen (BUN) > 5 mg/dL",
                      "Fluid sequestration > 6 L",
                      "Hematocrit decrease > 10%",
                      "PaO₂ < 60 mm Hg",
                      "Calcium < 8 mg/dL",
                      "Base deficit > 4 mmol/L"
                    ]
                  }
                ],
                "Diagnostic Challenges": [
                  {
                    "text": "Clinical symptoms are nonspecific"
                  },
                  {
                    "text": "Other conditions can manifest with hyperamylasemia and acute abdominal painAppendicitisPeritonitis",
                    "sub_points": [
                      "Appendicitis",
                      "Peritonitis"
                    ]
                  },
                  {
                    "text": "In patients with renal insufficiency, amylase levels can be 5 times greater than upper reference interval"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Testing for Malabsorption": {
            "name": "Laboratory Testing for Malabsorption",
            "url": "https://app.pathprimer.com/document/bc9fd9c4-9117-4b1b-a6ed-fa1187ce60b1/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Secretin-CCK testSecretion of pancreatic fluid can be stimulated by intravenous administration of secretin (peptide hormone)Pancreatic enzyme secretion can be stimulated by CCK (peptide hormone)Under these conditions, pancreatic fluid within duodenum is collected at intervals (over1 hr)",
                    "sub_points": [
                      "Secretion of pancreatic fluid can be stimulated by intravenous administration of secretin (peptide hormone)",
                      "Pancreatic enzyme secretion can be stimulated by CCK (peptide hormone)",
                      "Under these conditions, pancreatic fluid within duodenum is collected at intervals (over1 hr)"
                    ]
                  },
                  {
                    "text": "Fecal elastase-1Better biomarker than other stool testsLoses sensitivity in milder insufficiency casesNot affected by oral enzyme replacementNot degraded during GI passageCan be detected in feces at concentrations 6-fold greater than pancreatic fluid",
                    "sub_points": [
                      "Better biomarker than other stool tests",
                      "Loses sensitivity in milder insufficiency cases",
                      "Not affected by oral enzyme replacement",
                      "Not degraded during GI passage",
                      "Can be detected in feces at concentrations 6-fold greater than pancreatic fluid"
                    ]
                  },
                  {
                    "text": "Fecal chymotrypsinResidual enzyme activity stable and detectable in feces for several daysDecreased clinical sensitivity in mild insufficiency casesUseful in severe pancreatic insufficiency cases",
                    "sub_points": [
                      "Residual enzyme activity stable and detectable in feces for several days",
                      "Decreased clinical sensitivity in mild insufficiency cases",
                      "Useful in severe pancreatic insufficiency cases"
                    ]
                  },
                  {
                    "text": "Fecal fat: Used less frequently but requested often"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pancreatic Exocrine Function": [
                  {
                    "text": "Pancreas produces and secretes digestive fluid rich in enzymes and bicarbonatepH 8.0-8.3",
                    "sub_points": [
                      "pH 8.0-8.3"
                    ]
                  },
                  {
                    "text": "Under normal exocrine function, 3000 mL of pancreatic fluid can be secreted over 24 hr"
                  },
                  {
                    "text": "Clinically, pancreatic insufficiency is not apparent until 90% of acinar tissue is destroyed"
                  },
                  {
                    "text": "In pancreatic insufficiency, where exocrine function is in question, invasive and noninvasive laboratory tests are available for investigationNoninvasive tests are more comfortable for patients but can lack clinical sensitivity and specificity compared with invasive tests",
                    "sub_points": [
                      "Noninvasive tests are more comfortable for patients but can lack clinical sensitivity and specificity compared with invasive tests"
                    ]
                  },
                  {
                    "text": "Invasive testingGastrointestinal (GI) tube placement is part of invasive testing and not first line in clinical work-upPancreatic fluid is collected from duodenal and stomach regionsTotal volume, concentration of bicarbonate, and enzyme activities are assessedSpecific enzymes measuredTrypsinAmylaseLipaseChymotrypsinElastaseSecretin-cholecystokinin (CCK) testSecretion of pancreatic fluid can be stimulated by intravenous administration of secretin (peptide hormone)Pancreatic enzyme secretion can be stimulated by CCK (peptide hormone)Under these conditions, pancreatic fluid within duodenum is collected at intervals (over 1 hr)",
                    "sub_points": [
                      "Gastrointestinal (GI) tube placement is part of invasive testing and not first line in clinical work-up",
                      "Pancreatic fluid is collected from duodenal and stomach regionsTotal volume, concentration of bicarbonate, and enzyme activities are assessedSpecific enzymes measuredTrypsinAmylaseLipaseChymotrypsinElastase",
                      "Total volume, concentration of bicarbonate, and enzyme activities are assessed",
                      "Specific enzymes measuredTrypsinAmylaseLipaseChymotrypsinElastase",
                      "Trypsin",
                      "Amylase",
                      "Lipase",
                      "Chymotrypsin",
                      "Elastase",
                      "Secretin-cholecystokinin (CCK) testSecretion of pancreatic fluid can be stimulated by intravenous administration of secretin (peptide hormone)Pancreatic enzyme secretion can be stimulated by CCK (peptide hormone)Under these conditions, pancreatic fluid within duodenum is collected at intervals (over 1 hr)",
                      "Secretion of pancreatic fluid can be stimulated by intravenous administration of secretin (peptide hormone)",
                      "Pancreatic enzyme secretion can be stimulated by CCK (peptide hormone)",
                      "Under these conditions, pancreatic fluid within duodenum is collected at intervals (over 1 hr)"
                    ]
                  },
                  {
                    "text": "Noninvasive testingCan lack clinical sensitivity and specificity compared with invasive testsUseful to determine if pancreatic disease is cause of malabsorption seen in patientTestsFecal elastase-1Better biomarker than other stool testsLoses sensitivity in milder insufficiency casesNot affected by oral enzyme replacementNot degraded during GI passageCan be detected in feces at concentrations 6-fold greater than pancreatic fluidFecal chymotrypsinResidual enzyme activity stable and detectable in feces for several daysUseful in severe pancreatic insufficiency casesDecreased clinical sensitivity in mild insufficiency casesFecal fatUsed less frequently but requested oftenClinical picture often does not require test",
                    "sub_points": [
                      "Can lack clinical sensitivity and specificity compared with invasive tests",
                      "Useful to determine if pancreatic disease is cause of malabsorption seen in patient",
                      "TestsFecal elastase-1Better biomarker than other stool testsLoses sensitivity in milder insufficiency casesNot affected by oral enzyme replacementNot degraded during GI passageCan be detected in feces at concentrations 6-fold greater than pancreatic fluidFecal chymotrypsinResidual enzyme activity stable and detectable in feces for several daysUseful in severe pancreatic insufficiency casesDecreased clinical sensitivity in mild insufficiency casesFecal fatUsed less frequently but requested oftenClinical picture often does not require test",
                      "Fecal elastase-1Better biomarker than other stool testsLoses sensitivity in milder insufficiency casesNot affected by oral enzyme replacementNot degraded during GI passageCan be detected in feces at concentrations 6-fold greater than pancreatic fluid",
                      "Better biomarker than other stool tests",
                      "Loses sensitivity in milder insufficiency cases",
                      "Not affected by oral enzyme replacement",
                      "Not degraded during GI passage",
                      "Can be detected in feces at concentrations 6-fold greater than pancreatic fluid",
                      "Fecal chymotrypsinResidual enzyme activity stable and detectable in feces for several daysUseful in severe pancreatic insufficiency casesDecreased clinical sensitivity in mild insufficiency cases",
                      "Residual enzyme activity stable and detectable in feces for several days",
                      "Useful in severe pancreatic insufficiency cases",
                      "Decreased clinical sensitivity in mild insufficiency cases",
                      "Fecal fatUsed less frequently but requested oftenClinical picture often does not require test",
                      "Used less frequently but requested often",
                      "Clinical picture often does not require test"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lipase": {
            "name": "Lipase",
            "url": "https://app.pathprimer.com/document/afa3179d-38f3-4dc9-b9b8-fb7326b0a2ed/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Serum lipase measurement used to diagnose acute pancreatitisMore specific for acute pancreatitis than amylaseRises earlier, concentration is higher, and is detected longer than amylasePeak level at 24 hoursDetectable for up to 2 weeksUseful in patients with delayed presentation",
                    "sub_points": [
                      "More specific for acute pancreatitis than amylase",
                      "Rises earlier, concentration is higher, and is detected longer than amylasePeak level at 24 hoursDetectable for up to 2 weeksUseful in patients with delayed presentation",
                      "Peak level at 24 hours",
                      "Detectable for up to 2 weeksUseful in patients with delayed presentation",
                      "Useful in patients with delayed presentation"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Biochemistry and Physiology": [
                  {
                    "text": "Lipase catalyzes hydrolysis of glycerol esters within long-chain fatty acids (triglycerides)"
                  },
                  {
                    "text": "Most lipase is produced by pancreasSome produced by intestinal and gastric mucosa",
                    "sub_points": [
                      "Some produced by intestinal and gastric mucosa"
                    ]
                  },
                  {
                    "text": "Lipase function requires interaction with cofactor named colipaseColipase produced by pancreasLipase-colipase interaction depends on presence of bile acid",
                    "sub_points": [
                      "Colipase produced by pancreas",
                      "Lipase-colipase interaction depends on presence of bile acid"
                    ]
                  },
                  {
                    "text": "In normal physiologic state, lipase is absent from urineFiltered by glomerulus because of small size (48,000 Da), but completely reabsorbed by tubules",
                    "sub_points": [
                      "Filtered by glomerulus because of small size (48,000 Da), but completely reabsorbed by tubules"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methodology": [
                  {
                    "text": "Lipase analysis has encompassed wide range of methodologies (turbidimetric through immunologic approaches)"
                  },
                  {
                    "text": "Generally long-chain fatty acids have been used as substrate (preferred by pancreatic lipase compared with other forms of lipase)Because of poor automation capability, other substrates are used more frequently",
                    "sub_points": [
                      "Because of poor automation capability, other substrates are used more frequently"
                    ]
                  },
                  {
                    "text": "1,2-O-dilauryl-rac-glycero-3-glutaric acid-(4-methyl-resorufin)-ester is substrate commonly used for modern automated measurementAfter hydrolysis by lipase, a bluish-purple chromophore (methylresorufin) is producedDetected spectrophotometrically at 580 nmRate of methylresorufin formation directly proportional to lipase activity",
                    "sub_points": [
                      "After hydrolysis by lipase, a bluish-purple chromophore (methylresorufin) is produced",
                      "Detected spectrophotometrically at 580 nm",
                      "Rate of methylresorufin formation directly proportional to lipase activity"
                    ]
                  },
                  {
                    "text": "Lipase methodologies usually have bile acid and colipase presenceHelps increase reaction rate and enhance measurement",
                    "sub_points": [
                      "Helps increase reaction rate and enhance measurement"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Acute Pancreatitis": [
                  {
                    "text": "Serum lipase measurement used to diagnose acute pancreatitisMore specific for acute pancreatitis than amylaseRises earlier, concentration is higher, and is detected longer than amylasePeak level at 24 hoursDetectable for up to 2 weeksUseful in patients with delayed presentation",
                    "sub_points": [
                      "More specific for acute pancreatitis than amylase",
                      "Rises earlier, concentration is higher, and is detected longer than amylasePeak level at 24 hoursDetectable for up to 2 weeksUseful in patients with delayed presentation",
                      "Peak level at 24 hours",
                      "Detectable for up to 2 weeksUseful in patients with delayed presentation",
                      "Useful in patients with delayed presentation"
                    ]
                  },
                  {
                    "text": "Prolonged serum lipase elevation suggestsPoor prognosisPresence of pancreatic pseudocyst",
                    "sub_points": [
                      "Poor prognosis",
                      "Presence of pancreatic pseudocyst"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Reduced GFR": [
                  {
                    "text": "Serum lipase activity increased in setting of renal insufficiency"
                  }
                ]
              },
              "SPECIMENS": {
                "Sample Stability": [
                  {
                    "text": "Samples for lipase are stableRoom temperature for 1 weekRefrigerated for 3 weeksFrozen storage for multiple years",
                    "sub_points": [
                      "Room temperature for 1 week",
                      "Refrigerated for 3 weeks",
                      "Frozen storage for multiple years"
                    ]
                  }
                ],
                "Reference Interval": [
                  {
                    "text": "Differences because of age or gender not clinically significant"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Macroamylasemia": {
            "name": "Macroamylasemia",
            "url": "https://app.pathprimer.com/document/fe033de7-72f9-423b-978c-83d399b5571c/lesson/dd9bcd3a-ca41-419a-b68b-fbdf6396456a",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Macroamylase is formed as result of complexing of serum immunoglobulins (IgG or IgA) with normal amylase (often S-type amylase)"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Plasma amylase activity is elevated up to 8x normal in patients with macroamylases"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Although macroamylasemia is clinically benign, falsely elevated amylase measurement can lead to unnecessary additional testing"
                  }
                ]
              },
              "OVERVIEW": {
                "Description": [
                  {
                    "text": "Macroamylasemia is benign condition that results in persistent increase of serum amylaseNo clinical symptoms presentSerum lipase normal",
                    "sub_points": [
                      "No clinical symptoms present",
                      "Serum lipase normal"
                    ]
                  }
                ],
                "Etiology": [
                  {
                    "text": "Macroamylasemia is caused by presence of macroamylase"
                  },
                  {
                    "text": "Macroamylase is formed as result of complexing of serum immunoglobulins (IgG or IgA) with normal amylase (often S-type amylase)"
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Macroamylasemia is present in ~ 1% of general population"
                  },
                  {
                    "text": "Often found in patients in their 50s-70s"
                  },
                  {
                    "text": "Most frequently observed in men"
                  }
                ],
                "Classification": [
                  {
                    "text": "Macroamylasemia can be qualitatively divided into 3 typesType 1 (high macroamylase)Type 2 (moderately high macroamylase)Type 3 (trace macroamylase)",
                    "sub_points": [
                      "Type 1 (high macroamylase)",
                      "Type 2 (moderately high macroamylase)",
                      "Type 3 (trace macroamylase)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Salivary type (S-type)"
                  },
                  {
                    "text": "Pancreatic type (P-type)"
                  },
                  {
                    "text": "Polyethylene glycol (PEG)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Large Size": [
                  {
                    "text": "Macroamylases are not filtered through kidney because of their large sizeNot found in urine and retained within plasma",
                    "sub_points": [
                      "Not found in urine and retained within plasma"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Considerations": [
                  {
                    "text": "Most modern amylase testing methods measure P-type amylaseAccomplished through binding S-type amylase with blocking antibodies",
                    "sub_points": [
                      "Accomplished through binding S-type amylase with blocking antibodies"
                    ]
                  },
                  {
                    "text": "Macroamylase interferes by binding to S-type amylase, blocking antibodies in assaysAllows S-type amylase to be included in measurementFalsely increases measured amylase activity",
                    "sub_points": [
                      "Allows S-type amylase to be included in measurement",
                      "Falsely increases measured amylase activity"
                    ]
                  },
                  {
                    "text": "Plasma amylase activity is elevated up to 8x normal in patients with macroamylases"
                  }
                ],
                "﻿Macroamylasemia Confirmation Methods": [
                  {
                    "text": "ElectrophoresisMacroamylase forms broad, migrating band, differentiating it from typical banding pattern of amylase isoenzymes",
                    "sub_points": [
                      "Macroamylase forms broad, migrating band, differentiating it from typical banding pattern of amylase isoenzymes"
                    ]
                  },
                  {
                    "text": "PEGPEG 6000 preferentially binds and precipitates S-type amylase when added to specimenAfter centrifugation, P-type amylase is found exclusively in supernatantMacroamylasemia is confirmed if supernatant analysis reveals P-type amylase activity < 30%",
                    "sub_points": [
                      "PEG 6000 preferentially binds and precipitates S-type amylase when added to specimenAfter centrifugation, P-type amylase is found exclusively in supernatant",
                      "After centrifugation, P-type amylase is found exclusively in supernatant",
                      "Macroamylasemia is confirmed if supernatant analysis reveals P-type amylase activity < 30%"
                    ]
                  },
                  {
                    "text": "Ratio of amylase clearance to creatinine clearance has also been used to assess macroamylasemiaUnreliable in setting of renal insufficiency",
                    "sub_points": [
                      "Unreliable in setting of renal insufficiency"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Implications": [
                  {
                    "text": "Although macroamylasemia is clinically benign, falsely elevated amylase measurement can lead to unnecessary additional testing"
                  },
                  {
                    "text": "Macroamylasemia could pose challenge in certain diagnostic situationsAbdominal pain from nonpancreatic cause could be initially misdiagnosed as acute pancreatitis",
                    "sub_points": [
                      "Abdominal pain from nonpancreatic cause could be initially misdiagnosed as acute pancreatitis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Endocrine Testing": {
        "name": "Endocrine Testing",
        "url": "https://app.pathprimer.com/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
        "topics": {
          "Laboratory Testing of Thyroid Function": {
            "name": "Laboratory Testing of Thyroid Function",
            "url": "https://app.pathprimer.com/document/c510a803-8e49-4962-9fe7-059898cb3918/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Thyroid gland releases 2 main hormones (T₃, T₄) and secretes inactive hormone termed rT₃"
                  },
                  {
                    "text": "Thyroid hormones function to regulate metabolism by controlling basal metabolic rate and stimulating neuronal growth and development"
                  },
                  {
                    "text": "On TSH stimulation, thyroglobulin is taken from follicular lumen and digested by lysosomal enzymes, resulting in T₄ and T₃ release into circulationIn periphery, free T₄ undergoes deiodination to T₃Process occurs in various tissues, but primarily in liverUnder conditions of chronic stress or illness (nonthyroidal illness/sick euthyroid syndrome), increased fraction of T₄ is converted to rT₃",
                    "sub_points": [
                      "In periphery, free T₄ undergoes deiodination to T₃",
                      "Process occurs in various tissues, but primarily in liver",
                      "Under conditions of chronic stress or illness (nonthyroidal illness/sick euthyroid syndrome), increased fraction of T₄ is converted to rT₃"
                    ]
                  },
                  {
                    "text": "Most T₄ and T₃ in circulation is bound reversibly to carrier protein TBG"
                  },
                  {
                    "text": "TBG levels in blood increased by oral contraceptives and pregnancy"
                  },
                  {
                    "text": "TBG levels decreased by drugs (androgens) and low protein states"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thyroxine (T₄)"
                  },
                  {
                    "text": "Triiodothyronine (T₃)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone (TSH)"
                  },
                  {
                    "text": "Monoiodotyrosine (MIT)"
                  },
                  {
                    "text": "Diiodotyrosine (DIT)"
                  },
                  {
                    "text": "Thyroxine-binding globulin (TBG)"
                  },
                  {
                    "text": "Transthyretin (TTR)"
                  },
                  {
                    "text": "Thyrotropin-releasing hormone (TRH)"
                  },
                  {
                    "text": "Reverse T₃ (rT₃)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Thyroid Hormones": [
                  {
                    "text": "Thyroid gland releases 2 main hormones (T₃, T₄)Secretes inactive hormone termed rT₃",
                    "sub_points": [
                      "Secretes inactive hormone termed rT₃"
                    ]
                  },
                  {
                    "text": "Thyroid hormones function to regulate metabolism byControlling basal metabolic rateEnhancing mitochondrial metabolismStimulating neuronal growth and developmentPromoting sexual maturationStimulating carbohydrate metabolism and protein synthesisIncreasing lipid metabolismStimulating adrenergic activity",
                    "sub_points": [
                      "Controlling basal metabolic rate",
                      "Enhancing mitochondrial metabolism",
                      "Stimulating neuronal growth and development",
                      "Promoting sexual maturation",
                      "Stimulating carbohydrate metabolism and protein synthesis",
                      "Increasing lipid metabolism",
                      "Stimulating adrenergic activity"
                    ]
                  },
                  {
                    "text": "Synthesis of thyroid hormone (organification) involves sequence of stepsThyroid follicular cells capture circulating iodide under process stimulated by TSH from pituitary glandHigh levels of iodide inhibit this process and thyroid hormone synthesisIodide is oxidized to iodine and combined with thyroglobulin and tyrosine forming MIT and DITCombinations of MIT and DIT molecules attached to thyroglobulin form thyroid hormonesDIT plus DIT results in T₄ formationMIT plus DIT results in T₃ formationThyroglobulin with thyroid hormone stored in follicular lumen of thyroid gland",
                    "sub_points": [
                      "Thyroid follicular cells capture circulating iodide under process stimulated by TSH from pituitary glandHigh levels of iodide inhibit this process and thyroid hormone synthesis",
                      "High levels of iodide inhibit this process and thyroid hormone synthesis",
                      "Iodide is oxidized to iodine and combined with thyroglobulin and tyrosine forming MIT and DIT",
                      "Combinations of MIT and DIT molecules attached to thyroglobulin form thyroid hormonesDIT plus DIT results in T₄ formationMIT plus DIT results in T₃ formation",
                      "DIT plus DIT results in T₄ formation",
                      "MIT plus DIT results in T₃ formation",
                      "Thyroglobulin with thyroid hormone stored in follicular lumen of thyroid gland"
                    ]
                  },
                  {
                    "text": "On TSH stimulation, thyroglobulin is taken from follicular lumen and digested by lysosomal enzymesResults in T₄ and T₃ release into circulationIn periphery, free T₄ undergoes deiodination to T₃Process occurs in various tissues, but primarily in liverUnder conditions of chronic stress or illness (nonthyroidal illness/sick euthyroid syndrome), increased fraction of T₄ is converted to rT₃",
                    "sub_points": [
                      "Results in T₄ and T₃ release into circulation",
                      "In periphery, free T₄ undergoes deiodination to T₃Process occurs in various tissues, but primarily in liver",
                      "Process occurs in various tissues, but primarily in liver",
                      "Under conditions of chronic stress or illness (nonthyroidal illness/sick euthyroid syndrome), increased fraction of T₄ is converted to rT₃"
                    ]
                  },
                  {
                    "text": "Most T₄ and T₃ in circulation bound reversibly to 3 carrier proteinsTBG﻿Prealbumin (TTR)Albumin (minor fraction)",
                    "sub_points": [
                      "TBG﻿",
                      "Prealbumin (TTR)",
                      "Albumin (minor fraction)"
                    ]
                  },
                  {
                    "text": "This leaves only small fraction of biologically active free T₄ and T₃"
                  },
                  {
                    "text": "TBG levels in blood increased byOral contraceptivesPregnancy",
                    "sub_points": [
                      "Oral contraceptives",
                      "Pregnancy"
                    ]
                  },
                  {
                    "text": "TBG levels decreased byDrugs (androgens)Low protein states",
                    "sub_points": [
                      "Drugs (androgens)",
                      "Low protein states"
                    ]
                  },
                  {
                    "text": "Thyroid hormone regulationThyroid hormones under control of hypothalamic pituitary pathwayTRH released by hypothalamusStimulates TSH release from pituitaryResults in thyroid hormone release from thyroid gland follicular cells",
                    "sub_points": [
                      "Thyroid hormones under control of hypothalamic pituitary pathway",
                      "TRH released by hypothalamus",
                      "Stimulates TSH release from pituitary",
                      "Results in thyroid hormone release from thyroid gland follicular cells"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Thyroid Function Testing Algorithm": [
                  {
                    "text": "In combination with thorough history and physical examination, laboratory testing of thyroid function is critical to clinical management"
                  },
                  {
                    "text": "TSH is best first-line screening test for thyroid function"
                  },
                  {
                    "text": "In routine practice if TSH is normal, no further testing is sought"
                  },
                  {
                    "text": "Abnormally high or low TSH values warrant additional testingTotal and free T₄T₃ and rT₃",
                    "sub_points": [
                      "Total and free T₄",
                      "T₃ and rT₃"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hyperthyroidism": {
            "name": "Hyperthyroidism",
            "url": "https://app.pathprimer.com/document/8e1f486d-6d8b-4810-8824-85743a1e0483/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Graves disease is autoimmune disorder characterized by antibody against TSH receptorAssociated with HLA-DR3Classic symptoms include exophthalmos",
                    "sub_points": [
                      "Associated with HLA-DR3",
                      "Classic symptoms include exophthalmos"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thyroxine (T₄)"
                  },
                  {
                    "text": "Triiodothyronine (T₃)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone (TSH)"
                  },
                  {
                    "text": "Antithyroid peroxidase antibody (Anti-TPO)"
                  },
                  {
                    "text": "Antithyroglobulin antibody (Anti-Tg)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone receptor (anti-TSHR)"
                  },
                  {
                    "text": "Human chorionic gonadotropin (hCG)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Thyrotoxicosis often used interchangeably with hyperthyroidismTerms are technically not interchangeableHyperthyroidism refers to function, and thyrotoxicosis refers to elevated thyroid hormone levels (function may be normal)",
                    "sub_points": [
                      "Terms are technically not interchangeable",
                      "Hyperthyroidism refers to function, and thyrotoxicosis refers to elevated thyroid hormone levels (function may be normal)"
                    ]
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Hyperthyroidism characterized by excessive production of thyroid hormones (T₄ and T₃) with resultant excessive function (hypermetabolic state)"
                  },
                  {
                    "text": "Hypermetabolic symptomsWeight lossHeat intoleranceWeaknessMenstrual irregularitiesDiarrheaShiny hair and smooth skinTachycardia with potential arrhythmiaTremorEyelid retraction",
                    "sub_points": [
                      "Weight loss",
                      "Heat intolerance",
                      "Weakness",
                      "Menstrual irregularities",
                      "Diarrhea",
                      "Shiny hair and smooth skin",
                      "Tachycardia with potential arrhythmia",
                      "Tremor",
                      "Eyelid retraction"
                    ]
                  },
                  {
                    "text": "Hyperthyroidism can increase in severity (thyroid storm) resulting inHigh-output congestive heart failureFever (106°F)Delirium and coma",
                    "sub_points": [
                      "High-output congestive heart failure",
                      "Fever (106°F)",
                      "Delirium and coma"
                    ]
                  },
                  {
                    "text": "Causes of hyperthyroidismEndogenous disordersPrimary or intrinsic thyroid disease (most common)Ectopic thyroid diseaseOvarian production (struma ovarii)Pituitary or hypothalamic disorders (central hyperthyroidism)Increased production of TSH often due to tumorExogenous disordersThyroid gland infection and inflammationIodine inducedIngestion of thyroid hormone",
                    "sub_points": [
                      "Endogenous disordersPrimary or intrinsic thyroid disease (most common)Ectopic thyroid diseaseOvarian production (struma ovarii)Pituitary or hypothalamic disorders (central hyperthyroidism)Increased production of TSH often due to tumor",
                      "Primary or intrinsic thyroid disease (most common)",
                      "Ectopic thyroid diseaseOvarian production (struma ovarii)",
                      "Ovarian production (struma ovarii)",
                      "Pituitary or hypothalamic disorders (central hyperthyroidism)Increased production of TSH often due to tumor",
                      "Increased production of TSH often due to tumor",
                      "Exogenous disordersThyroid gland infection and inflammationIodine inducedIngestion of thyroid hormone",
                      "Thyroid gland infection and inflammation",
                      "Iodine induced",
                      "Ingestion of thyroid hormone"
                    ]
                  },
                  {
                    "text": "Women are more likely to develop hyperthyroidism"
                  }
                ],
                "Specific Causes of Hyperthyroidism": [
                  {
                    "text": "Graves diseaseAutoimmune disorder characterized by antibody against TSH receptorAntibody binds to and activates receptor (anti-TSHR)Patients also have high anti-Tg and anti-TPO present in serumMale-to-female ratio is 5:1Most common clinical syndrome associated with hyperthyroidismPrevalence in United States is 0.4%Associated with HLA-DR3Classic symptomsGoiterExophthalmosPretibial myxedema (rare)",
                    "sub_points": [
                      "Autoimmune disorder characterized by antibody against TSH receptorAntibody binds to and activates receptor (anti-TSHR)Patients also have high anti-Tg and anti-TPO present in serum",
                      "Antibody binds to and activates receptor (anti-TSHR)",
                      "Patients also have high anti-Tg and anti-TPO present in serum",
                      "Male-to-female ratio is 5:1",
                      "Most common clinical syndrome associated with hyperthyroidismPrevalence in United States is 0.4%",
                      "Prevalence in United States is 0.4%",
                      "Associated with HLA-DR3",
                      "Classic symptomsGoiterExophthalmosPretibial myxedema (rare)",
                      "Goiter",
                      "Exophthalmos",
                      "Pretibial myxedema (rare)"
                    ]
                  },
                  {
                    "text": "Thyroiditis due to various causesInflammatory damage to thyroid tissue releases large quantities of hormone",
                    "sub_points": [
                      "Inflammatory damage to thyroid tissue releases large quantities of hormone"
                    ]
                  },
                  {
                    "text": "Toxic multinodular goiter (Plummer disease)"
                  },
                  {
                    "text": "Toxic adenoma"
                  },
                  {
                    "text": "TSH receptor mutationsGain-of-function mutation (autosomal dominant)Can manifest as severe neonatal thyrotoxicosis",
                    "sub_points": [
                      "Gain-of-function mutation (autosomal dominant)Can manifest as severe neonatal thyrotoxicosis",
                      "Can manifest as severe neonatal thyrotoxicosis"
                    ]
                  },
                  {
                    "text": "hCG-mediated"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Treatments": [
                  {
                    "text": "Therapeutic goalsDecrease thyroid hormone productionInhibit interconversion of thyroid hormones (T₄ to T₃)",
                    "sub_points": [
                      "Decrease thyroid hormone production",
                      "Inhibit interconversion of thyroid hormones (T₄ to T₃)"
                    ]
                  },
                  {
                    "text": "Treatment optionsAntithyroid drugsPropylthiouracilMethimazoleSurgical removal of thyroid with hormone supplementationRadioiodine ablation",
                    "sub_points": [
                      "Antithyroid drugsPropylthiouracilMethimazole",
                      "Propylthiouracil",
                      "Methimazole",
                      "Surgical removal of thyroid with hormone supplementation",
                      "Radioiodine ablation"
                    ]
                  },
                  {
                    "text": "Laboratory monitoring after treatment has startedFree T₄ is measured every few weeks until values normalizePeriodic monitoring recommended in first year posttreatment",
                    "sub_points": [
                      "Free T₄ is measured every few weeks until values normalize",
                      "Periodic monitoring recommended in first year posttreatment"
                    ]
                  },
                  {
                    "text": "TSH is not a good monitor of thyroid status in first months after treatmentPituitary suppression from hyperthyroid state needs to reverse",
                    "sub_points": [
                      "Pituitary suppression from hyperthyroid state needs to reverse"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hypothyroidism": {
            "name": "Hypothyroidism",
            "url": "https://app.pathprimer.com/document/a65dd682-0d42-4531-829c-285aa78fa6ba/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Hypothyroidism is a clinical state characterized by decreased thyroid hormone (T₃ to T₄) secretion and action (hypometabolic)Compensatory mechanism to release more TRH/TSH and thyroid enlargement (goiter) results",
                    "sub_points": [
                      "Compensatory mechanism to release more TRH/TSH and thyroid enlargement (goiter) results"
                    ]
                  },
                  {
                    "text": "Hashimoto thyroiditis (chronic lymphocytic thyroiditis)Cell-mediated autoimmune disease that destroys thyroid tissueMost common form of thyroiditis and hypothyroidism (developed world)Thyroid initially enlarged with eventual atrophy over timeFemale-to-male ratio 10:1More common with advanced age (peaks at 30-50 yr old)Anti-TPO common found in most patients",
                    "sub_points": [
                      "Cell-mediated autoimmune disease that destroys thyroid tissue",
                      "Most common form of thyroiditis and hypothyroidism (developed world)",
                      "Thyroid initially enlarged with eventual atrophy over time",
                      "Female-to-male ratio 10:1",
                      "More common with advanced age (peaks at 30-50 yr old)",
                      "Anti-TPO common found in most patients"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thyroxine (T₄)"
                  },
                  {
                    "text": "Triiodothyronine (T₃)"
                  },
                  {
                    "text": "Thyroid-releasing hormone (TRH)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone (TSH)"
                  },
                  {
                    "text": "Antithyroid peroxidase antibody (Anti-TPO)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Pathophysiology": [
                  {
                    "text": "Hypothyroidism is a clinical state characterized by decreased thyroid hormone (T₃ to T₄) secretion and action (hypometabolic)Compensatory mechanism to release more TRH/TSH and thyroid enlargement (goiter) results",
                    "sub_points": [
                      "Compensatory mechanism to release more TRH/TSH and thyroid enlargement (goiter) results"
                    ]
                  },
                  {
                    "text": "Prevalence in United States is 2%-15%"
                  },
                  {
                    "text": "Women are more likely to develop hypothyroidism"
                  },
                  {
                    "text": "Hypometabolic symptomsDull mentation and lethargyWeight gainHair loss (including eyebrows later in disease course)Cold intoleranceMenstrual irregularitiesConstipationDepressionLow energyBradycardiaCool dry skin",
                    "sub_points": [
                      "Dull mentation and lethargy",
                      "Weight gain",
                      "Hair loss (including eyebrows later in disease course)",
                      "Cold intolerance",
                      "Menstrual irregularities",
                      "Constipation",
                      "Depression",
                      "Low energy",
                      "Bradycardia",
                      "Cool dry skin"
                    ]
                  },
                  {
                    "text": "Hypothyroidism can become severe (myxedema) resulting inDermal accumulation of mucopolysaccharidesFacial features become thickenedStuporHypothermiaDecreased respiration",
                    "sub_points": [
                      "Dermal accumulation of mucopolysaccharidesFacial features become thickened",
                      "Facial features become thickened",
                      "Stupor",
                      "Hypothermia",
                      "Decreased respiration"
                    ]
                  },
                  {
                    "text": "If hypothyroidism occurs in newborn period, irreversible neurologic damage occurs"
                  },
                  {
                    "text": "Primary hypothyroidism can be divided into 2 categoriesEndogenous disordersHashimoto thyroiditis (chronic lymphocytic thyroiditis)Cell-mediated autoimmune disease that destroys thyroid tissueMost common form of thyroiditis and hypothyroidism (developed world)Thyroid initially enlarged with eventual atrophy over timeFemale-to-male ratio 10:1More common with advanced age (peaks at 30-50 yr old)Anti-TPO common found in most patientsCongenital abnormalitiesOccurs in 3500-4000 live births a yearMost commonly due to thyroid gland agenesisCan be due to peripheral resistance to thyroid hormone (Refetoff syndrome)Exogenous disordersIodine deficiencyMost common cause of hypothyroidism worldwideDetrimental in first half of pregnancyDrugsDopamine (inhibits TSH secretion)Lithium (inhibits hormone synthesis/secretion)Iatrogenic causesSurgical removal in hyperthyroidism treatmentExternal radiation therapy for various disorders (lymphoma)Post-radioiodine ablation for hyperthyroidism",
                    "sub_points": [
                      "Endogenous disordersHashimoto thyroiditis (chronic lymphocytic thyroiditis)Cell-mediated autoimmune disease that destroys thyroid tissueMost common form of thyroiditis and hypothyroidism (developed world)Thyroid initially enlarged with eventual atrophy over timeFemale-to-male ratio 10:1More common with advanced age (peaks at 30-50 yr old)Anti-TPO common found in most patientsCongenital abnormalitiesOccurs in 3500-4000 live births a yearMost commonly due to thyroid gland agenesisCan be due to peripheral resistance to thyroid hormone (Refetoff syndrome)",
                      "Hashimoto thyroiditis (chronic lymphocytic thyroiditis)Cell-mediated autoimmune disease that destroys thyroid tissueMost common form of thyroiditis and hypothyroidism (developed world)Thyroid initially enlarged with eventual atrophy over timeFemale-to-male ratio 10:1More common with advanced age (peaks at 30-50 yr old)Anti-TPO common found in most patients",
                      "Cell-mediated autoimmune disease that destroys thyroid tissue",
                      "Most common form of thyroiditis and hypothyroidism (developed world)",
                      "Thyroid initially enlarged with eventual atrophy over time",
                      "Female-to-male ratio 10:1",
                      "More common with advanced age (peaks at 30-50 yr old)",
                      "Anti-TPO common found in most patients",
                      "Congenital abnormalitiesOccurs in 3500-4000 live births a yearMost commonly due to thyroid gland agenesisCan be due to peripheral resistance to thyroid hormone (Refetoff syndrome)",
                      "Occurs in 3500-4000 live births a year",
                      "Most commonly due to thyroid gland agenesis",
                      "Can be due to peripheral resistance to thyroid hormone (Refetoff syndrome)",
                      "Exogenous disordersIodine deficiencyMost common cause of hypothyroidism worldwideDetrimental in first half of pregnancyDrugsDopamine (inhibits TSH secretion)Lithium (inhibits hormone synthesis/secretion)Iatrogenic causesSurgical removal in hyperthyroidism treatmentExternal radiation therapy for various disorders (lymphoma)Post-radioiodine ablation for hyperthyroidism",
                      "Iodine deficiencyMost common cause of hypothyroidism worldwideDetrimental in first half of pregnancy",
                      "Most common cause of hypothyroidism worldwide",
                      "Detrimental in first half of pregnancy",
                      "DrugsDopamine (inhibits TSH secretion)Lithium (inhibits hormone synthesis/secretion)",
                      "Dopamine (inhibits TSH secretion)",
                      "Lithium (inhibits hormone synthesis/secretion)",
                      "Iatrogenic causesSurgical removal in hyperthyroidism treatmentExternal radiation therapy for various disorders (lymphoma)Post-radioiodine ablation for hyperthyroidism",
                      "Surgical removal in hyperthyroidism treatment",
                      "External radiation therapy for various disorders (lymphoma)",
                      "Post-radioiodine ablation for hyperthyroidism"
                    ]
                  },
                  {
                    "text": "Secondary hypothyroidismResults from pituitary dysfunction (tumor, hemorrhage)",
                    "sub_points": [
                      "Results from pituitary dysfunction (tumor, hemorrhage)"
                    ]
                  },
                  {
                    "text": "Tertiary hypothyroidism (rare)Due to dysfunction in hypothalamus",
                    "sub_points": [
                      "Due to dysfunction in hypothalamus"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Treatment": [
                  {
                    "text": "Treatment often involves thyroid hormone supplementation (oral T₄)"
                  },
                  {
                    "text": "If congenital hypothyroidism is present, immediate supplementation requiredScreening programs exist worldwide to address this critical public health problemInvolves measuring TSH and T₄/T₃Region-dependent cutoffs include elevated TSH or lower percentile thyroid hormones",
                    "sub_points": [
                      "Screening programs exist worldwide to address this critical public health problemInvolves measuring TSH and T₄/T₃Region-dependent cutoffs include elevated TSH or lower percentile thyroid hormones",
                      "Involves measuring TSH and T₄/T₃Region-dependent cutoffs include elevated TSH or lower percentile thyroid hormones",
                      "Region-dependent cutoffs include elevated TSH or lower percentile thyroid hormones"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Congenital Adrenal Hyperplasia": {
            "name": "Congenital Adrenal Hyperplasia",
            "url": "https://app.pathprimer.com/document/18a33591-12fd-4a86-9429-42e4f3e2eda9/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "CAH is inborn error of metabolism affecting cortisol and aldosterone biosynthesis"
                  },
                  {
                    "text": "Cortisol production is severely decreased resulting in greatly elevated ACTH levelsInduces hyperplasia of adrenal gland and increased steroid hormone precursors (17-hydroxyprogesterone, progesterone, pregnenolone)Increased levels of steroid hormone precursors result in diversion down other metabolic pathways and increased steroid hormone production",
                    "sub_points": [
                      "Induces hyperplasia of adrenal gland and increased steroid hormone precursors (17-hydroxyprogesterone, progesterone, pregnenolone)",
                      "Increased levels of steroid hormone precursors result in diversion down other metabolic pathways and increased steroid hormone production"
                    ]
                  },
                  {
                    "text": "Increased steroid hormones (DHEA and androstenedione) leads to virilization and ambiguous genitalia in females"
                  },
                  {
                    "text": "Major inheritable causes include 21-hydroxylase deficiency (autosomal recessive defect inCYP21) and 11-hydroxylase deficiency (autosomal recessive defect inCYP11B1)"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Congenital adrenal hyperplasia (CAH): Inborn error of metabolism affecting cortisol and aldosterone biosynthesis"
                  },
                  {
                    "text": "Cortisol production is severely decreased resulting in greatly elevated adrenocorticotropic hormone (ACTH) levelsInduces hyperplasia of adrenal gland and increased steroid hormone precursors17-hydroxyprogesteroneProgesteronePregnenolone",
                    "sub_points": [
                      "Induces hyperplasia of adrenal gland and increased steroid hormone precursors17-hydroxyprogesteroneProgesteronePregnenolone",
                      "17-hydroxyprogesterone",
                      "Progesterone",
                      "Pregnenolone"
                    ]
                  },
                  {
                    "text": "Increased levels of steroid hormone precursors result in diversion down other metabolic pathways and increased steroid hormone productionIncreased steroid hormones (dehydroepiandrosterone [DHEA] and androstenedione) lead to virilization and ambiguous genitalia in females",
                    "sub_points": [
                      "Increased steroid hormones (dehydroepiandrosterone [DHEA] and androstenedione) lead to virilization and ambiguous genitalia in females"
                    ]
                  },
                  {
                    "text": "Major inheritable causes21-Hydroxylase deficiency (autosomal recessive defect inCYP21)Accounts for ~ 95% of casesResults in 17-hydroxyprogesterone accumulationSalt wasting and hypotension occur as a result of block in aldosterone and other mineralocorticoid synthesisAffected infants may also havePoor appetiteLethargyFailure to thriveVomitingVirilization11-hydroxylase deficiency (autosomal recessive defect inCYP11B1)2nd most common cause of CAH11-hydroxylase deficiency differs from 21-hydroxylase deficiency in that 11-deoxycortisol accumulates11-deoxycortisol has mineralocorticoid activity prompting sodium reabsorption and resulting in hypertensionAffected infants also display virilization",
                    "sub_points": [
                      "21-Hydroxylase deficiency (autosomal recessive defect inCYP21)Accounts for ~ 95% of casesResults in 17-hydroxyprogesterone accumulationSalt wasting and hypotension occur as a result of block in aldosterone and other mineralocorticoid synthesisAffected infants may also havePoor appetiteLethargyFailure to thriveVomitingVirilization",
                      "Accounts for ~ 95% of cases",
                      "Results in 17-hydroxyprogesterone accumulation",
                      "Salt wasting and hypotension occur as a result of block in aldosterone and other mineralocorticoid synthesis",
                      "Affected infants may also havePoor appetiteLethargyFailure to thriveVomitingVirilization",
                      "Poor appetite",
                      "Lethargy",
                      "Failure to thrive",
                      "Vomiting",
                      "Virilization",
                      "11-hydroxylase deficiency (autosomal recessive defect inCYP11B1)2nd most common cause of CAH11-hydroxylase deficiency differs from 21-hydroxylase deficiency in that 11-deoxycortisol accumulates11-deoxycortisol has mineralocorticoid activity prompting sodium reabsorption and resulting in hypertensionAffected infants also display virilization",
                      "2nd most common cause of CAH",
                      "11-hydroxylase deficiency differs from 21-hydroxylase deficiency in that 11-deoxycortisol accumulates11-deoxycortisol has mineralocorticoid activity prompting sodium reabsorption and resulting in hypertension",
                      "11-deoxycortisol has mineralocorticoid activity prompting sodium reabsorption and resulting in hypertension",
                      "Affected infants also display virilization"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "CAH affects > 1 in 20,000 neonates"
                  },
                  {
                    "text": "21-hydroxylase deficiency has estimated heterozygote frequency of 1 in 50~ 1 in 10,000 births are homozygous for 21-hydroxylase deficiencyM:F = 1:1",
                    "sub_points": [
                      "~ 1 in 10,000 births are homozygous for 21-hydroxylase deficiency",
                      "M:F = 1:1"
                    ]
                  },
                  {
                    "text": "Newborn screening initiatives measure neonatal blood levels of 17-hydroxyprogesteronePrograms are widespread due to potential fatalities if diagnosis is missed",
                    "sub_points": [
                      "Programs are widespread due to potential fatalities if diagnosis is missed"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cortisol": {
            "name": "Cortisol",
            "url": "https://app.pathprimer.com/document/02a90cf8-5307-4ce9-9b5b-251f3e1abb03/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Cortisol displays circadian release profileLevels are highest in morning (just before waking)Evening hours (midnight) show lowest levels of cortisolCircadian release may be disrupted in patients who are nighttime workers",
                    "sub_points": [
                      "Levels are highest in morning (just before waking)",
                      "Evening hours (midnight) show lowest levels of cortisol",
                      "Circadian release may be disrupted in patients who are nighttime workers"
                    ]
                  },
                  {
                    "text": "Dexamethasone is potent glucocorticoid that under normal conditions will suppress both ACTH and cortisol release"
                  },
                  {
                    "text": "Dexamethasone suppression test is used to screen for Cushing syndrome"
                  },
                  {
                    "text": "Dexamethasone in low dose (1 mg) is administered before bed with subsequent morning plasma cortisol measured; if suppression observed in low-dose test, high-dose dexamethasone testing is pursued"
                  },
                  {
                    "text": "Done to distinguish source of ACTHIf suppression seen with high-dose dexamethasone, source of cortisol likely pituitary (adenoma)No suppression suggests either primary adrenal hypercortisolism or ectopic ACTH",
                    "sub_points": [
                      "If suppression seen with high-dose dexamethasone, source of cortisol likely pituitary (adenoma)",
                      "No suppression suggests either primary adrenal hypercortisolism or ectopic ACTH"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Corticosteroid-binding globulin (CBG)"
                  },
                  {
                    "text": "Very-low-density lipoprotein (VLDL)"
                  },
                  {
                    "text": "High-density lipoprotein (HDL)"
                  },
                  {
                    "text": "Corticotropin-releasing hormone (CRH)"
                  },
                  {
                    "text": "Adrenocorticotropic hormone (ACTH)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiologic Functions": [
                  {
                    "text": "Cortisol (glucocorticoid) is produced in adrenal cortex (primarily zona fasciculata)Cortisol production requires cholesterol as substrate",
                    "sub_points": [
                      "Cortisol production requires cholesterol as substrate"
                    ]
                  },
                  {
                    "text": "Cortisol metabolism occurs in liver with eventual excretion in urineCortisol and metabolites are conjugated to glucuronic acid (water soluble)",
                    "sub_points": [
                      "Cortisol and metabolites are conjugated to glucuronic acid (water soluble)"
                    ]
                  },
                  {
                    "text": "In circulation cortisol is bound to CBG"
                  },
                  {
                    "text": "Cortisol binds to glucocorticoid receptors in various tissuesHepatocytesLymphocytesBone",
                    "sub_points": [
                      "Hepatocytes",
                      "Lymphocytes",
                      "Bone"
                    ]
                  },
                  {
                    "text": "Cortisol and other glucocorticoids are essential for stress response, and physiologic effects includeElevated blood glucoseGluconeogenesis increasedGlucose-6-phosphatase and other enzyme synthesis enhancedEnhanced glycogen storage in liverInsulin resistance in muscle and fat tissueAccomplished by glycogen phosphorylation inhibitionEnhances protein breakdown, resulting inMuscle weaknessSkin thinningFractures (osteoporosis)Lipid metabolism effectsCentral redistribution of adipose tissue (face, neck, trunk)Increased VLDL and triglyceridesAdipose tissue lipase activity increased, resulting in enhanced triglyceride breakdown to free fatty acidsDecreased HDLWeight gainAntiinflammatory and immunosuppressive effectsSuppression of various proinflammatory mediatorsInterleukins (IL-1, IL-2, IL-6)Tumor necrosis factor-αInterferon-γCyclooxygenaseMaintenance of vascular responsiveness",
                    "sub_points": [
                      "Elevated blood glucoseGluconeogenesis increasedGlucose-6-phosphatase and other enzyme synthesis enhancedEnhanced glycogen storage in liverInsulin resistance in muscle and fat tissueAccomplished by glycogen phosphorylation inhibition",
                      "Gluconeogenesis increasedGlucose-6-phosphatase and other enzyme synthesis enhanced",
                      "Glucose-6-phosphatase and other enzyme synthesis enhanced",
                      "Enhanced glycogen storage in liver",
                      "Insulin resistance in muscle and fat tissueAccomplished by glycogen phosphorylation inhibition",
                      "Accomplished by glycogen phosphorylation inhibition",
                      "Enhances protein breakdown, resulting inMuscle weaknessSkin thinningFractures (osteoporosis)",
                      "Muscle weakness",
                      "Skin thinning",
                      "Fractures (osteoporosis)",
                      "Lipid metabolism effectsCentral redistribution of adipose tissue (face, neck, trunk)Increased VLDL and triglyceridesAdipose tissue lipase activity increased, resulting in enhanced triglyceride breakdown to free fatty acidsDecreased HDLWeight gain",
                      "Central redistribution of adipose tissue (face, neck, trunk)",
                      "Increased VLDL and triglyceridesAdipose tissue lipase activity increased, resulting in enhanced triglyceride breakdown to free fatty acids",
                      "Adipose tissue lipase activity increased, resulting in enhanced triglyceride breakdown to free fatty acids",
                      "Decreased HDL",
                      "Weight gain",
                      "Antiinflammatory and immunosuppressive effectsSuppression of various proinflammatory mediatorsInterleukins (IL-1, IL-2, IL-6)Tumor necrosis factor-αInterferon-γCyclooxygenase",
                      "Suppression of various proinflammatory mediatorsInterleukins (IL-1, IL-2, IL-6)Tumor necrosis factor-αInterferon-γCyclooxygenase",
                      "Interleukins (IL-1, IL-2, IL-6)",
                      "Tumor necrosis factor-α",
                      "Interferon-γ",
                      "Cyclooxygenase",
                      "Maintenance of vascular responsiveness"
                    ]
                  },
                  {
                    "text": "Cortisol secretion under hormonal controlCRH secreted by hypothalamus (paraventricular nucleus) reaches pituitaryAnterior pituitary is stimulated to synthesize, store, and release ACTHACTH stimulates cortisol synthesis and release by adrenal cortexDone through stimulation of cholesterol desmolaseNegative feedback control for cortisol releaseReleased cortisol inhibitsCRH secretion by hypothalamusACTH secretion by anterior pituitary",
                    "sub_points": [
                      "CRH secreted by hypothalamus (paraventricular nucleus) reaches pituitary",
                      "Anterior pituitary is stimulated to synthesize, store, and release ACTH",
                      "ACTH stimulates cortisol synthesis and release by adrenal cortexDone through stimulation of cholesterol desmolase",
                      "Done through stimulation of cholesterol desmolase",
                      "Negative feedback control for cortisol releaseReleased cortisol inhibitsCRH secretion by hypothalamusACTH secretion by anterior pituitary",
                      "Released cortisol inhibitsCRH secretion by hypothalamusACTH secretion by anterior pituitary",
                      "CRH secretion by hypothalamus",
                      "ACTH secretion by anterior pituitary"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Cortisol displays circadian release profileLevels are highest in morning (just before waking)Evening hours (midnight) show lowest levels of cortisolCircadian release may be disrupted in patients who are nighttime workers",
                    "sub_points": [
                      "Levels are highest in morning (just before waking)",
                      "Evening hours (midnight) show lowest levels of cortisol",
                      "Circadian release may be disrupted in patients who are nighttime workers"
                    ]
                  }
                ],
                "Dexamethasone Suppression Test": [
                  {
                    "text": "Dexamethasone is potent glucocorticoidUnder normal conditions, will suppress both ACTH and cortisol release",
                    "sub_points": [
                      "Under normal conditions, will suppress both ACTH and cortisol release"
                    ]
                  },
                  {
                    "text": "Dexamethasone suppression test is used to screen for Cushing syndromeDexamethasone does not cross-react with cortisol immunoassays",
                    "sub_points": [
                      "Dexamethasone does not cross-react with cortisol immunoassays"
                    ]
                  },
                  {
                    "text": "Dexamethasone in low dose (1 mg) is administered before bedSubsequent morning plasma cortisol is measuredImpaired suppression of cortisol signifies Cushing syndrome of any cause",
                    "sub_points": [
                      "Subsequent morning plasma cortisol is measured",
                      "Impaired suppression of cortisol signifies Cushing syndrome of any cause"
                    ]
                  },
                  {
                    "text": "If suppression observed in low-dose test, high-dose dexamethasone testing is pursuedDone to distinguish source of ACTHPituitary origin (Cushing disease)Primary adrenal diseaseEctopic source, such as small cell lung carcinomaIf suppression seen with high-dose dexamethasone, source of cortisol likely pituitary (adenoma)No suppression suggests eitherPrimary adrenal hypercortisolismEctopic ACTH",
                    "sub_points": [
                      "Done to distinguish source of ACTHPituitary origin (Cushing disease)Primary adrenal diseaseEctopic source, such as small cell lung carcinoma",
                      "Pituitary origin (Cushing disease)",
                      "Primary adrenal disease",
                      "Ectopic source, such as small cell lung carcinoma",
                      "If suppression seen with high-dose dexamethasone, source of cortisol likely pituitary (adenoma)",
                      "No suppression suggests eitherPrimary adrenal hypercortisolismEctopic ACTH",
                      "Primary adrenal hypercortisolism",
                      "Ectopic ACTH"
                    ]
                  }
                ],
                "CRH Stimulation Test": [
                  {
                    "text": "CRH is injected in patientNormal response is for ACTH to be secreted (within few hours)If ACTH elevation exaggeratedSuggests Cushing diseaseIf no response seenSuggests either primary adrenal hypercortisolism or ectopic ACTH",
                    "sub_points": [
                      "Normal response is for ACTH to be secreted (within few hours)",
                      "If ACTH elevation exaggeratedSuggests Cushing disease",
                      "Suggests Cushing disease",
                      "If no response seenSuggests either primary adrenal hypercortisolism or ectopic ACTH",
                      "Suggests either primary adrenal hypercortisolism or ectopic ACTH"
                    ]
                  }
                ],
                "Urine Free Cortisol": [
                  {
                    "text": "Urinary excretion of cortisol provides approximation of free cortisol concentration in serumUrine is usually collected over 24-hour periodFluctuations in CBG can alter free cortisol concentration in serum and urine",
                    "sub_points": [
                      "Urine is usually collected over 24-hour period",
                      "Fluctuations in CBG can alter free cortisol concentration in serum and urine"
                    ]
                  },
                  {
                    "text": "Used as screening test for hypercortisolism"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Cushing Syndrome": [
                  {
                    "text": "Characterized by excessive cortisol levels"
                  },
                  {
                    "text": "Disease manifestations are related to physiologic functions of cortisol but at pathologic levels"
                  },
                  {
                    "text": "Patient symptomsMoon facies, buffalo hump, truncal obesityHypertensionSecondary osteoporosisHyperglycemiaHypokalemia alkalosisSkin striaeNeuropsychiatric illness",
                    "sub_points": [
                      "Moon facies, buffalo hump, truncal obesity",
                      "Hypertension",
                      "Secondary osteoporosis",
                      "Hyperglycemia",
                      "Hypokalemia alkalosis",
                      "Skin striae",
                      "Neuropsychiatric illness"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Markers of Adrenal Medullary Tumors": {
            "name": "Markers of Adrenal Medullary Tumors",
            "url": "https://app.pathprimer.com/document/35d9133e-d302-4554-bc0d-948d1dac6e68/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Adrenal medullary tumors fall into 2 main categoriesPheochromocytomaNeuroblastoma",
                    "sub_points": [
                      "Pheochromocytoma",
                      "Neuroblastoma"
                    ]
                  },
                  {
                    "text": "Both tumors are derived from adrenal chromaffin cellsChromaffin cells secrete catecholamines (dopamine, norepinephrine, epinephrine)As a result, both pheochromocytoma and neuroblastoma display varying levels of catecholamine excess",
                    "sub_points": [
                      "Chromaffin cells secrete catecholamines (dopamine, norepinephrine, epinephrine)As a result, both pheochromocytoma and neuroblastoma display varying levels of catecholamine excess",
                      "As a result, both pheochromocytoma and neuroblastoma display varying levels of catecholamine excess"
                    ]
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Venipuncture can falsely increase catecholamine plasma concentration due to pain"
                  },
                  {
                    "text": "PheochromocytomaMeasurement of plasma normetanephrine and metanephrine is the preferred screening test",
                    "sub_points": [
                      "Measurement of plasma normetanephrine and metanephrine is the preferred screening test"
                    ]
                  },
                  {
                    "text": "NeuroblastomaNeuroblastoma primarily produces dopamine, making measurement of urine HVA most useful",
                    "sub_points": [
                      "Neuroblastoma primarily produces dopamine, making measurement of urine HVA most useful"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Adrenal medullary tumors fall into 2 main categoriesPheochromocytomaPatients often present withRefractory hypertensionPalpitationsExcessive sweatingTypically seen in adultsNeuroblastomaSecond most common solid malignant tumor of childhoodUsually occurs prior to 3 years of ageIn contrast to pheochromocytoma, hypertension is mild or absent",
                    "sub_points": [
                      "PheochromocytomaPatients often present withRefractory hypertensionPalpitationsExcessive sweatingTypically seen in adults",
                      "Patients often present withRefractory hypertensionPalpitationsExcessive sweating",
                      "Refractory hypertension",
                      "Palpitations",
                      "Excessive sweating",
                      "Typically seen in adults",
                      "NeuroblastomaSecond most common solid malignant tumor of childhoodUsually occurs prior to 3 years of ageIn contrast to pheochromocytoma, hypertension is mild or absent",
                      "Second most common solid malignant tumor of childhoodUsually occurs prior to 3 years of age",
                      "Usually occurs prior to 3 years of age",
                      "In contrast to pheochromocytoma, hypertension is mild or absent"
                    ]
                  },
                  {
                    "text": "Both tumors are derived from adrenal chromaffin cellsChromaffin cells secrete catecholamines (dopamine, norepinephrine, epinephrine)As a result, both pheochromocytoma and neuroblastoma display varying levels of catecholamine excess",
                    "sub_points": [
                      "Chromaffin cells secrete catecholamines (dopamine, norepinephrine, epinephrine)",
                      "As a result, both pheochromocytoma and neuroblastoma display varying levels of catecholamine excess"
                    ]
                  },
                  {
                    "text": "Catecholamine metabolism proceeds stepwise as follows: Dopamine → norepinephrine → epinephrineFirst reaction catalyzed by dopamine hydroxylaseSecond reaction (norepinephrine → epinephrine) catalyzed by phenylethanolamine-n-methyltransferaseNeuroblastoma lacks phenylethanolamine-n-methyltransferase enzymeDopamine and norepinephrine are primary catecholamines seen in neuroblastoma",
                    "sub_points": [
                      "First reaction catalyzed by dopamine hydroxylase",
                      "Second reaction (norepinephrine → epinephrine) catalyzed by phenylethanolamine-n-methyltransferaseNeuroblastoma lacks phenylethanolamine-n-methyltransferase enzymeDopamine and norepinephrine are primary catecholamines seen in neuroblastoma",
                      "Neuroblastoma lacks phenylethanolamine-n-methyltransferase enzymeDopamine and norepinephrine are primary catecholamines seen in neuroblastoma",
                      "Dopamine and norepinephrine are primary catecholamines seen in neuroblastoma"
                    ]
                  },
                  {
                    "text": "Individual catecholamines are metabolized as followsDopamine → homovanillic acid (HVA)Norepinephrine → normetanephrine → vanillylmandelic acid (VMA)Epinephrine → metanephrine → vanillylmandelic acid (VMA)",
                    "sub_points": [
                      "Dopamine → homovanillic acid (HVA)",
                      "Norepinephrine → normetanephrine → vanillylmandelic acid (VMA)",
                      "Epinephrine → metanephrine → vanillylmandelic acid (VMA)"
                    ]
                  },
                  {
                    "text": "Each of these reactions is catalyzed by either catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO)"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Catecholamine testing can be performed on plasma or urine specimensUrine specimen should be acidified",
                    "sub_points": [
                      "Urine specimen should be acidified"
                    ]
                  },
                  {
                    "text": "Venipuncture can falsely increase catecholamine plasma concentration due to painAllow for time between needle insertion and draw, letting acute catecholamine increase subside",
                    "sub_points": [
                      "Allow for time between needle insertion and draw, letting acute catecholamine increase subside"
                    ]
                  },
                  {
                    "text": "Positioning can also falsely increase catecholamine concentrationPatient should be supine and not stressed",
                    "sub_points": [
                      "Patient should be supine and not stressed"
                    ]
                  },
                  {
                    "text": "Plasma catecholamines should be drawn on ice with specimen immediately separated and frozen"
                  }
                ],
                "Pheochromocytoma": [
                  {
                    "text": "Measurement of plasma normetanephrine and metanephrine is preferred screening testFalse-positive results can be seen with plasma catecholamine measurement (stress)",
                    "sub_points": [
                      "False-positive results can be seen with plasma catecholamine measurement (stress)"
                    ]
                  },
                  {
                    "text": "If further testing is required (screening test equivocal) clonidine suppression test usedClonidine (alpha-adrenergic agonist) suppresses catecholamine releasePlasma levels of normetanephrine are measured pre- and post-clonidine administrationMetanephrines from tumor do not suppress",
                    "sub_points": [
                      "Clonidine (alpha-adrenergic agonist) suppresses catecholamine release",
                      "Plasma levels of normetanephrine are measured pre- and post-clonidine administrationMetanephrines from tumor do not suppress",
                      "Metanephrines from tumor do not suppress"
                    ]
                  }
                ],
                "Neuroblastoma": [
                  {
                    "text": "As neuroblastoma primarily produces dopamine, measurement of urine HVA most usefulUrine collected over 24-hour periodAnalyzed by gas or liquid chromatography coupled with mass spectrometry",
                    "sub_points": [
                      "Urine collected over 24-hour period",
                      "Analyzed by gas or liquid chromatography coupled with mass spectrometry"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Laboratory Testing in Adrenal Insufficiency": {
            "name": "Laboratory Testing in Adrenal Insufficiency",
            "url": "https://app.pathprimer.com/document/981fdb5a-d2aa-4a01-b7a1-dc4d753b08b3/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Patients with adrenal insufficiency display symptoms related to lack of glucocorticoids and mineralocorticoids"
                  },
                  {
                    "text": "Observed glucocorticoid deficiency also results in excessive pituitary-derived ACTH resulting in hyperpigmentation of skinACTH and MSH are derived from precursor molecule POMCMSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency",
                    "sub_points": [
                      "ACTH and MSH are derived from precursor molecule POMCMSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency",
                      "MSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency"
                    ]
                  },
                  {
                    "text": "Primary adrenal insufficiency is termed Addison disease and has various causes"
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Patients with adrenal insufficiency display symptoms related to lack of glucocorticoids and mineralocorticoidsGlucocorticoid (cortisol) deficiencyWeakness and fatigueGastrointestinal (GI) disturbanceFasting hypoglycemiaWeight lossMineralocorticoid (aldosterone) deficiencyHypotensionHyponatremiaHyperkalemiaAcidosis",
                    "sub_points": [
                      "Glucocorticoid (cortisol) deficiencyWeakness and fatigueGastrointestinal (GI) disturbanceFasting hypoglycemiaWeight loss",
                      "Weakness and fatigue",
                      "Gastrointestinal (GI) disturbance",
                      "Fasting hypoglycemia",
                      "Weight loss",
                      "Mineralocorticoid (aldosterone) deficiencyHypotensionHyponatremiaHyperkalemiaAcidosis",
                      "Hypotension",
                      "Hyponatremia",
                      "Hyperkalemia",
                      "Acidosis"
                    ]
                  },
                  {
                    "text": "Observed glucocorticoid deficiency results inExcessive pituitary-derived adrenocorticotropic hormone (ACTH) resulting in hyperpigmentation of skinACTH derived from precursor molecule proopiomelanocortin (POMC)Melanocyte-stimulating hormone (MSH) also derived from POMCMSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency",
                    "sub_points": [
                      "Excessive pituitary-derived adrenocorticotropic hormone (ACTH) resulting in hyperpigmentation of skinACTH derived from precursor molecule proopiomelanocortin (POMC)Melanocyte-stimulating hormone (MSH) also derived from POMCMSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency",
                      "ACTH derived from precursor molecule proopiomelanocortin (POMC)",
                      "Melanocyte-stimulating hormone (MSH) also derived from POMCMSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency",
                      "MSH overproduction is thought to be cause of hyperpigmentation seen in adrenal insufficiency"
                    ]
                  },
                  {
                    "text": "Primary adrenal insufficiency is termed Addison disease and has various causesAutoimmune destruction of adrenal glandInborn errors of metabolismMost often due to defects in cholesterol synthesisSystemic disordersAmyloidosisInfection of adrenal glandDrugs (ketoconazole)",
                    "sub_points": [
                      "Autoimmune destruction of adrenal gland",
                      "Inborn errors of metabolismMost often due to defects in cholesterol synthesis",
                      "Most often due to defects in cholesterol synthesis",
                      "Systemic disordersAmyloidosis",
                      "Amyloidosis",
                      "Infection of adrenal gland",
                      "Drugs (ketoconazole)"
                    ]
                  },
                  {
                    "text": "Secondary adrenal insufficiency caused by destructive processes involving pituitary &/or hypothalamusLong-term glucocorticoid administration most common causeClinical features in secondary and tertiary adrenal insufficiency similar to features seen in primary adrenal insufficiencyHyperpigmentation is not presentHypotension is not as severe because renin-angiotensin-aldosterone system maintains some mineralocorticoid production",
                    "sub_points": [
                      "Long-term glucocorticoid administration most common cause",
                      "Clinical features in secondary and tertiary adrenal insufficiency similar to features seen in primary adrenal insufficiencyHyperpigmentation is not presentHypotension is not as severe because renin-angiotensin-aldosterone system maintains some mineralocorticoid production",
                      "Hyperpigmentation is not present",
                      "Hypotension is not as severe because renin-angiotensin-aldosterone system maintains some mineralocorticoid production"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Prevalence of adrenal insufficiency 11 cases per 100,000 people"
                  },
                  {
                    "text": "Most common cause of primary adrenal insufficiency worldwide is infectious diseaseTuberculosisHistoplasmosis and other fungal infectionsCytomegalovirus",
                    "sub_points": [
                      "Tuberculosis",
                      "Histoplasmosis and other fungal infections",
                      "Cytomegalovirus"
                    ]
                  },
                  {
                    "text": "Autoimmune disease of adrenal glands accounts for 70% of cases in developed world"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Adrenal Insufficiency Work-Up": [
                  {
                    "text": "Cortisol can be measured in morningCortisol should be at or near peak with normal diurnal variationLow cortisol indicates further investigation",
                    "sub_points": [
                      "Cortisol should be at or near peak with normal diurnal variationLow cortisol indicates further investigation",
                      "Low cortisol indicates further investigation"
                    ]
                  },
                  {
                    "text": "Cosyntropin stimulation testTest determines adrenal gland response to ACTHCosyntropin is synthetic protein with biologic activity equivalent to ACTHCortisol level is measured after administration of cosyntropinAids in differentiation between primary and secondary/tertiary adrenal insufficiencyPrimary adrenal insufficiencyImpaired response to cosyntropin (lack of cortisol rise)Secondary/tertiary insufficiencyRise in cortisol",
                    "sub_points": [
                      "Test determines adrenal gland response to ACTH",
                      "Cosyntropin is synthetic protein with biologic activity equivalent to ACTH",
                      "Cortisol level is measured after administration of cosyntropin",
                      "Aids in differentiation between primary and secondary/tertiary adrenal insufficiencyPrimary adrenal insufficiencyImpaired response to cosyntropin (lack of cortisol rise)Secondary/tertiary insufficiencyRise in cortisol",
                      "Primary adrenal insufficiencyImpaired response to cosyntropin (lack of cortisol rise)",
                      "Impaired response to cosyntropin (lack of cortisol rise)",
                      "Secondary/tertiary insufficiencyRise in cortisol",
                      "Rise in cortisol"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prolactin": {
            "name": "Prolactin",
            "url": "https://app.pathprimer.com/document/64fd4c74-a6dd-401d-ac66-80b848aa8403/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Prolactin is a hormone produced within the anterior pituitary (adenohypophysis) by specialized cells called lactotrophs"
                  },
                  {
                    "text": "Dopamine inhibits prolactin secretionProlactin stimulates hypothalamic release of dopamine, inhibiting its own secretion",
                    "sub_points": [
                      "Prolactin stimulates hypothalamic release of dopamine, inhibiting its own secretion"
                    ]
                  },
                  {
                    "text": "Major prolactin actions, in setting of estrogen priming, include stimulating lactation and breast development"
                  },
                  {
                    "text": "Prolactin inhibits GnRH secretion"
                  },
                  {
                    "text": "Prolactin secretion is pulsatile and has circadian properties"
                  }
                ],
                "Limitations": [
                  {
                    "text": "Macroprolactin formed by complexing of prolactin with immunoglobulins and aggregation of monomeric prolactin"
                  },
                  {
                    "text": "Can falsely elevate measured serum prolactin concentration"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Thyrotropin-releasing hormone (TRH)"
                  },
                  {
                    "text": "Gonadotropin-releasing hormone (GnRH)"
                  },
                  {
                    "text": "Luteinizing hormone (LH)"
                  },
                  {
                    "text": "Follicle-stimulating hormone (FSH)"
                  },
                  {
                    "text": "Insulin-like growth factor I (IGF-I)"
                  },
                  {
                    "text": "Parathyroid hormone (PTH)"
                  },
                  {
                    "text": "Magnetic resonance imaging (MRI)"
                  },
                  {
                    "text": "Computed tomography (CT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lactogen"
                  },
                  {
                    "text": "Lactrotropin"
                  },
                  {
                    "text": "Mammotropin"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology and Biochemistry": [
                  {
                    "text": "Prolactin is a hormone produced within the anterior pituitary (adenohypophysis) by specialized cells called lactotrophs"
                  },
                  {
                    "text": "3 formsMonomeric (most bioactive)DimericPolymeric",
                    "sub_points": [
                      "Monomeric (most bioactive)",
                      "Dimeric",
                      "Polymeric"
                    ]
                  },
                  {
                    "text": "Prolactin increased in lactotrophs of pregnant women"
                  },
                  {
                    "text": "Dopamine inhibits prolactin secretionProlactin stimulates hypothalamic release of dopamine, inhibiting its own secretion",
                    "sub_points": [
                      "Prolactin stimulates hypothalamic release of dopamine, inhibiting its own secretion"
                    ]
                  },
                  {
                    "text": "Prolactin secretion also under minor hypothalamic control via TRH"
                  },
                  {
                    "text": "Major prolactin actions, in setting of estrogen primingStimulating lactationInduces synthesis of milk proteins (casein and lactalbumin)Breast developmentInduces ductal and breast lobular development",
                    "sub_points": [
                      "Stimulating lactationInduces synthesis of milk proteins (casein and lactalbumin)",
                      "Induces synthesis of milk proteins (casein and lactalbumin)",
                      "Breast developmentInduces ductal and breast lobular development",
                      "Induces ductal and breast lobular development"
                    ]
                  },
                  {
                    "text": "Prolactin inhibits GnRH secretionInhibits anterior pituitary from releasing LH and FSHLeads to failure of follicular maturation in womenDeficiency of FSH and LH in men results in a decrease in testosterone, affecting spermatogenesis",
                    "sub_points": [
                      "Inhibits anterior pituitary from releasing LH and FSHLeads to failure of follicular maturation in womenDeficiency of FSH and LH in men results in a decrease in testosterone, affecting spermatogenesis",
                      "Leads to failure of follicular maturation in women",
                      "Deficiency of FSH and LH in men results in a decrease in testosterone, affecting spermatogenesis"
                    ]
                  },
                  {
                    "text": "Prolactin secretion is pulsatile and has circadian propertiesHighest levels during sleepLowest levels between 10 AM and noon",
                    "sub_points": [
                      "Highest levels during sleep",
                      "Lowest levels between 10 AM and noon"
                    ]
                  },
                  {
                    "text": "Secretion can be affected by various stimuli in a dayStressExerciseMeals",
                    "sub_points": [
                      "Stress",
                      "Exercise",
                      "Meals"
                    ]
                  },
                  {
                    "text": "Serum half-life of prolactin approximately 26-47 minutes"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytic Methodology": [
                  {
                    "text": "Prolactin measured by automated 2-site sandwich immunoassays≥ 2 antibodies directed at different prolactin epitopesProne to hook effectDilution recommended when pretest probability of macroprolactinoma is 1:100",
                    "sub_points": [
                      "≥ 2 antibodies directed at different prolactin epitopes",
                      "Prone to hook effectDilution recommended when pretest probability of macroprolactinoma is 1:100",
                      "Dilution recommended when pretest probability of macroprolactinoma is 1:100"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Hyperprolactinemia": [
                  {
                    "text": "Most common hypothalamic/pituitary disorder seen clinically"
                  },
                  {
                    "text": "CausesDecreased dopaminergic inhibitionDamage to pituitary stalk (macroadenoma, trauma, surgery)Drugs that interfere with dopaminergic pathwayMethyldopa, metoclopramide, antipsychotics, some antidepressants, othersProlactinomasMost common secretory pituitary tumorHypothyroidismChronic renal failureAcromegalyHyperprolactinemia occurs in 40% of patientsIGF-I should be ordered in initial work-up of hyperprolactinemia",
                    "sub_points": [
                      "Decreased dopaminergic inhibitionDamage to pituitary stalk (macroadenoma, trauma, surgery)Drugs that interfere with dopaminergic pathwayMethyldopa, metoclopramide, antipsychotics, some antidepressants, others",
                      "Damage to pituitary stalk (macroadenoma, trauma, surgery)",
                      "Drugs that interfere with dopaminergic pathwayMethyldopa, metoclopramide, antipsychotics, some antidepressants, others",
                      "Methyldopa, metoclopramide, antipsychotics, some antidepressants, others",
                      "ProlactinomasMost common secretory pituitary tumor",
                      "Most common secretory pituitary tumor",
                      "Hypothyroidism",
                      "Chronic renal failure",
                      "AcromegalyHyperprolactinemia occurs in 40% of patientsIGF-I should be ordered in initial work-up of hyperprolactinemia",
                      "Hyperprolactinemia occurs in 40% of patients",
                      "IGF-I should be ordered in initial work-up of hyperprolactinemia"
                    ]
                  },
                  {
                    "text": "May result inInfertilityWomen with prolactinemiaAnovulationIrregular menstruationGalactorrheaAmenorrheaIncreased prolactin in menDecreased sperm countImpotenceLocalized tumor (macroadenomas more common in men)",
                    "sub_points": [
                      "Infertility",
                      "Women with prolactinemiaAnovulationIrregular menstruationGalactorrheaAmenorrhea",
                      "Anovulation",
                      "Irregular menstruation",
                      "Galactorrhea",
                      "Amenorrhea",
                      "Increased prolactin in menDecreased sperm countImpotenceLocalized tumor (macroadenomas more common in men)",
                      "Decreased sperm count",
                      "Impotence",
                      "Localized tumor (macroadenomas more common in men)"
                    ]
                  }
                ],
                "﻿Prolactin Deficiency": [
                  {
                    "text": "Causes includePituitary necrosis or infarctionPseudohypoparathyroidismTarget tissue resistance to PTH",
                    "sub_points": [
                      "Pituitary necrosis or infarction",
                      "PseudohypoparathyroidismTarget tissue resistance to PTH",
                      "Target tissue resistance to PTH"
                    ]
                  },
                  {
                    "text": "Women with deficiency developMenstrual disordersInfertility",
                    "sub_points": [
                      "Menstrual disorders",
                      "Infertility"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "﻿Macroprolactinemia": [
                  {
                    "text": "Macroprolactin formed byComplexing of prolactin with immunoglobulinsAggregation of monomeric prolactin",
                    "sub_points": [
                      "Complexing of prolactin with immunoglobulins",
                      "Aggregation of monomeric prolactin"
                    ]
                  },
                  {
                    "text": "Can falsely elevate measured serum prolactin concentrationMacroprolactinemia should be considered when pathologic etiology not present (head MRI or CT negative)",
                    "sub_points": [
                      "Macroprolactinemia should be considered when pathologic etiology not present (head MRI or CT negative)"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Because of circadian secretion and half-life of prolactin, screening for hyperprolactinemia should involve multiple blood draws3 serum specimens obtained at approximately 30-minute intervalsSamples may be analyzed separately with results averaged or pooled with 1 result",
                    "sub_points": [
                      "3 serum specimens obtained at approximately 30-minute intervals",
                      "Samples may be analyzed separately with results averaged or pooled with 1 result"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Growth Hormone": {
            "name": "Growth Hormone",
            "url": "https://app.pathprimer.com/document/72995aff-cfca-48d9-a760-10b3a70fbc66/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "GH promotes growth mainly through IGF; most important subtype is IGF-1"
                  },
                  {
                    "text": "Various environmental factors stimulate GH release pathway, including hypoglycemia"
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "GH concentrations fluctuate under normal conditions"
                  },
                  {
                    "text": "Single GH measurement is not clinically useful to diagnose disease; a single measurement of IGF-1 is considered representative of true production and is useful"
                  },
                  {
                    "text": "Dynamic testing to increase or suppress GH release is preferred for disease diagnosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Growth hormone (GH)"
                  },
                  {
                    "text": "Insulin-like growth factor (IGF)"
                  },
                  {
                    "text": "Growth hormone-releasing hormone (GHRH)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "GH is produced and released by anterior pituitary (adenohypophysis)"
                  },
                  {
                    "text": "GH is single-chain polypeptide structurally similar to prolactin and placental lactogen"
                  },
                  {
                    "text": "GH displays diurnal variationBaseline low levels throughout day with intermittent spikes after meals and exerciseHighest levels occur during sleep",
                    "sub_points": [
                      "Baseline low levels throughout day with intermittent spikes after meals and exercise",
                      "Highest levels occur during sleep"
                    ]
                  },
                  {
                    "text": "Regulation of GH release is under hypothalamic controlVia GHRH (stimulates release) and somatostatin (inhibits release)Various environmental factors stimulate GH release pathwayHypoglycemiaExerciseStressHormones (testosterone, estrogen, thyroxine)High amino acid concentration (arginine)",
                    "sub_points": [
                      "Via GHRH (stimulates release) and somatostatin (inhibits release)",
                      "Various environmental factors stimulate GH release pathwayHypoglycemiaExerciseStressHormones (testosterone, estrogen, thyroxine)High amino acid concentration (arginine)",
                      "Hypoglycemia",
                      "Exercise",
                      "Stress",
                      "Hormones (testosterone, estrogen, thyroxine)",
                      "High amino acid concentration (arginine)"
                    ]
                  },
                  {
                    "text": "Glucocorticoids suppress GH secretion"
                  },
                  {
                    "text": "GH stimulates liver to synthesize and release IGF"
                  },
                  {
                    "text": "IGF is polypeptide with similar sequence to insulin"
                  },
                  {
                    "text": "IGF circulates bound to various binding proteins and disassociates before entry into tissues"
                  },
                  {
                    "text": "GH promotes growth mainly through IGFMost important subtype is IGF-1",
                    "sub_points": [
                      "Most important subtype is IGF-1"
                    ]
                  },
                  {
                    "text": "Primary tissues affectedBoneSoft tissueCartilage",
                    "sub_points": [
                      "Bone",
                      "Soft tissue",
                      "Cartilage"
                    ]
                  },
                  {
                    "text": "GH stimulates fatty acid uptake and overall metabolism of fat"
                  },
                  {
                    "text": "Chronically elevated GH level enhances hepatic glycogenolysisEventually results in increased blood glucose levels",
                    "sub_points": [
                      "Eventually results in increased blood glucose levels"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "GH concentrations fluctuate under normal conditions"
                  },
                  {
                    "text": "Single GH measurement not clinically useful to diagnose diseaseSingle measurement of IGF-1 is considered representative of true production and is useful",
                    "sub_points": [
                      "Single measurement of IGF-1 is considered representative of true production and is useful"
                    ]
                  },
                  {
                    "text": "Dynamic testing to increase or suppress GH release is preferred for disease diagnosis"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Excess Growth Hormone": [
                  {
                    "text": "Often caused by pituitary adenoma"
                  },
                  {
                    "text": "Manifests as overgrowth in skeletal and soft tissueExcess GH before long bone epiphyseal fusion results in gigantismExcess GH after long bone epiphyseal fusion results in acromegaly",
                    "sub_points": [
                      "Excess GH before long bone epiphyseal fusion results in gigantism",
                      "Excess GH after long bone epiphyseal fusion results in acromegaly"
                    ]
                  },
                  {
                    "text": "Acromegaly is best diagnosed by glucose tolerance test with concomitant measurement of GHNormally GH concentration is low 60-120 min after 75-g oral glucose dosePatients with acromegaly demonstrate no change in baseline concentration of GH or demonstrate increase",
                    "sub_points": [
                      "Normally GH concentration is low 60-120 min after 75-g oral glucose dose",
                      "Patients with acromegaly demonstrate no change in baseline concentration of GH or demonstrate increase"
                    ]
                  }
                ],
                "Growth Hormone Deficiency": [
                  {
                    "text": "Poor GH production or defects in GH receptor impair normal skeletal development"
                  },
                  {
                    "text": "CausesCongenital etiologiesPituitary or hypothalamic damageAdenoma-induced damage is most common cause of GH deficiency in adultsIsolated GH deficiency",
                    "sub_points": [
                      "Congenital etiologies",
                      "Pituitary or hypothalamic damageAdenoma-induced damage is most common cause of GH deficiency in adults",
                      "Adenoma-induced damage is most common cause of GH deficiency in adults",
                      "Isolated GH deficiency"
                    ]
                  },
                  {
                    "text": "Only a few children evaluated for short stature have GH deficiencyRecombinant GH is available for therapy in these cases",
                    "sub_points": [
                      "Recombinant GH is available for therapy in these cases"
                    ]
                  },
                  {
                    "text": "Resistance to GH at receptor level can occurDisplays normal or increased GH concentration with decreased IGF-1 concentration",
                    "sub_points": [
                      "Displays normal or increased GH concentration with decreased IGF-1 concentration"
                    ]
                  },
                  {
                    "text": "GH deficiency best tested by taking advantage of normal increase in GH seen with hypoglycemiaInsulin administered with multiple samples drawn over 120 minGH is subsequently measuredTesting contraindicated in patients with various conditionsSeizure disorderCardiac diseaseCerebrovascular disease",
                    "sub_points": [
                      "Insulin administered with multiple samples drawn over 120 minGH is subsequently measured",
                      "GH is subsequently measured",
                      "Testing contraindicated in patients with various conditionsSeizure disorderCardiac diseaseCerebrovascular disease",
                      "Seizure disorder",
                      "Cardiac disease",
                      "Cerebrovascular disease"
                    ]
                  },
                  {
                    "text": "IGF-1 is low in various disordersIGF-1 nonspecific for GH deficiency diagnosis",
                    "sub_points": [
                      "IGF-1 nonspecific for GH deficiency diagnosis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Antidiuretic Hormone": {
            "name": "Antidiuretic Hormone",
            "url": "https://app.pathprimer.com/document/4357e83a-46b2-4066-962b-8abc8bdb683f/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "ADH increases absorption of water within renal collecting ductADH binds V2 receptors increasing cellular membrane water channels (aquaporin II)Results in urine concentration",
                    "sub_points": [
                      "ADH binds V2 receptors increasing cellular membrane water channels (aquaporin II)",
                      "Results in urine concentration"
                    ]
                  },
                  {
                    "text": "ADH stimulates muscle contractions within capillaries and arterioles (increases blood pressure)"
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "DI is hypofunction of ADH"
                  },
                  {
                    "text": "DI results in polyuria, which can be divided into 2 categories: ADH deficiency (hypothalamic DI) and renal resistance to ADH action (nephrogenic DI)"
                  },
                  {
                    "text": "Patients with SIADH subsequently experience hemodilutionDilutional hyponatremia: Most common cause of hyponatremia in hospitalized patients",
                    "sub_points": [
                      "Dilutional hyponatremia: Most common cause of hyponatremia in hospitalized patients"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Antidiuretic hormone (ADH)"
                  },
                  {
                    "text": "Diabetes insipidus (DI)"
                  },
                  {
                    "text": "Syndrome of inappropriate antidiuretic hormone (SIADH)"
                  },
                  {
                    "text": "Red blood cell (RBC)"
                  },
                  {
                    "text": "Central nervous system (CNS)"
                  },
                  {
                    "text": "Acquired immunodeficiency syndrome (AIDS)"
                  },
                  {
                    "text": "Angiotensin-converting enzyme (ACE)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Vasopressin"
                  },
                  {
                    "text": "Desmopressin"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Physiology and Biochemistry": [
                  {
                    "text": "Neuronal cells found in hypothalamus synthesize ADH"
                  },
                  {
                    "text": "ADH is complexed with neurophysin binding protein and packaged into granules"
                  },
                  {
                    "text": "Granules travel down hypothalamic axons to posterior pituitary (neurohypophysis)Oxytocin (only other posterior pituitary hormone) produced and stored similarly",
                    "sub_points": [
                      "Oxytocin (only other posterior pituitary hormone) produced and stored similarly"
                    ]
                  },
                  {
                    "text": "Secretion of ADH regulated byPlasma osmolality (major)2% increase in extracellular fluid osmolality can stimulate osmoreceptors in brainPlasma osmolality > 280 mOsm/kg is threshold for ADH releaseDecrease in plasma volumeProcess mediated by various baroreceptorsOther nonosmotic stimuliPainStressHypoglycemiaExerciseChemical agents (angiotensin II)",
                    "sub_points": [
                      "Plasma osmolality (major)2% increase in extracellular fluid osmolality can stimulate osmoreceptors in brainPlasma osmolality > 280 mOsm/kg is threshold for ADH release",
                      "2% increase in extracellular fluid osmolality can stimulate osmoreceptors in brain",
                      "Plasma osmolality > 280 mOsm/kg is threshold for ADH release",
                      "Decrease in plasma volumeProcess mediated by various baroreceptors",
                      "Process mediated by various baroreceptors",
                      "Other nonosmotic stimuliPainStressHypoglycemiaExerciseChemical agents (angiotensin II)",
                      "Pain",
                      "Stress",
                      "Hypoglycemia",
                      "Exercise",
                      "Chemical agents (angiotensin II)"
                    ]
                  },
                  {
                    "text": "Inhibition of ADH release caused byAlcoholGlucocorticoidsDrugs (phenytoin)",
                    "sub_points": [
                      "Alcohol",
                      "Glucocorticoids",
                      "Drugs (phenytoin)"
                    ]
                  },
                  {
                    "text": "ADH has various functionsIncreases absorption of water within renal collecting ductADH binds V2 receptors increasing cellular membrane water channels (aquaporin II)Results in urine concentrationStimulates muscle contractions within capillaries and arterioles (increases blood pressure)Increases intestinal peristalsisInfluences uterine contraction",
                    "sub_points": [
                      "Increases absorption of water within renal collecting ductADH binds V2 receptors increasing cellular membrane water channels (aquaporin II)Results in urine concentration",
                      "ADH binds V2 receptors increasing cellular membrane water channels (aquaporin II)",
                      "Results in urine concentration",
                      "Stimulates muscle contractions within capillaries and arterioles (increases blood pressure)",
                      "Increases intestinal peristalsis",
                      "Influences uterine contraction"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Analytic Methods": [
                  {
                    "text": "ADH measurement in plasma and urine done by immunoassay"
                  },
                  {
                    "text": "Requires initial extraction and concentrating steps"
                  },
                  {
                    "text": "Often done by reference laboratory when analysis necessary"
                  }
                ],
                "﻿Water Deprivation Test": [
                  {
                    "text": "Used in DI work-upPatient deprived of fluid (often overnight)Blood sample taken to measure plasma osmolality and ADHSubcutaneous ADH (desmopressin) is administered",
                    "sub_points": [
                      "Patient deprived of fluid (often overnight)",
                      "Blood sample taken to measure plasma osmolality and ADH",
                      "Subcutaneous ADH (desmopressin) is administered"
                    ]
                  },
                  {
                    "text": "In normal patients or patients with primary polydipsiaProgressive increase in urine osmolarityNo effect on urine concentration after ADH administration",
                    "sub_points": [
                      "Progressive increase in urine osmolarity",
                      "No effect on urine concentration after ADH administration"
                    ]
                  },
                  {
                    "text": "Hypothalamic DIUrine not concentrated, despite water deprivation with increase in urine osmolarity on administering ADH",
                    "sub_points": [
                      "Urine not concentrated, despite water deprivation with increase in urine osmolarity on administering ADH"
                    ]
                  },
                  {
                    "text": "Primary polydipsia urine osmolality"
                  },
                  {
                    "text": "Nephrogenic DIUrine not concentrated before or after ADH administration",
                    "sub_points": [
                      "Urine not concentrated before or after ADH administration"
                    ]
                  }
                ],
                "﻿SIADH Work-Up": [
                  {
                    "text": "Other causes of dilutional hypernatremia must be ruled out before SIADH diagnosisCongestive heart failureRenal diseaseLiver cirrhosisHypothyroidism",
                    "sub_points": [
                      "Congestive heart failure",
                      "Renal disease",
                      "Liver cirrhosis",
                      "Hypothyroidism"
                    ]
                  },
                  {
                    "text": "Plasma osmolality < 280 mOsm/kg"
                  },
                  {
                    "text": "Patients with SIADH display urine osmolality > 100 mOsm/kg"
                  },
                  {
                    "text": "Urine sodium concentration > 40 mmol/L"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Diabetes Insipidus": [
                  {
                    "text": "Hypofunction of ADHDeficient production or actionUrine output > 2.5 L /day warrants investigation",
                    "sub_points": [
                      "Deficient production or action",
                      "Urine output > 2.5 L /day warrants investigation"
                    ]
                  },
                  {
                    "text": "Results in polyuria, which can be divided into 2 categoriesADH deficiency (hypothalamic DI)Failure of pituitary gland to secrete normal ADH amountsCausesTumor (primary or metastatic)Head traumaInfection and inflammation (meningitis)Granulomatous disease (sarcoidosis)Vascular malformationRenal resistance to ADH action (nephrogenic DI)2 major causesX-linked mutation in V2 receptor (90% of cases)Autosomal recessive mutation in aquaporin II water channelAcquired formsDrugs (lithium)Metabolic disorders (amyloidosis)Renal disease (polycystic kidney)IdiopathicExcessive water consumption (primary polydipsia)ADH secretion suppressed by excessive water intakePsychogenic factors most common",
                    "sub_points": [
                      "ADH deficiency (hypothalamic DI)Failure of pituitary gland to secrete normal ADH amountsCausesTumor (primary or metastatic)Head traumaInfection and inflammation (meningitis)Granulomatous disease (sarcoidosis)Vascular malformation",
                      "Failure of pituitary gland to secrete normal ADH amounts",
                      "CausesTumor (primary or metastatic)Head traumaInfection and inflammation (meningitis)Granulomatous disease (sarcoidosis)Vascular malformation",
                      "Tumor (primary or metastatic)",
                      "Head trauma",
                      "Infection and inflammation (meningitis)",
                      "Granulomatous disease (sarcoidosis)",
                      "Vascular malformation",
                      "Renal resistance to ADH action (nephrogenic DI)2 major causesX-linked mutation in V2 receptor (90% of cases)Autosomal recessive mutation in aquaporin II water channelAcquired formsDrugs (lithium)Metabolic disorders (amyloidosis)Renal disease (polycystic kidney)IdiopathicExcessive water consumption (primary polydipsia)ADH secretion suppressed by excessive water intakePsychogenic factors most common",
                      "2 major causesX-linked mutation in V2 receptor (90% of cases)Autosomal recessive mutation in aquaporin II water channel",
                      "X-linked mutation in V2 receptor (90% of cases)",
                      "Autosomal recessive mutation in aquaporin II water channel",
                      "Acquired formsDrugs (lithium)Metabolic disorders (amyloidosis)Renal disease (polycystic kidney)Idiopathic",
                      "Drugs (lithium)",
                      "Metabolic disorders (amyloidosis)",
                      "Renal disease (polycystic kidney)",
                      "Idiopathic",
                      "Excessive water consumption (primary polydipsia)ADH secretion suppressed by excessive water intakePsychogenic factors most common",
                      "ADH secretion suppressed by excessive water intake",
                      "Psychogenic factors most common"
                    ]
                  }
                ],
                "﻿Syndrome of Inappropriate Antidiuretic Hormone": [
                  {
                    "text": "Sustained production of ADH independent of known release stimuli"
                  },
                  {
                    "text": "Uninhibited ADH leads to excessive reabsorption of free waterUrine volume decreasedUrine sodium increasedUrine osmolality increased",
                    "sub_points": [
                      "Urine volume decreased",
                      "Urine sodium increased",
                      "Urine osmolality increased"
                    ]
                  },
                  {
                    "text": "Patients with SIADH subsequently experience hemodilutionDilutional hyponatremiaMost common cause of hyponatremia in hospitalized patientsLow plasma osmolalityHematocrit unchangedIncreased RBC volume as a result of water shift offsets dilutional effect",
                    "sub_points": [
                      "Dilutional hyponatremiaMost common cause of hyponatremia in hospitalized patients",
                      "Most common cause of hyponatremia in hospitalized patients",
                      "Low plasma osmolality",
                      "Hematocrit unchangedIncreased RBC volume as a result of water shift offsets dilutional effect",
                      "Increased RBC volume as a result of water shift offsets dilutional effect"
                    ]
                  },
                  {
                    "text": "Various conditions cause SIADHCNS disease (brain tumor, meningitis)LeukemiaPulmonary disease (pneumonia, small cell carcinoma)AIDSDrugs (ACE inhibitor)",
                    "sub_points": [
                      "CNS disease (brain tumor, meningitis)",
                      "Leukemia",
                      "Pulmonary disease (pneumonia, small cell carcinoma)",
                      "AIDS",
                      "Drugs (ACE inhibitor)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Follicle Stimulating and Luteinizing Hormones": {
            "name": "Follicle Stimulating and Luteinizing Hormones",
            "url": "https://app.pathprimer.com/document/804fa6a6-0178-41a7-8a7c-828d8d5e4ef8/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Anterior pituitary (adenohypophysis) produces FSH and LH; both are composed of α and β subunitα subunit of both homologous with TSH and placental chorionic gonadotropinβ subunit unique and confers functional specificity",
                    "sub_points": [
                      "α subunit of both homologous with TSH and placental chorionic gonadotropin",
                      "β subunit unique and confers functional specificity"
                    ]
                  },
                  {
                    "text": "FSH functionsPromotion of ovarian follicle growth and maturationIn males promotes spermatogenesisFSH critical for proliferative phase (first half) endometrial change in menstrual cycle",
                    "sub_points": [
                      "Promotion of ovarian follicle growth and maturation",
                      "In males promotes spermatogenesis",
                      "FSH critical for proliferative phase (first half) endometrial change in menstrual cycle"
                    ]
                  },
                  {
                    "text": "LH functionsLH surge during mid-menstrual cycle promoting ovulationMaintenance of secretory phase of menstrual cycle (second half)Promotion of ruptured ovarian follicle luteinizationPulsatile LH release also stimulates corpus luteum to secrete progesterone and estradiolSupports development and function of Leydig cells promoting testosterone production",
                    "sub_points": [
                      "LH surge during mid-menstrual cycle promoting ovulation",
                      "Maintenance of secretory phase of menstrual cycle (second half)",
                      "Promotion of ruptured ovarian follicle luteinization",
                      "Pulsatile LH release also stimulates corpus luteum to secrete progesterone and estradiol",
                      "Supports development and function of Leydig cells promoting testosterone production"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Follicle-stimulating hormone (FSH)"
                  },
                  {
                    "text": "Luteinizing hormone (LH)"
                  },
                  {
                    "text": "Gonadotropin-releasing hormone (GnRH)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone (TSH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Gonadotropins"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "Anterior pituitary (adenohypophysis) produces FSH and LHBoth are composed of α and β subunitα subunit of both homologous with TSH and placental chorionic gonadotropinβ subunit unique and confers functional specificity",
                    "sub_points": [
                      "Both are composed of α and β subunitα subunit of both homologous with TSH and placental chorionic gonadotropinβ subunit unique and confers functional specificity",
                      "α subunit of both homologous with TSH and placental chorionic gonadotropin",
                      "β subunit unique and confers functional specificity"
                    ]
                  },
                  {
                    "text": "FSH functionsPromotion of ovarian follicle growth and maturationStimulates secretion of estrogen by maturing ovarian folliclesIn males promotes spermatogenesisFSH critical for proliferative phase (first half) endometrial change in menstrual cycle",
                    "sub_points": [
                      "Promotion of ovarian follicle growth and maturationStimulates secretion of estrogen by maturing ovarian follicles",
                      "Stimulates secretion of estrogen by maturing ovarian follicles",
                      "In males promotes spermatogenesis",
                      "FSH critical for proliferative phase (first half) endometrial change in menstrual cycle"
                    ]
                  },
                  {
                    "text": "LH works in concert with FSH"
                  },
                  {
                    "text": "LH functionsLH surge during mid-menstrual cycle promoting ovulationAndrogen and progesterone secretionMaintenance of secretory phase of menstrual cycle (second half)Promotion of ruptured ovarian follicle luteinizationResults in corpus luteum formationPulsatile LH release also stimulates corpus luteum to secrete progesterone and estradiolSupports development and function of Leydig cells promoting testosterone production",
                    "sub_points": [
                      "LH surge during mid-menstrual cycle promoting ovulation",
                      "Androgen and progesterone secretion",
                      "Maintenance of secretory phase of menstrual cycle (second half)",
                      "Promotion of ruptured ovarian follicle luteinizationResults in corpus luteum formation",
                      "Results in corpus luteum formation",
                      "Pulsatile LH release also stimulates corpus luteum to secrete progesterone and estradiol",
                      "Supports development and function of Leydig cells promoting testosterone production"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Immunoassay": [
                  {
                    "text": "Analytic methods must be specific for β subunits of LH and FSH because of α subunit homology among pituitary hormones"
                  },
                  {
                    "text": "Two-site heterogeneous immunoassay often used"
                  },
                  {
                    "text": "Lower limit of detection important in testing of certain patient populationsPrepubescent childrenPatients with hypothalamic disorders",
                    "sub_points": [
                      "Prepubescent children",
                      "Patients with hypothalamic disorders"
                    ]
                  }
                ],
                "Preanalytic Considerations": [
                  {
                    "text": "Serum is specimen of choice"
                  },
                  {
                    "text": "LH and FSH are stable > 1 week at room temperature"
                  },
                  {
                    "text": "Single blood measurements of FSH and LH have limited clinical utilityDue to pulsatile nature of gonadotropin release",
                    "sub_points": [
                      "Due to pulsatile nature of gonadotropin release"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hypogonadotropic Hypogonadism": [
                  {
                    "text": "Clinical syndrome characterized by LH and FSH deficiencyResults in low testosterone (males) and estradiol (females)",
                    "sub_points": [
                      "Results in low testosterone (males) and estradiol (females)"
                    ]
                  },
                  {
                    "text": "CausesGnRH deficiency from hypothalamus (Kallmann syndrome)Unique symptom is loss or reduced sense of smellAnorexiaOvertrained female athleteSevere stressPituitary macroadenoma (rare)",
                    "sub_points": [
                      "GnRH deficiency from hypothalamus (Kallmann syndrome)Unique symptom is loss or reduced sense of smell",
                      "Unique symptom is loss or reduced sense of smell",
                      "Anorexia",
                      "Overtrained female athlete",
                      "Severe stress",
                      "Pituitary macroadenoma (rare)"
                    ]
                  }
                ],
                "Reproductive Endocrinology": [
                  {
                    "text": "LH can be found in urine shortly after LH surge and before ovulation (up to 36 hr)Provides a guide of when to initiate intercourse to enhance chance of becoming pregnantHome ovulation kits measure LH in urineAble to predict ovulation in most women (70%)",
                    "sub_points": [
                      "Provides a guide of when to initiate intercourse to enhance chance of becoming pregnant",
                      "Home ovulation kits measure LH in urineAble to predict ovulation in most women (70%)",
                      "Able to predict ovulation in most women (70%)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Conn Syndrome": {
            "name": "Conn Syndrome",
            "url": "https://app.pathprimer.com/document/9f991554-24b4-41be-bc3e-35460b0c9585/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Correlates": [
                  {
                    "text": "Conn syndrome (primary hyperaldosteronism) due to excessive aldosterone produced by adrenal cortex (zona glomerulosa)"
                  },
                  {
                    "text": "Refractory hypertension (multiple medications ineffective)"
                  },
                  {
                    "text": "Hypokalemia (< 3.5 mmol/L)"
                  },
                  {
                    "text": "Hypochloremic metabolic alkalosis"
                  }
                ],
                "Laboratory Diagnosis": [
                  {
                    "text": "Plasma aldosterone concentration (PAC) to plasma renin activity (PRA) is considered best screening testPAC/PRA ratio > 20-50 is suggestive of Conn syndrome",
                    "sub_points": [
                      "PAC/PRA ratio > 20-50 is suggestive of Conn syndrome"
                    ]
                  }
                ]
              },
              "CLINICAL CORRELATES": {
                "Pathophysiology": [
                  {
                    "text": "Conn syndrome (primary hyperaldosteronism) due to excessive aldosterone produced by adrenal cortex (zona glomerulosa)Renal sodium reabsorption increasedRenal potassium excretion increasedRenal hydrogen ion secretion increased",
                    "sub_points": [
                      "Renal sodium reabsorption increased",
                      "Renal potassium excretion increased",
                      "Renal hydrogen ion secretion increased"
                    ]
                  },
                  {
                    "text": "Renin enzyme activity suppressed due to excess aldosteroneNormally, renin secretion leads to eventual production of angiotensin II via renin-angiotensin-aldosterone system (RAAS)Angiotensin II acts upon adrenal zona glomerulosa, enhancing aldosterone synthase mediated conversion of corticosterone to aldosterone",
                    "sub_points": [
                      "Normally, renin secretion leads to eventual production of angiotensin II via renin-angiotensin-aldosterone system (RAAS)",
                      "Angiotensin II acts upon adrenal zona glomerulosa, enhancing aldosterone synthase mediated conversion of corticosterone to aldosterone"
                    ]
                  }
                ],
                "Epidemiology": [
                  {
                    "text": "Conn syndrome causesAldosterone-secreting adrenal adenoma (approximately 50% of cases)Bilateral adrenal cortex hyperplasia (45% of cases)Adrenal carcinoma (5% of cases)",
                    "sub_points": [
                      "Aldosterone-secreting adrenal adenoma (approximately 50% of cases)",
                      "Bilateral adrenal cortex hyperplasia (45% of cases)",
                      "Adrenal carcinoma (5% of cases)"
                    ]
                  },
                  {
                    "text": "Conn syndrome may account for 5-13% of new hypertensives"
                  }
                ],
                "Classic Clinical Findings": [
                  {
                    "text": "Refractory hypertension (multiple medications ineffective)"
                  },
                  {
                    "text": "Mild hypernatremia"
                  },
                  {
                    "text": "Hypokalemia (< 3.5 mmol/L)Results in cardiac arrhythmias and muscular weaknessHowever, half of Conn syndrome patients have normal potassium",
                    "sub_points": [
                      "Results in cardiac arrhythmias and muscular weakness",
                      "However, half of Conn syndrome patients have normal potassium"
                    ]
                  },
                  {
                    "text": "Hypochloremic metabolic alkalosis"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Depending on etiology, Conn syndrome can be treated with surgery"
                  }
                ]
              },
              "LABORATORY DIAGNOSIS": {
                "Conn Syndrome Work-Up": [
                  {
                    "text": "Plasma aldosterone concentration (PAC) to plasma renin activity (PRA) is considered best screening testPAC/PRA ratio > 20-50 suggestive of Conn syndrome",
                    "sub_points": [
                      "PAC/PRA ratio > 20-50 suggestive of Conn syndrome"
                    ]
                  },
                  {
                    "text": "Dynamic function test (e.g., saline infusion) can be used for confirmation300-2000 mL of normal saline infused over 4 hoursConn syndrome confirmed if aldosterone production not suppressed (plasma aldosterone > 10 ng/dL)",
                    "sub_points": [
                      "300-2000 mL of normal saline infused over 4 hours",
                      "Conn syndrome confirmed if aldosterone production not suppressed (plasma aldosterone > 10 ng/dL)"
                    ]
                  },
                  {
                    "text": "24-hour urine potassium levels often > 30 mmol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Parathyroid Hormone": {
            "name": "Parathyroid Hormone",
            "url": "https://app.pathprimer.com/document/9dc1ff2f-13b2-49c7-b48d-4e5c58104657/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "PTH is produced by parathyroid gland4 parathyroid glands located on posterior thyroid surface synthesize, store, and secrete PTH",
                    "sub_points": [
                      "4 parathyroid glands located on posterior thyroid surface synthesize, store, and secrete PTH"
                    ]
                  },
                  {
                    "text": "PTH is integral in calcium and phosphate homeostasis"
                  },
                  {
                    "text": "Free calcium is important in regulation of PTH synthesis and secretion"
                  },
                  {
                    "text": "Hypomagnesemia has varying effects on PTH secretionChronic, severe hypomagnesemia impairs PTH secretion",
                    "sub_points": [
                      "Chronic, severe hypomagnesemia impairs PTH secretion"
                    ]
                  },
                  {
                    "text": "Effect of PTH on nephron of kidney includesEnhanced reabsorption of calcium by distal convoluted tubuleDecreased phosphate reabsorption in proximal tubuleStimulated 1-alpha-hydroxylase enzyme to convert 25-OH vitamin D to active formResults in increased calcium and phosphate absorption by intestines",
                    "sub_points": [
                      "Enhanced reabsorption of calcium by distal convoluted tubule",
                      "Decreased phosphate reabsorption in proximal tubule",
                      "Stimulated 1-alpha-hydroxylase enzyme to convert 25-OH vitamin D to active formResults in increased calcium and phosphate absorption by intestines",
                      "Results in increased calcium and phosphate absorption by intestines"
                    ]
                  },
                  {
                    "text": "Various malignancies produce PTHrP, hormone similar in structure to PTHPTHrP-producing tumorsSquamous cell carcinoma (lung, among other sites)",
                    "sub_points": [
                      "PTHrP-producing tumorsSquamous cell carcinoma (lung, among other sites)",
                      "Squamous cell carcinoma (lung, among other sites)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Parathyroid hormone (PTH)"
                  },
                  {
                    "text": "Parathyroid-related protein (PTHrP)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Physiology and Biochemistry": [
                  {
                    "text": "PTH is produced by parathyroid gland4 parathyroid glands located on posterior thyroid surface synthesize, store, and secrete PTH",
                    "sub_points": [
                      "4 parathyroid glands located on posterior thyroid surface synthesize, store, and secrete PTH"
                    ]
                  },
                  {
                    "text": "Synthesis of PTH begins with formation of pre-pro-PTHPre-pro-PTH is enzymatically cleaved, resulting in PTH molecule with N-terminal and C regions leaving intact PTH84 amino acid PTH molecule with N-terminal (physiologically active) portion and C fragment sequenceIntact PTH plasma half-life is < 5 minutes",
                    "sub_points": [
                      "Pre-pro-PTH is enzymatically cleaved, resulting in PTH molecule with N-terminal and C regions leaving intact PTH84 amino acid PTH molecule with N-terminal (physiologically active) portion and C fragment sequenceIntact PTH plasma half-life is < 5 minutes",
                      "84 amino acid PTH molecule with N-terminal (physiologically active) portion and C fragment sequence",
                      "Intact PTH plasma half-life is < 5 minutes"
                    ]
                  },
                  {
                    "text": "PTH is integral in calcium and phosphate homeostasis"
                  },
                  {
                    "text": "PTH is metabolized and cleared from body by liver and kidneysRenal disease impairs clearance and increases C-terminal fragment found in bloodUp to 25% of blood PTH is intact hormone, with remainder and majority as C-terminal fragments",
                    "sub_points": [
                      "Renal disease impairs clearance and increases C-terminal fragment found in blood",
                      "Up to 25% of blood PTH is intact hormone, with remainder and majority as C-terminal fragments"
                    ]
                  },
                  {
                    "text": "Free calcium is important in regulation of PTH synthesis and secretionCalcium-sensing receptors on surface of parathyroid cells bind with free calciumIncreases PTH metabolism; inhibits PTH synthesis and secretionOpposite effect when free calcium is decreased1,25-hydroxy vitamin D (active form) suppresses parathyroid gland synthesis of PTHLow free calcium stimulates secretion of PTHHigh blood calcium inhibits production and secretion of PTHPTH mobilizes calcium from bone, increasing blood calcium levelsPTH stimulates osteoclast function within bone, mobilizing calcium and increasing blood calcium levels",
                    "sub_points": [
                      "Calcium-sensing receptors on surface of parathyroid cells bind with free calciumIncreases PTH metabolism; inhibits PTH synthesis and secretion",
                      "Increases PTH metabolism; inhibits PTH synthesis and secretion",
                      "Opposite effect when free calcium is decreased",
                      "1,25-hydroxy vitamin D (active form) suppresses parathyroid gland synthesis of PTH",
                      "Low free calcium stimulates secretion of PTH",
                      "High blood calcium inhibits production and secretion of PTH",
                      "PTH mobilizes calcium from bone, increasing blood calcium levels",
                      "PTH stimulates osteoclast function within bone, mobilizing calcium and increasing blood calcium levels"
                    ]
                  },
                  {
                    "text": "Hypomagnesemia has varying effects on PTH secretionChronic, severe hypomagnesemia impairs PTH secretionAcute hypomagnesemia could stimulate PTH secretion",
                    "sub_points": [
                      "Chronic, severe hypomagnesemia impairs PTH secretion",
                      "Acute hypomagnesemia could stimulate PTH secretion"
                    ]
                  },
                  {
                    "text": "Free calcium concentrations in blood, as well as extracellular fluid, responsible for PTH synthesis and secretion regulation"
                  },
                  {
                    "text": "PTH acts upon PTH and PTHrP receptors throughout body"
                  },
                  {
                    "text": "Results in multiple intracellular events beginning with increased cyclic AMP"
                  },
                  {
                    "text": "Effect of PTH on nephron of kidney includesEnhanced reabsorption of calcium by distal convoluted tubuleDecreased phosphate reabsorption in proximal tubuleStimulated 1-alpha-hydroxylase enzyme to convert 25-OH vitamin D to active formResults in increased calcium and phosphate absorption by intestines",
                    "sub_points": [
                      "Enhanced reabsorption of calcium by distal convoluted tubule",
                      "Decreased phosphate reabsorption in proximal tubule",
                      "Stimulated 1-alpha-hydroxylase enzyme to convert 25-OH vitamin D to active formResults in increased calcium and phosphate absorption by intestines",
                      "Results in increased calcium and phosphate absorption by intestines"
                    ]
                  }
                ],
                "PTHrP": [
                  {
                    "text": "Various malignancies produce PTHrP, hormone similar in structure to PTHMimics biological actions of PTH",
                    "sub_points": [
                      "Mimics biological actions of PTH"
                    ]
                  },
                  {
                    "text": "PTHrP-producing tumorsSquamous cell carcinomaLung, among other sitesOvarianBladderRenal",
                    "sub_points": [
                      "Squamous cell carcinomaLung, among other sites",
                      "Lung, among other sites",
                      "Ovarian",
                      "Bladder",
                      "Renal"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Analytical Methodologies": [
                  {
                    "text": "PTH measured by 2-site immunoassay"
                  },
                  {
                    "text": "Early methods overestimated intact PTH measurementMeasured truncated and terminal fragments",
                    "sub_points": [
                      "Measured truncated and terminal fragments"
                    ]
                  },
                  {
                    "text": "Competitive or radio immunoassays are problematic because they primarily measure inactive C-terminal PTH fragments"
                  },
                  {
                    "text": "Success of parathyroid surgical removal relies on intraoperative PTH determinationConsidered successful removal of hyperfunctioning tissue when decline of 50% from baseline is seen",
                    "sub_points": [
                      "Considered successful removal of hyperfunctioning tissue when decline of 50% from baseline is seen"
                    ]
                  },
                  {
                    "text": "PTHrPImmunoassays for intact PTH do not cross-react with PTHrP",
                    "sub_points": [
                      "Immunoassays for intact PTH do not cross-react with PTHrP"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Hypercalcemia": [
                  {
                    "text": "PTH measurement useful in generation of differential diagnosis for hypercalcemiaExcess PTH secretion due toPrimary hyperparathyroidismSingle parathyroid adenomaMultiple hyperplastic parathyroid glandsParathyroid carcinomaLow PTH secretion due toNonparathyroid hypercalcemiaMalignancy-associated hypercalcemia",
                    "sub_points": [
                      "Excess PTH secretion due toPrimary hyperparathyroidismSingle parathyroid adenomaMultiple hyperplastic parathyroid glandsParathyroid carcinoma",
                      "Primary hyperparathyroidismSingle parathyroid adenomaMultiple hyperplastic parathyroid glandsParathyroid carcinoma",
                      "Single parathyroid adenoma",
                      "Multiple hyperplastic parathyroid glands",
                      "Parathyroid carcinoma",
                      "Low PTH secretion due toNonparathyroid hypercalcemiaMalignancy-associated hypercalcemia",
                      "Nonparathyroid hypercalcemiaMalignancy-associated hypercalcemia",
                      "Malignancy-associated hypercalcemia"
                    ]
                  }
                ],
                "Hypocalcemia": [
                  {
                    "text": "PTH measurement useful in generation of differential diagnosis for hypocalcemiaPTH highSecondary hypoparathyroidismChronic renal failure (most common cause)PTH will increase before significant decrease in calcium is observedPseudohypoparathyroidismPTH low/normalMagnesium deficiencyPrimary hypoparathyroidism",
                    "sub_points": [
                      "PTH highSecondary hypoparathyroidismChronic renal failure (most common cause)PTH will increase before significant decrease in calcium is observedPseudohypoparathyroidism",
                      "Secondary hypoparathyroidismChronic renal failure (most common cause)PTH will increase before significant decrease in calcium is observed",
                      "Chronic renal failure (most common cause)",
                      "PTH will increase before significant decrease in calcium is observed",
                      "Pseudohypoparathyroidism",
                      "PTH low/normalMagnesium deficiency",
                      "Magnesium deficiency",
                      "Primary hypoparathyroidism"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Preanalytic considerationsEDTA plasma or serum preferredAnalysis should be immediateAfter only few hours at room temperature, serum PTH falsely loweredPTH will even decrease at 4°C if > 24 hours have passed",
                    "sub_points": [
                      "EDTA plasma or serum preferred",
                      "Analysis should be immediateAfter only few hours at room temperature, serum PTH falsely lowered",
                      "After only few hours at room temperature, serum PTH falsely lowered",
                      "PTH will even decrease at 4°C if > 24 hours have passed"
                    ]
                  },
                  {
                    "text": "Function of PTH is important in regulation of bone and mineral metabolism"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Vitamin D": {
            "name": "Vitamin D",
            "url": "https://app.pathprimer.com/document/877cd35c-bb61-4413-bb29-5666a880d5c7/lesson/6d361400-134f-41ca-b3ea-904941bf1826",
            "content": {
              "KEY CONCEPTS": {
                "Clinical Applications": [
                  {
                    "text": "Measure 25(OH)D to determine if patient has adequate vitamin D storesMain circulating form of vitamin D is 25(OH)D25(OH)D has half-life of 2-3 weeks; ﻿1,25(OH)₂D has half-life of 5-8 hoursBlood levels of 25(OH)D vary less with sunlight exposure and food intakeAnalytic measurement is less complicated",
                    "sub_points": [
                      "Main circulating form of vitamin D is 25(OH)D",
                      "25(OH)D has half-life of 2-3 weeks; ﻿1,25(OH)₂D has half-life of 5-8 hours",
                      "Blood levels of 25(OH)D vary less with sunlight exposure and food intake",
                      "Analytic measurement is less complicated"
                    ]
                  },
                  {
                    "text": "In children, vitamin D deficiency is termed rickets; as skeletal development progresses, deformities (e.g., bowed legs) occur"
                  },
                  {
                    "text": "In adults, vitamin D deficiency is termed osteomalacia"
                  },
                  {
                    "text": "Sarcoidosis and other granulomatous diseases increase 1,25(OH)₂D, contributing to hypercalcemia typically seen in these disease states"
                  }
                ],
                "Specimens": [
                  {
                    "text": "Vitamin D metabolites in serum specimens are not light sensitive"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ultraviolet B (UVB)"
                  },
                  {
                    "text": "25-hydroxyvitamin D (25(OH)D)"
                  },
                  {
                    "text": "1,25-dihydroxyvitamin D (1,25(OH)₂D)"
                  },
                  {
                    "text": "Parathyroid hormone (PTH)"
                  },
                  {
                    "text": "High-performance liquid chromatography (HPLC)"
                  },
                  {
                    "text": "Liquid chromatography-tandem mass spectrometry (LC-MS/MS)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "Vitamin D is both endogenously produced and exogenously obtained through diet"
                  },
                  {
                    "text": "2 main forms of vitamin DVitamin D₃ (cholecalciferol)Cholecalciferol production occurs in skin by conversion of 7-dehydrocholesterol via sunlight (UVB)Vitamin D₃ production influenced bySeason and latitudeSunscreen useBaseline skin pigmentationVitamin D₂ (ergocalciferol)Commercially synthesized after yeast-derived ergosterol is irradiatedFound in milk, bread, cereal",
                    "sub_points": [
                      "Vitamin D₃ (cholecalciferol)Cholecalciferol production occurs in skin by conversion of 7-dehydrocholesterol via sunlight (UVB)Vitamin D₃ production influenced bySeason and latitudeSunscreen useBaseline skin pigmentation",
                      "Cholecalciferol production occurs in skin by conversion of 7-dehydrocholesterol via sunlight (UVB)",
                      "Vitamin D₃ production influenced bySeason and latitudeSunscreen useBaseline skin pigmentation",
                      "Season and latitude",
                      "Sunscreen use",
                      "Baseline skin pigmentation",
                      "Vitamin D₂ (ergocalciferol)Commercially synthesized after yeast-derived ergosterol is irradiatedFound in milk, bread, cereal",
                      "Commercially synthesized after yeast-derived ergosterol is irradiated",
                      "Found in milk, bread, cereal"
                    ]
                  },
                  {
                    "text": "Vitamins D₃ and D₂ metabolized by vitamin D 25-hydroxylase in liver to 25(OH)D₃ and 25(OH)D₂, respectively"
                  },
                  {
                    "text": "25(OH)D, of either vitamin D₂ or vitamin D₃ origin, is converted to 1,25(OH)₂D by 1α-hydroxylase in kidneys25(OH)D is main form found in blood1,25(OH)₂D is most biologically active form",
                    "sub_points": [
                      "25(OH)D is main form found in blood",
                      "1,25(OH)₂D is most biologically active form"
                    ]
                  },
                  {
                    "text": "1α-Hydroxylase activity increased byDecreased blood calcium levelsDecreased blood phosphate levelsIncreased PTH levels",
                    "sub_points": [
                      "Decreased blood calcium levels",
                      "Decreased blood phosphate levels",
                      "Increased PTH levels"
                    ]
                  },
                  {
                    "text": "1,25(OH)₂D main function is to increase calcium and phosphate concentrations in blood throughEnhanced intestinal calcium (duodenum) and phosphate (jejunum) absorptionIncreased reabsorption of calcium and phosphate in kidneysIncreased bone reabsorption",
                    "sub_points": [
                      "Enhanced intestinal calcium (duodenum) and phosphate (jejunum) absorption",
                      "Increased reabsorption of calcium and phosphate in kidneys",
                      "Increased bone reabsorption"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Vitamin D Measurement": [
                  {
                    "text": "Both vitamin D₂ and vitamin D₃ are metabolized to produce 1,25(OH)₂DLaboratory assays should measure both fractions",
                    "sub_points": [
                      "Laboratory assays should measure both fractions"
                    ]
                  },
                  {
                    "text": "Serum 25(OH)D can be measured by various methods with each having specific considerationsImmunoassaySome methods underestimate vitamin D₂ form of 25(OH)DCompetitive protein binding assayOverestimates 25(OH)D by 10% because other vitamin D metabolites are measuredHPLC with ultraviolet absorbanceMeasures 25(OH)D D₂ and 25(OH)D D₃ separatelyMeasured fractions must be addedLC-MS/MSMeasures 25(OH)D D₂ and 25(OH)D D₃ separatelyMeasured fractions must be added",
                    "sub_points": [
                      "ImmunoassaySome methods underestimate vitamin D₂ form of 25(OH)D",
                      "Some methods underestimate vitamin D₂ form of 25(OH)D",
                      "Competitive protein binding assayOverestimates 25(OH)D by 10% because other vitamin D metabolites are measured",
                      "Overestimates 25(OH)D by 10% because other vitamin D metabolites are measured",
                      "HPLC with ultraviolet absorbanceMeasures 25(OH)D D₂ and 25(OH)D D₃ separatelyMeasured fractions must be added",
                      "Measures 25(OH)D D₂ and 25(OH)D D₃ separately",
                      "Measured fractions must be added",
                      "LC-MS/MSMeasures 25(OH)D D₂ and 25(OH)D D₃ separatelyMeasured fractions must be added",
                      "Measures 25(OH)D D₂ and 25(OH)D D₃ separately",
                      "Measured fractions must be added"
                    ]
                  },
                  {
                    "text": "1,25(OH)₂D measurement should be pursued only in specific clinical situationsPatients with significant renal diseaseHypercalcemia of unclear etiologyDifferential diagnosis for metabolic bone diseaseUnknown cause of vitamin D deficiency",
                    "sub_points": [
                      "Patients with significant renal disease",
                      "Hypercalcemia of unclear etiology",
                      "Differential diagnosis for metabolic bone disease",
                      "Unknown cause of vitamin D deficiency"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Nutritional Status": [
                  {
                    "text": "Measure 25(OH)D to determine if patient has adequate vitamin D storesMain circulating form of vitamin D is 25(OH)D25(OH)D has longer half-life of 2-3 weeks1,25(OH)₂D half-life 5-8 hrBlood levels of 25(OH)D vary less with sunlight exposure and food intakeAnalytic measurement less complicated",
                    "sub_points": [
                      "Main circulating form of vitamin D is 25(OH)D",
                      "25(OH)D has longer half-life of 2-3 weeks1,25(OH)₂D half-life 5-8 hr",
                      "1,25(OH)₂D half-life 5-8 hr",
                      "Blood levels of 25(OH)D vary less with sunlight exposure and food intake",
                      "Analytic measurement less complicated"
                    ]
                  }
                ],
                "Vitamin D Deficiency": [
                  {
                    "text": "Vitamin D deficiency more likely to occur in certain groupsVegetarians with no egg or milk intakeInfants primarily breastfedElderly adults",
                    "sub_points": [
                      "Vegetarians with no egg or milk intake",
                      "Infants primarily breastfed",
                      "Elderly adults"
                    ]
                  },
                  {
                    "text": "Bone formation impaired in vitamin D deficiencyMineralization in newly formed bone osteoid is decreasedOsteoid formation proceedsOver time, ratio of osteoid to mineralized bone increases resulting in softer bones",
                    "sub_points": [
                      "Mineralization in newly formed bone osteoid is decreasedOsteoid formation proceedsOver time, ratio of osteoid to mineralized bone increases resulting in softer bones",
                      "Osteoid formation proceeds",
                      "Over time, ratio of osteoid to mineralized bone increases resulting in softer bones"
                    ]
                  },
                  {
                    "text": "Clinical name of deficiency depends on patient ageIn children, vitamin D deficiency is termed ricketsWrist and knee abnormalities seen on x-ray within first 6 months of lifePreterm infants can display decreased breathing effort secondary to rib cage weakeningAs skeletal development progresses, deformities (e.g., bowed legs) occurIn adults, deficiency in vitamin D is called osteomalaciaSymptomsWeaknessSkeletal painFractures",
                    "sub_points": [
                      "In children, vitamin D deficiency is termed ricketsWrist and knee abnormalities seen on x-ray within first 6 months of lifePreterm infants can display decreased breathing effort secondary to rib cage weakeningAs skeletal development progresses, deformities (e.g., bowed legs) occur",
                      "Wrist and knee abnormalities seen on x-ray within first 6 months of life",
                      "Preterm infants can display decreased breathing effort secondary to rib cage weakening",
                      "As skeletal development progresses, deformities (e.g., bowed legs) occur",
                      "In adults, deficiency in vitamin D is called osteomalaciaSymptomsWeaknessSkeletal painFractures",
                      "SymptomsWeaknessSkeletal painFractures",
                      "Weakness",
                      "Skeletal pain",
                      "Fractures"
                    ]
                  }
                ],
                "Vitamin D Intoxication and Increase": [
                  {
                    "text": "Excess vitamin D often occurs due to excessive intake of commercial supplements"
                  },
                  {
                    "text": "Clinical symptomsNausea and vomitingDiarrheaIrritabilityGeneralized weaknessSoft tissue calcification",
                    "sub_points": [
                      "Nausea and vomiting",
                      "Diarrhea",
                      "Irritability",
                      "Generalized weakness",
                      "Soft tissue calcification"
                    ]
                  },
                  {
                    "text": "After decreasing vitamin D intake, clinical effects may persist for months due to vitamin D storage in adipose tissue"
                  },
                  {
                    "text": "Sarcoidosis and other granulomatous diseases increase 1,25(OH)₂DContributes to hypercalcemia typically seen in these disease states",
                    "sub_points": [
                      "Contributes to hypercalcemia typically seen in these disease states"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Collection": [
                  {
                    "text": "Preanalytic considerationsSerum is routine specimen type and is relatively stableVitamin D metabolites in serum specimens are not light sensitive",
                    "sub_points": [
                      "Serum is routine specimen type and is relatively stable",
                      "Vitamin D metabolites in serum specimens are not light sensitive"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Testing in Pregnancy": {
        "name": "Testing in Pregnancy",
        "url": "https://app.pathprimer.com/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
        "topics": {
          "Expected Laboratory Changes in Pregnancy": {
            "name": "Expected Laboratory Changes in Pregnancy",
            "url": "https://app.pathprimer.com/document/0c1b301f-57f3-4c08-afe6-dfd574c4000f/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Lab reference intervals should be adjusted for pregnant patients"
                  }
                ],
                "Biologic Concepts": [
                  {
                    "text": "Hormones increased during pregnancy: Progesterone, estrogen, prolactin, PTH, and PL (insulin antagonist)"
                  },
                  {
                    "text": "Albumin levels decreaseConsequently, total calcium also decreases (albumin binding)",
                    "sub_points": [
                      "Consequently, total calcium also decreases (albumin binding)"
                    ]
                  },
                  {
                    "text": "Maternal blood volume increases significantly (~ 45%)"
                  }
                ]
              },
              "OVERVIEW": {
                "﻿Maternal Adaptation": [
                  {
                    "text": "Understanding major physiological and hormonal changes seen in pregnancy allows for correct interpretation of testing results"
                  },
                  {
                    "text": "Lab reference intervals should be adjusted for pregnant patients"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Glomerular filtration rate (GFR)"
                  },
                  {
                    "text": "Placental lactogen (PL)"
                  },
                  {
                    "text": "Thyroxine-binding globulin (TBG)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Hormonal Changes": [
                  {
                    "text": "Hormones increased during pregnancyProgesteroneEstrogenStimulates production of cortisol binding by liver globulinHepatic clearance of cortisol decreasesTotal and free cortisol increasedProlactinResults from increase in pituitary gland sizeLevels fall back to baseline ~ 3 weeks postpartum in nonbreastfeeding womenBreastfeeding mothers continue to have moderately elevated prolactin due to infant sucklingSuppresses LH and FSHPLInsulin antagonist",
                    "sub_points": [
                      "Progesterone",
                      "EstrogenStimulates production of cortisol binding by liver globulinHepatic clearance of cortisol decreasesTotal and free cortisol increased",
                      "Stimulates production of cortisol binding by liver globulin",
                      "Hepatic clearance of cortisol decreases",
                      "Total and free cortisol increased",
                      "ProlactinResults from increase in pituitary gland sizeLevels fall back to baseline ~ 3 weeks postpartum in nonbreastfeeding womenBreastfeeding mothers continue to have moderately elevated prolactin due to infant sucklingSuppresses LH and FSH",
                      "Results from increase in pituitary gland size",
                      "Levels fall back to baseline ~ 3 weeks postpartum in nonbreastfeeding women",
                      "Breastfeeding mothers continue to have moderately elevated prolactin due to infant suckling",
                      "Suppresses LH and FSH",
                      "PLInsulin antagonist",
                      "Insulin antagonist"
                    ]
                  },
                  {
                    "text": "1,25-dihydroxyvitamin D increasedCalcium absorption increases to support fetus",
                    "sub_points": [
                      "Calcium absorption increases to support fetus"
                    ]
                  },
                  {
                    "text": "TBGResults in increased total thyroxine (T4) and triiodothyronine (T3)",
                    "sub_points": [
                      "Results in increased total thyroxine (T4) and triiodothyronine (T3)"
                    ]
                  }
                ],
                "Kidney Function": [
                  {
                    "text": "GFR increases during pregnancySerum levels decreased for renally cleared markersCreatinineUreaUric acidProtein loss in urine increases",
                    "sub_points": [
                      "Serum levels decreased for renally cleared markersCreatinineUreaUric acid",
                      "Creatinine",
                      "Urea",
                      "Uric acid",
                      "Protein loss in urine increases"
                    ]
                  }
                ],
                "Other Changes and Considerations": [
                  {
                    "text": "Serum cholesterol, triglycerides, and free fatty acid levels increase by ~ 40%"
                  },
                  {
                    "text": "Sex hormone binding globulin levels increase"
                  },
                  {
                    "text": "Alkaline phosphatase activity increasesPlacental origin alkaline phosphatase",
                    "sub_points": [
                      "Placental origin alkaline phosphatase"
                    ]
                  },
                  {
                    "text": "Albumin levels decreaseConsequently, total calcium also decreases (albumin binding)",
                    "sub_points": [
                      "Consequently, total calcium also decreases (albumin binding)"
                    ]
                  },
                  {
                    "text": "Electrolytes (sodium, potassium) are similar to nonpregnant levels"
                  },
                  {
                    "text": "Maternal blood volume increases significantly (~ 45%)Result of dilution effectDecreased hematocritDecreased hemoglobinDecreased erythrocyte count",
                    "sub_points": [
                      "Result of dilution effectDecreased hematocritDecreased hemoglobinDecreased erythrocyte count",
                      "Decreased hematocrit",
                      "Decreased hemoglobin",
                      "Decreased erythrocyte count"
                    ]
                  },
                  {
                    "text": "Coagulation factors (fibrinogen) levels increaseCoagulation testing (PTT, PT) values therefore decrease",
                    "sub_points": [
                      "Coagulation testing (PTT, PT) values therefore decrease"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Testing for Amniotic Fluid Bilirubin": {
            "name": "Testing for Amniotic Fluid Bilirubin",
            "url": "https://app.pathprimer.com/document/c8d1bb89-d97b-46e7-93a6-5f6b7df9408a/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Overview": [
                  {
                    "text": "Since advent of middle cerebral artery Doppler measurement, amniocentesis use has decreased in fetal erythroblastosis assessmentHowever, amniotic fluid bilirubin measurement still used in instances where amniotic fluid can be obtained procedurally (fetal transfusion)",
                    "sub_points": [
                      "However, amniotic fluid bilirubin measurement still used in instances where amniotic fluid can be obtained procedurally (fetal transfusion)"
                    ]
                  }
                ],
                "Laboratory Methods": [
                  {
                    "text": "Plotting ΔOD450 on Liley chart places patients in possible risk zone and guides clinical managementZone 1: Mild or low hemolysisZone 2: Moderate hemolysisZone 3: Severe hemolysisDelivery or intrauterine transfusion undertaken",
                    "sub_points": [
                      "Zone 1: Mild or low hemolysis",
                      "Zone 2: Moderate hemolysis",
                      "Zone 3: Severe hemolysisDelivery or intrauterine transfusion undertaken",
                      "Delivery or intrauterine transfusion undertaken"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "﻿Amniotic Bilirubin": [
                  {
                    "text": "Analysis of amniotic fluid for bilirubin is part of work-up for pregnancy complicated by alloimmunizationIncreased bilirubin in amniotic fluid indicates fetal erythroblastosisBilirubin level is directly related to level of fetal hemolysis",
                    "sub_points": [
                      "Increased bilirubin in amniotic fluid indicates fetal erythroblastosisBilirubin level is directly related to level of fetal hemolysis",
                      "Bilirubin level is directly related to level of fetal hemolysis"
                    ]
                  },
                  {
                    "text": "In the past, ultrasound-guided amniotic fluid sampling was commonplace to assess bilirubin level and fetal risk in alloimmunized mothers"
                  },
                  {
                    "text": "Since advent of middle cerebral artery Doppler measurement, amniocentesis use has decreased in fetal erythroblastosis assessmentHowever, amniotic fluid bilirubin measurement still used in instances where amniotic fluid can be obtained procedurally (fetal transfusion)",
                    "sub_points": [
                      "However, amniotic fluid bilirubin measurement still used in instances where amniotic fluid can be obtained procedurally (fetal transfusion)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Optical density (OD)"
                  },
                  {
                    "text": "Change OD at 450 nm (ΔOD450)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Bilirubin in amniotic fluid imparts yellow color, but visual inspection of amniotic fluid is unreliable"
                  },
                  {
                    "text": "Meconium imparts green color and may interfere with spectrophotometric analysis of bilirubin"
                  },
                  {
                    "text": "Blood in specimen also affects accuracyHemoglobin absorbs light at 450 nm",
                    "sub_points": [
                      "Hemoglobin absorbs light at 450 nm"
                    ]
                  },
                  {
                    "text": "Bilirubin is photosensitive; specimens should be protected from light after collectionSample often collected in brown tube",
                    "sub_points": [
                      "Sample often collected in brown tube"
                    ]
                  }
                ],
                "﻿Liley Chart": [
                  {
                    "text": "Liley introduced measurement of amniotic fluid bilirubin using ΔOD450 in 1961"
                  },
                  {
                    "text": "Liley chart uses plot of gestational age (x-axis) versus ΔOD450 (y-axis)ΔOD450 value is proportional to bilirubin concentration and level of hemolysisMaximal wavelength absorbance of bilirubin occurs at 450 nm",
                    "sub_points": [
                      "ΔOD450 value is proportional to bilirubin concentration and level of hemolysis",
                      "Maximal wavelength absorbance of bilirubin occurs at 450 nm"
                    ]
                  },
                  {
                    "text": "Liley chart used in gestational ages > 27 weeksIf < 27 weeks, then slightly different chart is used (called Queenan curve)",
                    "sub_points": [
                      "If < 27 weeks, then slightly different chart is used (called Queenan curve)"
                    ]
                  },
                  {
                    "text": "Plotting ΔOD450 on Liley chart places patients in possible risk zone and guides clinical managementZone 1: Mild or low hemolysisZone 2: Moderate hemolysisZone 3: Severe hemolysisDelivery or intrauterine transfusion undertaken",
                    "sub_points": [
                      "Zone 1: Mild or low hemolysis",
                      "Zone 2: Moderate hemolysis",
                      "Zone 3: Severe hemolysisDelivery or intrauterine transfusion undertaken",
                      "Delivery or intrauterine transfusion undertaken"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Human Chorionic Gonadotropin": {
            "name": "Human Chorionic Gonadotropin",
            "url": "https://app.pathprimer.com/document/0df3b2e7-8add-4d0a-b99d-f905455e1830/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Biologic Concepts": [
                  {
                    "text": "Alpha subunits of hCG, TSH, LH, and FSH are identicalEncoded by single gene on chromosome 6",
                    "sub_points": [
                      "Encoded by single gene on chromosome 6"
                    ]
                  },
                  {
                    "text": "Beta subunit gives hCG its biologic specificity"
                  },
                  {
                    "text": "Pituitary gland also produces small amount of hCG in older adults"
                  },
                  {
                    "text": "hCG concentration rises logarithmically in first 8 weeks of normal pregnancyLevel doubles every 2 daysReaches peak concentration (approximately 100,000 IU/L) at about 8-10 weeks",
                    "sub_points": [
                      "Level doubles every 2 days",
                      "Reaches peak concentration (approximately 100,000 IU/L) at about 8-10 weeks"
                    ]
                  },
                  {
                    "text": "Cause for suspicion of ectopic pregnancyLower than expected maternal hCG for gestational ageSlow rise in hCG (lack of doubling every 2 days)",
                    "sub_points": [
                      "Lower than expected maternal hCG for gestational age",
                      "Slow rise in hCG (lack of doubling every 2 days)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Human chorionic gonadotropin (hCG)"
                  },
                  {
                    "text": "Thyroid-stimulating hormone (TSH)"
                  },
                  {
                    "text": "Luteinizing hormone (LH)"
                  },
                  {
                    "text": "Follicle-stimulating hormone (FSH)"
                  },
                  {
                    "text": "Clinical Laboratory Improvement Amendments (CLIA)"
                  },
                  {
                    "text": "Human antimouse antibody (HAMA)"
                  },
                  {
                    "text": "Ethylenediaminetetraacetic acid (EDTA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Ectopic pregnancy: Abnormal implantation of fertilized egg outside of uterus"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "Biochemistry and Physiology": [
                  {
                    "text": "hCG is heterodimer hormone composed of 2 glycoprotein subunits (alpha and beta)"
                  },
                  {
                    "text": "Alpha subunits of hCG, TSH, LH, and FSH are identicalEncoded by single gene on chromosome 6",
                    "sub_points": [
                      "Encoded by single gene on chromosome 6"
                    ]
                  },
                  {
                    "text": "Beta subunit gives hCG its biologic specificity"
                  },
                  {
                    "text": "Placental syncytiotrophoblasts synthesize hCG hormone"
                  },
                  {
                    "text": "Pituitary gland also produces small amount of hCG in older adultsPerimenopausal women: Can measure FSH level or administer estrogen to identifyPituitary neoplasm: Source of positive pregnancy tests accidentally ordered on men",
                    "sub_points": [
                      "Perimenopausal women: Can measure FSH level or administer estrogen to identify",
                      "Pituitary neoplasm: Source of positive pregnancy tests accidentally ordered on men"
                    ]
                  },
                  {
                    "text": "hCG hormone heavily glycosylatedIntact hCG with attached oligosaccharide chains",
                    "sub_points": [
                      "Intact hCG with attached oligosaccharide chains"
                    ]
                  },
                  {
                    "text": "In early gestation, placental production of progesterone inadequate to maintain pregnancyhCG stimulates necessary additional progesterone synthesis by ovarian corpus luteum",
                    "sub_points": [
                      "hCG stimulates necessary additional progesterone synthesis by ovarian corpus luteum"
                    ]
                  }
                ],
                "Normal Pregnancy and hCG": [
                  {
                    "text": "First becomes detectable in serum 8-11 days after conceptionLevels approximately ≥ 5 IU/L",
                    "sub_points": [
                      "Levels approximately ≥ 5 IU/L"
                    ]
                  },
                  {
                    "text": "hCG concentration rises logarithmically in first 8 weeksLevel doubles every 2 daysReaches peak concentration (approximately 100,000 IU/L) at about 8-10 weeks",
                    "sub_points": [
                      "Level doubles every 2 days",
                      "Reaches peak concentration (approximately 100,000 IU/L) at about 8-10 weeks"
                    ]
                  },
                  {
                    "text": "Hyperglycosylated hCG is predominant form in early pregnancy"
                  },
                  {
                    "text": "Second trimester sees gradual decline in hCG concentrationEventual plateau to 10,000 IU/L for average pregnancy",
                    "sub_points": [
                      "Eventual plateau to 10,000 IU/L for average pregnancy"
                    ]
                  },
                  {
                    "text": "Twin gestation doubles expected hCG concentration"
                  },
                  {
                    "text": "hCG undetectable approximately 21 days after delivery"
                  }
                ],
                "Ectopic Pregnancy and hCG": [
                  {
                    "text": "Cause for suspicionLower than expected maternal hCG for gestational ageSlow rise in hCG (lack of doubling every 2 days)",
                    "sub_points": [
                      "Lower than expected maternal hCG for gestational age",
                      "Slow rise in hCG (lack of doubling every 2 days)"
                    ]
                  },
                  {
                    "text": "Most abnormal implantation occurs in fallopian tubeCan lead to life-threatening tubal rupture and hemorrhage",
                    "sub_points": [
                      "Can lead to life-threatening tubal rupture and hemorrhage"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Quantitative Methodologies": [
                  {
                    "text": "Numerous hCG variants complicate analysisFree alpha or beta subunitsNicked hCG (cleaved free beta subunit)Beta core fragment",
                    "sub_points": [
                      "Free alpha or beta subunits",
                      "Nicked hCG (cleaved free beta subunit)",
                      "Beta core fragment"
                    ]
                  },
                  {
                    "text": "Serum immunometric methods directed toward measuring free beta subunit and intact hCG with 2 antibodiesCan detect hCG over wide range of concentrations1-2 IU/L to 15,000 IU/LDilution protocols often necessary",
                    "sub_points": [
                      "Can detect hCG over wide range of concentrations1-2 IU/L to 15,000 IU/L",
                      "1-2 IU/L to 15,000 IU/L",
                      "Dilution protocols often necessary"
                    ]
                  },
                  {
                    "text": "Assays used to monitor hCG in malignancy must be able to detect different variantsHydatidiform moles (release intact hCG, free beta subunit, hyperglycosylated)Choriocarcinoma (release hyperglycosylated)Germ cell tumors (release free beta subunit)",
                    "sub_points": [
                      "Hydatidiform moles (release intact hCG, free beta subunit, hyperglycosylated)",
                      "Choriocarcinoma (release hyperglycosylated)",
                      "Germ cell tumors (release free beta subunit)"
                    ]
                  },
                  {
                    "text": "hCG testing harmonization remains a challengeImmunoassay antibodies bind different epitopes of beta subunit",
                    "sub_points": [
                      "Immunoassay antibodies bind different epitopes of beta subunit"
                    ]
                  }
                ],
                "Qualitative Methodology": [
                  {
                    "text": "Home pregnancy testAmong most commonly used CLIA-waived testsDetects hCG in urineSingle-use device that utilizes immunochromatographyCommonly detects hCG levels > 10-25 IU/LAfter a missed menstrual period, test can confirm gestation after first week",
                    "sub_points": [
                      "Among most commonly used CLIA-waived tests",
                      "Detects hCG in urine",
                      "Single-use device that utilizes immunochromatography",
                      "Commonly detects hCG levels > 10-25 IU/L",
                      "After a missed menstrual period, test can confirm gestation after first week"
                    ]
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Uses of hCG": [
                  {
                    "text": "Diagnose pregnancy and time gestation (hCG measurement is most useful test)"
                  },
                  {
                    "text": "Identify ectopic pregnancy"
                  },
                  {
                    "text": "Assess risk of congenital anomaliesDown syndromeTrisomy 18",
                    "sub_points": [
                      "Down syndrome",
                      "Trisomy 18"
                    ]
                  },
                  {
                    "text": "Management of neoplasmsChoriocarcinomaGestational trophoblastic disease (complete or partial moles)Testicular tumors (germ cell tumors)",
                    "sub_points": [
                      "Choriocarcinoma",
                      "Gestational trophoblastic disease (complete or partial moles)",
                      "Testicular tumors (germ cell tumors)"
                    ]
                  }
                ]
              },
              "LIMITATIONS": {
                "Unexpected Positive Result": [
                  {
                    "text": "HAMACommon cause of false-positive hCG test for qualitative and quantitative methodologiesSuggested work-upSerially dilute serum specimen to assess appropriate dose responseAdd antibody blocking agents (often already part of method)Test patient urineSend specimen out for analysis by different methodology",
                    "sub_points": [
                      "Common cause of false-positive hCG test for qualitative and quantitative methodologies",
                      "Suggested work-upSerially dilute serum specimen to assess appropriate dose responseAdd antibody blocking agents (often already part of method)Test patient urineSend specimen out for analysis by different methodology",
                      "Serially dilute serum specimen to assess appropriate dose response",
                      "Add antibody blocking agents (often already part of method)",
                      "Test patient urine",
                      "Send specimen out for analysis by different methodology"
                    ]
                  }
                ],
                "False-Negative Result": [
                  {
                    "text": "Dilute urine can be causeFollow-up serum testing suggested when clinical suspicion of pregnancy high",
                    "sub_points": [
                      "Follow-up serum testing suggested when clinical suspicion of pregnancy high"
                    ]
                  }
                ]
              },
              "SPECIMENS": {
                "Preanalytic Considerations": [
                  {
                    "text": "SerumSeparator tube is acceptable",
                    "sub_points": [
                      "Separator tube is acceptable"
                    ]
                  },
                  {
                    "text": "PlasmaSome methods may be affected by EDTA anticoagulant",
                    "sub_points": [
                      "Some methods may be affected by EDTA anticoagulant"
                    ]
                  },
                  {
                    "text": "UrineFirst morning void preferred (slightly higher hCG)Can be stored 8 hours at room temperature or refrigerated up to 72 hoursShould not be frozen",
                    "sub_points": [
                      "First morning void preferred (slightly higher hCG)Can be stored 8 hours at room temperature or refrigerated up to 72 hoursShould not be frozen",
                      "Can be stored 8 hours at room temperature or refrigerated up to 72 hours",
                      "Should not be frozen"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Prenatal Screening": {
            "name": "Prenatal Screening",
            "url": "https://app.pathprimer.com/document/4a85c578-fad5-4e03-b6f6-59b9773b04d9/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Quad screenhCG, AFP, uE, and inhA drawn in 2nd trimester",
                    "sub_points": [
                      "hCG, AFP, uE, and inhA drawn in 2nd trimester"
                    ]
                  },
                  {
                    "text": "First trimester combined screenPAPP-A, hCG, and fetal NT scan are obtained and combined with maternal age to derive risk",
                    "sub_points": [
                      "PAPP-A, hCG, and fetal NT scan are obtained and combined with maternal age to derive risk"
                    ]
                  },
                  {
                    "text": "Integrated screenCombines 1st and 2nd trimester markersSecond blood sample is drawn and hCG, AFP, uE, and inhA are measured",
                    "sub_points": [
                      "Combines 1st and 2nd trimester markers",
                      "Second blood sample is drawn and hCG, AFP, uE, and inhA are measured"
                    ]
                  }
                ]
              },
              "OVERVIEW": {
                "Prenatal Screening": [
                  {
                    "text": "Involves testing that identifies pregnancies at high risk of birth defect and related conditionsPrimary examplesDown syndromeNeural tube defectsTrisomy 18",
                    "sub_points": [
                      "Primary examplesDown syndromeNeural tube defectsTrisomy 18",
                      "Down syndrome",
                      "Neural tube defects",
                      "Trisomy 18"
                    ]
                  },
                  {
                    "text": "In past, obstetricians would only offer fetal karyotyping by amniocentesis for mothers > 35 years of ageHowever, data from early 2000s showed using maternal age alone would miss large proportion of Down syndrome pregnanciesIn addition, noninvasive screening was shown to be more accurate in assessing risk of Down syndrome than maternal age alone",
                    "sub_points": [
                      "However, data from early 2000s showed using maternal age alone would miss large proportion of Down syndrome pregnancies",
                      "In addition, noninvasive screening was shown to be more accurate in assessing risk of Down syndrome than maternal age alone"
                    ]
                  },
                  {
                    "text": "ACOG now recommends noninvasive screening using serum markers for pregnant women of all ages"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "American College of Obstetricians and Gynecologists (ACOG)"
                  },
                  {
                    "text": "Multiple of the median (MoM)"
                  },
                  {
                    "text": "Pregnancy-associated plasma protein-A (PAPP-A)"
                  },
                  {
                    "text": "Unconjugated estriol (uE)"
                  },
                  {
                    "text": "Human chorionic gonadotropin (hCG)"
                  },
                  {
                    "text": "Alpha fetoprotein (AFP)"
                  },
                  {
                    "text": "Inhibin A (inhA)"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Risk Calculation": [
                  {
                    "text": "MoM: Statistical calculation used to normalize serum analyte values used in prenatal screeningUsed as interpretable unit to calculate riskCalculated using set median values (derived by individual laboratory assay values), for either each week or day of gestation within screened population",
                    "sub_points": [
                      "Used as interpretable unit to calculate risk",
                      "Calculated using set median values (derived by individual laboratory assay values), for either each week or day of gestation within screened population"
                    ]
                  },
                  {
                    "text": "Individualized patient risk calculated by equationPatient risk = pretest risk x likelihood ratioPretest risk obtained from epidemiological studiesLikelihood ratio derived in part using MoM data",
                    "sub_points": [
                      "Patient risk = pretest risk x likelihood ratioPretest risk obtained from epidemiological studiesLikelihood ratio derived in part using MoM data",
                      "Pretest risk obtained from epidemiological studies",
                      "Likelihood ratio derived in part using MoM data"
                    ]
                  },
                  {
                    "text": "Risk assessment is optimized by considering additional factors that have been shown to effect serum analyte concentrationsMaternal weightGenerally, as maternal weight increases average serum analyte concentration decreasesMaternal raceAfrican American women have serum AFP and hCG concentrations up to 15% higher than white womenInhA is 8% lower in African AmericansNo difference in uEInsulin-dependent diabetesAFP lower by 20% in mothers taking insulinTwin pregnancySerum analytes are increased by almost 2-fold when compared to single gestation pregnancy",
                    "sub_points": [
                      "Maternal weightGenerally, as maternal weight increases average serum analyte concentration decreases",
                      "Generally, as maternal weight increases average serum analyte concentration decreases",
                      "Maternal raceAfrican American women have serum AFP and hCG concentrations up to 15% higher than white womenInhA is 8% lower in African AmericansNo difference in uE",
                      "African American women have serum AFP and hCG concentrations up to 15% higher than white women",
                      "InhA is 8% lower in African Americans",
                      "No difference in uE",
                      "Insulin-dependent diabetesAFP lower by 20% in mothers taking insulin",
                      "AFP lower by 20% in mothers taking insulin",
                      "Twin pregnancySerum analytes are increased by almost 2-fold when compared to single gestation pregnancy",
                      "Serum analytes are increased by almost 2-fold when compared to single gestation pregnancy"
                    ]
                  }
                ],
                "Serum Screening Approaches": [
                  {
                    "text": "Different maternal serum screening approaches have evolved over timeQuad screenhCG, AFP, uE, and inhA drawn in 2nd trimesterValues of serum analytes and maternal age used to derive riskDetection rate for Down syndrome is ~ 80%",
                    "sub_points": [
                      "Quad screenhCG, AFP, uE, and inhA drawn in 2nd trimesterValues of serum analytes and maternal age used to derive riskDetection rate for Down syndrome is ~ 80%",
                      "hCG, AFP, uE, and inhA drawn in 2nd trimester",
                      "Values of serum analytes and maternal age used to derive risk",
                      "Detection rate for Down syndrome is ~ 80%"
                    ]
                  },
                  {
                    "text": "First trimester combined screenDone at 10-13 weeks' gestationPAPP-A, hCG, and fetal nuchal translucency (NT) scan are obtained and combined with maternal age to derive riskNT scan looks at subcutaneous space between skin and cervical spineDetection rate for Down syndrome and trisomy 18 are ~ 85% and 80%, respectively",
                    "sub_points": [
                      "Done at 10-13 weeks' gestation",
                      "PAPP-A, hCG, and fetal nuchal translucency (NT) scan are obtained and combined with maternal age to derive riskNT scan looks at subcutaneous space between skin and cervical spine",
                      "NT scan looks at subcutaneous space between skin and cervical spine",
                      "Detection rate for Down syndrome and trisomy 18 are ~ 85% and 80%, respectively"
                    ]
                  },
                  {
                    "text": "Integrated screenCombines 1st and 2nd trimester markersNT scan and PAPP-A test are performed in 1st trimesterResults are not interpreted or acted on until 2nd trimester testing is completeSecond blood sample is drawn and hCG, AFP, uE, and inhA are measuredDetection rate for Down syndrome is 85% with 1% false-positive rate",
                    "sub_points": [
                      "Combines 1st and 2nd trimester markers",
                      "NT scan and PAPP-A test are performed in 1st trimesterResults are not interpreted or acted on until 2nd trimester testing is complete",
                      "Results are not interpreted or acted on until 2nd trimester testing is complete",
                      "Second blood sample is drawn and hCG, AFP, uE, and inhA are measured",
                      "Detection rate for Down syndrome is 85% with 1% false-positive rate"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fetal Lung Maturity": {
            "name": "Fetal Lung Maturity",
            "url": "https://app.pathprimer.com/document/1737a000-fec0-4753-9aea-96548fcc74ba/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "L/S ratio less predictive of FLM in diabetic mothers"
                  },
                  {
                    "text": "Lamellar bodies are approximately the size of platelets; platelet channels in whole blood cell counters can be used to count lamellar bodies"
                  },
                  {
                    "text": "Meconium falsely increases LBC"
                  },
                  {
                    "text": "PG useful because it is not affected by meconium and blood"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fetal lung maturity (FLM)"
                  },
                  {
                    "text": "Phosphatidyl glycerol (PG)"
                  },
                  {
                    "text": "Lamellar body count (LBC)"
                  },
                  {
                    "text": "Lecithin-sphingomyelin ratio (L/S ratio)"
                  },
                  {
                    "text": "Respiratory distress syndrome (RDS)"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Fetal Lung Maturation": [
                  {
                    "text": "FLM depends on production of surfactant by type II pneumocytesBegins at week 28 of gestation",
                    "sub_points": [
                      "Begins at week 28 of gestation"
                    ]
                  },
                  {
                    "text": "Surfactant lines alveolar space and decreases surface tension, preventing alveolar collapse"
                  },
                  {
                    "text": "Surfactant composition is a mixture of primarily phospholipids and other minor constituents, includingLecithin (major phospholipid)PhosphatidylcholinePGSphingomyelin",
                    "sub_points": [
                      "Lecithin (major phospholipid)",
                      "Phosphatidylcholine",
                      "PG",
                      "Sphingomyelin"
                    ]
                  },
                  {
                    "text": "Surfactant found in amniotic fluid by third trimester"
                  }
                ]
              },
              "LABORATORY METHODS": {
                "﻿Preanalytic Considerations": [
                  {
                    "text": "Specimen of choice to assess FLM is amniotic fluid obtained by transabdominal amniocentesisVaginal pool specimens should be avoidedSpecimens with meconium or blood contamination should be avoidedParticulate matter often removed through centrifugation",
                    "sub_points": [
                      "Vaginal pool specimens should be avoided",
                      "Specimens with meconium or blood contamination should be avoided",
                      "Particulate matter often removed through centrifugation"
                    ]
                  },
                  {
                    "text": "Amniotic fluid testing should be conducted without delayIf analysis delayed by few hours, fluid should be refrigerated at 4°CLamellar bodies found in amniotic fluid are stable for approximately 30 daysFreeze/thaw cycle decreases LBC",
                    "sub_points": [
                      "If analysis delayed by few hours, fluid should be refrigerated at 4°C",
                      "Lamellar bodies found in amniotic fluid are stable for approximately 30 daysFreeze/thaw cycle decreases LBC",
                      "Freeze/thaw cycle decreases LBC"
                    ]
                  },
                  {
                    "text": "Amniotic fluid should be inverted repeatedly to obtain uniform suspension before analysis"
                  }
                ],
                "Lecithin-Sphingomyelin Ratio": [
                  {
                    "text": "L/S ratio, introduced in 1971, first chemical test to access FLM"
                  },
                  {
                    "text": "Sphingomyelin concentration constant throughout gestation"
                  },
                  {
                    "text": "Lecithin increases during gestation and directly correlated with FLM"
                  },
                  {
                    "text": "L/S ratio > 2.0 indicates FLM"
                  },
                  {
                    "text": "L/S ratio < 1.5 suggests immaturity"
                  },
                  {
                    "text": "L/S ratio less predictive of FLM in diabetic mothersRDS may still develop with L/S ratio > 2.0",
                    "sub_points": [
                      "RDS may still develop with L/S ratio > 2.0"
                    ]
                  }
                ],
                "﻿Lamellar Body Counting": [
                  {
                    "text": "Surfactant particles, termed lamellar bodies, used as marker for FLM"
                  },
                  {
                    "text": "Type II pneumocytes package surfactant in laminated storage granules called lamellar bodies"
                  },
                  {
                    "text": "Lamellar bodies are approximately the size of plateletsPlatelet channels in whole blood cell counters can be used to count lamellar bodiesLBC ≥ 50,000 μL suggests FLM by most laboratory methods",
                    "sub_points": [
                      "Platelet channels in whole blood cell counters can be used to count lamellar bodies",
                      "LBC ≥ 50,000 μL suggests FLM by most laboratory methods"
                    ]
                  },
                  {
                    "text": "Blood contamination results in fibrin-based trapping of lamellar bodies, falsely decreasing LBC"
                  },
                  {
                    "text": "Meconium falsely increases LBC"
                  },
                  {
                    "text": "Mucus contamination can lead to erroneous results"
                  }
                ],
                "PG": [
                  {
                    "text": "PG useful because it is not affected by meconium and bloodAppears later in gestation (approximately week 36)",
                    "sub_points": [
                      "Appears later in gestation (approximately week 36)"
                    ]
                  },
                  {
                    "text": "Can be used with vaginal pool specimens"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "﻿Fetal Lung Maturity": [
                  {
                    "text": "FLM assessed between 32 and 38 weeks' gestationFLM unlikely before 32 weeks",
                    "sub_points": [
                      "FLM unlikely before 32 weeks"
                    ]
                  },
                  {
                    "text": "FLM should be assessed in delivery before 39 weeks"
                  },
                  {
                    "text": "Common causes for early delivery (< 39 weeks)Premature rupture of membranesIntrauterine growth retardationFetal distressPreterm laborMaternal hypertensionMaternal renal diseaseAge of gestation uncertain",
                    "sub_points": [
                      "Premature rupture of membranes",
                      "Intrauterine growth retardation",
                      "Fetal distress",
                      "Preterm labor",
                      "Maternal hypertension",
                      "Maternal renal disease",
                      "Age of gestation uncertain"
                    ]
                  }
                ],
                "Respiratory Distress Syndrome": [
                  {
                    "text": "RDS due to incomplete development of fetal lungs with deficiency in pulmonary surfactant (also termed hyaline membrane disease)"
                  },
                  {
                    "text": "Additional risk factorsMaternal diabetes mellitusBirth by cesarean delivery",
                    "sub_points": [
                      "Maternal diabetes mellitus",
                      "Birth by cesarean delivery"
                    ]
                  },
                  {
                    "text": "RDS risk inversely proportional to gestational age at birth"
                  },
                  {
                    "text": "Major cause of morbidity in premature infants"
                  },
                  {
                    "text": "Focus of RDS treatmentPrevention of preterm birthStimulation of surfactant production through steroid administration",
                    "sub_points": [
                      "Prevention of preterm birth",
                      "Stimulation of surfactant production through steroid administration"
                    ]
                  },
                  {
                    "text": "Newborns affected by RDS displayNasal flaringGrunting on expirationTachypnea with intercostal retraction",
                    "sub_points": [
                      "Nasal flaring",
                      "Grunting on expiration",
                      "Tachypnea with intercostal retraction"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Preterm Labor Testing": {
            "name": "Preterm Labor Testing",
            "url": "https://app.pathprimer.com/document/650cbdb2-4858-41e8-9c94-0b05ecb415cc/lesson/d311cc2a-5a57-4ae8-92a7-412797ec6f0b",
            "content": {
              "KEY CONCEPTS": {
                "Laboratory Methods": [
                  {
                    "text": "Cervicovaginal fluid with fetal fibronectin > 50 ng/mL is consistent preterm labor risk"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Preterm labor: Uterine contractions and cervical change prior to 37 weeks' gestation"
                  }
                ]
              },
              "BIOLOGIC CONCEPTS": {
                "﻿Physiology": [
                  {
                    "text": "Fetal fibronectin is a glycoprotein found at placental-uterine junctionResponsible for cellular adhesion of placenta to uterus",
                    "sub_points": [
                      "Responsible for cellular adhesion of placenta to uterus"
                    ]
                  },
                  {
                    "text": "Fetal fibronectin can be detected at various intervals during majority of gestationDetectable during first 20 weeks of gestationThen absent until just before labor onset",
                    "sub_points": [
                      "Detectable during first 20 weeks of gestation",
                      "Then absent until just before labor onset"
                    ]
                  },
                  {
                    "text": "Fetal fibronectin presence in cervical secretions is associated with preterm laborLabor initiation disrupts cellular adhesion between placenta and uterusCervical and vaginal fetal fibronectin increases",
                    "sub_points": [
                      "Labor initiation disrupts cellular adhesion between placenta and uterus",
                      "Cervical and vaginal fetal fibronectin increases"
                    ]
                  }
                ]
              },
              "LABORATORY METHODS": {
                "Preanalytic Considerations": [
                  {
                    "text": "Specimen is swab of cervical or vaginal mucusShould be collected 24 hours postSexual intercourseVarious gynecological exams (e.g., Papanicolaou smear, vaginal ultrasound)Cervical dilation (< 3 cm)Intact membranesAbsence of uterine blood",
                    "sub_points": [
                      "Should be collected 24 hours postSexual intercourseVarious gynecological exams (e.g., Papanicolaou smear, vaginal ultrasound)",
                      "Sexual intercourse",
                      "Various gynecological exams (e.g., Papanicolaou smear, vaginal ultrasound)",
                      "Cervical dilation (< 3 cm)",
                      "Intact membranes",
                      "Absence of uterine blood"
                    ]
                  }
                ],
                "﻿Immunoassay": [
                  {
                    "text": "Enzyme immunoassay approved for assessment between 24 and 35 weeks' gestationFibronectin identified by antibody FDL-6",
                    "sub_points": [
                      "Fibronectin identified by antibody FDL-6"
                    ]
                  },
                  {
                    "text": "Cervicovaginal fluid with fetal fibronectin > 50 ng/mL is consistent preterm labor risk"
                  }
                ]
              },
              "CLINICAL APPLICATIONS": {
                "Fetal Fibronectin Use in Preterm Labor": [
                  {
                    "text": "Identifying asymptomatic women at risk for preterm delivery"
                  },
                  {
                    "text": "Predicting risk of delivery in symptomatic women (preterm contractions)"
                  },
                  {
                    "text": "Determining risk of preterm laborAvoids interventions in symptomatic patientsReduces unnecessary hospitalization",
                    "sub_points": [
                      "Avoids interventions in symptomatic patients",
                      "Reduces unnecessary hospitalization"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}